[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fyeZJJYlgm4tpfjZPLJZkgJgmvi0eVunMKIlAAKAy490":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":38,"phaseBuckets":89,"rows":96},"Duke University",[4],2031,false,322,60,2389109,137,1437,[14,17,20,23,26,29,32,35],{"name":15,"count":16},"Obesity",53,{"name":18,"count":19},"Breast Cancer",48,{"name":21,"count":22},"Heart Failure",42,{"name":24,"count":25},"Prostate Cancer",39,{"name":27,"count":28},"Hypertension",38,{"name":30,"count":31},"Depression",37,{"name":33,"count":34},"Brain and Central Nervous System Tumors",30,{"name":36,"count":37},"Pain",26,[39,44,49,54,59,64,69,74,79,84],{"nctId":40,"briefTitle":41,"date":42,"intervention":43},"NCT04071769","Genentech Xenon MRI Idiopathic Pulmonary Fibrosis","2024-10-17","Hyperpolarized 129 Xenon Gas Comparing Idiopathic Pulmonary Fibrosis (IPF) Treatment",{"nctId":45,"briefTitle":46,"date":47,"intervention":48},"NCT05553834","PCSK9 Inhibitor and PD-1 Inhibitor in Patients With Metastatic, Refractory To Prior Anti PD-1 Non-small Cell Lung","2025-09-16","Alirocumab and Cemiplimab",{"nctId":50,"briefTitle":51,"date":52,"intervention":53},"NCT05241275","Xenon MRI and Progressive ILD","2025-11-03","Hyperpolarized 129 Xenon Gas Comparing Progressive Pulmonary Fibrosis Treatment",{"nctId":55,"briefTitle":56,"date":57,"intervention":58},"NCT05634720","Hepatic Artery Chemotherapy for Patients With Localized Pancreas Cancer","2025-11-18","HA Chemotherapy",{"nctId":60,"briefTitle":61,"date":62,"intervention":63},"NCT05127109","The PASTDUe Nutrition Ecosystem Project (PASTDUe)","2026-02-20","Nutrition Ecosystem pathway",{"nctId":65,"briefTitle":66,"date":67,"intervention":68},"NCT06404112","RECOVER-SLEEP: Platform Protocol, Appendix_B (CPSD)","2026-03-03","Melatonin",{"nctId":70,"briefTitle":71,"date":72,"intervention":73},"NCT06404099","RECOVER-SLEEP: Platform Protocol, Appendix_A (Hypersomnia)","2026-03-18","Modafinil",{"nctId":75,"briefTitle":76,"date":77,"intervention":78},"NCT06541145","Bacterial Decolonization Within Dyads","2026-04","Mupirocin",{"nctId":80,"briefTitle":81,"date":82,"intervention":83},"NCT06822972","HCMT\u002FMM2401: Ph2 Study of Selinexor + Bispecific Antibody for RRMM","2026-04-30","Selinexor 40 mg",{"nctId":85,"briefTitle":86,"date":87,"intervention":88},"NCT02127398","Stool Transplants to Treat Refractory Clostridium Difficile Colitis","2026-05","fecal microbiota",[90,91,92,93,94,95],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[97,227,285,322,401,456,492,514,552,579,613,637,664,692,716,740,758,782,814,839,863,881,901,928,946,973,991,1009,1027,1045,1070,1095,1113,1143,1239,1285,1307,1335,1353,1381,1399,1417,1435,1464,1482,1500,1518,1551,1600,1644,1692,1729,1751,1773,1795,1817,1844,1862,1880,1903,1924,1944,1966,1984,2011,2033,2051,2074,2100,2123,2150,2174,2192,2216,2240,2261,2284,2311,2362,2386,2404,2430,2448,2469,2493,2517,2544,2568,2709,2727,2752,2783,2896,2996,3078,3152,3208,3259,3296,3336,3365,3391,3419,3450,3472,3500,3536,3563,3591,3617,3647,3668,3686,3714,3760,3785,3803,3821,3839,3857,3875,3893,3911,3929,3947,3965,3983,4001,4019,4037,4055,4073,4091,4109,4127,4145,4163,4189,4233,4271,4304,4347,4369,4408,4430,4452,4487,4530,4560,4592,4627,4661,4689,4718,4746,4777,4808,4842,4880,4912,4936,4954,4972,4990,5008,5030,5048,5066,5091,5109,5132,5159,5177,5195,5223,5241,5267,5285,5303,5327,5345,5369,5387,5410,5436,5454,5477,5495,5513,5536,5554,5578,5596,5621,5644,5668,5690,5715,5742,5760,5786,5804,5827,5852,5870,5888,5911,5935,5958,5984,6002,6020,6038,6063,6087,6115,6133,6160,6178,6196,6214,6237,6259,6277,6299,6325,6347,6371,6389,6407,6432,6453,6478,6496,6519,6541,6566,6584,6607,6632,6657,6675,6697,6715,6737,6761,6783,6808,6833,6851,6877,6898,6921,6944,6968,6990,7015,7040,7058,7082,7105,7123,7150,7168,7186,7204,7232,7250,7268,7286,7311,7329,7356,7374,7392,7417,7435,7453,7476,7494,7512,7530,7548,7571,7595,7613,7635,7653,7677,7695,7717,7742,7760,7806,7858,7889,7920,7951,7983,8006,8024,8042,8066,8084,8107,8125,8148,8171,8192,8216,8242,8260,8278,8296,8314,8340,8358,8376,8394,8419,8441,8464,8486,8509,8532,8556,8577,8595,8617,8639,8664,8682,8705,8727,8749,8819,8889,8944,8997,9059,9092,9122,9164,9200,9241,9277,9322,9357,9392,9418,9444,9466,9498,9527,9558,9583,9610,9637,9668,9699,9727,9754,9776,9806,9828,9850,9879,9901,9924,9947,9965,9983,10007,10029,10056,10077,10102,10120,10138,10161,10179,10197,10215,10236,10254,10272,10290,10308,10333,10351,10375,10401,10419,10437,10460,10478,10496,10514,10532,10554,10579,10597,10615,10638,10661,10682,10707,10730,10755,10773,10798,10823,10841,10865,10883,10906,10932,10957,10975,10993,11017,11043,11061,11082,11106,11124,11142,11160,11178,11200,11222,11246,11264,11282,11304,11325,11350,11374,11392,11414,11437,11458,11481,11505,11527,11545,11569,11590,11613,11636,11659,11677,11698,11721,11747,11765,11787,11812,11836,11860,11884,11902,11923,11946,11972,11990,12011,12033,12055,12073,12095,12119,12140,12162,12187,12210,12232,12256,12278,12296,12314,12332,12354,12376,12394,12415,12438,12456,12478,12499,12517,12550,12568,12591,12609,12633,12651,12669,12687,12710,12733,12760,12778,12796,12820,12851,12875,12898,12920,12941,12963,12985,13003,13026,13049,13070,13088,13110,13140,13158,13182,13200,13221,13243,13264,13285,13307,13330,13348,13369,13391,13412,13430,13448,13466,13484,13509,13535,13559,13582,13600,13623,13646,13664,13690,13708,13729,13750,13773,13798,13816,13837,13855,13873,13895,13918,13939,13963,13985,14009,14027,14045,14069,14091,14112,14134,14157,14179,14206,14230,14254,14278,14305,14329,14423,14483,14536,14572,14612,14642,14668,14694,14729,14760,14795,14827,14853,14879,14909,14942,14967,14989,15019,15041,15071,15102,15127,15165,15192,15223,15250,15282,15304,15330,15348,15366,15389,15407,15433,15451,15474,15496,15519,15541,15564,15590,15608,15631,15653,15676,15698,15716,15734,15752,15770,15788,15806,15824,15845,15867,15892,15915,15937,15955,15979,16003,16021,16045,16063,16081,16105,16128,16150,16175,16193,16211,16234,16258,16283,16301,16319,16337,16360,16378,16401,16426,16449,16467,16492,16510,16534,16562,16580,16598,16616,16640,16658,16680,16698,16716,16734,16752,16770,16788,16806,16824,16842,16867,16885,16903,16921,16944,16967,16985,17007,17032,17050,17068,17090,17111],{"intervention":98,"totalTrials":99,"cells":100},"Saline",9,{"EARLY_PHASE1":101,"PHASE1":104,"PHASE2":106,"PHASE3":133,"PHASE4":135,"NA":225},{"trials":102,"activeCount":103},[],0,{"trials":105,"activeCount":103},[],{"trials":107,"activeCount":132,"soonestReadout":126},[108,121],{"nctId":109,"briefTitle":110,"status":111,"phases":112,"primaryCompletion":113,"completion":113,"start":114,"enrollment":115,"conditions":116,"interventions":119},"NCT03331965","Metoclopramide Versus Placebo for GJ Placement","COMPLETED",[92],"2019-10-03","2018-04-09",110,[117,118],"Radiation Exposure","Enteral Nutrition",[120,98],"Metoclopramide 5 MG\u002FML Injectable Solution",{"nctId":122,"briefTitle":123,"status":124,"phases":125,"primaryCompletion":126,"completion":126,"start":77,"enrollment":127,"conditions":128,"interventions":130},"NCT07300982","Studies of Insulin and Glucagon Action in the Liver","NOT_YET_RECRUITING",[91,92],"2029-12",40,[129],"Diabetes (DM)",[131,98],"Glucagon",1,{"trials":134,"activeCount":103},[],{"trials":136,"activeCount":132,"soonestReadout":171},[137,152,166,176,187,200,213],{"nctId":138,"briefTitle":139,"status":111,"phases":140,"primaryCompletion":141,"completion":142,"start":143,"enrollment":144,"conditions":145,"interventions":150},"NCT03390426","Femoral Peri-arterial Local Anesthetic Injection Decreases Tourniquet Associated Ischemic Hypertension",[94],"2018-10-27","2018-10-28","2018-05-03",31,[146,147,148,149],"Tourniquet Hypertension","Intraoperative Hypertension","Total Ankle Arthroplasty","Ankle Fusion",[151,98],"Mepivacaine",{"nctId":153,"briefTitle":154,"status":155,"phases":156,"primaryCompletion":157,"completion":158,"start":159,"enrollment":160,"conditions":161,"interventions":164},"NCT02933671","Suprainguinal Fascia Iliaca (SIFI) Block Improves Analgesia Following Total Hip Arthroplasty","TERMINATED",[94],"2020-03-16","2020-03-17","2017-08-01",11,[162,163,36],"Hip Osteoarthritis","Primary Total Hip Arthroplasty",[165,98],"Ropivacaine",{"nctId":167,"briefTitle":168,"status":169,"phases":170,"primaryCompletion":171,"completion":172,"start":173,"enrollment":127,"conditions":174,"interventions":175},"NCT04454203","Femoral Peri-arterial Local Anesthetic Injection Via Peri-arterial Perineural Catheter Reverses Tourniquet Associated Ischemic Hypertension","RECRUITING",[94],"2027-02-01","2027-02-03","2021-02-05",[146,147,148,149],[151,98],{"nctId":177,"briefTitle":178,"status":111,"phases":179,"primaryCompletion":180,"completion":181,"start":182,"enrollment":127,"conditions":183,"interventions":185},"NCT03706313","Genicular Nerve Block for Total Knee Arthroplasty",[94],"2019-10-16","2019-10-22","2019-01-15",[184],"Post-operative Pain",[186,98],"15mL 0.25% bupivacaine",{"nctId":188,"briefTitle":189,"status":111,"phases":190,"primaryCompletion":191,"completion":192,"start":143,"enrollment":193,"conditions":194,"interventions":199},"NCT03353233","Evaluation of Utility of Ultrasound Guided iPACK Block for Knee Extension After Total Knee Arthroplasty.",[94],"2021-01-22","2021-01-23",50,[195,196,197,36,198],"Knee Osteoarthritis","Primary Total Knee Arthroplasty","Physical Therapy","Knee Extension",[165,98],{"nctId":201,"briefTitle":202,"status":111,"phases":203,"primaryCompletion":204,"completion":204,"start":205,"enrollment":206,"conditions":207,"interventions":209},"NCT02170532","Aerosolized Beta-Agonist Isomers in Asthma",[94],"2009-07","2007-07",10,[208],"Asthma",[210,211,212],"levalbuterol","saline","ipratroprium",{"nctId":214,"briefTitle":215,"status":111,"phases":216,"primaryCompletion":217,"completion":217,"start":218,"enrollment":219,"conditions":220,"interventions":222},"NCT02431598","Eovist vs. Dotarem Healthy Volunteer MRI",[94],"2015-09","2015-06",44,[221],"Transient Severe Arterial Phase Motion",[223,224,98],"gadoxetate disodium","gadoterate dimeglumine",{"trials":226,"activeCount":103},[],{"intervention":228,"totalTrials":229,"cells":230},"Fentanyl\u002FHydromorphone",3,{"EARLY_PHASE1":231,"PHASE1":233,"PHASE2":235,"PHASE3":250,"PHASE4":252,"NA":283},{"trials":232,"activeCount":103},[],{"trials":234,"activeCount":103},[],{"trials":236,"activeCount":103},[237],{"nctId":238,"briefTitle":239,"status":111,"phases":240,"primaryCompletion":241,"completion":241,"start":242,"enrollment":243,"conditions":244,"interventions":248},"NCT05244226","Pediatric Pain Optimization After Tonsillectomy",[92],"2023-05-10","2022-04-08",66,[245,246,247],"Obstructive Sleep Apnea","Tonsillitis","Pain, Procedural",[228,249],"Methadone",{"trials":251,"activeCount":103},[],{"trials":253,"activeCount":282,"soonestReadout":272},[254,268],{"nctId":255,"briefTitle":256,"status":169,"phases":257,"primaryCompletion":258,"completion":259,"start":260,"enrollment":261,"conditions":262,"interventions":267},"NCT06576830","Optimization of Pediatric Tonsillectomy to IMprove AnaLgesia",[94],"2028-12-31","2029-06-01","2024-11-21",440,[263,264,246,265,266],"Pain, Postoperative","Tonsillar Hypertrophy","Pediatric Sleep Apnea","Sleep-Disordered Breathing",[249,228],{"nctId":269,"briefTitle":270,"status":169,"phases":271,"primaryCompletion":272,"completion":273,"start":274,"enrollment":9,"conditions":275,"interventions":280},"NCT06962306","Optimizing Perioperative Analgesia to Lower Pain Following Cleft Palate Surgery",[94],"2027-06-04","2027-07-04","2025-06-04",[276,36,277,278,279],"Cleft Palate","Postoperative Care","Perioperative Care","Children",[281,228],"Methadone hydrochloride",2,{"trials":284,"activeCount":103},[],{"intervention":286,"totalTrials":282,"cells":287},"Chloroprocaine",{"EARLY_PHASE1":288,"PHASE1":290,"PHASE2":292,"PHASE3":294,"PHASE4":296,"NA":320},{"trials":289,"activeCount":103},[],{"trials":291,"activeCount":103},[],{"trials":293,"activeCount":103},[],{"trials":295,"activeCount":103},[],{"trials":297,"activeCount":282,"soonestReadout":302},[298,309],{"nctId":299,"briefTitle":300,"status":124,"phases":301,"primaryCompletion":302,"completion":303,"start":304,"enrollment":305,"conditions":306,"interventions":308},"NCT07444827","Targeted Nerve Injection to the Knee (Nerve to Vastus Medialis): Comparing Two Adductor Canal Block Approaches",[94],"2027-07-01","2027-12-01","2026-07-01",25,[307],"Anesthesia, Local",[286],{"nctId":310,"briefTitle":311,"status":124,"phases":312,"primaryCompletion":313,"completion":314,"start":87,"enrollment":315,"conditions":316,"interventions":318},"NCT07348614","Flex Appeal: Evaluating the Efficacy of Anesthetic Techniques for Manipulation of Knees Under Anesthesia",[94],"2027-08","2027-09",128,[317],"Knee Stiffness After Total Knee Arthroplasty",[319,286],"Propofol",{"trials":321,"activeCount":103},[],{"intervention":323,"totalTrials":282,"cells":324},"Buprenorphine",{"EARLY_PHASE1":325,"PHASE1":327,"PHASE2":329,"PHASE3":331,"PHASE4":333,"NA":350},{"trials":326,"activeCount":103},[],{"trials":328,"activeCount":103},[],{"trials":330,"activeCount":103},[],{"trials":332,"activeCount":103},[],{"trials":334,"activeCount":132,"soonestReadout":126},[335],{"nctId":336,"briefTitle":337,"status":124,"phases":338,"primaryCompletion":126,"completion":339,"start":340,"enrollment":341,"conditions":342,"interventions":346},"NCT06854029","NOTRE: Optimizing Long-Acting Pre-Exposure Prophylaxis and Medications for Opioid Use Disorder Interventions in Carceral Settings",[94],"2030-06","2026-06",450,[343,344,345],"HIV Infections","Opioid Use Disorder","Incarceration; Lens",[347,348,323,349],"Cabotegravir","Cabotegravir Pill","Buprenorphine Pill",{"trials":351,"activeCount":132,"soonestReadout":356},[352],{"nctId":353,"briefTitle":354,"status":169,"phases":355,"primaryCompletion":356,"completion":357,"start":358,"enrollment":359,"conditions":360,"interventions":363},"NCT03511118","Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants",[],"2027-07-23","2028-07-31","2018-10-04",1600,[361,362],"Lactating Women on Select DOI","Breastfed Infants of Mothers on Select DOI",[364,365,366,367,368,369,370,371,372,373,374,375,376,377,378,379,380,381,382,383,384,385,386,387,388,389,390,391,392,393,394,395,396,397,398,399,400,323],"Tranexamic acid","labetalol","metformin","nifedipine","clindamycin","oxycodone","azithromycin","escitalopram","sertraline","ondansetron","Ciprofloxacin","Doxycycline","Levofloxacin","Methylphenidate","Sumatriptan","Citalopram","Cyclobenzaprine","Furosemide","Gabapentin","Hydrochlorothiazide","Hydroxyurea","Rosuvastatin","Topiramate","Trazodone","Valganciclovir","Venlafaxine","Verapamil","Remdesivir","Anakinra","Tocilizumab","Fluvoxamine","Amoxicillin","Bupropion","Duloxetine","Hydrocodone","Levetiracetam","Paroxetine",{"intervention":319,"totalTrials":402,"cells":403},4,{"EARLY_PHASE1":404,"PHASE1":406,"PHASE2":419,"PHASE3":421,"PHASE4":423,"NA":454},{"trials":405,"activeCount":103},[],{"trials":407,"activeCount":103},[408],{"nctId":409,"briefTitle":410,"status":111,"phases":411,"primaryCompletion":412,"completion":412,"start":413,"enrollment":414,"conditions":415,"interventions":417},"NCT01640275","Markers of Alzheimers Disease After Propofol or Isoflurane Anesthesia",[91],"2015-03","2012-03",105,[416],"General Anesthesia",[319,418],"Isoflurane",{"trials":420,"activeCount":103},[],{"trials":422,"activeCount":103},[],{"trials":424,"activeCount":132,"soonestReadout":313},[425,438,442],{"nctId":426,"briefTitle":427,"status":428,"phases":429,"completion":430,"start":431,"enrollment":103,"conditions":432,"interventions":434},"NCT00333632","Effect of Dexmedetomidine Upon Sleep Postoperatively","WITHDRAWN",[94],"2011-06","2006-06",[433],"Sleep",[435,319,436,437,418],"Dexmedetomidine","Midazolam","Fentanyl",{"nctId":310,"briefTitle":311,"status":124,"phases":439,"primaryCompletion":313,"completion":314,"start":87,"enrollment":315,"conditions":440,"interventions":441},[94],[317],[319,286],{"nctId":443,"briefTitle":444,"status":155,"phases":445,"primaryCompletion":446,"completion":446,"start":447,"enrollment":448,"conditions":449,"interventions":453},"NCT02903407","Pain, Agitation and Delirium (PAD) Protocol in the Duke CICU",[94],"2019-06-30","2017-09-01",7,[450,451,452],"Deep Sedation","Ventilators, Mechanical","Critical Illness",[436,319,435],{"trials":455,"activeCount":103},[],{"intervention":249,"totalTrials":229,"cells":457},{"EARLY_PHASE1":458,"PHASE1":460,"PHASE2":462,"PHASE3":468,"PHASE4":470,"NA":490},{"trials":459,"activeCount":103},[],{"trials":461,"activeCount":103},[],{"trials":463,"activeCount":103},[464],{"nctId":238,"briefTitle":239,"status":111,"phases":465,"primaryCompletion":241,"completion":241,"start":242,"enrollment":243,"conditions":466,"interventions":467},[92],[245,246,247],[228,249],{"trials":469,"activeCount":103},[],{"trials":471,"activeCount":132,"soonestReadout":258},[472,486],{"nctId":473,"briefTitle":474,"status":111,"phases":475,"primaryCompletion":476,"completion":477,"start":478,"enrollment":479,"conditions":480,"interventions":482},"NCT03726268","Optimizing Outpatient Anesthesia (OSPREy-Outpatient Surgery Pain Relief Enhancement)",[94],"2023-07-30","2024-01-30","2018-11-29",907,[481,263],"Opioid Use",[249,437,483,484,485],"Hydromorphone","Morphine","Sufentanil",{"nctId":255,"briefTitle":256,"status":169,"phases":487,"primaryCompletion":258,"completion":259,"start":260,"enrollment":261,"conditions":488,"interventions":489},[94],[263,264,246,265,266],[249,228],{"trials":491,"activeCount":103},[],{"intervention":151,"totalTrials":282,"cells":493},{"EARLY_PHASE1":494,"PHASE1":496,"PHASE2":498,"PHASE3":500,"PHASE4":502,"NA":512},{"trials":495,"activeCount":103},[],{"trials":497,"activeCount":103},[],{"trials":499,"activeCount":103},[],{"trials":501,"activeCount":103},[],{"trials":503,"activeCount":132,"soonestReadout":171},[504,508],{"nctId":138,"briefTitle":139,"status":111,"phases":505,"primaryCompletion":141,"completion":142,"start":143,"enrollment":144,"conditions":506,"interventions":507},[94],[146,147,148,149],[151,98],{"nctId":167,"briefTitle":168,"status":169,"phases":509,"primaryCompletion":171,"completion":172,"start":173,"enrollment":127,"conditions":510,"interventions":511},[94],[146,147,148,149],[151,98],{"trials":513,"activeCount":103},[],{"intervention":515,"totalTrials":282,"cells":516},"Hyperbaric Oxygen",{"EARLY_PHASE1":517,"PHASE1":519,"PHASE2":521,"PHASE3":533,"PHASE4":535,"NA":550},{"trials":518,"activeCount":103},[],{"trials":520,"activeCount":103},[],{"trials":522,"activeCount":103},[523],{"nctId":524,"briefTitle":525,"status":155,"phases":526,"primaryCompletion":527,"completion":528,"start":529,"enrollment":402,"conditions":530,"interventions":532},"NCT04717557","Hyperbaric Oxygen and Outcome After Below Knee Amputations",[91,92],"2023-07-31","2023-10-31","2021-01-01",[531],"Amputation; Postoperative, Sequelae",[515],{"trials":534,"activeCount":103},[],{"trials":536,"activeCount":132,"soonestReadout":542},[537],{"nctId":538,"briefTitle":539,"status":540,"phases":541,"primaryCompletion":542,"completion":542,"start":543,"enrollment":544,"conditions":545,"interventions":548},"NCT03144206","Hyperbaric Oxygen Therapy for Soft Tissue Sarcoma Pilot Study","ACTIVE_NOT_RECRUITING",[94],"2026-07-12","2017-10-19",20,[546,547],"Sarcoma","Hyperbaric Oxygen Therapy",[549],"Hyperbaric oxygen",{"trials":551,"activeCount":103},[],{"intervention":553,"totalTrials":132,"cells":554},"Respiratory Syncytial Virus (RSV) Preventive Monoclonal Antibody",{"EARLY_PHASE1":555,"PHASE1":557,"PHASE2":559,"PHASE3":561,"PHASE4":563,"NA":577},{"trials":556,"activeCount":103},[],{"trials":558,"activeCount":103},[],{"trials":560,"activeCount":103},[],{"trials":562,"activeCount":103},[],{"trials":564,"activeCount":132,"soonestReadout":569},[565],{"nctId":566,"briefTitle":567,"status":169,"phases":568,"primaryCompletion":569,"completion":570,"start":571,"enrollment":572,"conditions":573,"interventions":576},"NCT07158814","Safety of RSV Preventive Monoclonal Antibody",[94],"2027-02","2027-04","2025-10-02",524,[574,575],"Fever","Adverse Event Following Immunisation",[553],{"trials":578,"activeCount":103},[],{"intervention":63,"totalTrials":132,"cells":580},{"EARLY_PHASE1":581,"PHASE1":583,"PHASE2":585,"PHASE3":587,"PHASE4":589,"NA":611},{"trials":582,"activeCount":103},[],{"trials":584,"activeCount":103},[],{"trials":586,"activeCount":103},[],{"trials":588,"activeCount":103},[],{"trials":590,"activeCount":132,"soonestReadout":62},[591],{"nctId":60,"briefTitle":61,"status":540,"phases":592,"primaryCompletion":62,"completion":593,"start":594,"enrollment":595,"conditions":596,"interventions":610},[94],"2027-02-20","2022-04-25",300,[597,598,599,600,601,602,603,604,605,606,607,608,609],"Diet, Healthy","Food","Nutrition","Intensive Care","Abdominal Trauma","Surgery","Intra-abdominal Infection","Sepsis","Ischemic Bowel","Vascular","Penetrating Abdominal Trauma","Enteral Feeding","Oral",[63],{"trials":612,"activeCount":103},[],{"intervention":614,"totalTrials":132,"cells":615},"Lidocaine 2%",{"EARLY_PHASE1":616,"PHASE1":618,"PHASE2":620,"PHASE3":622,"PHASE4":624,"NA":635},{"trials":617,"activeCount":103},[],{"trials":619,"activeCount":103},[],{"trials":621,"activeCount":103},[],{"trials":623,"activeCount":103},[],{"trials":625,"activeCount":132,"soonestReadout":630},[626],{"nctId":627,"briefTitle":628,"status":124,"phases":629,"primaryCompletion":630,"completion":570,"start":87,"enrollment":544,"conditions":631,"interventions":634},"NCT07429292","SPARK Study - Sympathetic Periarterial Radial Block in Healthy Volunteers",[94],"2026-12",[632,633],"Healthy Volunteers","Sympathetic Activity",[614],{"trials":636,"activeCount":103},[],{"intervention":638,"totalTrials":132,"cells":639},"Atorvastatin 40 Mg Oral",{"EARLY_PHASE1":640,"PHASE1":642,"PHASE2":644,"PHASE3":646,"PHASE4":648,"NA":662},{"trials":641,"activeCount":103},[],{"trials":643,"activeCount":103},[],{"trials":645,"activeCount":103},[],{"trials":647,"activeCount":103},[],{"trials":649,"activeCount":132,"soonestReadout":654},[650],{"nctId":651,"briefTitle":652,"status":169,"phases":653,"primaryCompletion":654,"completion":654,"start":655,"enrollment":656,"conditions":657,"interventions":661},"NCT04262206","Pragmatic Evaluation of Events And Benefits of Lipid-lowering in Older Adults",[94],"2026-12-31","2020-09-01",20000,[658,659,660],"Cognitive Impairment, Mild","Dementia","Cardiovascular Diseases",[638],{"trials":663,"activeCount":103},[],{"intervention":665,"totalTrials":132,"cells":666},"Liposomal Bupivacaine with Bupivacaine",{"EARLY_PHASE1":667,"PHASE1":669,"PHASE2":671,"PHASE3":673,"PHASE4":675,"NA":690},{"trials":668,"activeCount":103},[],{"trials":670,"activeCount":103},[],{"trials":672,"activeCount":103},[],{"trials":674,"activeCount":103},[],{"trials":676,"activeCount":132,"soonestReadout":681},[677],{"nctId":678,"briefTitle":679,"status":124,"phases":680,"primaryCompletion":681,"completion":682,"start":683,"enrollment":684,"conditions":685,"interventions":688},"NCT07614802","Exparel and Dexamethasone",[94],"2027-08-01","2027-09-01","2026-08-01",80,[686,687],"Postoperative Pain","Shoulder Arthroscopic Surgeries",[665,689],"Dexamethasone",{"trials":691,"activeCount":103},[],{"intervention":693,"totalTrials":132,"cells":694},"Inclisiran",{"EARLY_PHASE1":695,"PHASE1":697,"PHASE2":699,"PHASE3":701,"PHASE4":703,"NA":714},{"trials":696,"activeCount":103},[],{"trials":698,"activeCount":103},[],{"trials":700,"activeCount":103},[],{"trials":702,"activeCount":103},[],{"trials":704,"activeCount":132,"soonestReadout":630},[705],{"nctId":706,"briefTitle":707,"status":540,"phases":708,"primaryCompletion":630,"completion":569,"start":709,"enrollment":710,"conditions":711,"interventions":713},"NCT06249165","VictORION-INCLUSION: Evaluating Inclisiran for Cholesterol Managment in Heart Disease",[94],"2024-12-16",130,[712],"Atherosclerotic Cardiovascular Disease",[693],{"trials":715,"activeCount":103},[],{"intervention":717,"totalTrials":132,"cells":718},"ESP Block with Bupivacaine",{"EARLY_PHASE1":719,"PHASE1":721,"PHASE2":723,"PHASE3":725,"PHASE4":727,"NA":738},{"trials":720,"activeCount":103},[],{"trials":722,"activeCount":103},[],{"trials":724,"activeCount":103},[],{"trials":726,"activeCount":103},[],{"trials":728,"activeCount":132,"soonestReadout":733},[729],{"nctId":730,"briefTitle":731,"status":124,"phases":732,"primaryCompletion":733,"completion":733,"start":87,"enrollment":734,"conditions":735,"interventions":736},"NCT07228039","ESP Blocks for Posterior Spinal Fusion",[94],"2028-01",75,[686],[717,737],"ESP Block with Bupivacaine + Liposomal Bupivacaine",{"trials":739,"activeCount":103},[],{"intervention":737,"totalTrials":132,"cells":741},{"EARLY_PHASE1":742,"PHASE1":744,"PHASE2":746,"PHASE3":748,"PHASE4":750,"NA":756},{"trials":743,"activeCount":103},[],{"trials":745,"activeCount":103},[],{"trials":747,"activeCount":103},[],{"trials":749,"activeCount":103},[],{"trials":751,"activeCount":132,"soonestReadout":733},[752],{"nctId":730,"briefTitle":731,"status":124,"phases":753,"primaryCompletion":733,"completion":733,"start":87,"enrollment":734,"conditions":754,"interventions":755},[94],[686],[717,737],{"trials":757,"activeCount":103},[],{"intervention":759,"totalTrials":132,"cells":760},"Quadratus Lumborum with 1.5% Lidocaine",{"EARLY_PHASE1":761,"PHASE1":763,"PHASE2":765,"PHASE3":767,"PHASE4":769,"NA":780},{"trials":762,"activeCount":103},[],{"trials":764,"activeCount":103},[],{"trials":766,"activeCount":103},[],{"trials":768,"activeCount":103},[],{"trials":770,"activeCount":132,"soonestReadout":775},[771],{"nctId":772,"briefTitle":773,"status":124,"phases":774,"primaryCompletion":775,"completion":630,"start":87,"enrollment":305,"conditions":776,"interventions":779},"NCT07566312","Study of QL Analgesic Response and Extent",[94],"2026-11",[777,686,778],"Acute Pain","Regional Anesthesia Block",[759],{"trials":781,"activeCount":103},[],{"intervention":783,"totalTrials":132,"cells":784},"Artemether-lumefantrine",{"EARLY_PHASE1":785,"PHASE1":787,"PHASE2":789,"PHASE3":791,"PHASE4":793,"NA":812},{"trials":786,"activeCount":103},[],{"trials":788,"activeCount":103},[],{"trials":790,"activeCount":103},[],{"trials":792,"activeCount":103},[],{"trials":794,"activeCount":132,"soonestReadout":630},[795],{"nctId":796,"briefTitle":797,"status":540,"phases":798,"primaryCompletion":630,"completion":630,"start":799,"enrollment":800,"conditions":801,"interventions":811},"NCT05757167","Improving Neonatal Health Through Rapid Malaria Testing in Early Pregnancy With High-Sensitivity Diagnostics",[94],"2023-11-06",2174,[802,803,804,805,806,807,808,809,810],"Malaria,Falciparum","Malaria in Pregnancy","Malaria in Childbirth","Pregnancy","Neonatal Health","Low Birthweight","Stillbirth","Gestational Age and Weight Conditions","Preterm Birth",[783],{"trials":813,"activeCount":103},[],{"intervention":815,"totalTrials":132,"cells":816},"Pre-Exposure Prophylaxis",{"EARLY_PHASE1":817,"PHASE1":819,"PHASE2":821,"PHASE3":823,"PHASE4":825,"NA":837},{"trials":818,"activeCount":103},[],{"trials":820,"activeCount":103},[],{"trials":822,"activeCount":103},[],{"trials":824,"activeCount":103},[],{"trials":826,"activeCount":132,"soonestReadout":831},[827],{"nctId":828,"briefTitle":829,"status":169,"phases":830,"primaryCompletion":831,"completion":832,"start":833,"enrollment":544,"conditions":834,"interventions":836},"NCT06908252","MAPS PrEP Van Study",[94],"2026-06-30","2026-07-31","2025-09-17",[835],"HIV Infection",[815],{"trials":838,"activeCount":103},[],{"intervention":840,"totalTrials":132,"cells":841},"Oxymetazoline 0.1%",{"EARLY_PHASE1":842,"PHASE1":844,"PHASE2":846,"PHASE3":848,"PHASE4":850,"NA":861},{"trials":843,"activeCount":103},[],{"trials":845,"activeCount":103},[],{"trials":847,"activeCount":103},[],{"trials":849,"activeCount":103},[],{"trials":851,"activeCount":132,"soonestReadout":681},[852],{"nctId":853,"briefTitle":854,"status":124,"phases":855,"primaryCompletion":681,"completion":303,"start":856,"enrollment":193,"conditions":857,"interventions":859},"NCT07390578","Upneeq vs. Lumify Ptosis",[94],"2026-12-01",[858],"Acquired Ptosis",[840,860],"Brimonidine 0.025%",{"trials":862,"activeCount":103},[],{"intervention":860,"totalTrials":132,"cells":864},{"EARLY_PHASE1":865,"PHASE1":867,"PHASE2":869,"PHASE3":871,"PHASE4":873,"NA":879},{"trials":866,"activeCount":103},[],{"trials":868,"activeCount":103},[],{"trials":870,"activeCount":103},[],{"trials":872,"activeCount":103},[],{"trials":874,"activeCount":132,"soonestReadout":681},[875],{"nctId":853,"briefTitle":854,"status":124,"phases":876,"primaryCompletion":681,"completion":303,"start":856,"enrollment":193,"conditions":877,"interventions":878},[94],[858],[840,860],{"trials":880,"activeCount":103},[],{"intervention":58,"totalTrials":132,"cells":882},{"EARLY_PHASE1":883,"PHASE1":885,"PHASE2":887,"PHASE3":889,"PHASE4":891,"NA":899},{"trials":884,"activeCount":103},[],{"trials":886,"activeCount":103},[],{"trials":888,"activeCount":103},[],{"trials":890,"activeCount":103},[],{"trials":892,"activeCount":132,"soonestReadout":57},[893],{"nctId":55,"briefTitle":56,"status":540,"phases":894,"primaryCompletion":57,"completion":258,"start":895,"enrollment":544,"conditions":896,"interventions":898},[94],"2024-01-02",[897],"Pancreatic Ductal Adenocarcinoma",[58],{"trials":900,"activeCount":103},[],{"intervention":902,"totalTrials":132,"cells":903},"Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL",{"EARLY_PHASE1":904,"PHASE1":906,"PHASE2":908,"PHASE3":910,"PHASE4":912,"NA":926},{"trials":905,"activeCount":103},[],{"trials":907,"activeCount":103},[],{"trials":909,"activeCount":103},[],{"trials":911,"activeCount":103},[],{"trials":913,"activeCount":132,"soonestReadout":918},[914],{"nctId":915,"briefTitle":916,"status":169,"phases":917,"primaryCompletion":918,"completion":126,"start":919,"enrollment":920,"conditions":921,"interventions":924},"NCT06909565","Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Intervention",[94],"2029-10","2025-07-23",6000,[922,923],"Percutaneous Coronary Intervention","Peripheral Endovascular Intervention",[902,925],"Normal Saline",{"trials":927,"activeCount":103},[],{"intervention":925,"totalTrials":132,"cells":929},{"EARLY_PHASE1":930,"PHASE1":932,"PHASE2":934,"PHASE3":936,"PHASE4":938,"NA":944},{"trials":931,"activeCount":103},[],{"trials":933,"activeCount":103},[],{"trials":935,"activeCount":103},[],{"trials":937,"activeCount":103},[],{"trials":939,"activeCount":132,"soonestReadout":918},[940],{"nctId":915,"briefTitle":916,"status":169,"phases":941,"primaryCompletion":918,"completion":126,"start":919,"enrollment":920,"conditions":942,"interventions":943},[94],[922,923],[902,925],{"trials":945,"activeCount":103},[],{"intervention":947,"totalTrials":132,"cells":948},"Sofosbuvir \u002F Velpatasvir Oral Tablet [Epclusa]",{"EARLY_PHASE1":949,"PHASE1":951,"PHASE2":953,"PHASE3":955,"PHASE4":957,"NA":971},{"trials":950,"activeCount":103},[],{"trials":952,"activeCount":103},[],{"trials":954,"activeCount":103},[],{"trials":956,"activeCount":103},[],{"trials":958,"activeCount":132,"soonestReadout":963},[959],{"nctId":960,"briefTitle":961,"status":124,"phases":962,"primaryCompletion":963,"completion":964,"start":683,"enrollment":965,"conditions":966,"interventions":970},"NCT07560046","Combating Related Epidemics in HCV",[94],"2030-11-30","2030-12-30",1280,[967,968,969],"HIV - Human Immunodeficiency Virus","Hepatitis B Virus (HBV)","HEPATITIS C (HCV)",[947],{"trials":972,"activeCount":103},[],{"intervention":347,"totalTrials":132,"cells":974},{"EARLY_PHASE1":975,"PHASE1":977,"PHASE2":979,"PHASE3":981,"PHASE4":983,"NA":989},{"trials":976,"activeCount":103},[],{"trials":978,"activeCount":103},[],{"trials":980,"activeCount":103},[],{"trials":982,"activeCount":103},[],{"trials":984,"activeCount":132,"soonestReadout":126},[985],{"nctId":336,"briefTitle":337,"status":124,"phases":986,"primaryCompletion":126,"completion":339,"start":340,"enrollment":341,"conditions":987,"interventions":988},[94],[343,344,345],[347,348,323,349],{"trials":990,"activeCount":103},[],{"intervention":348,"totalTrials":132,"cells":992},{"EARLY_PHASE1":993,"PHASE1":995,"PHASE2":997,"PHASE3":999,"PHASE4":1001,"NA":1007},{"trials":994,"activeCount":103},[],{"trials":996,"activeCount":103},[],{"trials":998,"activeCount":103},[],{"trials":1000,"activeCount":103},[],{"trials":1002,"activeCount":132,"soonestReadout":126},[1003],{"nctId":336,"briefTitle":337,"status":124,"phases":1004,"primaryCompletion":126,"completion":339,"start":340,"enrollment":341,"conditions":1005,"interventions":1006},[94],[343,344,345],[347,348,323,349],{"trials":1008,"activeCount":103},[],{"intervention":349,"totalTrials":132,"cells":1010},{"EARLY_PHASE1":1011,"PHASE1":1013,"PHASE2":1015,"PHASE3":1017,"PHASE4":1019,"NA":1025},{"trials":1012,"activeCount":103},[],{"trials":1014,"activeCount":103},[],{"trials":1016,"activeCount":103},[],{"trials":1018,"activeCount":103},[],{"trials":1020,"activeCount":132,"soonestReadout":126},[1021],{"nctId":336,"briefTitle":337,"status":124,"phases":1022,"primaryCompletion":126,"completion":339,"start":340,"enrollment":341,"conditions":1023,"interventions":1024},[94],[343,344,345],[347,348,323,349],{"trials":1026,"activeCount":103},[],{"intervention":281,"totalTrials":132,"cells":1028},{"EARLY_PHASE1":1029,"PHASE1":1031,"PHASE2":1033,"PHASE3":1035,"PHASE4":1037,"NA":1043},{"trials":1030,"activeCount":103},[],{"trials":1032,"activeCount":103},[],{"trials":1034,"activeCount":103},[],{"trials":1036,"activeCount":103},[],{"trials":1038,"activeCount":132,"soonestReadout":272},[1039],{"nctId":269,"briefTitle":270,"status":169,"phases":1040,"primaryCompletion":272,"completion":273,"start":274,"enrollment":9,"conditions":1041,"interventions":1042},[94],[276,36,277,278,279],[281,228],{"trials":1044,"activeCount":103},[],{"intervention":1046,"totalTrials":132,"cells":1047},"transdermal nicotine replacement therapy",{"EARLY_PHASE1":1048,"PHASE1":1050,"PHASE2":1052,"PHASE3":1054,"PHASE4":1056,"NA":1068},{"trials":1049,"activeCount":103},[],{"trials":1051,"activeCount":103},[],{"trials":1053,"activeCount":103},[],{"trials":1055,"activeCount":103},[],{"trials":1057,"activeCount":132,"soonestReadout":1062},[1058],{"nctId":1059,"briefTitle":1060,"status":169,"phases":1061,"primaryCompletion":1062,"completion":1062,"start":1063,"enrollment":1064,"conditions":1065,"interventions":1067},"NCT07089901","Project DEDUCE: Digital Envirotyping to Develop Understanding of Cigarette Smoking and the Environment",[94],"2030-03-31","2026-05-06",600,[1066],"Smoking",[1046],{"trials":1069,"activeCount":103},[],{"intervention":1071,"totalTrials":132,"cells":1072},"Tirzepatide",{"EARLY_PHASE1":1073,"PHASE1":1075,"PHASE2":1077,"PHASE3":1079,"PHASE4":1081,"NA":1093},{"trials":1074,"activeCount":103},[],{"trials":1076,"activeCount":103},[],{"trials":1078,"activeCount":103},[],{"trials":1080,"activeCount":103},[],{"trials":1082,"activeCount":132,"soonestReadout":569},[1083],{"nctId":1084,"briefTitle":1085,"status":124,"phases":1086,"primaryCompletion":569,"completion":1087,"start":1088,"enrollment":9,"conditions":1089,"interventions":1091},"NCT07191873","Tirzepatide in Idiopathic Intracranial Hypertension Trial",[94],"2028-02","2026-02",[1090],"Idiopathic Intracranial Hypertension (IIH)",[1071,1092],"Tirzepatide Placebo",{"trials":1094,"activeCount":103},[],{"intervention":1092,"totalTrials":132,"cells":1096},{"EARLY_PHASE1":1097,"PHASE1":1099,"PHASE2":1101,"PHASE3":1103,"PHASE4":1105,"NA":1111},{"trials":1098,"activeCount":103},[],{"trials":1100,"activeCount":103},[],{"trials":1102,"activeCount":103},[],{"trials":1104,"activeCount":103},[],{"trials":1106,"activeCount":132,"soonestReadout":569},[1107],{"nctId":1084,"briefTitle":1085,"status":124,"phases":1108,"primaryCompletion":569,"completion":1087,"start":1088,"enrollment":9,"conditions":1109,"interventions":1110},[94],[1090],[1071,1092],{"trials":1112,"activeCount":103},[],{"intervention":1114,"totalTrials":132,"cells":1115},"Lenacapavir long-acting",{"EARLY_PHASE1":1116,"PHASE1":1118,"PHASE2":1120,"PHASE3":1122,"PHASE4":1124,"NA":1141},{"trials":1117,"activeCount":103},[],{"trials":1119,"activeCount":103},[],{"trials":1121,"activeCount":103},[],{"trials":1123,"activeCount":103},[],{"trials":1125,"activeCount":132,"soonestReadout":1130},[1126],{"nctId":1127,"briefTitle":1128,"status":169,"phases":1129,"primaryCompletion":1130,"completion":1131,"start":1132,"enrollment":1133,"conditions":1134,"interventions":1140},"NCT07218211","Enhancing PrEP Uptake and Retention Among Latine TGW and GBM in the South Using Long-Acting Injectable PrEP",[94],"2027-01-05","2028-01-05","2026-01-13",100,[1135,1136,1137,1138,1139],"HIV Prevention","HIV Pre-exposure Prophylaxis","HIV Prevention Program","HIV Prevention and Care","HIV Pre-exposure Prophylaxis Use",[1114],{"trials":1142,"activeCount":103},[],{"intervention":689,"totalTrials":1144,"cells":1145},8,{"EARLY_PHASE1":1146,"PHASE1":1148,"PHASE2":1150,"PHASE3":1188,"PHASE4":1190,"NA":1227},{"trials":1147,"activeCount":103},[],{"trials":1149,"activeCount":103},[],{"trials":1151,"activeCount":103},[1152,1164,1174],{"nctId":1153,"briefTitle":1154,"status":111,"phases":1155,"primaryCompletion":1156,"completion":1157,"start":1158,"enrollment":1159,"conditions":1160,"interventions":1162},"NCT03389620","Transforaminal Versus Lateralized Interlaminar Cervical Epidurals",[92],"2023-07-16","2023-09-16","2018-01-05",74,[1161],"Cervicogenic Upper Extremity Radiculopathy",[1163],"dexamethasone",{"nctId":1165,"briefTitle":1166,"status":155,"phases":1167,"primaryCompletion":1168,"completion":1168,"start":1169,"enrollment":1170,"conditions":1171,"interventions":1173},"NCT02154048","Analgesic Efficacy of Perineural Dexamethasone During Supraclavicular Block for Hand Surgery",[92],"2013-09","2012-04",5,[1172],"Surgery, Hand",[165,689],{"nctId":1175,"briefTitle":1176,"status":155,"phases":1177,"primaryCompletion":1178,"completion":1168,"start":1179,"enrollment":1180,"conditions":1181,"interventions":1183},"NCT00510887","Bortezomib (Velcade) With Standard Chemotherapy for Relapsed or Refractory Follicular Lymphoma",[92],"2012-11","2007-01",14,[1182],"Lymphoma, Follicular",[1184,1185,1186,1187,689],"Bortezomib","Rituximab","Fludarabine","Mitoxantrone",{"trials":1189,"activeCount":103},[],{"trials":1191,"activeCount":132,"soonestReadout":681},[1192,1196,1206,1216],{"nctId":678,"briefTitle":679,"status":124,"phases":1193,"primaryCompletion":681,"completion":682,"start":683,"enrollment":684,"conditions":1194,"interventions":1195},[94],[686,687],[665,689],{"nctId":1197,"briefTitle":1198,"status":111,"phases":1199,"primaryCompletion":1200,"completion":1201,"start":1202,"enrollment":16,"conditions":1203,"interventions":1205},"NCT01812057","Dexamethasone for Post-cesarean Delivery Pain",[94],"2016-05-27","2016-09-21","2012-12",[263,1204],"Postoperative Nausea and Vomiting",[689],{"nctId":1207,"briefTitle":1208,"status":155,"phases":1209,"primaryCompletion":1210,"completion":1210,"start":1211,"enrollment":1212,"conditions":1213,"interventions":1214},"NCT04541147","Opioid & Steroid Use Following Tonsillectomy in Pediatric Patients",[94],"2023-12-26","2021-04-14",24,[263],[689,1215],"Analgesics",{"nctId":1217,"briefTitle":1218,"status":111,"phases":1219,"primaryCompletion":1220,"completion":1221,"start":1222,"enrollment":1223,"conditions":1224,"interventions":1226},"NCT02271698","Dexamethasone and Pain Following Total Knee Arthroplasty",[94],"2016-01","2016-07","2014-12",45,[777,1225],"Chronic Pain",[689],{"trials":1228,"activeCount":103},[1229],{"nctId":1230,"briefTitle":1231,"status":428,"phases":1232,"primaryCompletion":1233,"completion":1233,"start":1234,"enrollment":103,"conditions":1235,"interventions":1237},"NCT01169415","Effects of Steroid Tapering on Functional Capacity and Neurocognition",[95],"2014-05","2010-06",[1236],"Glioblastoma Multiforme",[1238,689],"Dexamethasone acetate",{"intervention":1240,"totalTrials":229,"cells":1241},"Abatacept",{"EARLY_PHASE1":1242,"PHASE1":1254,"PHASE2":1256,"PHASE3":1258,"PHASE4":1281,"NA":1283},{"trials":1243,"activeCount":132,"soonestReadout":1248},[1244],{"nctId":1245,"briefTitle":1246,"status":169,"phases":1247,"primaryCompletion":1248,"completion":1249,"start":1250,"enrollment":206,"conditions":1251,"interventions":1253},"NCT06731504","HMCT\u002FCT2401: Abatacept GVHD Prophylaxis Following Omidubicel HCT",[90],"2027-12","2028-07","2025-11-12",[1252],"Hematologic Malignancy",[1240],{"trials":1255,"activeCount":103},[],{"trials":1257,"activeCount":103},[],{"trials":1259,"activeCount":132,"soonestReadout":630},[1260,1270],{"nctId":1261,"briefTitle":1262,"status":111,"phases":1263,"primaryCompletion":1264,"completion":1264,"start":1265,"enrollment":1266,"conditions":1267,"interventions":1269},"NCT03841357","Preventing Extension of Oligoarticular Juvenile Idiopathic Arthritis JIA (Limit-JIA)",[93],"2025-01-22","2019-10-29",121,[1268],"Juvenile Idiopathic Arthritis",[1240],{"nctId":1271,"briefTitle":1272,"status":169,"phases":1273,"primaryCompletion":630,"completion":630,"start":1274,"enrollment":1275,"conditions":1276,"interventions":1278},"NCT06654882","Trial of Sequential Medications AfteR TNFi Failure in Juvenile Idiopathic Arthritis",[93],"2026-01-09",400,[1277],"Polyarticular Course Juvenile Idiopathic Arthritis (JIA)",[1279,1240,393,1280],"TNFi (Tumor Necrosis Factor inhibitor) medication","Tofacitinib",{"trials":1282,"activeCount":103},[],{"trials":1284,"activeCount":103},[],{"intervention":393,"totalTrials":282,"cells":1286},{"EARLY_PHASE1":1287,"PHASE1":1289,"PHASE2":1291,"PHASE3":1293,"PHASE4":1299,"NA":1301},{"trials":1288,"activeCount":103},[],{"trials":1290,"activeCount":103},[],{"trials":1292,"activeCount":103},[],{"trials":1294,"activeCount":132,"soonestReadout":630},[1295],{"nctId":1271,"briefTitle":1272,"status":169,"phases":1296,"primaryCompletion":630,"completion":630,"start":1274,"enrollment":1275,"conditions":1297,"interventions":1298},[93],[1277],[1279,1240,393,1280],{"trials":1300,"activeCount":103},[],{"trials":1302,"activeCount":132,"soonestReadout":356},[1303],{"nctId":353,"briefTitle":354,"status":169,"phases":1304,"primaryCompletion":356,"completion":357,"start":358,"enrollment":359,"conditions":1305,"interventions":1306},[],[361,362],[364,365,366,367,368,369,370,371,372,373,374,375,376,377,378,379,380,381,382,383,384,385,386,387,388,389,390,391,392,393,394,395,396,397,398,399,400,323],{"intervention":1308,"totalTrials":132,"cells":1309},"Rosuvastatin 20 Mg Oral",{"EARLY_PHASE1":1310,"PHASE1":1312,"PHASE2":1314,"PHASE3":1316,"PHASE4":1331,"NA":1333},{"trials":1311,"activeCount":103},[],{"trials":1313,"activeCount":103},[],{"trials":1315,"activeCount":103},[],{"trials":1317,"activeCount":132,"soonestReadout":1322},[1318],{"nctId":1319,"briefTitle":1320,"status":124,"phases":1321,"primaryCompletion":1322,"completion":1322,"start":304,"enrollment":1323,"conditions":1324,"interventions":1329},"NCT07232069","PRE-EMPT: Prospective RandomizEd Evaluation and Management of Premature aTherosclerosis",[93],"2031-07",1500,[1325,1326,1327,1328],"Coronary Artery Disease Risk Factors Multiple","Coronary Artery Disease Progression","Prevention & Control","Premature Atherosclerosis",[1308,1330],"Colchicine 0.5 MG Oral Tablet Once Daily",{"trials":1332,"activeCount":103},[],{"trials":1334,"activeCount":103},[],{"intervention":1330,"totalTrials":132,"cells":1336},{"EARLY_PHASE1":1337,"PHASE1":1339,"PHASE2":1341,"PHASE3":1343,"PHASE4":1349,"NA":1351},{"trials":1338,"activeCount":103},[],{"trials":1340,"activeCount":103},[],{"trials":1342,"activeCount":103},[],{"trials":1344,"activeCount":132,"soonestReadout":1322},[1345],{"nctId":1319,"briefTitle":1320,"status":124,"phases":1346,"primaryCompletion":1322,"completion":1322,"start":304,"enrollment":1323,"conditions":1347,"interventions":1348},[93],[1325,1326,1327,1328],[1308,1330],{"trials":1350,"activeCount":103},[],{"trials":1352,"activeCount":103},[],{"intervention":1354,"totalTrials":132,"cells":1355},"Liposomal Amphotericin B",{"EARLY_PHASE1":1356,"PHASE1":1358,"PHASE2":1360,"PHASE3":1362,"PHASE4":1377,"NA":1379},{"trials":1357,"activeCount":103},[],{"trials":1359,"activeCount":103},[],{"trials":1361,"activeCount":103},[],{"trials":1363,"activeCount":132,"soonestReadout":1368},[1364],{"nctId":1365,"briefTitle":1366,"status":124,"phases":1367,"primaryCompletion":1368,"completion":1369,"start":304,"enrollment":1370,"conditions":1371,"interventions":1373},"NCT06525389","Liposomal Amphotericin B and Flucytosine Antifungal Strategy for Talaromycosis (LAmB-FAST)",[93],"2030-07-01","2031-07-01",428,[1372],"Talaromycosis",[1354,1374,1375,1376],"Flucytosine","Flucytosine (5FC) placebo pill","Deoxycholate Amphotericin B",{"trials":1378,"activeCount":103},[],{"trials":1380,"activeCount":103},[],{"intervention":1374,"totalTrials":132,"cells":1382},{"EARLY_PHASE1":1383,"PHASE1":1385,"PHASE2":1387,"PHASE3":1389,"PHASE4":1395,"NA":1397},{"trials":1384,"activeCount":103},[],{"trials":1386,"activeCount":103},[],{"trials":1388,"activeCount":103},[],{"trials":1390,"activeCount":132,"soonestReadout":1368},[1391],{"nctId":1365,"briefTitle":1366,"status":124,"phases":1392,"primaryCompletion":1368,"completion":1369,"start":304,"enrollment":1370,"conditions":1393,"interventions":1394},[93],[1372],[1354,1374,1375,1376],{"trials":1396,"activeCount":103},[],{"trials":1398,"activeCount":103},[],{"intervention":1375,"totalTrials":132,"cells":1400},{"EARLY_PHASE1":1401,"PHASE1":1403,"PHASE2":1405,"PHASE3":1407,"PHASE4":1413,"NA":1415},{"trials":1402,"activeCount":103},[],{"trials":1404,"activeCount":103},[],{"trials":1406,"activeCount":103},[],{"trials":1408,"activeCount":132,"soonestReadout":1368},[1409],{"nctId":1365,"briefTitle":1366,"status":124,"phases":1410,"primaryCompletion":1368,"completion":1369,"start":304,"enrollment":1370,"conditions":1411,"interventions":1412},[93],[1372],[1354,1374,1375,1376],{"trials":1414,"activeCount":103},[],{"trials":1416,"activeCount":103},[],{"intervention":1376,"totalTrials":132,"cells":1418},{"EARLY_PHASE1":1419,"PHASE1":1421,"PHASE2":1423,"PHASE3":1425,"PHASE4":1431,"NA":1433},{"trials":1420,"activeCount":103},[],{"trials":1422,"activeCount":103},[],{"trials":1424,"activeCount":103},[],{"trials":1426,"activeCount":132,"soonestReadout":1368},[1427],{"nctId":1365,"briefTitle":1366,"status":124,"phases":1428,"primaryCompletion":1368,"completion":1369,"start":304,"enrollment":1370,"conditions":1429,"interventions":1430},[93],[1372],[1354,1374,1375,1376],{"trials":1432,"activeCount":103},[],{"trials":1434,"activeCount":103},[],{"intervention":1436,"totalTrials":132,"cells":1437},"Phenobarbital",{"EARLY_PHASE1":1438,"PHASE1":1440,"PHASE2":1442,"PHASE3":1444,"PHASE4":1460,"NA":1462},{"trials":1439,"activeCount":103},[],{"trials":1441,"activeCount":103},[],{"trials":1443,"activeCount":103},[],{"trials":1445,"activeCount":132,"soonestReadout":1450},[1446],{"nctId":1447,"briefTitle":1448,"status":124,"phases":1449,"primaryCompletion":1450,"completion":1451,"start":340,"enrollment":1452,"conditions":1453,"interventions":1458},"NCT07548489","Phenobarbital for Agitated Delirium",[93],"2027-01","2027-07",150,[1454,1455,1456,1457],"Agitated Delirium","Delirium Confusional State","Delirium in the Intensive Care Unit","Hyperactive Delirium",[1436,1459],"Conventional therapy group",{"trials":1461,"activeCount":103},[],{"trials":1463,"activeCount":103},[],{"intervention":1459,"totalTrials":132,"cells":1465},{"EARLY_PHASE1":1466,"PHASE1":1468,"PHASE2":1470,"PHASE3":1472,"PHASE4":1478,"NA":1480},{"trials":1467,"activeCount":103},[],{"trials":1469,"activeCount":103},[],{"trials":1471,"activeCount":103},[],{"trials":1473,"activeCount":132,"soonestReadout":1450},[1474],{"nctId":1447,"briefTitle":1448,"status":124,"phases":1475,"primaryCompletion":1450,"completion":1451,"start":340,"enrollment":1452,"conditions":1476,"interventions":1477},[93],[1454,1455,1456,1457],[1436,1459],{"trials":1479,"activeCount":103},[],{"trials":1481,"activeCount":103},[],{"intervention":1279,"totalTrials":132,"cells":1483},{"EARLY_PHASE1":1484,"PHASE1":1486,"PHASE2":1488,"PHASE3":1490,"PHASE4":1496,"NA":1498},{"trials":1485,"activeCount":103},[],{"trials":1487,"activeCount":103},[],{"trials":1489,"activeCount":103},[],{"trials":1491,"activeCount":132,"soonestReadout":630},[1492],{"nctId":1271,"briefTitle":1272,"status":169,"phases":1493,"primaryCompletion":630,"completion":630,"start":1274,"enrollment":1275,"conditions":1494,"interventions":1495},[93],[1277],[1279,1240,393,1280],{"trials":1497,"activeCount":103},[],{"trials":1499,"activeCount":103},[],{"intervention":1280,"totalTrials":132,"cells":1501},{"EARLY_PHASE1":1502,"PHASE1":1504,"PHASE2":1506,"PHASE3":1508,"PHASE4":1514,"NA":1516},{"trials":1503,"activeCount":103},[],{"trials":1505,"activeCount":103},[],{"trials":1507,"activeCount":103},[],{"trials":1509,"activeCount":132,"soonestReadout":630},[1510],{"nctId":1271,"briefTitle":1272,"status":169,"phases":1511,"primaryCompletion":630,"completion":630,"start":1274,"enrollment":1275,"conditions":1512,"interventions":1513},[93],[1277],[1279,1240,393,1280],{"trials":1515,"activeCount":103},[],{"trials":1517,"activeCount":103},[],{"intervention":1519,"totalTrials":282,"cells":1520},"Memantine",{"EARLY_PHASE1":1521,"PHASE1":1523,"PHASE2":1525,"PHASE3":1536,"PHASE4":1538,"NA":1549},{"trials":1522,"activeCount":103},[],{"trials":1524,"activeCount":103},[],{"trials":1526,"activeCount":132,"soonestReadout":775},[1527],{"nctId":1528,"briefTitle":1529,"status":169,"phases":1530,"primaryCompletion":775,"completion":775,"start":1531,"enrollment":1223,"conditions":1532,"interventions":1534},"NCT06041789","Effect of Acetylcholinesterase Inhibitors on Bone Metabolism",[92],"2025-02-03",[1533],"Osteoporosis",[1535,1519],"Donepezil",{"trials":1537,"activeCount":103},[],{"trials":1539,"activeCount":103},[1540],{"nctId":1541,"briefTitle":1542,"status":155,"phases":1543,"primaryCompletion":1544,"completion":1544,"start":1545,"enrollment":1546,"conditions":1547,"interventions":1548},"NCT01032759","Memantine and Postoperative Pain",[94],"2015-01","2009-12",77,[36],[1519],{"trials":1550,"activeCount":103},[],{"intervention":73,"totalTrials":229,"cells":1552},{"EARLY_PHASE1":1553,"PHASE1":1555,"PHASE2":1557,"PHASE3":1583,"PHASE4":1596,"NA":1598},{"trials":1554,"activeCount":103},[],{"trials":1556,"activeCount":103},[],{"trials":1558,"activeCount":132,"soonestReadout":72},[1559,1572],{"nctId":70,"briefTitle":71,"status":540,"phases":1560,"primaryCompletion":72,"completion":1561,"start":1562,"enrollment":1563,"conditions":1564,"interventions":1568},[92],"2026-04-15","2024-08-12",361,[1565,1566,1567],"Long COVID","Long COVID-19","Hypersomnia",[73,1569,1570,1571],"Modafinil Placebo","Solriamfetol","Solriamfetol Placebo",{"nctId":1573,"briefTitle":1574,"status":111,"phases":1575,"primaryCompletion":1576,"completion":1576,"start":1577,"enrollment":1578,"conditions":1579,"interventions":1581},"NCT06404086","RECOVER-SLEEP: Platform Protocol",[92],"2025-12-31","2024-07-31",830,[1565,1566,1567,1580],"Sleep Disturbance",[73,1569,1570,1571,68,1582],"Melantonin Placebo",{"trials":1584,"activeCount":103},[1585],{"nctId":1586,"briefTitle":1587,"status":111,"phases":1588,"completion":1589,"start":1590,"enrollment":1591,"conditions":1592,"interventions":1594},"NCT00215176","Modafinil for Atypical Depression",[92,93],"2005-04","2003-02",65,[1593],"Atypical Depression",[1595],"modafinil",{"trials":1597,"activeCount":103},[],{"trials":1599,"activeCount":103},[],{"intervention":1601,"totalTrials":229,"cells":1602},"Oxygen",{"EARLY_PHASE1":1603,"PHASE1":1605,"PHASE2":1618,"PHASE3":1638,"PHASE4":1640,"NA":1642},{"trials":1604,"activeCount":103},[],{"trials":1606,"activeCount":103},[1607],{"nctId":1608,"briefTitle":1609,"status":111,"phases":1610,"primaryCompletion":1611,"completion":1611,"start":1612,"enrollment":34,"conditions":1613,"interventions":1615},"NCT02473354","Predictors of Opioid-Induced Respiratory Depression (OIRD)",[91],"2018-04-29","2015-04",[1614],"Respiratory Depression",[1616,1601,1617],"Remifentanil","Carbon dioxide",{"trials":1619,"activeCount":132,"soonestReadout":1633},[1620,1629],{"nctId":1621,"briefTitle":1622,"status":155,"phases":1623,"primaryCompletion":1624,"completion":1624,"start":1625,"enrollment":305,"conditions":1626,"interventions":1628},"NCT02356900","Hyperbaric VO2max Study",[92],"2016-05","2015-02",[1627],"Exercise Training",[1601],{"nctId":1630,"briefTitle":1631,"status":124,"phases":1632,"primaryCompletion":1633,"completion":1633,"start":304,"enrollment":206,"conditions":1634,"interventions":1636},"NCT06327373","A Feasibility Study of Supplemental Oxygen to Improve Pulmonary Hypertension in People With Intradialytic Hypoxemia",[91,92],"2027-06-30",[1635],"Pulmonary Hypertension",[1601,1637],"Room air",{"trials":1639,"activeCount":103},[],{"trials":1641,"activeCount":103},[],{"trials":1643,"activeCount":103},[],{"intervention":1645,"totalTrials":229,"cells":1646},"Atezolizumab",{"EARLY_PHASE1":1647,"PHASE1":1649,"PHASE2":1651,"PHASE3":1686,"PHASE4":1688,"NA":1690},{"trials":1648,"activeCount":103},[],{"trials":1650,"activeCount":103},[],{"trials":1652,"activeCount":132,"soonestReadout":1657},[1653,1662,1676],{"nctId":1654,"briefTitle":1655,"status":169,"phases":1656,"primaryCompletion":1657,"completion":1657,"start":1658,"enrollment":684,"conditions":1659,"interventions":1661},"NCT06069726","A Multicenter Trial to Identify Optimal Atezolizumab Biomarkers in the Setting of Recurrent Glioblastoma. The MOAB Trial",[92],"2028-01-01","2024-03-21",[1660],"Recurrent Glioblastoma",[1645],{"nctId":1663,"briefTitle":1664,"status":111,"phases":1665,"primaryCompletion":1666,"completion":1666,"start":1667,"enrollment":1668,"conditions":1669,"interventions":1672},"NCT03394885","Atezolizumab With Neoadjuvant Chemotherapy for Patients With Newly-Diagnosed Advanced-Stage Ovarian Cancer",[91,92],"2020-07-20","2018-06-19",18,[1670,1671],"Ovarian Cancer","Ovarian Neoplasms",[1645,1673,1674,1675],"Carboplatin","Paclitaxel","Bevacizumab",{"nctId":1677,"briefTitle":1678,"status":155,"phases":1679,"primaryCompletion":1680,"completion":1681,"start":1682,"enrollment":448,"conditions":1683,"interventions":1685},"NCT04099836","Atezolizumab and Bevacizumab in EGFR Mutant NSCLC in Patients With Progressive Disease After Receiving Osimertinib",[92],"2022-11-13","2023-06-15","2020-07-09",[1684],"Non Small Cell Lung Cancer",[1645,1675],{"trials":1687,"activeCount":103},[],{"trials":1689,"activeCount":103},[],{"trials":1691,"activeCount":103},[],{"intervention":68,"totalTrials":229,"cells":1693},{"EARLY_PHASE1":1694,"PHASE1":1696,"PHASE2":1698,"PHASE3":1723,"PHASE4":1725,"NA":1727},{"trials":1695,"activeCount":103},[],{"trials":1697,"activeCount":103},[],{"trials":1699,"activeCount":132,"soonestReadout":67},[1700,1713,1717],{"nctId":1701,"briefTitle":1702,"status":111,"phases":1703,"primaryCompletion":1704,"completion":1705,"start":1706,"enrollment":193,"conditions":1707,"interventions":1709},"NCT06429059","ROAR-DIGAP: A Widely Inclusive, Largely Virtual Pilot Trial Utilizing DIGAP (Deep Integrated Genomics Analysis Platform) To Personalize Treatments",[92],"2025-05-22","2025-06-24","2024-06-12",[1708],"Amyotrophic Lateral Sclerosis ALS",[1710,1711,68,1712],"Astaxanthin","Protandim","MitoQ",{"nctId":1573,"briefTitle":1574,"status":111,"phases":1714,"primaryCompletion":1576,"completion":1576,"start":1577,"enrollment":1578,"conditions":1715,"interventions":1716},[92],[1565,1566,1567,1580],[73,1569,1570,1571,68,1582],{"nctId":65,"briefTitle":66,"status":540,"phases":1718,"primaryCompletion":67,"completion":1719,"start":1577,"enrollment":1720,"conditions":1721,"interventions":1722},[92],"2026-04-03",470,[1565,1566,1580],[68,1582],{"trials":1724,"activeCount":103},[],{"trials":1726,"activeCount":103},[],{"trials":1728,"activeCount":103},[],{"intervention":1569,"totalTrials":282,"cells":1730},{"EARLY_PHASE1":1731,"PHASE1":1733,"PHASE2":1735,"PHASE3":1745,"PHASE4":1747,"NA":1749},{"trials":1732,"activeCount":103},[],{"trials":1734,"activeCount":103},[],{"trials":1736,"activeCount":132,"soonestReadout":72},[1737,1741],{"nctId":70,"briefTitle":71,"status":540,"phases":1738,"primaryCompletion":72,"completion":1561,"start":1562,"enrollment":1563,"conditions":1739,"interventions":1740},[92],[1565,1566,1567],[73,1569,1570,1571],{"nctId":1573,"briefTitle":1574,"status":111,"phases":1742,"primaryCompletion":1576,"completion":1576,"start":1577,"enrollment":1578,"conditions":1743,"interventions":1744},[92],[1565,1566,1567,1580],[73,1569,1570,1571,68,1582],{"trials":1746,"activeCount":103},[],{"trials":1748,"activeCount":103},[],{"trials":1750,"activeCount":103},[],{"intervention":1570,"totalTrials":282,"cells":1752},{"EARLY_PHASE1":1753,"PHASE1":1755,"PHASE2":1757,"PHASE3":1767,"PHASE4":1769,"NA":1771},{"trials":1754,"activeCount":103},[],{"trials":1756,"activeCount":103},[],{"trials":1758,"activeCount":132,"soonestReadout":72},[1759,1763],{"nctId":70,"briefTitle":71,"status":540,"phases":1760,"primaryCompletion":72,"completion":1561,"start":1562,"enrollment":1563,"conditions":1761,"interventions":1762},[92],[1565,1566,1567],[73,1569,1570,1571],{"nctId":1573,"briefTitle":1574,"status":111,"phases":1764,"primaryCompletion":1576,"completion":1576,"start":1577,"enrollment":1578,"conditions":1765,"interventions":1766},[92],[1565,1566,1567,1580],[73,1569,1570,1571,68,1582],{"trials":1768,"activeCount":103},[],{"trials":1770,"activeCount":103},[],{"trials":1772,"activeCount":103},[],{"intervention":1571,"totalTrials":282,"cells":1774},{"EARLY_PHASE1":1775,"PHASE1":1777,"PHASE2":1779,"PHASE3":1789,"PHASE4":1791,"NA":1793},{"trials":1776,"activeCount":103},[],{"trials":1778,"activeCount":103},[],{"trials":1780,"activeCount":132,"soonestReadout":72},[1781,1785],{"nctId":70,"briefTitle":71,"status":540,"phases":1782,"primaryCompletion":72,"completion":1561,"start":1562,"enrollment":1563,"conditions":1783,"interventions":1784},[92],[1565,1566,1567],[73,1569,1570,1571],{"nctId":1573,"briefTitle":1574,"status":111,"phases":1786,"primaryCompletion":1576,"completion":1576,"start":1577,"enrollment":1578,"conditions":1787,"interventions":1788},[92],[1565,1566,1567,1580],[73,1569,1570,1571,68,1582],{"trials":1790,"activeCount":103},[],{"trials":1792,"activeCount":103},[],{"trials":1794,"activeCount":103},[],{"intervention":1582,"totalTrials":282,"cells":1796},{"EARLY_PHASE1":1797,"PHASE1":1799,"PHASE2":1801,"PHASE3":1811,"PHASE4":1813,"NA":1815},{"trials":1798,"activeCount":103},[],{"trials":1800,"activeCount":103},[],{"trials":1802,"activeCount":132,"soonestReadout":67},[1803,1807],{"nctId":1573,"briefTitle":1574,"status":111,"phases":1804,"primaryCompletion":1576,"completion":1576,"start":1577,"enrollment":1578,"conditions":1805,"interventions":1806},[92],[1565,1566,1567,1580],[73,1569,1570,1571,68,1582],{"nctId":65,"briefTitle":66,"status":540,"phases":1808,"primaryCompletion":67,"completion":1719,"start":1577,"enrollment":1720,"conditions":1809,"interventions":1810},[92],[1565,1566,1580],[68,1582],{"trials":1812,"activeCount":103},[],{"trials":1814,"activeCount":103},[],{"trials":1816,"activeCount":103},[],{"intervention":1818,"totalTrials":132,"cells":1819},"Nivolumab",{"EARLY_PHASE1":1820,"PHASE1":1822,"PHASE2":1824,"PHASE3":1838,"PHASE4":1840,"NA":1842},{"trials":1821,"activeCount":103},[],{"trials":1823,"activeCount":103},[],{"trials":1825,"activeCount":132,"soonestReadout":259},[1826],{"nctId":1827,"briefTitle":1828,"status":169,"phases":1829,"primaryCompletion":259,"completion":1830,"start":1831,"enrollment":1832,"conditions":1833,"interventions":1835},"NCT06816927","Trial of Glioblastoma Immunotherapy Advancement With Nivolumab and Relatlimab",[92],"2031-06-01","2025-11-28",92,[1834],"Newly Diagnosed Glioblastoma",[1818,1836,1837],"Relatlimab","TMZ",{"trials":1839,"activeCount":103},[],{"trials":1841,"activeCount":103},[],{"trials":1843,"activeCount":103},[],{"intervention":1836,"totalTrials":132,"cells":1845},{"EARLY_PHASE1":1846,"PHASE1":1848,"PHASE2":1850,"PHASE3":1856,"PHASE4":1858,"NA":1860},{"trials":1847,"activeCount":103},[],{"trials":1849,"activeCount":103},[],{"trials":1851,"activeCount":132,"soonestReadout":259},[1852],{"nctId":1827,"briefTitle":1828,"status":169,"phases":1853,"primaryCompletion":259,"completion":1830,"start":1831,"enrollment":1832,"conditions":1854,"interventions":1855},[92],[1834],[1818,1836,1837],{"trials":1857,"activeCount":103},[],{"trials":1859,"activeCount":103},[],{"trials":1861,"activeCount":103},[],{"intervention":1837,"totalTrials":132,"cells":1863},{"EARLY_PHASE1":1864,"PHASE1":1866,"PHASE2":1868,"PHASE3":1874,"PHASE4":1876,"NA":1878},{"trials":1865,"activeCount":103},[],{"trials":1867,"activeCount":103},[],{"trials":1869,"activeCount":132,"soonestReadout":259},[1870],{"nctId":1827,"briefTitle":1828,"status":169,"phases":1871,"primaryCompletion":259,"completion":1830,"start":1831,"enrollment":1832,"conditions":1872,"interventions":1873},[92],[1834],[1818,1836,1837],{"trials":1875,"activeCount":103},[],{"trials":1877,"activeCount":103},[],{"trials":1879,"activeCount":103},[],{"intervention":1881,"totalTrials":132,"cells":1882},"Tc 99m tilmanocept",{"EARLY_PHASE1":1883,"PHASE1":1885,"PHASE2":1887,"PHASE3":1897,"PHASE4":1899,"NA":1901},{"trials":1884,"activeCount":103},[],{"trials":1886,"activeCount":103},[],{"trials":1888,"activeCount":132,"soonestReadout":856},[1889],{"nctId":1890,"briefTitle":1891,"status":169,"phases":1892,"primaryCompletion":856,"completion":654,"start":833,"enrollment":1893,"conditions":1894,"interventions":1896},"NCT07159074","Repurposing Tilmanocept for Cardiac Sarcoidosis",[92],15,[1895],"Cardiac Sarcoidosis",[1881,1881],{"trials":1898,"activeCount":103},[],{"trials":1900,"activeCount":103},[],{"trials":1902,"activeCount":103},[],{"intervention":48,"totalTrials":132,"cells":1904},{"EARLY_PHASE1":1905,"PHASE1":1907,"PHASE2":1909,"PHASE3":1918,"PHASE4":1920,"NA":1922},{"trials":1906,"activeCount":103},[],{"trials":1908,"activeCount":103},[],{"trials":1910,"activeCount":132,"soonestReadout":47},[1911],{"nctId":45,"briefTitle":46,"status":540,"phases":1912,"primaryCompletion":47,"completion":1913,"start":1914,"enrollment":9,"conditions":1915,"interventions":1917},[92],"2026-11-01","2023-05-16",[1916],"Non-small Cell Lung Cancer (NSCLC)",[48],{"trials":1919,"activeCount":103},[],{"trials":1921,"activeCount":103},[],{"trials":1923,"activeCount":103},[],{"intervention":88,"totalTrials":132,"cells":1925},{"EARLY_PHASE1":1926,"PHASE1":1928,"PHASE2":1930,"PHASE3":1938,"PHASE4":1940,"NA":1942},{"trials":1927,"activeCount":103},[],{"trials":1929,"activeCount":103},[],{"trials":1931,"activeCount":132,"soonestReadout":87},[1932],{"nctId":85,"briefTitle":86,"status":169,"phases":1933,"primaryCompletion":87,"completion":87,"start":1934,"enrollment":1546,"conditions":1935,"interventions":1937},[92],"2016-04",[1936],"Clostridium Difficile Colitis",[88],{"trials":1939,"activeCount":103},[],{"trials":1941,"activeCount":103},[],{"trials":1943,"activeCount":103},[],{"intervention":1945,"totalTrials":132,"cells":1946},"MTP-101C",{"EARLY_PHASE1":1947,"PHASE1":1949,"PHASE2":1951,"PHASE3":1960,"PHASE4":1962,"NA":1964},{"trials":1948,"activeCount":103},[],{"trials":1950,"activeCount":103},[],{"trials":1952,"activeCount":132,"soonestReadout":1913},[1953],{"nctId":1954,"briefTitle":1955,"status":169,"phases":1956,"primaryCompletion":1913,"completion":1913,"start":1957,"enrollment":544,"conditions":1958,"interventions":1959},"NCT07017946","Intestinal Microbiome Transplant in ALS",[91,92],"2026-01-27",[1708],[1945],{"trials":1961,"activeCount":103},[],{"trials":1963,"activeCount":103},[],{"trials":1965,"activeCount":103},[],{"intervention":131,"totalTrials":132,"cells":1967},{"EARLY_PHASE1":1968,"PHASE1":1970,"PHASE2":1972,"PHASE3":1978,"PHASE4":1980,"NA":1982},{"trials":1969,"activeCount":103},[],{"trials":1971,"activeCount":103},[],{"trials":1973,"activeCount":132,"soonestReadout":126},[1974],{"nctId":122,"briefTitle":123,"status":124,"phases":1975,"primaryCompletion":126,"completion":126,"start":77,"enrollment":127,"conditions":1976,"interventions":1977},[91,92],[129],[131,98],{"trials":1979,"activeCount":103},[],{"trials":1981,"activeCount":103},[],{"trials":1983,"activeCount":103},[],{"intervention":1985,"totalTrials":132,"cells":1986},"Ampicillin prescribed by provider per standard of care for evaluation of early onset sepsis",{"EARLY_PHASE1":1987,"PHASE1":1989,"PHASE2":1991,"PHASE3":2005,"PHASE4":2007,"NA":2009},{"trials":1988,"activeCount":103},[],{"trials":1990,"activeCount":103},[],{"trials":1992,"activeCount":132,"soonestReadout":1451},[1993],{"nctId":1994,"briefTitle":1995,"status":124,"phases":1996,"primaryCompletion":1451,"completion":1248,"start":1997,"enrollment":9,"conditions":1998,"interventions":2004},"NCT07610486","Optimizing PreTerm Infant Ampicillin Dosing",[91,92],"2026-07",[1999,2000,2001,2002,2003],"Early Onset Sepsis","Preterm Neonates","NICU","Ampicillin","Safety and Pharmacokinetics",[1985],{"trials":2006,"activeCount":103},[],{"trials":2008,"activeCount":103},[],{"trials":2010,"activeCount":103},[],{"intervention":43,"totalTrials":132,"cells":2012},{"EARLY_PHASE1":2013,"PHASE1":2015,"PHASE2":2017,"PHASE3":2027,"PHASE4":2029,"NA":2031},{"trials":2014,"activeCount":103},[],{"trials":2016,"activeCount":103},[],{"trials":2018,"activeCount":132,"soonestReadout":42},[2019],{"nctId":40,"briefTitle":41,"status":540,"phases":2020,"primaryCompletion":42,"completion":2021,"start":2022,"enrollment":2023,"conditions":2024,"interventions":2026},[92],"2029-09-30","2020-08-03",34,[2025],"Idiopathic Pulmonary Fibrosis",[43],{"trials":2028,"activeCount":103},[],{"trials":2030,"activeCount":103},[],{"trials":2032,"activeCount":103},[],{"intervention":1535,"totalTrials":132,"cells":2034},{"EARLY_PHASE1":2035,"PHASE1":2037,"PHASE2":2039,"PHASE3":2045,"PHASE4":2047,"NA":2049},{"trials":2036,"activeCount":103},[],{"trials":2038,"activeCount":103},[],{"trials":2040,"activeCount":132,"soonestReadout":775},[2041],{"nctId":1528,"briefTitle":1529,"status":169,"phases":2042,"primaryCompletion":775,"completion":775,"start":1531,"enrollment":1223,"conditions":2043,"interventions":2044},[92],[1533],[1535,1519],{"trials":2046,"activeCount":103},[],{"trials":2048,"activeCount":103},[],{"trials":2050,"activeCount":103},[],{"intervention":2052,"totalTrials":132,"cells":2053},"1.0% lidocaine with epinephrine",{"EARLY_PHASE1":2054,"PHASE1":2056,"PHASE2":2058,"PHASE3":2068,"PHASE4":2070,"NA":2072},{"trials":2055,"activeCount":103},[],{"trials":2057,"activeCount":103},[],{"trials":2059,"activeCount":132,"soonestReadout":2064},[2060],{"nctId":2061,"briefTitle":2062,"status":124,"phases":2063,"primaryCompletion":2064,"completion":630,"start":87,"enrollment":305,"conditions":2065,"interventions":2067},"NCT07068243","REctus Sheath Trial",[92],"2026-09",[777,2066],"Postoperative Pain, Acute",[2052],{"trials":2069,"activeCount":103},[],{"trials":2071,"activeCount":103},[],{"trials":2073,"activeCount":103},[],{"intervention":2075,"totalTrials":132,"cells":2076},"Sulindac 400 MG",{"EARLY_PHASE1":2077,"PHASE1":2079,"PHASE2":2081,"PHASE3":2094,"PHASE4":2096,"NA":2098},{"trials":2078,"activeCount":103},[],{"trials":2080,"activeCount":103},[],{"trials":2082,"activeCount":132,"soonestReadout":2087},[2083],{"nctId":2084,"briefTitle":2085,"status":540,"phases":2086,"primaryCompletion":2087,"completion":2088,"start":2089,"enrollment":1133,"conditions":2090,"interventions":2093},"NCT04207944","The Prevention of Progression to Pancreatic Cancer Trial (The 3P-C Trial)",[92],"2026-07-30","2026-10-31","2020-07-10",[2091,2092],"IPMN","IPMN, Pancreatic",[2075],{"trials":2095,"activeCount":103},[],{"trials":2097,"activeCount":103},[],{"trials":2099,"activeCount":103},[],{"intervention":83,"totalTrials":132,"cells":2101},{"EARLY_PHASE1":2102,"PHASE1":2104,"PHASE2":2106,"PHASE3":2117,"PHASE4":2119,"NA":2121},{"trials":2103,"activeCount":103},[],{"trials":2105,"activeCount":103},[],{"trials":2107,"activeCount":132,"soonestReadout":82},[2108],{"nctId":80,"briefTitle":81,"status":169,"phases":2109,"primaryCompletion":82,"completion":2110,"start":2111,"enrollment":2112,"conditions":2113,"interventions":2116},[92],"2027-12-31","2025-08-22",27,[2114,2115],"Multiple Myeloma in Relapse","Multiple Myeloma, Refractory",[83],{"trials":2118,"activeCount":103},[],{"trials":2120,"activeCount":103},[],{"trials":2122,"activeCount":103},[],{"intervention":2124,"totalTrials":132,"cells":2125},"montelukast 4 mg granule",{"EARLY_PHASE1":2126,"PHASE1":2128,"PHASE2":2130,"PHASE3":2144,"PHASE4":2146,"NA":2148},{"trials":2127,"activeCount":103},[],{"trials":2129,"activeCount":103},[],{"trials":2131,"activeCount":132,"soonestReadout":2136},[2132],{"nctId":2133,"briefTitle":2134,"status":169,"phases":2135,"primaryCompletion":2136,"completion":2137,"start":2138,"enrollment":2139,"conditions":2140,"interventions":2143},"NCT07101640","PK, Safety and Preliminary Efficacy Study of Montelukast in Critically Ill Infants With Developing Bronchopulmonary Dysplasia",[91,92],"2028-03-01","2028-06-30","2026-02-23",28,[2141,2142,452],"Bronchopulmonary Dysplasia (BPD)","Premature Births",[2124],{"trials":2145,"activeCount":103},[],{"trials":2147,"activeCount":103},[],{"trials":2149,"activeCount":103},[],{"intervention":2151,"totalTrials":132,"cells":2152},"FOLFOX",{"EARLY_PHASE1":2153,"PHASE1":2155,"PHASE2":2157,"PHASE3":2168,"PHASE4":2170,"NA":2172},{"trials":2154,"activeCount":103},[],{"trials":2156,"activeCount":103},[],{"trials":2158,"activeCount":132,"soonestReadout":2163},[2159],{"nctId":2160,"briefTitle":2161,"status":124,"phases":2162,"primaryCompletion":2163,"completion":2164,"start":683,"enrollment":9,"conditions":2165,"interventions":2167},"NCT07603375","Upfront Chemotherapy With Radiation Therapy (CRT) Followed by Chemotherapy in Localized Esophageal Adenocarcinoma",[92],"2029-08-01","2034-02",[2166],"Esophageal Adenocarcinoma",[2151],{"trials":2169,"activeCount":103},[],{"trials":2171,"activeCount":103},[],{"trials":2173,"activeCount":103},[],{"intervention":1637,"totalTrials":132,"cells":2175},{"EARLY_PHASE1":2176,"PHASE1":2178,"PHASE2":2180,"PHASE3":2186,"PHASE4":2188,"NA":2190},{"trials":2177,"activeCount":103},[],{"trials":2179,"activeCount":103},[],{"trials":2181,"activeCount":132,"soonestReadout":1633},[2182],{"nctId":1630,"briefTitle":1631,"status":124,"phases":2183,"primaryCompletion":1633,"completion":1633,"start":304,"enrollment":206,"conditions":2184,"interventions":2185},[91,92],[1635],[1601,1637],{"trials":2187,"activeCount":103},[],{"trials":2189,"activeCount":103},[],{"trials":2191,"activeCount":103},[],{"intervention":2193,"totalTrials":132,"cells":2194},"Asciminib and Trastuzumab",{"EARLY_PHASE1":2195,"PHASE1":2197,"PHASE2":2199,"PHASE3":2210,"PHASE4":2212,"NA":2214},{"trials":2196,"activeCount":103},[],{"trials":2198,"activeCount":103},[],{"trials":2200,"activeCount":132,"soonestReadout":2205},[2201],{"nctId":2202,"briefTitle":2203,"status":124,"phases":2204,"primaryCompletion":2205,"completion":2206,"start":1997,"enrollment":22,"conditions":2207,"interventions":2209},"NCT07136428","Asciminib in HER2+ Breast Cancer Brain Metastases",[91,92],"2030-11-01","2032-11-01",[2208],"HER2+ Metastatic Breast Cancer",[2193],{"trials":2211,"activeCount":103},[],{"trials":2213,"activeCount":103},[],{"trials":2215,"activeCount":103},[],{"intervention":2217,"totalTrials":132,"cells":2218},"Zuranolone",{"EARLY_PHASE1":2219,"PHASE1":2221,"PHASE2":2223,"PHASE3":2234,"PHASE4":2236,"NA":2238},{"trials":2220,"activeCount":103},[],{"trials":2222,"activeCount":103},[],{"trials":2224,"activeCount":132,"soonestReadout":831},[2225],{"nctId":2226,"briefTitle":2227,"status":169,"phases":2228,"primaryCompletion":831,"completion":831,"start":2229,"enrollment":2230,"conditions":2231,"interventions":2233},"NCT06759558","Allopregnanolone (Zuranolone) in Post-stroke Depression",[92],"2026-01-14",6,[2232],"Post Stroke Depression",[2217],{"trials":2235,"activeCount":103},[],{"trials":2237,"activeCount":103},[],{"trials":2239,"activeCount":103},[],{"intervention":53,"totalTrials":132,"cells":2241},{"EARLY_PHASE1":2242,"PHASE1":2244,"PHASE2":2246,"PHASE3":2255,"PHASE4":2257,"NA":2259},{"trials":2243,"activeCount":103},[],{"trials":2245,"activeCount":103},[],{"trials":2247,"activeCount":132,"soonestReadout":52},[2248],{"nctId":50,"briefTitle":51,"status":540,"phases":2249,"primaryCompletion":52,"completion":2250,"start":2251,"enrollment":9,"conditions":2252,"interventions":2254},[92],"2026-08-31","2022-07-19",[2025,2253],"Progressive Pulmonary Fibrosis",[53],{"trials":2256,"activeCount":103},[],{"trials":2258,"activeCount":103},[],{"trials":2260,"activeCount":103},[],{"intervention":2262,"totalTrials":132,"cells":2263},"Deferiprone pill",{"EARLY_PHASE1":2264,"PHASE1":2266,"PHASE2":2268,"PHASE3":2278,"PHASE4":2280,"NA":2282},{"trials":2265,"activeCount":103},[],{"trials":2267,"activeCount":103},[],{"trials":2269,"activeCount":132,"soonestReadout":831},[2270],{"nctId":2271,"briefTitle":2272,"status":169,"phases":2273,"primaryCompletion":831,"completion":654,"start":2274,"enrollment":243,"conditions":2275,"interventions":2277},"NCT03754725","Ferritin and Iron Burden in SAH sIRB",[91,92],"2020-10-01",[2276,659],"SAH",[2262],{"trials":2279,"activeCount":103},[],{"trials":2281,"activeCount":103},[],{"trials":2283,"activeCount":103},[],{"intervention":2285,"totalTrials":132,"cells":2286},"PK\u002FPD Model Based Dosing of Digoxin in Infants with Single Ventricle Heart Disease",{"EARLY_PHASE1":2287,"PHASE1":2289,"PHASE2":2291,"PHASE3":2305,"PHASE4":2307,"NA":2309},{"trials":2288,"activeCount":103},[],{"trials":2290,"activeCount":103},[],{"trials":2292,"activeCount":132,"soonestReadout":2297},[2293],{"nctId":2294,"briefTitle":2295,"status":169,"phases":2296,"primaryCompletion":2297,"completion":2297,"start":2298,"enrollment":544,"conditions":2299,"interventions":2304},"NCT06613477","PK\u002FPD of Digoxin in Infants With SVHD",[91,92],"2026-11-30","2024-10-10",[2300,2301,2302,2303],"Single-ventricle","Infant Conditions","Infant, Newborn, Diseases","Infant, Premature, Diseases",[2285],{"trials":2306,"activeCount":103},[],{"trials":2308,"activeCount":103},[],{"trials":2310,"activeCount":103},[],{"intervention":2312,"totalTrials":402,"cells":2313},"Metformin",{"EARLY_PHASE1":2314,"PHASE1":2316,"PHASE2":2328,"PHASE3":2330,"PHASE4":2332,"NA":2356},{"trials":2315,"activeCount":103},[],{"trials":2317,"activeCount":132,"soonestReadout":2322},[2318],{"nctId":2319,"briefTitle":2320,"status":124,"phases":2321,"primaryCompletion":2322,"completion":2323,"start":2324,"enrollment":1223,"conditions":2325,"interventions":2327},"NCT07275359","Investigating Senolytic Properties in Pulmonary Rehabilitation and Metformin in COPD Exacerbations",[91],"2028-09-01","2029-10-02","2026-09-01",[2326],"Chronic Obstructive Pulmonary Disease (COPD)",[2312],{"trials":2329,"activeCount":103},[],{"trials":2331,"activeCount":103},[],{"trials":2333,"activeCount":103},[2334,2346],{"nctId":2335,"briefTitle":2336,"status":428,"phases":2337,"primaryCompletion":1545,"completion":2338,"start":2339,"enrollment":103,"conditions":2340,"interventions":2343},"NCT00672464","Cardio Risk of Acute Schizophrenia Olanzapine Duke",[94],"2010-02","2008-04",[2341,2342],"Schizophrenia","Schizoaffective Disorder",[2344,2312,2345],"Olanzapine","Simvastatin",{"nctId":2347,"briefTitle":2348,"status":155,"phases":2349,"primaryCompletion":2350,"completion":2350,"start":2351,"enrollment":2023,"conditions":2352,"interventions":2354},"NCT02140788","Effects of Metformin and Fish Oil on Treatment With Clozapine",[94],"2013-02","2011-05",[2341,2353],"Schizo-affective Disorder",[2312,2355],"Fish Oil",{"trials":2357,"activeCount":132,"soonestReadout":356},[2358],{"nctId":353,"briefTitle":354,"status":169,"phases":2359,"primaryCompletion":356,"completion":357,"start":358,"enrollment":359,"conditions":2360,"interventions":2361},[],[361,362],[364,365,366,367,368,369,370,371,372,373,374,375,376,377,378,379,380,381,382,383,384,385,386,387,388,389,390,391,392,393,394,395,396,397,398,399,400,323],{"intervention":2363,"totalTrials":132,"cells":2364},"Tetanus Diptheria Vaccine",{"EARLY_PHASE1":2365,"PHASE1":2367,"PHASE2":2378,"PHASE3":2380,"PHASE4":2382,"NA":2384},{"trials":2366,"activeCount":103},[],{"trials":2368,"activeCount":132,"soonestReadout":2324},[2369],{"nctId":2370,"briefTitle":2371,"status":169,"phases":2372,"primaryCompletion":2324,"completion":2324,"start":2373,"enrollment":305,"conditions":2374,"interventions":2376},"NCT05077137","A Feasibility Study Utilizing Immune Recall to Increase Response to Checkpoint Therapy",[91],"2021-09-07",[2375],"Melanoma",[2363,2377],"Polio Boost Immunization",{"trials":2379,"activeCount":103},[],{"trials":2381,"activeCount":103},[],{"trials":2383,"activeCount":103},[],{"trials":2385,"activeCount":103},[],{"intervention":2377,"totalTrials":132,"cells":2387},{"EARLY_PHASE1":2388,"PHASE1":2390,"PHASE2":2396,"PHASE3":2398,"PHASE4":2400,"NA":2402},{"trials":2389,"activeCount":103},[],{"trials":2391,"activeCount":132,"soonestReadout":2324},[2392],{"nctId":2370,"briefTitle":2371,"status":169,"phases":2393,"primaryCompletion":2324,"completion":2324,"start":2373,"enrollment":305,"conditions":2394,"interventions":2395},[91],[2375],[2363,2377],{"trials":2397,"activeCount":103},[],{"trials":2399,"activeCount":103},[],{"trials":2401,"activeCount":103},[],{"trials":2403,"activeCount":103},[],{"intervention":2405,"totalTrials":132,"cells":2406},"Minoxidil",{"EARLY_PHASE1":2407,"PHASE1":2409,"PHASE2":2422,"PHASE3":2424,"PHASE4":2426,"NA":2428},{"trials":2408,"activeCount":103},[],{"trials":2410,"activeCount":132,"soonestReadout":314},[2411],{"nctId":2412,"briefTitle":2413,"status":169,"phases":2414,"primaryCompletion":314,"completion":314,"start":77,"enrollment":305,"conditions":2415,"interventions":2420},"NCT07264790","Assessment of Topical Minoxidil on Intraoperative Flap Perfusion and Cutaneous Flap Viability in Breast Recon",[91],[2416,2417,2418,2419],"Breast Reconstruction","Perfusion; Complications","High Risk for Breast Cancer","Genetic Predisposition",[2405,2421],"Hair mousse",{"trials":2423,"activeCount":103},[],{"trials":2425,"activeCount":103},[],{"trials":2427,"activeCount":103},[],{"trials":2429,"activeCount":103},[],{"intervention":2421,"totalTrials":132,"cells":2431},{"EARLY_PHASE1":2432,"PHASE1":2434,"PHASE2":2440,"PHASE3":2442,"PHASE4":2444,"NA":2446},{"trials":2433,"activeCount":103},[],{"trials":2435,"activeCount":132,"soonestReadout":314},[2436],{"nctId":2412,"briefTitle":2413,"status":169,"phases":2437,"primaryCompletion":314,"completion":314,"start":77,"enrollment":305,"conditions":2438,"interventions":2439},[91],[2416,2417,2418,2419],[2405,2421],{"trials":2441,"activeCount":103},[],{"trials":2443,"activeCount":103},[],{"trials":2445,"activeCount":103},[],{"trials":2447,"activeCount":103},[],{"intervention":2449,"totalTrials":132,"cells":2450},"β-hydroxy-β-methylbutyrate",{"EARLY_PHASE1":2451,"PHASE1":2453,"PHASE2":2461,"PHASE3":2463,"PHASE4":2465,"NA":2467},{"trials":2452,"activeCount":103},[],{"trials":2454,"activeCount":132,"soonestReadout":304},[2455],{"nctId":2456,"briefTitle":2457,"status":124,"phases":2458,"primaryCompletion":304,"completion":683,"start":304,"enrollment":1133,"conditions":2459,"interventions":2460},"NCT07589764","A Widely Inclusive, Hybrid-Decentralized Pilot Trial Utilizing β-hydroxy-β-methylbutyrate to Lower IGFBP7 Levels in People With ALS",[91],[1708],[2449],{"trials":2462,"activeCount":103},[],{"trials":2464,"activeCount":103},[],{"trials":2466,"activeCount":103},[],{"trials":2468,"activeCount":103},[],{"intervention":2470,"totalTrials":132,"cells":2471},"Lactobacillus crispatus probiotic",{"EARLY_PHASE1":2472,"PHASE1":2474,"PHASE2":2485,"PHASE3":2487,"PHASE4":2489,"NA":2491},{"trials":2473,"activeCount":103},[],{"trials":2475,"activeCount":132,"soonestReadout":2480},[2476],{"nctId":2477,"briefTitle":2478,"status":124,"phases":2479,"primaryCompletion":2480,"completion":1087,"start":340,"enrollment":2481,"conditions":2482,"interventions":2484},"NCT07234227","Genitourinary Study of Fostering Lactobacillus to Optimize the Microbiome in Women's Health (GUD-FLORA)",[91],"2027-11",156,[2483],"Recurrent UTIs",[2470],{"trials":2486,"activeCount":103},[],{"trials":2488,"activeCount":103},[],{"trials":2490,"activeCount":103},[],{"trials":2492,"activeCount":103},[],{"intervention":2494,"totalTrials":132,"cells":2495},"Secukinumab",{"EARLY_PHASE1":2496,"PHASE1":2498,"PHASE2":2509,"PHASE3":2511,"PHASE4":2513,"NA":2515},{"trials":2497,"activeCount":103},[],{"trials":2499,"activeCount":132,"soonestReadout":1633},[2500],{"nctId":2501,"briefTitle":2502,"status":124,"phases":2503,"primaryCompletion":1633,"completion":2504,"start":2505,"enrollment":402,"conditions":2506,"interventions":2508},"NCT07237594","IL-17 Blockade to Decrease irAEs (REPLAY)",[91],"2030-06-30","2026-05-01",[2507],"Metastatic Melanoma",[2494],{"trials":2510,"activeCount":103},[],{"trials":2512,"activeCount":103},[],{"trials":2514,"activeCount":103},[],{"trials":2516,"activeCount":103},[],{"intervention":2518,"totalTrials":132,"cells":2519},"CoV-RBD-scNP-001 and 3M-052-AF",{"EARLY_PHASE1":2520,"PHASE1":2522,"PHASE2":2536,"PHASE3":2538,"PHASE4":2540,"NA":2542},{"trials":2521,"activeCount":103},[],{"trials":2523,"activeCount":132,"soonestReadout":2528},[2524],{"nctId":2525,"briefTitle":2526,"status":540,"phases":2527,"primaryCompletion":2528,"completion":2528,"start":2529,"enrollment":2530,"conditions":2531,"interventions":2535},"NCT06950177","Pancoronavirus Vaccine Study in Healthy Adults",[91],"2026-08-30","2025-07-08",51,[2532,2533,2534],"COVID-19 Respiratory Infection","SARS CoV 2 Infection","COVID-19 Vaccine",[2518],{"trials":2537,"activeCount":103},[],{"trials":2539,"activeCount":103},[],{"trials":2541,"activeCount":103},[],{"trials":2543,"activeCount":103},[],{"intervention":2545,"totalTrials":132,"cells":2546},"MVR-C5252",{"EARLY_PHASE1":2547,"PHASE1":2549,"PHASE2":2560,"PHASE3":2562,"PHASE4":2564,"NA":2566},{"trials":2548,"activeCount":103},[],{"trials":2550,"activeCount":132,"soonestReadout":303},[2551],{"nctId":2552,"briefTitle":2553,"status":169,"phases":2554,"primaryCompletion":303,"completion":2555,"start":2556,"enrollment":2530,"conditions":2557,"interventions":2559},"NCT06126744","Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of the Oncolytic HSV1 MVR-C5252",[91],"2028-12-01","2024-06-11",[2558],"Recurrent High Grade Glioma",[2545],{"trials":2561,"activeCount":103},[],{"trials":2563,"activeCount":103},[],{"trials":2565,"activeCount":103},[],{"trials":2567,"activeCount":103},[],{"intervention":2569,"totalTrials":2570,"cells":2571},"temozolomide",13,{"EARLY_PHASE1":2572,"PHASE1":2587,"PHASE2":2616,"PHASE3":2703,"PHASE4":2705,"NA":2707},{"trials":2573,"activeCount":132,"soonestReadout":2578},[2574],{"nctId":2575,"briefTitle":2576,"status":540,"phases":2577,"primaryCompletion":2578,"completion":2579,"start":2580,"enrollment":206,"conditions":2581,"interventions":2584},"NCT05634707","Evaluation of Fluoxetine and Cytotoxic Lysosomal Stress in Glioma (FLIRT)",[90],"2026-12-05","2027-06-05","2023-08-05",[2582,2583],"Primary Brain Tumor","Brain Tumor, Recurrent",[2585,2586],"Fluoxetine","Temozolomide",{"trials":2588,"activeCount":103},[2589,2598,2607],{"nctId":2590,"briefTitle":2591,"status":111,"phases":2592,"primaryCompletion":2593,"completion":2593,"start":2594,"enrollment":1591,"conditions":2595,"interventions":2596},"NCT00354068","Imatinib Mesylate and Temozolomide in Treating Patients With Malignant Glioma",[91],"2008-11","2004-07",[33],[2597,2569],"imatinib mesylate",{"nctId":2599,"briefTitle":2600,"status":111,"phases":2601,"primaryCompletion":2602,"completion":2602,"start":2603,"conditions":2604,"interventions":2605},"NCT00005951","Irinotecan Plus Temozolomide in Treating Patients With Recurrent Primary Malignant Glioma",[91],"2006-04","2000-08",[33],[2606,2569],"irinotecan hydrochloride",{"nctId":2608,"briefTitle":2609,"status":111,"phases":2610,"primaryCompletion":2611,"completion":2611,"start":2612,"conditions":2613,"interventions":2614},"NCT00006474","Temozolomide and O6-benzylguanine in Treating Patients With Newly Diagnosed, Recurrent, or Progressive Anaplastic Glioma",[91],"2004-08","2001-03",[33],[2615,2569],"O6-benzylguanine",{"trials":2617,"activeCount":103},[2618,2625,2633,2646,2656,2668,2676,2683,2691],{"nctId":2619,"briefTitle":2620,"status":111,"phases":2621,"completion":2622,"start":2603,"conditions":2623,"interventions":2624},"NCT00005954","Temozolomide in Treating Patients With Brain Metastases",[92],"2003-06",[33],[2569],{"nctId":2626,"briefTitle":2627,"status":111,"phases":2628,"primaryCompletion":2629,"completion":2629,"start":2630,"enrollment":1133,"conditions":2631,"interventions":2632},"NCT00003466","Temozolomide in Treating Patients With Progressive Low-Grade Glioma",[92],"2005-07","1998-03",[33],[2569],{"nctId":2634,"briefTitle":2635,"status":111,"phases":2636,"primaryCompletion":2637,"completion":2637,"start":2638,"enrollment":2639,"conditions":2640,"interventions":2645},"NCT01740258","Bevacizumab Beyond Progression (BBP)",[92],"2019-11-14","2013-01",68,[2641,2642,2643,2644],"Malignant Glioma","Grade 4 Malignant Glioma","Glioblastoma","Gliosarcoma",[2586,1675],{"nctId":2647,"briefTitle":2648,"status":111,"phases":2649,"primaryCompletion":2650,"completion":2651,"start":2652,"enrollment":684,"conditions":2653,"interventions":2654},"NCT01004874","Avastin\u002FRadiation (XRT)\u002FTemozolomide (Temodar) Followed by Avastin\u002FTemodar\u002FTopotecan for Glioblastoma",[92],"2012-07","2021-11-02","2009-12-30",[2641,2643,2644],[1675,2586,2655],"Topotecan",{"nctId":2657,"briefTitle":2658,"status":111,"phases":2659,"primaryCompletion":2660,"completion":2661,"start":205,"enrollment":2662,"conditions":2663,"interventions":2665},"NCT00597402","Avastin in Combination With Radiation (XRT) & Temozolomide, Followed by Avastin, Temozolomide and Irinotecan for Glioblastoma (GBM) and Gliosarcomas",[92],"2011-08","2013-05",125,[2643,2644,2664],"Brain Tumor",[2666,2586,2667],"Avastin","Irinotecan",{"nctId":2669,"briefTitle":2670,"status":111,"phases":2671,"completion":2672,"start":2603,"conditions":2673,"interventions":2675},"NCT00005955","Temozolomide Followed by Radiation Therapy in Treating Children With Newly Diagnosed Malignant CNS Tumors",[92],"2002-09",[33,2674],"Neuroblastoma",[2569],{"nctId":2677,"briefTitle":2678,"status":111,"phases":2679,"completion":2680,"start":2630,"enrollment":9,"conditions":2681,"interventions":2682},"NCT00003465","Temozolomide in Treating Patients With Anaplastic Oligodendroglioma",[92],"2001-02",[33],[2569],{"nctId":2684,"briefTitle":2685,"status":111,"phases":2686,"completion":2687,"start":2688,"enrollment":193,"conditions":2689,"interventions":2690},"NCT00003464","Temozolomide in Treating Adults With Newly Diagnosed Primary Malignant Glioblastoma Multiforme",[92],"2003-08","1997-09",[33],[2569],{"nctId":2692,"briefTitle":2693,"status":111,"phases":2694,"primaryCompletion":2695,"completion":2695,"start":2603,"enrollment":34,"conditions":2696,"interventions":2701},"NCT00005952","Temozolomide Plus Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Malignant Glioma or Recurrent CNS or Other Solid Tumors",[91,92],"2005-11",[33,2697,2698,2699,2674,1670,546,2700],"Childhood Germ Cell Tumor","Head and Neck Cancer","Kidney Cancer","Testicular Germ Cell Tumor",[2702,2569],"filgrastim",{"trials":2704,"activeCount":103},[],{"trials":2706,"activeCount":103},[],{"trials":2708,"activeCount":103},[],{"intervention":2585,"totalTrials":132,"cells":2710},{"EARLY_PHASE1":2711,"PHASE1":2717,"PHASE2":2719,"PHASE3":2721,"PHASE4":2723,"NA":2725},{"trials":2712,"activeCount":132,"soonestReadout":2578},[2713],{"nctId":2575,"briefTitle":2576,"status":540,"phases":2714,"primaryCompletion":2578,"completion":2579,"start":2580,"enrollment":206,"conditions":2715,"interventions":2716},[90],[2582,2583],[2585,2586],{"trials":2718,"activeCount":103},[],{"trials":2720,"activeCount":103},[],{"trials":2722,"activeCount":103},[],{"trials":2724,"activeCount":103},[],{"trials":2726,"activeCount":103},[],{"intervention":2728,"totalTrials":132,"cells":2729},"Nicotine nasal spray 0.5 mg",{"EARLY_PHASE1":2730,"PHASE1":2742,"PHASE2":2744,"PHASE3":2746,"PHASE4":2748,"NA":2750},{"trials":2731,"activeCount":132,"soonestReadout":2736},[2732],{"nctId":2733,"briefTitle":2734,"status":169,"phases":2735,"primaryCompletion":2736,"completion":2736,"start":2737,"enrollment":1452,"conditions":2738,"interventions":2741},"NCT05665465","Neurobehavioral Mechanisms Linking Childhood Adversity to Increased Risk for Smoking",[90],"2027-05-31","2024-01-19",[2739,2740],"Adverse Childhood Experiences","Nicotine Dependence, Cigarettes",[2728],{"trials":2743,"activeCount":103},[],{"trials":2745,"activeCount":103},[],{"trials":2747,"activeCount":103},[],{"trials":2749,"activeCount":103},[],{"trials":2751,"activeCount":103},[],{"intervention":377,"totalTrials":282,"cells":2753},{"EARLY_PHASE1":2754,"PHASE1":2756,"PHASE2":2758,"PHASE3":2760,"PHASE4":2762,"NA":2764},{"trials":2755,"activeCount":103},[],{"trials":2757,"activeCount":103},[],{"trials":2759,"activeCount":103},[],{"trials":2761,"activeCount":103},[],{"trials":2763,"activeCount":103},[],{"trials":2765,"activeCount":282,"soonestReadout":2250},[2766,2779],{"nctId":2767,"briefTitle":2768,"status":169,"phases":2769,"primaryCompletion":2250,"completion":2250,"start":2770,"enrollment":2771,"conditions":2772,"interventions":2776},"NCT05761756","Oxygen Toxicity: Mechanisms in Humans",[95],"2023-11-28",62,[2773,2774,2775],"Oxygen Toxicity","Hypercapnia","Seizures",[2777,377,2778],"Caffeine","Carbon Dioxide",{"nctId":353,"briefTitle":354,"status":169,"phases":2780,"primaryCompletion":356,"completion":357,"start":358,"enrollment":359,"conditions":2781,"interventions":2782},[],[361,362],[364,365,366,367,368,369,370,371,372,373,374,375,376,377,378,379,380,381,382,383,384,385,386,387,388,389,390,391,392,393,394,395,396,397,398,399,400,323],{"intervention":396,"totalTrials":206,"cells":2784},{"EARLY_PHASE1":2785,"PHASE1":2787,"PHASE2":2789,"PHASE3":2791,"PHASE4":2829,"NA":2851},{"trials":2786,"activeCount":103},[],{"trials":2788,"activeCount":103},[],{"trials":2790,"activeCount":103},[],{"trials":2792,"activeCount":103},[2793,2807,2817],{"nctId":2794,"briefTitle":2795,"status":111,"phases":2796,"primaryCompletion":2797,"completion":2798,"start":2799,"enrollment":2800,"conditions":2801,"interventions":2803},"NCT01303861","Concurrent Bupropion \u002F Varenicline for Smoking Cessation",[93],"2013-03","2013-07","2011-03",702,[2802],"Nicotine Dependence",[2804,396,2805,2806],"Varenicline","Nicotine patches","Nicotine Inhaler",{"nctId":2808,"briefTitle":2809,"status":111,"phases":2810,"primaryCompletion":2811,"completion":2812,"start":2813,"enrollment":2814,"conditions":2815,"interventions":2816},"NCT01406223","Mechanistic Evaluations of Pre-Cessation Therapies for Smoking Cessation",[93],"2013-12","2014-06","2011-07",282,[2802],[2804,396,2805],{"nctId":2818,"briefTitle":2819,"status":155,"phases":2820,"primaryCompletion":2798,"completion":2798,"start":2821,"enrollment":2822,"conditions":2823,"interventions":2825},"NCT01560507","Tailored Smoking Cessation Treatment for LIVE FOR LIFE® Participants",[92,93],"2012-05",19,[2824,2802],"Cigarette Smoking",[2826,2827,2828],"varenicline","bupropion","nicotine patches",{"trials":2830,"activeCount":103},[2831,2841],{"nctId":2832,"briefTitle":2833,"status":111,"phases":2834,"primaryCompletion":2835,"completion":2835,"start":2836,"enrollment":1223,"conditions":2837,"interventions":2840},"NCT02995915","Mobile Contingency Management for Concurrent Abstinence From Alcohol and Smoking",[94],"2020-03-02","2016-11",[2838,2839],"Smoking Cessation","Alcohol Drinking",[396],{"nctId":2842,"briefTitle":2843,"status":111,"phases":2844,"primaryCompletion":2845,"completion":2845,"start":2846,"enrollment":2847,"conditions":2848,"interventions":2849},"NCT02420015","Mobile Health Technology to Enhance Abstinence in Smokers With Schizophrenia",[94],"2019-01-24","2017-03-27",35,[2341,2824],[2850,396],"Nicotine replacement therapy",{"trials":2852,"activeCount":132,"soonestReadout":356},[2853,2862,2866,2874,2886],{"nctId":2854,"briefTitle":2855,"status":111,"phases":2856,"primaryCompletion":2857,"completion":2857,"start":2811,"enrollment":1893,"conditions":2858,"interventions":2860},"NCT01990079","Use of Technological Advances to Prevent Smoking Relapse Among Smokers With PTSD",[95],"2015-08",[2859,1066],"PTSD",[396,2861],"nicotine replacement therapy",{"nctId":353,"briefTitle":354,"status":169,"phases":2863,"primaryCompletion":356,"completion":357,"start":358,"enrollment":359,"conditions":2864,"interventions":2865},[],[361,362],[364,365,366,367,368,369,370,371,372,373,374,375,376,377,378,379,380,381,382,383,384,385,386,387,388,389,390,391,392,393,394,395,396,397,398,399,400,323],{"nctId":2867,"briefTitle":2868,"status":111,"phases":2869,"primaryCompletion":2870,"completion":2870,"start":2638,"enrollment":305,"conditions":2871,"interventions":2873},"NCT01789710","Contingency Management for Smoking Cessation in Homeless Smokers",[95],"2014-09",[1066,2872],"Homeless Persons",[396,2850],{"nctId":2875,"briefTitle":2876,"status":111,"phases":2877,"primaryCompletion":2878,"completion":2878,"start":2879,"enrollment":448,"conditions":2880,"interventions":2882},"NCT02869451","Mobile Contingency Management for Marijuana and Tobacco Cessation",[95],"2017-05-17","2016-08",[2824,2881],"Marijuana Abuse",[2827,2883,2884,2885],"transdermal nicotine patch","Nicotine polacrilex","nicotine lozenge",{"nctId":2887,"briefTitle":2888,"status":111,"phases":2889,"primaryCompletion":2890,"completion":2890,"start":2891,"enrollment":160,"conditions":2892,"interventions":2893},"NCT02873754","Smoking Treatment and Exercise Program for Underserved Populations (STEP UP)",[95],"2017-07","2017-01",[1066],[396,2894,2884,2895],"Transdermal nicotine patch","Nicotine lozenge",{"intervention":2897,"totalTrials":99,"cells":2898},"Sertraline",{"EARLY_PHASE1":2899,"PHASE1":2901,"PHASE2":2903,"PHASE3":2915,"PHASE4":2968,"NA":2970},{"trials":2900,"activeCount":103},[],{"trials":2902,"activeCount":103},[],{"trials":2904,"activeCount":103},[2905],{"nctId":2906,"briefTitle":2907,"status":111,"phases":2908,"primaryCompletion":2909,"completion":204,"start":2910,"enrollment":2530,"conditions":2911,"interventions":2913},"NCT00215150","Geodon for the Treatment of Refractory Social Anxiety Disorder",[92],"2008-12","2004-11",[2912],"Social Anxiety Disorder",[2914,2897],"Ziprasidone",{"trials":2916,"activeCount":103},[2917,2929,2939,2948,2959],{"nctId":2918,"briefTitle":2919,"status":111,"phases":2920,"primaryCompletion":2921,"completion":2922,"start":2923,"enrollment":2924,"conditions":2925,"interventions":2928},"NCT00078286","Antidepressant Medication Treatment for Depression in Individuals With Chronic Heart Failure",[92,93],"2008-03","2008-09","2003-11",469,[2926,2927,30],"Heart Failure, Congestive","Chronic Heart Failure",[2897],{"nctId":2930,"briefTitle":2931,"status":111,"phases":2932,"primaryCompletion":2813,"completion":2933,"start":2934,"enrollment":2935,"conditions":2936,"interventions":2938},"NCT00302068","Exercise to Treat Depression in Individuals With Coronary Heart Disease",[93],"2011-12","2006-07",101,[30,2937],"Heart Diseases",[2897],{"nctId":2940,"briefTitle":2941,"status":155,"phases":2942,"primaryCompletion":2943,"completion":2339,"start":2695,"enrollment":2944,"conditions":2945,"interventions":2947},"NCT00299611","Augmentation Study of Levetiracetam in Obsessive Compulsive Disorder",[92,93],"2007-12",12,[2946],"Obsessive-Compulsive Disorder",[2897,399],{"nctId":2949,"briefTitle":2950,"status":111,"phases":2951,"primaryCompletion":2952,"completion":2952,"start":2953,"enrollment":2954,"conditions":2955,"interventions":2957},"NCT00340379","Ziprasidone vs. Sertraline\u002FHaloperidol in Psychotic Depression",[92,93],"2005-08","2003-04",72,[2956],"Affective Disorders",[2914,2897,2958],"Haloperidol",{"nctId":2960,"briefTitle":2961,"status":111,"phases":2962,"completion":2963,"start":2964,"enrollment":2965,"conditions":2966,"interventions":2967},"NCT00331305","Exercise Training Versus Drug Therapy for Treating Depression in Older Adults",[93],"2007-05","1999-08",457,[30],[2897],{"trials":2969,"activeCount":103},[],{"trials":2971,"activeCount":132,"soonestReadout":356},[2972,2976,2985],{"nctId":353,"briefTitle":354,"status":169,"phases":2973,"primaryCompletion":356,"completion":357,"start":358,"enrollment":359,"conditions":2974,"interventions":2975},[],[361,362],[364,365,366,367,368,369,370,371,372,373,374,375,376,377,378,379,380,381,382,383,384,385,386,387,388,389,390,391,392,393,394,395,396,397,398,399,400,323],{"nctId":2977,"briefTitle":2978,"status":111,"phases":2979,"primaryCompletion":2980,"completion":2980,"start":2981,"enrollment":2982,"conditions":2983,"interventions":2984},"NCT00339066","Effect of Brain Lesion Severity on Treatment Response in Late-Life Depression",[95],"2006-03","2001-08",131,[30],[2897],{"nctId":2986,"briefTitle":2987,"status":155,"phases":2988,"primaryCompletion":2989,"completion":2989,"start":2879,"enrollment":2570,"conditions":2990,"interventions":2995},"NCT02813447","Safety of Anti-Depressant for Chronic Obstructive Pulmonary Disease (SAD-COPD)",[95],"2019-02-20",[2991,2992,30,2993,2994],"COPD","Anxiety","Stress","Interstitial Lung Disease",[2897],{"intervention":165,"totalTrials":1144,"cells":2997},{"EARLY_PHASE1":2998,"PHASE1":3000,"PHASE2":3002,"PHASE3":3008,"PHASE4":3010,"NA":3058},{"trials":2999,"activeCount":103},[],{"trials":3001,"activeCount":103},[],{"trials":3003,"activeCount":103},[3004],{"nctId":1165,"briefTitle":1166,"status":155,"phases":3005,"primaryCompletion":1168,"completion":1168,"start":1169,"enrollment":1170,"conditions":3006,"interventions":3007},[92],[1172],[165,689],{"trials":3009,"activeCount":103},[],{"trials":3011,"activeCount":103},[3012,3016,3023,3027,3037,3047],{"nctId":153,"briefTitle":154,"status":155,"phases":3013,"primaryCompletion":157,"completion":158,"start":159,"enrollment":160,"conditions":3014,"interventions":3015},[94],[162,163,36],[165,98],{"nctId":3017,"briefTitle":3018,"status":428,"phases":3019,"primaryCompletion":3020,"completion":3020,"start":3020,"enrollment":103,"conditions":3021,"interventions":3022},"NCT02946268","Optimal Volume, Rate, and Interval of Bolus Nerve Catheters for Shoulder Surgery",[94],"2017-02-21",[36],[165],{"nctId":188,"briefTitle":189,"status":111,"phases":3024,"primaryCompletion":191,"completion":192,"start":143,"enrollment":193,"conditions":3025,"interventions":3026},[94],[195,196,197,36,198],[165,98],{"nctId":3028,"briefTitle":3029,"status":111,"phases":3030,"primaryCompletion":3031,"completion":3031,"start":3032,"enrollment":3033,"conditions":3034,"interventions":3036},"NCT02949271","Comparison of PIEB vs CEI for Labor Analgesia",[94],"2017-11-01","2016-11-08",179,[3035],"Labor Pain",[165,437],{"nctId":3038,"briefTitle":3039,"status":111,"phases":3040,"primaryCompletion":3041,"completion":3042,"start":2836,"enrollment":3043,"conditions":3044,"interventions":3045},"NCT02829944","Impact of Local Anesthetic Wound Infiltration on Postoperative Pain Following Cesarean Delivery",[94],"2019-03","2019-09",84,[36],[165,3046],"Ketorolac",{"nctId":3048,"briefTitle":3049,"status":155,"phases":3050,"primaryCompletion":3051,"completion":3052,"start":3053,"enrollment":2944,"conditions":3054,"interventions":3056},"NCT03695172","Comparison of TAP, Anterior QL, or ESP Block for Elective Cesarean Section",[94],"2021-03-18","2021-03-20","2019-09-12",[263,3055],"Cesarean Section",[165,3057],"QL block",{"trials":3059,"activeCount":132,"soonestReadout":2250},[3060],{"nctId":3061,"briefTitle":3062,"status":169,"phases":3063,"primaryCompletion":2250,"completion":2250,"start":3064,"enrollment":9,"conditions":3065,"interventions":3076},"NCT04209504","Evaluating Hemidiaphragmatic Paralysis With Prolonged Neural Blockade From an Interscalene Brachial Plexus Block",[],"2021-10-12",[3066,3067,3068,3069,3070,3071,3072,3073,3074,3075],"Shoulder Surgery","Shoulder Pain","Shoulder Injuries","Shoulder Arthritis","Shoulder Disease","Rotator Cuff Tears","Rotator Cuff Injuries","Rotator Cuff Arthropathy of Left Shoulder","Rotator Cuff Arthropathy of Right Shoulder","Rotator Cuff Repair",[165,3077],"Bupivacaine",{"intervention":3079,"totalTrials":448,"cells":3080},"Escitalopram",{"EARLY_PHASE1":3081,"PHASE1":3083,"PHASE2":3085,"PHASE3":3097,"PHASE4":3116,"NA":3137},{"trials":3082,"activeCount":103},[],{"trials":3084,"activeCount":103},[],{"trials":3086,"activeCount":103},[3087],{"nctId":3088,"briefTitle":3089,"status":111,"phases":3090,"primaryCompletion":3091,"completion":3092,"start":3093,"enrollment":1180,"conditions":3094,"interventions":3096},"NCT00215137","Pilot Study to Evaluate Escitalopram in Obsessive-compulsive Disorder",[92],"2009-01","2009-03","2004-10",[3095],"OCD",[371],{"trials":3098,"activeCount":103},[3099,3109],{"nctId":3100,"briefTitle":3101,"status":111,"phases":3102,"primaryCompletion":3103,"completion":3104,"start":3105,"enrollment":34,"conditions":3106,"interventions":3108},"NCT00887679","Treatment Effects of Escitalopram (Lexapro®) on Generalized Anxiety Disorder in Patients With HIV and AIDS",[93],"2009-09","2010-09","2009-05",[3107,343],"Anxiety Disorders",[3079],{"nctId":3110,"briefTitle":3111,"status":111,"phases":3112,"primaryCompletion":2963,"completion":2963,"start":3113,"enrollment":1893,"conditions":3114,"interventions":3115},"NCT00610506","Escitalopram (Lexapro®) In Patients With Major Depression With Atypical Features",[93],"2005-10",[1593],[3079],{"trials":3117,"activeCount":103},[3118,3127],{"nctId":3119,"briefTitle":3120,"status":155,"phases":3121,"primaryCompletion":3122,"completion":3122,"start":3123,"enrollment":1170,"conditions":3124,"interventions":3126},"NCT01797380","A Trial Examining the Efficacy of Escitalopram Oxalate Upon Depressive Symptoms and Fatigue in HIV Seropositive Women",[94],"2009-04","2008-01",[30,3125],"HIV",[3079],{"nctId":3128,"briefTitle":3129,"status":111,"phases":3130,"primaryCompletion":3131,"completion":3131,"start":3132,"enrollment":3133,"conditions":3134,"interventions":3136},"NCT00574847","Responses of Myocardial Ischemia to Escitalopram Treatment",[94],"2011-11","2006-09",127,[3135],"Myocardial Ischemia",[3079],{"trials":3138,"activeCount":132,"soonestReadout":356},[3139,3148],{"nctId":3140,"briefTitle":3141,"status":111,"phases":3142,"primaryCompletion":3143,"completion":2813,"start":3144,"enrollment":127,"conditions":3145,"interventions":3147},"NCT00636649","Escitalopram Treatment of Night Eating Syndrome",[95],"2010-08","2008-10",[3146],"Night Eating Syndrome",[3079],{"nctId":353,"briefTitle":354,"status":169,"phases":3149,"primaryCompletion":356,"completion":357,"start":358,"enrollment":359,"conditions":3150,"interventions":3151},[],[361,362],[364,365,366,367,368,369,370,371,372,373,374,375,376,377,378,379,380,381,382,383,384,385,386,387,388,389,390,391,392,393,394,395,396,397,398,399,400,323],{"intervention":399,"totalTrials":1170,"cells":3153},{"EARLY_PHASE1":3154,"PHASE1":3156,"PHASE2":3158,"PHASE3":3183,"PHASE4":3200,"NA":3202},{"trials":3155,"activeCount":103},[],{"trials":3157,"activeCount":103},[],{"trials":3159,"activeCount":103},[3160,3171],{"nctId":3161,"briefTitle":3162,"status":155,"phases":3163,"primaryCompletion":3164,"completion":3164,"start":3165,"enrollment":402,"conditions":3166,"interventions":3169},"NCT03436433","Seizure Prophylaxis in Patients With Glioma or Brain Metastasis",[92],"2020-12-04","2019-01-31",[3167,3168,2664],"Glioma","Glioma of Brain",[3170,399],"Lacosamide",{"nctId":3172,"briefTitle":3173,"status":111,"phases":3174,"primaryCompletion":2943,"completion":3175,"start":3176,"enrollment":544,"conditions":3177,"interventions":3182},"NCT00324454","Levetiracetam for Cramps, Spasticity and Neuroprotection in Motor Neuron Disease",[92],"2008-06","2006-05",[3178,3179,3180,3181],"Motor Neuron Disease","Amyotrophic Lateral Sclerosis","Primary Lateral Sclerosis","Progressive Muscular Atrophy",[399],{"trials":3184,"activeCount":103},[3185,3196],{"nctId":3186,"briefTitle":3187,"status":111,"phases":3188,"primaryCompletion":3189,"completion":2921,"start":2695,"enrollment":3190,"conditions":3191,"interventions":3193},"NCT00413296","Levetiracetam in Post-Traumatic Stress Disorder",[92,93],"2007-09",16,[3192],"Post-Traumatic Stress Disorder",[3194,3195],"levetiracetam","Levetriracetam",{"nctId":2940,"briefTitle":2941,"status":155,"phases":3197,"primaryCompletion":2943,"completion":2339,"start":2695,"enrollment":2944,"conditions":3198,"interventions":3199},[92,93],[2946],[2897,399],{"trials":3201,"activeCount":103},[],{"trials":3203,"activeCount":132,"soonestReadout":356},[3204],{"nctId":353,"briefTitle":354,"status":169,"phases":3205,"primaryCompletion":356,"completion":357,"start":358,"enrollment":359,"conditions":3206,"interventions":3207},[],[361,362],[364,365,366,367,368,369,370,371,372,373,374,375,376,377,378,379,380,381,382,383,384,385,386,387,388,389,390,391,392,393,394,395,396,397,398,399,400,323],{"intervention":3209,"totalTrials":1170,"cells":3210},"hydroxyurea",{"EARLY_PHASE1":3211,"PHASE1":3213,"PHASE2":3222,"PHASE3":3240,"PHASE4":3242,"NA":3244},{"trials":3212,"activeCount":103},[],{"trials":3214,"activeCount":103},[3215],{"nctId":3216,"briefTitle":3217,"status":111,"phases":3218,"primaryCompletion":3091,"start":2629,"enrollment":31,"conditions":3219,"interventions":3220},"NCT00387933","Imatinib Mesylate, Vatalanib, and Hydroxyurea in Treating Patients With Recurrent or Relapsed Malignant Glioma",[91],[33],[3209,2597,3221],"vatalanib",{"trials":3223,"activeCount":103},[3224,3231],{"nctId":3225,"briefTitle":3226,"status":111,"phases":3227,"completion":2980,"start":2953,"enrollment":193,"conditions":3228,"interventions":3230},"NCT00402480","Hydroxyurea to Prevent Stroke in Children With Sickle Cell Anemia and Elevated TCD Flow Velocity",[92],[3229],"Stroke",[384],{"nctId":3232,"briefTitle":3233,"status":111,"phases":3234,"primaryCompletion":3092,"completion":3235,"start":3236,"enrollment":3237,"conditions":3238,"interventions":3239},"NCT00354913","Imatinib Mesylate and Hydroxyurea in Treating Patients With Recurrent or Progressive Meningioma",[92],"2010-10","2005-05",21,[2643,2644],[3209,2597],{"trials":3241,"activeCount":103},[],{"trials":3243,"activeCount":103},[],{"trials":3245,"activeCount":132,"soonestReadout":356},[3246,3250],{"nctId":353,"briefTitle":354,"status":169,"phases":3247,"primaryCompletion":356,"completion":357,"start":358,"enrollment":359,"conditions":3248,"interventions":3249},[],[361,362],[364,365,366,367,368,369,370,371,372,373,374,375,376,377,378,379,380,381,382,383,384,385,386,387,388,389,390,391,392,393,394,395,396,397,398,399,400,323],{"nctId":3251,"briefTitle":3252,"status":111,"phases":3253,"completion":3254,"start":3255,"enrollment":1180,"conditions":3256,"interventions":3258},"NCT00519701","Hydroxyurea in Young Children With Sickle Cell Anemia",[95],"2007-02","2002-04",[3257],"Sickle Cell Anemia",[3209],{"intervention":3260,"totalTrials":229,"cells":3261},"Ondansetron",{"EARLY_PHASE1":3262,"PHASE1":3264,"PHASE2":3266,"PHASE3":3286,"PHASE4":3288,"NA":3290},{"trials":3263,"activeCount":103},[],{"trials":3265,"activeCount":103},[],{"trials":3267,"activeCount":103},[3268,3275],{"nctId":3269,"briefTitle":3270,"status":428,"phases":3271,"primaryCompletion":2870,"enrollment":103,"conditions":3272,"interventions":3273},"NCT01952886","Patient Satisfaction, Efficacy and Compliance of Antiemetic Patch vs Pill in Malignant Glioma Patients",[92],[2641],[3274,3260],"Granisetron",{"nctId":3276,"briefTitle":3277,"status":111,"phases":3278,"primaryCompletion":3279,"completion":3280,"start":3281,"enrollment":19,"conditions":3282,"interventions":3284},"NCT02991456","Rolapitant as an Antiemetic in Malignant Glioma Patients Receiving Radiotherapy and Temozolomide",[92],"2022-05-09","2022-06-20","2017-10-09",[3283],"Chemo-radiation Induced Nausea and Vomiting",[3285,3260],"Rolapitant",{"trials":3287,"activeCount":103},[],{"trials":3289,"activeCount":103},[],{"trials":3291,"activeCount":132,"soonestReadout":356},[3292],{"nctId":353,"briefTitle":354,"status":169,"phases":3293,"primaryCompletion":356,"completion":357,"start":358,"enrollment":359,"conditions":3294,"interventions":3295},[],[361,362],[364,365,366,367,368,369,370,371,372,373,374,375,376,377,378,379,380,381,382,383,384,385,386,387,388,389,390,391,392,393,394,395,396,397,398,399,400,323],{"intervention":3077,"totalTrials":229,"cells":3297},{"EARLY_PHASE1":3298,"PHASE1":3300,"PHASE2":3302,"PHASE3":3304,"PHASE4":3306,"NA":3330},{"trials":3299,"activeCount":103},[],{"trials":3301,"activeCount":103},[],{"trials":3303,"activeCount":103},[],{"trials":3305,"activeCount":103},[],{"trials":3307,"activeCount":103},[3308,3319],{"nctId":3309,"briefTitle":3310,"status":111,"phases":3311,"primaryCompletion":3312,"completion":3312,"start":3313,"enrollment":1223,"conditions":3314,"interventions":3318},"NCT03781388","ED90 for Hyperbaric Bupivacaine in Super Obese Parturients",[94],"2022-12-06","2019-05-01",[3315,3316,3317],"Obesity, Morbid","Spinal Anesthesia","Cesarean Delivery",[3077],{"nctId":3320,"briefTitle":3321,"status":111,"phases":3322,"primaryCompletion":3323,"completion":3323,"start":3324,"enrollment":1452,"conditions":3325,"interventions":3327},"NCT05664958","ESP Block for Post Cesarean Analgesia",[94],"2023-11-09","2023-04-17",[3326],"Cesarean Section Complications",[3328,3329],"bupivacaine liposome injectable suspension","bupivacaine",{"trials":3331,"activeCount":132,"soonestReadout":2250},[3332],{"nctId":3061,"briefTitle":3062,"status":169,"phases":3333,"primaryCompletion":2250,"completion":2250,"start":3064,"enrollment":9,"conditions":3334,"interventions":3335},[],[3066,3067,3068,3069,3070,3071,3072,3073,3074,3075],[165,3077],{"intervention":382,"totalTrials":282,"cells":3337},{"EARLY_PHASE1":3338,"PHASE1":3340,"PHASE2":3342,"PHASE3":3355,"PHASE4":3357,"NA":3359},{"trials":3339,"activeCount":103},[],{"trials":3341,"activeCount":103},[],{"trials":3343,"activeCount":103},[3344],{"nctId":3345,"briefTitle":3346,"status":111,"phases":3347,"primaryCompletion":3348,"completion":3349,"start":2879,"enrollment":3350,"conditions":3351,"interventions":3354},"NCT02725710","Gabapentin as an Adjunct to Perioperative Pain Management Regimens for Uterine Aspiration",[92],"2018-06-13","2018-06-14",96,[3352,3353],"Other Abortion","Spontaneous Abortion",[382],{"trials":3356,"activeCount":103},[],{"trials":3358,"activeCount":103},[],{"trials":3360,"activeCount":132,"soonestReadout":356},[3361],{"nctId":353,"briefTitle":354,"status":169,"phases":3362,"primaryCompletion":356,"completion":357,"start":358,"enrollment":359,"conditions":3363,"interventions":3364},[],[361,362],[364,365,366,367,368,369,370,371,372,373,374,375,376,377,378,379,380,381,382,383,384,385,386,387,388,389,390,391,392,393,394,395,396,397,398,399,400,323],{"intervention":385,"totalTrials":282,"cells":3366},{"EARLY_PHASE1":3367,"PHASE1":3369,"PHASE2":3379,"PHASE3":3381,"PHASE4":3383,"NA":3385},{"trials":3368,"activeCount":103},[],{"trials":3370,"activeCount":103},[3371],{"nctId":3372,"briefTitle":3373,"status":428,"phases":3374,"primaryCompletion":3375,"completion":3375,"start":3376,"enrollment":103,"conditions":3377,"interventions":3378},"NCT02483871","Dose Optimization of Rosuvastatin in Early Stage and Metastatic Estrogen Receptor Positive Breast Cancer Patients on Endocrine Therapy",[91],"2017-05-10","2015-10",[18],[385],{"trials":3380,"activeCount":103},[],{"trials":3382,"activeCount":103},[],{"trials":3384,"activeCount":103},[],{"trials":3386,"activeCount":132,"soonestReadout":356},[3387],{"nctId":353,"briefTitle":354,"status":169,"phases":3388,"primaryCompletion":356,"completion":357,"start":358,"enrollment":359,"conditions":3389,"interventions":3390},[],[361,362],[364,365,366,367,368,369,370,371,372,373,374,375,376,377,378,379,380,381,382,383,384,385,386,387,388,389,390,391,392,393,394,395,396,397,398,399,400,323],{"intervention":381,"totalTrials":282,"cells":3392},{"EARLY_PHASE1":3393,"PHASE1":3395,"PHASE2":3397,"PHASE3":3399,"PHASE4":3411,"NA":3413},{"trials":3394,"activeCount":103},[],{"trials":3396,"activeCount":103},[],{"trials":3398,"activeCount":103},[],{"trials":3400,"activeCount":103},[3401],{"nctId":3402,"briefTitle":3403,"status":111,"phases":3404,"primaryCompletion":3405,"completion":3405,"start":3406,"enrollment":3407,"conditions":3408,"interventions":3409},"NCT03296813","TRANSFORM-HF: ToRsemide compArisoN With furoSemide FORManagement of Heart Failure",[93],"2022-07-29","2018-07-11",2973,[21],[3410,381],"Torsemide",{"trials":3412,"activeCount":103},[],{"trials":3414,"activeCount":132,"soonestReadout":356},[3415],{"nctId":353,"briefTitle":354,"status":169,"phases":3416,"primaryCompletion":356,"completion":357,"start":358,"enrollment":359,"conditions":3417,"interventions":3418},[],[361,362],[364,365,366,367,368,369,370,371,372,373,374,375,376,377,378,379,380,381,382,383,384,385,386,387,388,389,390,391,392,393,394,395,396,397,398,399,400,323],{"intervention":3420,"totalTrials":282,"cells":3421},"Blood draw",{"EARLY_PHASE1":3422,"PHASE1":3424,"PHASE2":3426,"PHASE3":3428,"PHASE4":3430,"NA":3432},{"trials":3423,"activeCount":103},[],{"trials":3425,"activeCount":103},[],{"trials":3427,"activeCount":103},[],{"trials":3429,"activeCount":103},[],{"trials":3431,"activeCount":103},[],{"trials":3433,"activeCount":132,"soonestReadout":1913},[3434,3443],{"nctId":3435,"briefTitle":3436,"status":111,"phases":3437,"primaryCompletion":3438,"completion":3438,"start":3439,"enrollment":1893,"conditions":3440,"interventions":3442},"NCT02132182","Monocyte Phenotypic and Functional Differences",[],"2017-03-23","2014-10",[3441],"Osteosarcoma",[3420],{"nctId":3444,"briefTitle":3445,"status":169,"phases":3446,"primaryCompletion":1913,"completion":1913,"start":3447,"enrollment":193,"conditions":3448,"interventions":3449},"NCT05397132","Mechanisms of Disease R\u002FR in CAR-T for Hematologic Malignancies",[],"2022-05-27",[1252],[3420],{"intervention":1617,"totalTrials":282,"cells":3451},{"EARLY_PHASE1":3452,"PHASE1":3454,"PHASE2":3460,"PHASE3":3462,"PHASE4":3464,"NA":3466},{"trials":3453,"activeCount":103},[],{"trials":3455,"activeCount":103},[3456],{"nctId":1608,"briefTitle":1609,"status":111,"phases":3457,"primaryCompletion":1611,"completion":1611,"start":1612,"enrollment":34,"conditions":3458,"interventions":3459},[91],[1614],[1616,1601,1617],{"trials":3461,"activeCount":103},[],{"trials":3463,"activeCount":103},[],{"trials":3465,"activeCount":103},[],{"trials":3467,"activeCount":132,"soonestReadout":2250},[3468],{"nctId":2767,"briefTitle":2768,"status":169,"phases":3469,"primaryCompletion":2250,"completion":2250,"start":2770,"enrollment":2771,"conditions":3470,"interventions":3471},[95],[2773,2774,2775],[2777,377,2778],{"intervention":397,"totalTrials":282,"cells":3473},{"EARLY_PHASE1":3474,"PHASE1":3476,"PHASE2":3478,"PHASE3":3490,"PHASE4":3492,"NA":3494},{"trials":3475,"activeCount":103},[],{"trials":3477,"activeCount":103},[],{"trials":3479,"activeCount":103},[3480],{"nctId":3481,"briefTitle":3482,"status":111,"phases":3483,"primaryCompletion":3484,"completion":3485,"start":3486,"enrollment":1668,"conditions":3487,"interventions":3489},"NCT00331799","Pilot Study of Duloxetine in Psychological Resilience",[92],"2008-05","2008-07","2007-04",[3488],"Major Depressive Disorder",[397],{"trials":3491,"activeCount":103},[],{"trials":3493,"activeCount":103},[],{"trials":3495,"activeCount":132,"soonestReadout":356},[3496],{"nctId":353,"briefTitle":354,"status":169,"phases":3497,"primaryCompletion":356,"completion":357,"start":358,"enrollment":359,"conditions":3498,"interventions":3499},[],[361,362],[364,365,366,367,368,369,370,371,372,373,374,375,376,377,378,379,380,381,382,383,384,385,386,387,388,389,390,391,392,393,394,395,396,397,398,399,400,323],{"intervention":3501,"totalTrials":282,"cells":3502},"Biomarker studies",{"EARLY_PHASE1":3503,"PHASE1":3505,"PHASE2":3507,"PHASE3":3509,"PHASE4":3511,"NA":3513},{"trials":3504,"activeCount":103},[],{"trials":3506,"activeCount":103},[],{"trials":3508,"activeCount":103},[],{"trials":3510,"activeCount":103},[],{"trials":3512,"activeCount":103},[],{"trials":3514,"activeCount":132,"soonestReadout":630},[3515,3524],{"nctId":3516,"briefTitle":3517,"status":540,"phases":3518,"primaryCompletion":630,"completion":630,"start":3519,"enrollment":3520,"conditions":3521,"interventions":3523},"NCT01708408","The MURDOCK Study Registry and Biorepository Horizon 1.5",[],"2009-02",50000,[3522,632],"Chronic Disease",[3501],{"nctId":3525,"briefTitle":3526,"status":111,"phases":3527,"primaryCompletion":3528,"completion":3528,"start":2821,"enrollment":3529,"conditions":3530,"interventions":3535},"NCT01720472","Implementing a Physical and Cognitive Performance Assessment Cohort in the MURDOCK Study Community Registry and Biorepository",[],"2018-08-28",1000,[3531,3532,3533,3534],"Aging","Physical Functioning","Cognitive Functioning","Fitness",[3501],{"intervention":2777,"totalTrials":282,"cells":3537},{"EARLY_PHASE1":3538,"PHASE1":3540,"PHASE2":3542,"PHASE3":3544,"PHASE4":3546,"NA":3548},{"trials":3539,"activeCount":103},[],{"trials":3541,"activeCount":103},[],{"trials":3543,"activeCount":103},[],{"trials":3545,"activeCount":103},[],{"trials":3547,"activeCount":103},[],{"trials":3549,"activeCount":132,"soonestReadout":2250},[3550,3554],{"nctId":2767,"briefTitle":2768,"status":169,"phases":3551,"primaryCompletion":2250,"completion":2250,"start":2770,"enrollment":2771,"conditions":3552,"interventions":3553},[95],[2773,2774,2775],[2777,377,2778],{"nctId":3555,"briefTitle":3556,"status":111,"phases":3557,"primaryCompletion":3558,"completion":3558,"start":1222,"enrollment":193,"conditions":3559,"interventions":3562},"NCT02293824","Effect of Feedings on Caffeine in Premature Infants",[],"2017-06-30",[3560,3561,2777],"Apnea of Prematurity","Premature Newborn",[2777],{"intervention":3564,"totalTrials":282,"cells":3565},"valganciclovir",{"EARLY_PHASE1":3566,"PHASE1":3568,"PHASE2":3570,"PHASE3":3572,"PHASE4":3583,"NA":3585},{"trials":3567,"activeCount":103},[],{"trials":3569,"activeCount":103},[],{"trials":3571,"activeCount":103},[],{"trials":3573,"activeCount":103},[3574],{"nctId":3575,"briefTitle":3576,"status":111,"phases":3577,"primaryCompletion":2339,"completion":2909,"start":3578,"enrollment":3579,"conditions":3580,"interventions":3582},"NCT00227370","Comparison of Oral Valganciclovir and Placebo for the Prevention of Cytomegalovirus (CMV) After Lung Transplantation",[93],"2003-07",136,[3581],"Cytomegalovirus Infections",[3564],{"trials":3584,"activeCount":103},[],{"trials":3586,"activeCount":132,"soonestReadout":356},[3587],{"nctId":353,"briefTitle":354,"status":169,"phases":3588,"primaryCompletion":356,"completion":357,"start":358,"enrollment":359,"conditions":3589,"interventions":3590},[],[361,362],[364,365,366,367,368,369,370,371,372,373,374,375,376,377,378,379,380,381,382,383,384,385,386,387,388,389,390,391,392,393,394,395,396,397,398,399,400,323],{"intervention":392,"totalTrials":282,"cells":3592},{"EARLY_PHASE1":3593,"PHASE1":3595,"PHASE2":3597,"PHASE3":3607,"PHASE4":3609,"NA":3611},{"trials":3594,"activeCount":103},[],{"trials":3596,"activeCount":103},[],{"trials":3598,"activeCount":103},[3599],{"nctId":3600,"briefTitle":3601,"status":111,"phases":3602,"primaryCompletion":3603,"completion":3603,"start":2980,"enrollment":206,"conditions":3604,"interventions":3606},"NCT00332254","Study to Prevent Cartilage Damage Following Acute Knee Injury.",[91,92],"2007-06",[3605],"Knee Injury",[392],{"trials":3608,"activeCount":103},[],{"trials":3610,"activeCount":103},[],{"trials":3612,"activeCount":132,"soonestReadout":356},[3613],{"nctId":353,"briefTitle":354,"status":169,"phases":3614,"primaryCompletion":356,"completion":357,"start":358,"enrollment":359,"conditions":3615,"interventions":3616},[],[361,362],[364,365,366,367,368,369,370,371,372,373,374,375,376,377,378,379,380,381,382,383,384,385,386,387,388,389,390,391,392,393,394,395,396,397,398,399,400,323],{"intervention":370,"totalTrials":282,"cells":3618},{"EARLY_PHASE1":3619,"PHASE1":3621,"PHASE2":3623,"PHASE3":3637,"PHASE4":3639,"NA":3641},{"trials":3620,"activeCount":103},[],{"trials":3622,"activeCount":103},[],{"trials":3624,"activeCount":103},[3625],{"nctId":3626,"briefTitle":3627,"status":155,"phases":3628,"primaryCompletion":3629,"completion":3630,"start":3631,"enrollment":160,"conditions":3632,"interventions":3634},"NCT04335552","Pragmatic Factorial Trial of Hydroxychloroquine, Azithromycin, or Both for Treatment of Severe SARS-CoV-2 Infection",[92],"2020-06-17","2020-06-26","2020-04-17",[3633],"SARS-CoV-2",[3635,3636],"Hydroxychloroquine","Azithromycin",{"trials":3638,"activeCount":103},[],{"trials":3640,"activeCount":103},[],{"trials":3642,"activeCount":132,"soonestReadout":356},[3643],{"nctId":353,"briefTitle":354,"status":169,"phases":3644,"primaryCompletion":356,"completion":357,"start":358,"enrollment":359,"conditions":3645,"interventions":3646},[],[361,362],[364,365,366,367,368,369,370,371,372,373,374,375,376,377,378,379,380,381,382,383,384,385,386,387,388,389,390,391,392,393,394,395,396,397,398,399,400,323],{"intervention":78,"totalTrials":132,"cells":3648},{"EARLY_PHASE1":3649,"PHASE1":3651,"PHASE2":3653,"PHASE3":3655,"PHASE4":3657,"NA":3659},{"trials":3650,"activeCount":103},[],{"trials":3652,"activeCount":103},[],{"trials":3654,"activeCount":103},[],{"trials":3656,"activeCount":103},[],{"trials":3658,"activeCount":103},[],{"trials":3660,"activeCount":132,"soonestReadout":77},[3661],{"nctId":75,"briefTitle":76,"status":169,"phases":3662,"primaryCompletion":77,"completion":340,"start":3663,"enrollment":544,"conditions":3664,"interventions":3666},[95],"2024-08-21",[3665],"Bacterial Colonization",[78,3667],"Chlorhexidine baths",{"intervention":3667,"totalTrials":132,"cells":3669},{"EARLY_PHASE1":3670,"PHASE1":3672,"PHASE2":3674,"PHASE3":3676,"PHASE4":3678,"NA":3680},{"trials":3671,"activeCount":103},[],{"trials":3673,"activeCount":103},[],{"trials":3675,"activeCount":103},[],{"trials":3677,"activeCount":103},[],{"trials":3679,"activeCount":103},[],{"trials":3681,"activeCount":132,"soonestReadout":77},[3682],{"nctId":75,"briefTitle":76,"status":169,"phases":3683,"primaryCompletion":77,"completion":340,"start":3663,"enrollment":544,"conditions":3684,"interventions":3685},[95],[3665],[78,3667],{"intervention":3687,"totalTrials":132,"cells":3688},"The OPTIC study is collecting PK data on children prescribed understudied drugs of interest per standard of care.",{"EARLY_PHASE1":3689,"PHASE1":3691,"PHASE2":3693,"PHASE3":3695,"PHASE4":3697,"NA":3699},{"trials":3690,"activeCount":103},[],{"trials":3692,"activeCount":103},[],{"trials":3694,"activeCount":103},[],{"trials":3696,"activeCount":103},[],{"trials":3698,"activeCount":103},[],{"trials":3700,"activeCount":132,"soonestReadout":3705},[3701],{"nctId":3702,"briefTitle":3703,"status":169,"phases":3704,"primaryCompletion":3705,"completion":3706,"start":3707,"enrollment":3708,"conditions":3709,"interventions":3713},"NCT05055830","Opportunistic PK\u002FPD Trial in Critically Ill Children (OPTIC)",[],"2027-10-30","2028-10-30","2021-10-05",2000,[3710,3711,3712],"Cardiac Disease","Critically Ill","Children, Adult",[3687],{"intervention":3715,"totalTrials":132,"cells":3716},"The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:",{"EARLY_PHASE1":3717,"PHASE1":3719,"PHASE2":3721,"PHASE3":3723,"PHASE4":3725,"NA":3727},{"trials":3718,"activeCount":103},[],{"trials":3720,"activeCount":103},[],{"trials":3722,"activeCount":103},[],{"trials":3724,"activeCount":103},[],{"trials":3726,"activeCount":103},[],{"trials":3728,"activeCount":132,"soonestReadout":3733},[3729],{"nctId":3730,"briefTitle":3731,"status":169,"phases":3732,"primaryCompletion":3733,"completion":1451,"start":3734,"enrollment":3735,"conditions":3736,"interventions":3759},"NCT04278404","Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)",[],"2027-03","2020-03-05",5000,[3737,3738,3739,27,36,3740,3741,3742,3743,21,3744,3745,3746,3747,3748,3749,3750,3751,3752,3753,3754,3755,3756,3757,3758],"Coronavirus Infection (COVID-19)","Pulmonary Arterial Hypertension","Urinary Tract Infections in Children","Hyperphosphatemia","Primary Hyperaldosteronism","Edema","Hypokalemia","Hemophilia","Menorrhagia","Insomnia","Pneumonia","Skin Infection","Arrythmia","Asthma in Children","Bronchopulmonary Dysplasia","Adrenal Insufficiency","Fibrinolysis; Hemorrhage","Attention Deficit Hyperactivity Disorder","Multisystem Inflammatory Syndrome in Children (MIS-C)","Kawasaki Disease","Coagulation Disorder","Down Syndrome",[3715],{"intervention":3761,"totalTrials":132,"cells":3762},"Standard of care drug",{"EARLY_PHASE1":3763,"PHASE1":3765,"PHASE2":3767,"PHASE3":3769,"PHASE4":3771,"NA":3773},{"trials":3764,"activeCount":103},[],{"trials":3766,"activeCount":103},[],{"trials":3768,"activeCount":103},[],{"trials":3770,"activeCount":103},[],{"trials":3772,"activeCount":103},[],{"trials":3774,"activeCount":132,"soonestReadout":3779},[3775],{"nctId":3776,"briefTitle":3777,"status":169,"phases":3778,"primaryCompletion":3779,"completion":3779,"start":3780,"enrollment":3781,"conditions":3782,"interventions":3784},"NCT03481881","Pharmacokinetics of Drugs Administered to Children",[],"2033-08-14","2013-08-14",200,[3783],"Pediatric ALL",[3761],{"intervention":364,"totalTrials":132,"cells":3786},{"EARLY_PHASE1":3787,"PHASE1":3789,"PHASE2":3791,"PHASE3":3793,"PHASE4":3795,"NA":3797},{"trials":3788,"activeCount":103},[],{"trials":3790,"activeCount":103},[],{"trials":3792,"activeCount":103},[],{"trials":3794,"activeCount":103},[],{"trials":3796,"activeCount":103},[],{"trials":3798,"activeCount":132,"soonestReadout":356},[3799],{"nctId":353,"briefTitle":354,"status":169,"phases":3800,"primaryCompletion":356,"completion":357,"start":358,"enrollment":359,"conditions":3801,"interventions":3802},[],[361,362],[364,365,366,367,368,369,370,371,372,373,374,375,376,377,378,379,380,381,382,383,384,385,386,387,388,389,390,391,392,393,394,395,396,397,398,399,400,323],{"intervention":365,"totalTrials":132,"cells":3804},{"EARLY_PHASE1":3805,"PHASE1":3807,"PHASE2":3809,"PHASE3":3811,"PHASE4":3813,"NA":3815},{"trials":3806,"activeCount":103},[],{"trials":3808,"activeCount":103},[],{"trials":3810,"activeCount":103},[],{"trials":3812,"activeCount":103},[],{"trials":3814,"activeCount":103},[],{"trials":3816,"activeCount":132,"soonestReadout":356},[3817],{"nctId":353,"briefTitle":354,"status":169,"phases":3818,"primaryCompletion":356,"completion":357,"start":358,"enrollment":359,"conditions":3819,"interventions":3820},[],[361,362],[364,365,366,367,368,369,370,371,372,373,374,375,376,377,378,379,380,381,382,383,384,385,386,387,388,389,390,391,392,393,394,395,396,397,398,399,400,323],{"intervention":367,"totalTrials":132,"cells":3822},{"EARLY_PHASE1":3823,"PHASE1":3825,"PHASE2":3827,"PHASE3":3829,"PHASE4":3831,"NA":3833},{"trials":3824,"activeCount":103},[],{"trials":3826,"activeCount":103},[],{"trials":3828,"activeCount":103},[],{"trials":3830,"activeCount":103},[],{"trials":3832,"activeCount":103},[],{"trials":3834,"activeCount":132,"soonestReadout":356},[3835],{"nctId":353,"briefTitle":354,"status":169,"phases":3836,"primaryCompletion":356,"completion":357,"start":358,"enrollment":359,"conditions":3837,"interventions":3838},[],[361,362],[364,365,366,367,368,369,370,371,372,373,374,375,376,377,378,379,380,381,382,383,384,385,386,387,388,389,390,391,392,393,394,395,396,397,398,399,400,323],{"intervention":368,"totalTrials":132,"cells":3840},{"EARLY_PHASE1":3841,"PHASE1":3843,"PHASE2":3845,"PHASE3":3847,"PHASE4":3849,"NA":3851},{"trials":3842,"activeCount":103},[],{"trials":3844,"activeCount":103},[],{"trials":3846,"activeCount":103},[],{"trials":3848,"activeCount":103},[],{"trials":3850,"activeCount":103},[],{"trials":3852,"activeCount":132,"soonestReadout":356},[3853],{"nctId":353,"briefTitle":354,"status":169,"phases":3854,"primaryCompletion":356,"completion":357,"start":358,"enrollment":359,"conditions":3855,"interventions":3856},[],[361,362],[364,365,366,367,368,369,370,371,372,373,374,375,376,377,378,379,380,381,382,383,384,385,386,387,388,389,390,391,392,393,394,395,396,397,398,399,400,323],{"intervention":369,"totalTrials":132,"cells":3858},{"EARLY_PHASE1":3859,"PHASE1":3861,"PHASE2":3863,"PHASE3":3865,"PHASE4":3867,"NA":3869},{"trials":3860,"activeCount":103},[],{"trials":3862,"activeCount":103},[],{"trials":3864,"activeCount":103},[],{"trials":3866,"activeCount":103},[],{"trials":3868,"activeCount":103},[],{"trials":3870,"activeCount":132,"soonestReadout":356},[3871],{"nctId":353,"briefTitle":354,"status":169,"phases":3872,"primaryCompletion":356,"completion":357,"start":358,"enrollment":359,"conditions":3873,"interventions":3874},[],[361,362],[364,365,366,367,368,369,370,371,372,373,374,375,376,377,378,379,380,381,382,383,384,385,386,387,388,389,390,391,392,393,394,395,396,397,398,399,400,323],{"intervention":374,"totalTrials":132,"cells":3876},{"EARLY_PHASE1":3877,"PHASE1":3879,"PHASE2":3881,"PHASE3":3883,"PHASE4":3885,"NA":3887},{"trials":3878,"activeCount":103},[],{"trials":3880,"activeCount":103},[],{"trials":3882,"activeCount":103},[],{"trials":3884,"activeCount":103},[],{"trials":3886,"activeCount":103},[],{"trials":3888,"activeCount":132,"soonestReadout":356},[3889],{"nctId":353,"briefTitle":354,"status":169,"phases":3890,"primaryCompletion":356,"completion":357,"start":358,"enrollment":359,"conditions":3891,"interventions":3892},[],[361,362],[364,365,366,367,368,369,370,371,372,373,374,375,376,377,378,379,380,381,382,383,384,385,386,387,388,389,390,391,392,393,394,395,396,397,398,399,400,323],{"intervention":375,"totalTrials":132,"cells":3894},{"EARLY_PHASE1":3895,"PHASE1":3897,"PHASE2":3899,"PHASE3":3901,"PHASE4":3903,"NA":3905},{"trials":3896,"activeCount":103},[],{"trials":3898,"activeCount":103},[],{"trials":3900,"activeCount":103},[],{"trials":3902,"activeCount":103},[],{"trials":3904,"activeCount":103},[],{"trials":3906,"activeCount":132,"soonestReadout":356},[3907],{"nctId":353,"briefTitle":354,"status":169,"phases":3908,"primaryCompletion":356,"completion":357,"start":358,"enrollment":359,"conditions":3909,"interventions":3910},[],[361,362],[364,365,366,367,368,369,370,371,372,373,374,375,376,377,378,379,380,381,382,383,384,385,386,387,388,389,390,391,392,393,394,395,396,397,398,399,400,323],{"intervention":376,"totalTrials":132,"cells":3912},{"EARLY_PHASE1":3913,"PHASE1":3915,"PHASE2":3917,"PHASE3":3919,"PHASE4":3921,"NA":3923},{"trials":3914,"activeCount":103},[],{"trials":3916,"activeCount":103},[],{"trials":3918,"activeCount":103},[],{"trials":3920,"activeCount":103},[],{"trials":3922,"activeCount":103},[],{"trials":3924,"activeCount":132,"soonestReadout":356},[3925],{"nctId":353,"briefTitle":354,"status":169,"phases":3926,"primaryCompletion":356,"completion":357,"start":358,"enrollment":359,"conditions":3927,"interventions":3928},[],[361,362],[364,365,366,367,368,369,370,371,372,373,374,375,376,377,378,379,380,381,382,383,384,385,386,387,388,389,390,391,392,393,394,395,396,397,398,399,400,323],{"intervention":378,"totalTrials":132,"cells":3930},{"EARLY_PHASE1":3931,"PHASE1":3933,"PHASE2":3935,"PHASE3":3937,"PHASE4":3939,"NA":3941},{"trials":3932,"activeCount":103},[],{"trials":3934,"activeCount":103},[],{"trials":3936,"activeCount":103},[],{"trials":3938,"activeCount":103},[],{"trials":3940,"activeCount":103},[],{"trials":3942,"activeCount":132,"soonestReadout":356},[3943],{"nctId":353,"briefTitle":354,"status":169,"phases":3944,"primaryCompletion":356,"completion":357,"start":358,"enrollment":359,"conditions":3945,"interventions":3946},[],[361,362],[364,365,366,367,368,369,370,371,372,373,374,375,376,377,378,379,380,381,382,383,384,385,386,387,388,389,390,391,392,393,394,395,396,397,398,399,400,323],{"intervention":379,"totalTrials":132,"cells":3948},{"EARLY_PHASE1":3949,"PHASE1":3951,"PHASE2":3953,"PHASE3":3955,"PHASE4":3957,"NA":3959},{"trials":3950,"activeCount":103},[],{"trials":3952,"activeCount":103},[],{"trials":3954,"activeCount":103},[],{"trials":3956,"activeCount":103},[],{"trials":3958,"activeCount":103},[],{"trials":3960,"activeCount":132,"soonestReadout":356},[3961],{"nctId":353,"briefTitle":354,"status":169,"phases":3962,"primaryCompletion":356,"completion":357,"start":358,"enrollment":359,"conditions":3963,"interventions":3964},[],[361,362],[364,365,366,367,368,369,370,371,372,373,374,375,376,377,378,379,380,381,382,383,384,385,386,387,388,389,390,391,392,393,394,395,396,397,398,399,400,323],{"intervention":380,"totalTrials":132,"cells":3966},{"EARLY_PHASE1":3967,"PHASE1":3969,"PHASE2":3971,"PHASE3":3973,"PHASE4":3975,"NA":3977},{"trials":3968,"activeCount":103},[],{"trials":3970,"activeCount":103},[],{"trials":3972,"activeCount":103},[],{"trials":3974,"activeCount":103},[],{"trials":3976,"activeCount":103},[],{"trials":3978,"activeCount":132,"soonestReadout":356},[3979],{"nctId":353,"briefTitle":354,"status":169,"phases":3980,"primaryCompletion":356,"completion":357,"start":358,"enrollment":359,"conditions":3981,"interventions":3982},[],[361,362],[364,365,366,367,368,369,370,371,372,373,374,375,376,377,378,379,380,381,382,383,384,385,386,387,388,389,390,391,392,393,394,395,396,397,398,399,400,323],{"intervention":383,"totalTrials":132,"cells":3984},{"EARLY_PHASE1":3985,"PHASE1":3987,"PHASE2":3989,"PHASE3":3991,"PHASE4":3993,"NA":3995},{"trials":3986,"activeCount":103},[],{"trials":3988,"activeCount":103},[],{"trials":3990,"activeCount":103},[],{"trials":3992,"activeCount":103},[],{"trials":3994,"activeCount":103},[],{"trials":3996,"activeCount":132,"soonestReadout":356},[3997],{"nctId":353,"briefTitle":354,"status":169,"phases":3998,"primaryCompletion":356,"completion":357,"start":358,"enrollment":359,"conditions":3999,"interventions":4000},[],[361,362],[364,365,366,367,368,369,370,371,372,373,374,375,376,377,378,379,380,381,382,383,384,385,386,387,388,389,390,391,392,393,394,395,396,397,398,399,400,323],{"intervention":386,"totalTrials":132,"cells":4002},{"EARLY_PHASE1":4003,"PHASE1":4005,"PHASE2":4007,"PHASE3":4009,"PHASE4":4011,"NA":4013},{"trials":4004,"activeCount":103},[],{"trials":4006,"activeCount":103},[],{"trials":4008,"activeCount":103},[],{"trials":4010,"activeCount":103},[],{"trials":4012,"activeCount":103},[],{"trials":4014,"activeCount":132,"soonestReadout":356},[4015],{"nctId":353,"briefTitle":354,"status":169,"phases":4016,"primaryCompletion":356,"completion":357,"start":358,"enrollment":359,"conditions":4017,"interventions":4018},[],[361,362],[364,365,366,367,368,369,370,371,372,373,374,375,376,377,378,379,380,381,382,383,384,385,386,387,388,389,390,391,392,393,394,395,396,397,398,399,400,323],{"intervention":387,"totalTrials":132,"cells":4020},{"EARLY_PHASE1":4021,"PHASE1":4023,"PHASE2":4025,"PHASE3":4027,"PHASE4":4029,"NA":4031},{"trials":4022,"activeCount":103},[],{"trials":4024,"activeCount":103},[],{"trials":4026,"activeCount":103},[],{"trials":4028,"activeCount":103},[],{"trials":4030,"activeCount":103},[],{"trials":4032,"activeCount":132,"soonestReadout":356},[4033],{"nctId":353,"briefTitle":354,"status":169,"phases":4034,"primaryCompletion":356,"completion":357,"start":358,"enrollment":359,"conditions":4035,"interventions":4036},[],[361,362],[364,365,366,367,368,369,370,371,372,373,374,375,376,377,378,379,380,381,382,383,384,385,386,387,388,389,390,391,392,393,394,395,396,397,398,399,400,323],{"intervention":389,"totalTrials":132,"cells":4038},{"EARLY_PHASE1":4039,"PHASE1":4041,"PHASE2":4043,"PHASE3":4045,"PHASE4":4047,"NA":4049},{"trials":4040,"activeCount":103},[],{"trials":4042,"activeCount":103},[],{"trials":4044,"activeCount":103},[],{"trials":4046,"activeCount":103},[],{"trials":4048,"activeCount":103},[],{"trials":4050,"activeCount":132,"soonestReadout":356},[4051],{"nctId":353,"briefTitle":354,"status":169,"phases":4052,"primaryCompletion":356,"completion":357,"start":358,"enrollment":359,"conditions":4053,"interventions":4054},[],[361,362],[364,365,366,367,368,369,370,371,372,373,374,375,376,377,378,379,380,381,382,383,384,385,386,387,388,389,390,391,392,393,394,395,396,397,398,399,400,323],{"intervention":390,"totalTrials":132,"cells":4056},{"EARLY_PHASE1":4057,"PHASE1":4059,"PHASE2":4061,"PHASE3":4063,"PHASE4":4065,"NA":4067},{"trials":4058,"activeCount":103},[],{"trials":4060,"activeCount":103},[],{"trials":4062,"activeCount":103},[],{"trials":4064,"activeCount":103},[],{"trials":4066,"activeCount":103},[],{"trials":4068,"activeCount":132,"soonestReadout":356},[4069],{"nctId":353,"briefTitle":354,"status":169,"phases":4070,"primaryCompletion":356,"completion":357,"start":358,"enrollment":359,"conditions":4071,"interventions":4072},[],[361,362],[364,365,366,367,368,369,370,371,372,373,374,375,376,377,378,379,380,381,382,383,384,385,386,387,388,389,390,391,392,393,394,395,396,397,398,399,400,323],{"intervention":391,"totalTrials":132,"cells":4074},{"EARLY_PHASE1":4075,"PHASE1":4077,"PHASE2":4079,"PHASE3":4081,"PHASE4":4083,"NA":4085},{"trials":4076,"activeCount":103},[],{"trials":4078,"activeCount":103},[],{"trials":4080,"activeCount":103},[],{"trials":4082,"activeCount":103},[],{"trials":4084,"activeCount":103},[],{"trials":4086,"activeCount":132,"soonestReadout":356},[4087],{"nctId":353,"briefTitle":354,"status":169,"phases":4088,"primaryCompletion":356,"completion":357,"start":358,"enrollment":359,"conditions":4089,"interventions":4090},[],[361,362],[364,365,366,367,368,369,370,371,372,373,374,375,376,377,378,379,380,381,382,383,384,385,386,387,388,389,390,391,392,393,394,395,396,397,398,399,400,323],{"intervention":394,"totalTrials":132,"cells":4092},{"EARLY_PHASE1":4093,"PHASE1":4095,"PHASE2":4097,"PHASE3":4099,"PHASE4":4101,"NA":4103},{"trials":4094,"activeCount":103},[],{"trials":4096,"activeCount":103},[],{"trials":4098,"activeCount":103},[],{"trials":4100,"activeCount":103},[],{"trials":4102,"activeCount":103},[],{"trials":4104,"activeCount":132,"soonestReadout":356},[4105],{"nctId":353,"briefTitle":354,"status":169,"phases":4106,"primaryCompletion":356,"completion":357,"start":358,"enrollment":359,"conditions":4107,"interventions":4108},[],[361,362],[364,365,366,367,368,369,370,371,372,373,374,375,376,377,378,379,380,381,382,383,384,385,386,387,388,389,390,391,392,393,394,395,396,397,398,399,400,323],{"intervention":395,"totalTrials":132,"cells":4110},{"EARLY_PHASE1":4111,"PHASE1":4113,"PHASE2":4115,"PHASE3":4117,"PHASE4":4119,"NA":4121},{"trials":4112,"activeCount":103},[],{"trials":4114,"activeCount":103},[],{"trials":4116,"activeCount":103},[],{"trials":4118,"activeCount":103},[],{"trials":4120,"activeCount":103},[],{"trials":4122,"activeCount":132,"soonestReadout":356},[4123],{"nctId":353,"briefTitle":354,"status":169,"phases":4124,"primaryCompletion":356,"completion":357,"start":358,"enrollment":359,"conditions":4125,"interventions":4126},[],[361,362],[364,365,366,367,368,369,370,371,372,373,374,375,376,377,378,379,380,381,382,383,384,385,386,387,388,389,390,391,392,393,394,395,396,397,398,399,400,323],{"intervention":398,"totalTrials":132,"cells":4128},{"EARLY_PHASE1":4129,"PHASE1":4131,"PHASE2":4133,"PHASE3":4135,"PHASE4":4137,"NA":4139},{"trials":4130,"activeCount":103},[],{"trials":4132,"activeCount":103},[],{"trials":4134,"activeCount":103},[],{"trials":4136,"activeCount":103},[],{"trials":4138,"activeCount":103},[],{"trials":4140,"activeCount":132,"soonestReadout":356},[4141],{"nctId":353,"briefTitle":354,"status":169,"phases":4142,"primaryCompletion":356,"completion":357,"start":358,"enrollment":359,"conditions":4143,"interventions":4144},[],[361,362],[364,365,366,367,368,369,370,371,372,373,374,375,376,377,378,379,380,381,382,383,384,385,386,387,388,389,390,391,392,393,394,395,396,397,398,399,400,323],{"intervention":400,"totalTrials":132,"cells":4146},{"EARLY_PHASE1":4147,"PHASE1":4149,"PHASE2":4151,"PHASE3":4153,"PHASE4":4155,"NA":4157},{"trials":4148,"activeCount":103},[],{"trials":4150,"activeCount":103},[],{"trials":4152,"activeCount":103},[],{"trials":4154,"activeCount":103},[],{"trials":4156,"activeCount":103},[],{"trials":4158,"activeCount":132,"soonestReadout":356},[4159],{"nctId":353,"briefTitle":354,"status":169,"phases":4160,"primaryCompletion":356,"completion":357,"start":358,"enrollment":359,"conditions":4161,"interventions":4162},[],[361,362],[364,365,366,367,368,369,370,371,372,373,374,375,376,377,378,379,380,381,382,383,384,385,386,387,388,389,390,391,392,393,394,395,396,397,398,399,400,323],{"intervention":4164,"totalTrials":132,"cells":4165},"Adenosine Stress Cardiac Magnetic Resonance Imaging",{"EARLY_PHASE1":4166,"PHASE1":4168,"PHASE2":4170,"PHASE3":4172,"PHASE4":4174,"NA":4176},{"trials":4167,"activeCount":103},[],{"trials":4169,"activeCount":103},[],{"trials":4171,"activeCount":103},[],{"trials":4173,"activeCount":103},[],{"trials":4175,"activeCount":103},[],{"trials":4177,"activeCount":132,"soonestReadout":4182},[4178],{"nctId":4179,"briefTitle":4180,"status":169,"phases":4181,"primaryCompletion":4182,"completion":2555,"start":4183,"enrollment":4184,"conditions":4185,"interventions":4188},"NCT05309655","Cardiac Outcomes With Near-Complete Estrogen Deprivation",[95],"2028-05-01","2022-09-02",90,[18,4186,4187],"Triple Negative Breast Cancer","Cardiovascular Complications",[4164],{"intervention":437,"totalTrials":1170,"cells":4190},{"EARLY_PHASE1":4191,"PHASE1":4193,"PHASE2":4205,"PHASE3":4215,"PHASE4":4217,"NA":4231},{"trials":4192,"activeCount":103},[],{"trials":4194,"activeCount":103},[4195],{"nctId":4196,"briefTitle":4197,"status":155,"phases":4198,"primaryCompletion":4199,"completion":4200,"start":4201,"enrollment":34,"conditions":4202,"interventions":4204},"NCT03938857","DOSE Trial of Opioid Sparing Effect",[91],"2020-10-21","2020-11-06","2019-07-18",[435,4203,3711],"Mechanical Ventilation Complication",[437,435,435,435],{"trials":4206,"activeCount":103},[4207],{"nctId":4208,"briefTitle":4209,"status":428,"phases":4210,"primaryCompletion":4211,"completion":4211,"start":114,"enrollment":103,"conditions":4212,"interventions":4214},"NCT03293927","Polypharmacy-related Adverse Events in Critically Ill Children",[92],"2019-07-01",[4213],"Delirium",[437,435],{"trials":4216,"activeCount":103},[],{"trials":4218,"activeCount":103},[4219,4223,4227],{"nctId":426,"briefTitle":427,"status":428,"phases":4220,"completion":430,"start":431,"enrollment":103,"conditions":4221,"interventions":4222},[94],[433],[435,319,436,437,418],{"nctId":473,"briefTitle":474,"status":111,"phases":4224,"primaryCompletion":476,"completion":477,"start":478,"enrollment":479,"conditions":4225,"interventions":4226},[94],[481,263],[249,437,483,484,485],{"nctId":3028,"briefTitle":3029,"status":111,"phases":4228,"primaryCompletion":3031,"completion":3031,"start":3032,"enrollment":3033,"conditions":4229,"interventions":4230},[94],[3035],[165,437],{"trials":4232,"activeCount":103},[],{"intervention":435,"totalTrials":1170,"cells":4234},{"EARLY_PHASE1":4235,"PHASE1":4237,"PHASE2":4243,"PHASE3":4249,"PHASE4":4259,"NA":4269},{"trials":4236,"activeCount":103},[],{"trials":4238,"activeCount":103},[4239],{"nctId":4196,"briefTitle":4197,"status":155,"phases":4240,"primaryCompletion":4199,"completion":4200,"start":4201,"enrollment":34,"conditions":4241,"interventions":4242},[91],[435,4203,3711],[437,435,435,435],{"trials":4244,"activeCount":103},[4245],{"nctId":4208,"briefTitle":4209,"status":428,"phases":4246,"primaryCompletion":4211,"completion":4211,"start":114,"enrollment":103,"conditions":4247,"interventions":4248},[92],[4213],[437,435],{"trials":4250,"activeCount":103},[4251],{"nctId":4252,"briefTitle":4253,"status":428,"phases":4254,"primaryCompletion":4255,"completion":4256,"start":412,"enrollment":103,"conditions":4257,"interventions":4258},"NCT01733043","Sedative Effects in Obstructive Sleep Apnea",[92,93],"2015-05","2015-11",[245],[435],{"trials":4260,"activeCount":103},[4261,4265],{"nctId":426,"briefTitle":427,"status":428,"phases":4262,"completion":430,"start":431,"enrollment":103,"conditions":4263,"interventions":4264},[94],[433],[435,319,436,437,418],{"nctId":443,"briefTitle":444,"status":155,"phases":4266,"primaryCompletion":446,"completion":446,"start":447,"enrollment":448,"conditions":4267,"interventions":4268},[94],[450,451,452],[436,319,435],{"trials":4270,"activeCount":103},[],{"intervention":4272,"totalTrials":282,"cells":4273},"Rejuvesol",{"EARLY_PHASE1":4274,"PHASE1":4276,"PHASE2":4278,"PHASE3":4280,"PHASE4":4282,"NA":4302},{"trials":4275,"activeCount":103},[],{"trials":4277,"activeCount":103},[],{"trials":4279,"activeCount":103},[],{"trials":4281,"activeCount":103},[],{"trials":4283,"activeCount":103},[4284,4293],{"nctId":4285,"briefTitle":4286,"status":111,"phases":4287,"primaryCompletion":4288,"completion":4288,"start":4289,"enrollment":402,"conditions":4290,"interventions":4292},"NCT02731157","Rejuvesol® Washed RBC in Sickle Cell Patients Requiring Frequent Transfusions",[94],"2017-12-31","2016-12",[4291],"Sickle Cell Disease",[4272],{"nctId":4294,"briefTitle":4295,"status":428,"phases":4296,"primaryCompletion":4297,"completion":4297,"start":4298,"enrollment":103,"conditions":4299,"interventions":4301},"NCT02485366","Rejuvenated, Washed Packed Red Blood Cells in Pediatric Cardiac Surgery",[94],"2021-06","2020-06",[4300],"Heart Defects, Congenital",[4272],{"trials":4303,"activeCount":103},[],{"intervention":4305,"totalTrials":282,"cells":4306},"PCV13",{"EARLY_PHASE1":4307,"PHASE1":4309,"PHASE2":4311,"PHASE3":4313,"PHASE4":4315,"NA":4345},{"trials":4308,"activeCount":103},[],{"trials":4310,"activeCount":103},[],{"trials":4312,"activeCount":103},[],{"trials":4314,"activeCount":103},[],{"trials":4316,"activeCount":103},[4317,4333],{"nctId":4318,"briefTitle":4319,"status":111,"phases":4320,"primaryCompletion":4321,"completion":4321,"start":4322,"enrollment":4323,"conditions":4324,"interventions":4328},"NCT03530124","Apnea in Hospitalized Preterm Infants Following the Administration of Routine Childhood Vaccines",[94],"2021-11-01","2018-07-17",223,[4325,4326,4327],"Apnea","Apnea Neonatal","Prematurity",[4305,4329,4330,4331,4332],"DTaP","HBV","IPV","Hib",{"nctId":4334,"briefTitle":4335,"status":111,"phases":4336,"primaryCompletion":4337,"completion":4337,"start":4338,"enrollment":4339,"conditions":4340,"interventions":4343},"NCT03165981","Fever After Simultaneous Versus Sequential Vaccination in Young Children",[94],"2018-01-15","2017-08-25",221,[4341,574,4342],"Fever After Vaccination","Febrile Seizure",[4305,4329,4344],"IIV",{"trials":4346,"activeCount":103},[],{"intervention":4329,"totalTrials":282,"cells":4348},{"EARLY_PHASE1":4349,"PHASE1":4351,"PHASE2":4353,"PHASE3":4355,"PHASE4":4357,"NA":4367},{"trials":4350,"activeCount":103},[],{"trials":4352,"activeCount":103},[],{"trials":4354,"activeCount":103},[],{"trials":4356,"activeCount":103},[],{"trials":4358,"activeCount":103},[4359,4363],{"nctId":4318,"briefTitle":4319,"status":111,"phases":4360,"primaryCompletion":4321,"completion":4321,"start":4322,"enrollment":4323,"conditions":4361,"interventions":4362},[94],[4325,4326,4327],[4305,4329,4330,4331,4332],{"nctId":4334,"briefTitle":4335,"status":111,"phases":4364,"primaryCompletion":4337,"completion":4337,"start":4338,"enrollment":4339,"conditions":4365,"interventions":4366},[94],[4341,574,4342],[4305,4329,4344],{"trials":4368,"activeCount":103},[],{"intervention":4370,"totalTrials":282,"cells":4371},"Vancomycin",{"EARLY_PHASE1":4372,"PHASE1":4374,"PHASE2":4376,"PHASE3":4388,"PHASE4":4390,"NA":4406},{"trials":4373,"activeCount":103},[],{"trials":4375,"activeCount":103},[],{"trials":4377,"activeCount":103},[4378],{"nctId":4379,"briefTitle":4380,"status":111,"phases":4381,"primaryCompletion":4382,"completion":4382,"start":4383,"enrollment":4384,"conditions":4385,"interventions":4387},"NCT01191840","Treatment Algorithm to Reduce the Use of Vancomycin in Adults With Blood Stream Infection",[92],"2017-03-04","2011-02",509,[4386],"Bacteremia",[4370,4370],{"trials":4389,"activeCount":103},[],{"trials":4391,"activeCount":103},[4392],{"nctId":4393,"briefTitle":4394,"status":111,"phases":4395,"primaryCompletion":4396,"completion":4396,"start":4397,"enrollment":4398,"conditions":4399,"interventions":4403},"NCT02057198","Impact of Oral Antibiotic Treatment on C. Difficile",[94],"2017-06-27","2014-06-10",33,[4400,4401,4402],"C. Difficile","Diarrhea","Enterocolitis",[4404,4405,4370],"Fidaxomicin","Metronidazole",{"trials":4407,"activeCount":103},[],{"intervention":436,"totalTrials":282,"cells":4409},{"EARLY_PHASE1":4410,"PHASE1":4412,"PHASE2":4414,"PHASE3":4416,"PHASE4":4418,"NA":4428},{"trials":4411,"activeCount":103},[],{"trials":4413,"activeCount":103},[],{"trials":4415,"activeCount":103},[],{"trials":4417,"activeCount":103},[],{"trials":4419,"activeCount":103},[4420,4424],{"nctId":426,"briefTitle":427,"status":428,"phases":4421,"completion":430,"start":431,"enrollment":103,"conditions":4422,"interventions":4423},[94],[433],[435,319,436,437,418],{"nctId":443,"briefTitle":444,"status":155,"phases":4425,"primaryCompletion":446,"completion":446,"start":447,"enrollment":448,"conditions":4426,"interventions":4427},[94],[450,451,452],[436,319,435],{"trials":4429,"activeCount":103},[],{"intervention":418,"totalTrials":282,"cells":4431},{"EARLY_PHASE1":4432,"PHASE1":4434,"PHASE2":4440,"PHASE3":4442,"PHASE4":4444,"NA":4450},{"trials":4433,"activeCount":103},[],{"trials":4435,"activeCount":103},[4436],{"nctId":409,"briefTitle":410,"status":111,"phases":4437,"primaryCompletion":412,"completion":412,"start":413,"enrollment":414,"conditions":4438,"interventions":4439},[91],[416],[319,418],{"trials":4441,"activeCount":103},[],{"trials":4443,"activeCount":103},[],{"trials":4445,"activeCount":103},[4446],{"nctId":426,"briefTitle":427,"status":428,"phases":4447,"completion":430,"start":431,"enrollment":103,"conditions":4448,"interventions":4449},[94],[433],[435,319,436,437,418],{"trials":4451,"activeCount":103},[],{"intervention":4453,"totalTrials":282,"cells":4454},"1% Lidocaine",{"EARLY_PHASE1":4455,"PHASE1":4457,"PHASE2":4459,"PHASE3":4461,"PHASE4":4463,"NA":4485},{"trials":4456,"activeCount":103},[],{"trials":4458,"activeCount":103},[],{"trials":4460,"activeCount":103},[],{"trials":4462,"activeCount":103},[],{"trials":4464,"activeCount":103},[4465,4474],{"nctId":4466,"briefTitle":4467,"status":111,"phases":4468,"primaryCompletion":2857,"completion":2857,"start":1222,"enrollment":4469,"conditions":4470,"interventions":4472},"NCT02288364","Reducing Pain of Lidocaine Injection",[94],88,[4471],"Pain of Anesthesia at Breast Biopsy",[4453,4473],"1% Lidocaine plus sodium bicarbonate",{"nctId":4475,"briefTitle":4476,"status":111,"phases":4477,"primaryCompletion":2813,"completion":2813,"start":4478,"enrollment":4479,"conditions":4480,"interventions":4482},"NCT02162680","An Evaluation of the Effectiveness of Local Anesthetics Used During Intravenous Catheter Insertion",[94],"2010-03",99,[4481],"IV Insertion Pain",[4483,4484],"1% lidocaine","bacteriostatic normal saline",{"trials":4486,"activeCount":103},[],{"intervention":4488,"totalTrials":282,"cells":4489},"IIV4",{"EARLY_PHASE1":4490,"PHASE1":4492,"PHASE2":4494,"PHASE3":4496,"PHASE4":4498,"NA":4528},{"trials":4491,"activeCount":103},[],{"trials":4493,"activeCount":103},[],{"trials":4495,"activeCount":103},[],{"trials":4497,"activeCount":103},[],{"trials":4499,"activeCount":103},[4500,4514],{"nctId":4501,"briefTitle":4502,"status":111,"phases":4503,"primaryCompletion":4504,"completion":1681,"start":4505,"enrollment":4506,"conditions":4507,"interventions":4512},"NCT05028361","Simultaneous mRNA COVID-19 and IIV4 Vaccination Study",[94],"2023-03-03","2021-10-04",348,[4508,4509,4510,4511],"Quality of Life","Injection Site Reaction","Adverse Drug Event","Systemic Reaction",[4513,4488],"mRNA COVID-19",{"nctId":4515,"briefTitle":4516,"status":111,"phases":4517,"primaryCompletion":4518,"completion":4519,"start":4520,"enrollment":4521,"conditions":4522,"interventions":4526},"NCT06503900","Simultaneous mRNA COVID-19 and IIV Vaccination in Pregnancy Study",[94],"2025-08-20","2025-11-19","2024-09-12",98,[4523,4524,4525],"Birth Outcomes","Safety","Adverse Event Following Immunization",[4527,4488],"mRNA COVID-19 vaccine",{"trials":4529,"activeCount":103},[],{"intervention":4531,"totalTrials":282,"cells":4532},"Ranolazine",{"EARLY_PHASE1":4533,"PHASE1":4535,"PHASE2":4537,"PHASE3":4539,"PHASE4":4541,"NA":4558},{"trials":4534,"activeCount":103},[],{"trials":4536,"activeCount":103},[],{"trials":4538,"activeCount":103},[],{"trials":4540,"activeCount":103},[],{"trials":4542,"activeCount":103},[4543,4550],{"nctId":4544,"briefTitle":4545,"status":111,"phases":4546,"primaryCompletion":4256,"completion":1624,"start":1178,"enrollment":1180,"conditions":4547,"interventions":4549},"NCT01721967","Ranolazine for the Treatment of Chest Pain in HCM Patients",[94],[4548],"Hypertrophic Cardiomyopathy",[4531],{"nctId":4551,"briefTitle":4552,"status":111,"phases":4553,"primaryCompletion":4554,"completion":4554,"start":2811,"enrollment":28,"conditions":4555,"interventions":4557},"NCT01948310","Effects of Ranolazine and Exercise on Daily Physical Activity Trial",[94],"2016-10-10",[4556],"Chronic Stable Angina",[4531],{"trials":4559,"activeCount":103},[],{"intervention":4561,"totalTrials":282,"cells":4562},"Ketamine",{"EARLY_PHASE1":4563,"PHASE1":4565,"PHASE2":4567,"PHASE3":4577,"PHASE4":4579,"NA":4590},{"trials":4564,"activeCount":103},[],{"trials":4566,"activeCount":103},[],{"trials":4568,"activeCount":103},[4569],{"nctId":4570,"briefTitle":4571,"status":111,"phases":4572,"primaryCompletion":2943,"completion":2943,"start":205,"enrollment":127,"conditions":4573,"interventions":4575},"NCT00504725","Ketamine In Thoracic Surgery (KITS) Trial",[92],[4574],"Lung Cancer",[4561,4576],"0.9% saline",{"trials":4578,"activeCount":103},[],{"trials":4580,"activeCount":103},[4581],{"nctId":4582,"briefTitle":4583,"status":428,"phases":4584,"primaryCompletion":4585,"completion":4585,"start":4586,"enrollment":103,"conditions":4587,"interventions":4589},"NCT04005209","Ketamine Infusion for Sickle Cell Pain Crisis",[94],"2022-11","2022-01",[4588,777],"Anemia; Sickle-Cell, With Crisis",[4561],{"trials":4591,"activeCount":103},[],{"intervention":4593,"totalTrials":282,"cells":4594},"Cefazolin",{"EARLY_PHASE1":4595,"PHASE1":4597,"PHASE2":4599,"PHASE3":4601,"PHASE4":4603,"NA":4625},{"trials":4596,"activeCount":103},[],{"trials":4598,"activeCount":103},[],{"trials":4600,"activeCount":103},[],{"trials":4602,"activeCount":103},[],{"trials":4604,"activeCount":103},[4605,4614],{"nctId":4606,"briefTitle":4607,"status":428,"phases":4608,"primaryCompletion":4609,"completion":4610,"start":4255,"enrollment":103,"conditions":4611,"interventions":4613},"NCT02433704","Preoperative Antibiotic Dosing for Total Knee Arthroplasty",[94],"2017-05","2018-06",[4612],"Acute Infection of Total Knee Replacement",[4593],{"nctId":4615,"briefTitle":4616,"status":111,"phases":4617,"primaryCompletion":4618,"completion":2111,"start":4619,"enrollment":4620,"conditions":4621,"interventions":4624},"NCT03283878","Antibiotic Prophylaxis in Patients Undergoing Elective Total Knee Arthroplasty- Multi-center Trial",[94],"2024-11-20","2017-10-24",1770,[4622,4623],"Arthropathy of Knee","Antibiotic Prophylaxis",[4593],{"trials":4626,"activeCount":103},[],{"intervention":4628,"totalTrials":282,"cells":4629},"Isovue 370",{"EARLY_PHASE1":4630,"PHASE1":4632,"PHASE2":4634,"PHASE3":4636,"PHASE4":4647,"NA":4659},{"trials":4631,"activeCount":103},[],{"trials":4633,"activeCount":103},[],{"trials":4635,"activeCount":103},[],{"trials":4637,"activeCount":103},[4638],{"nctId":4639,"briefTitle":4640,"status":111,"phases":4641,"primaryCompletion":4642,"completion":4642,"start":2339,"enrollment":2847,"conditions":4643,"interventions":4645},"NCT02171247","Comparison of Isovue 370 vs. Standard Protocol in Coronary Computed Tomographic Angiography (CTA)",[93],"2010-12",[4644],"Coronary Computed Tomographic Angiography",[4628,4646],"Visipaque 320",{"trials":4648,"activeCount":103},[4649],{"nctId":4650,"briefTitle":4651,"status":111,"phases":4652,"primaryCompletion":4653,"completion":4653,"start":4654,"enrollment":4655,"conditions":4656,"interventions":4658},"NCT02170688","Use of Electrical Impedence to Measure Lean Body Weight as a Determinant of the Dose of Contrast Media for Abdominal CT",[94],"2014-07","2004-02",139,[4657],"IV Contrast Dosing",[4628],{"trials":4660,"activeCount":103},[],{"intervention":3635,"totalTrials":282,"cells":4662},{"EARLY_PHASE1":4663,"PHASE1":4665,"PHASE2":4667,"PHASE3":4673,"PHASE4":4675,"NA":4687},{"trials":4664,"activeCount":103},[],{"trials":4666,"activeCount":103},[],{"trials":4668,"activeCount":103},[4669],{"nctId":3626,"briefTitle":3627,"status":155,"phases":4670,"primaryCompletion":3629,"completion":3630,"start":3631,"enrollment":160,"conditions":4671,"interventions":4672},[92],[3633],[3635,3636],{"trials":4674,"activeCount":103},[],{"trials":4676,"activeCount":103},[4677],{"nctId":4678,"briefTitle":4679,"status":155,"phases":4680,"primaryCompletion":4681,"completion":4682,"start":4683,"enrollment":1212,"conditions":4684,"interventions":4686},"NCT03025087","Hydroxychloroquine and Cognitive Function After Surgery",[94],"2023-05-22","2024-04-19","2017-06-19",[4685],"Individuals Undergoing Cardiac and General Surgery",[3635],{"trials":4688,"activeCount":103},[],{"intervention":4690,"totalTrials":282,"cells":4691},"Temazepam",{"EARLY_PHASE1":4692,"PHASE1":4694,"PHASE2":4696,"PHASE3":4698,"PHASE4":4700,"NA":4716},{"trials":4693,"activeCount":103},[],{"trials":4695,"activeCount":103},[],{"trials":4697,"activeCount":103},[],{"trials":4699,"activeCount":103},[],{"trials":4701,"activeCount":103},[4702,4708],{"nctId":4703,"briefTitle":4704,"status":111,"phases":4705,"primaryCompletion":3104,"start":3103,"enrollment":219,"conditions":4706,"interventions":4707},"NCT02153788","Efficacy and Safety of Temazepam in HIV Seropositive Patients With Insomnia",[94],[3746],[4690],{"nctId":4709,"briefTitle":4710,"status":111,"phases":4711,"primaryCompletion":3143,"completion":3143,"start":4712,"enrollment":219,"conditions":4713,"interventions":4714},"NCT00465972","The Treatment of Insomnia in Patients With HIV Disease",[94],"2007-03",[343,3746],[4715,4690],"Doxepin",{"trials":4717,"activeCount":103},[],{"intervention":484,"totalTrials":282,"cells":4719},{"EARLY_PHASE1":4720,"PHASE1":4722,"PHASE2":4724,"PHASE3":4726,"PHASE4":4738,"NA":4744},{"trials":4721,"activeCount":103},[],{"trials":4723,"activeCount":103},[],{"trials":4725,"activeCount":103},[],{"trials":4727,"activeCount":103},[4728],{"nctId":4729,"briefTitle":4730,"status":155,"phases":4731,"primaryCompletion":4732,"completion":4733,"start":4734,"enrollment":4735,"conditions":4736,"interventions":4737},"NCT03933397","Comparing Individualized vs. Weight Based Protocols to Treat Vaso-Occlusive Episodes in Sickle Cell Disease",[93],"2022-05-13","2022-05-20","2019-08-13",328,[4291],[484,483],{"trials":4739,"activeCount":103},[4740],{"nctId":473,"briefTitle":474,"status":111,"phases":4741,"primaryCompletion":476,"completion":477,"start":478,"enrollment":479,"conditions":4742,"interventions":4743},[94],[481,263],[249,437,483,484,485],{"trials":4745,"activeCount":103},[],{"intervention":4747,"totalTrials":282,"cells":4748},"mRNA COVID-19 Vaccine",{"EARLY_PHASE1":4749,"PHASE1":4751,"PHASE2":4753,"PHASE3":4755,"PHASE4":4757,"NA":4775},{"trials":4750,"activeCount":103},[],{"trials":4752,"activeCount":103},[],{"trials":4754,"activeCount":103},[],{"trials":4756,"activeCount":103},[],{"trials":4758,"activeCount":103},[4759,4771],{"nctId":4760,"briefTitle":4761,"status":111,"phases":4762,"primaryCompletion":4763,"completion":4764,"start":4765,"enrollment":4766,"conditions":4767,"interventions":4769},"NCT06038617","Safety of Simultaneous mRNA COVID-19 Vaccine With Other Childhood Vaccines in Young Children",[94],"2025-04-24","2025-07-25","2023-10-30",347,[4341,574,4768],"Seizures Fever",[4747,4770],"Routine Childhood Vaccinations",{"nctId":4515,"briefTitle":4516,"status":111,"phases":4772,"primaryCompletion":4518,"completion":4519,"start":4520,"enrollment":4521,"conditions":4773,"interventions":4774},[94],[4523,4524,4525],[4527,4488],{"trials":4776,"activeCount":103},[],{"intervention":4778,"totalTrials":282,"cells":4779},"Milnacipran",{"EARLY_PHASE1":4780,"PHASE1":4782,"PHASE2":4784,"PHASE3":4786,"PHASE4":4796,"NA":4806},{"trials":4781,"activeCount":103},[],{"trials":4783,"activeCount":103},[],{"trials":4785,"activeCount":103},[],{"trials":4787,"activeCount":103},[4788],{"nctId":4789,"briefTitle":4790,"status":111,"phases":4791,"primaryCompletion":2661,"completion":2661,"start":2813,"enrollment":37,"conditions":4792,"interventions":4795},"NCT01829243","Milnacipran and Neurocognition, Pain and Fatigue in Fibromyalgia : A 13-week Randomized, Placebo Controlled Cross Over Trial",[93],[4793,4794],"Fibromyalgia","Neurocognition",[4778],{"trials":4797,"activeCount":103},[4798],{"nctId":4799,"briefTitle":4800,"status":111,"phases":4801,"primaryCompletion":4802,"completion":4802,"start":4478,"enrollment":2570,"conditions":4803,"interventions":4805},"NCT01777581","Milnacipran for Lumbosacral Radicular Pain",[94],"2011-10",[4804],"Radicular Pain Related to Lumbosacral Disc Disease",[4778],{"trials":4807,"activeCount":103},[],{"intervention":4809,"totalTrials":282,"cells":4810},"Warfarin",{"EARLY_PHASE1":4811,"PHASE1":4813,"PHASE2":4815,"PHASE3":4817,"PHASE4":4828,"NA":4840},{"trials":4812,"activeCount":103},[],{"trials":4814,"activeCount":103},[],{"trials":4816,"activeCount":103},[],{"trials":4818,"activeCount":103},[4819],{"nctId":4820,"briefTitle":4821,"status":155,"phases":4822,"primaryCompletion":2813,"completion":2813,"start":4823,"enrollment":4824,"conditions":4825,"interventions":4826},"NCT00957242","AntiCoagulant Effectiveness in Idiopathic Pulmonary Fibrosis",[93],"2009-10",145,[2025],[4827],"warfarin",{"trials":4829,"activeCount":103},[4830],{"nctId":4831,"briefTitle":4832,"status":155,"phases":4833,"primaryCompletion":3313,"completion":3313,"start":4834,"enrollment":219,"conditions":4835,"interventions":4837},"NCT03196349","Comparison of Oral Anticoagulants for Extended VEnous Thromboembolism",[94],"2018-08-01",[4836],"Venous Thromboembolism",[4809,4838,4839],"Apixaban 2.5 MG","Rivaroxaban 10 MG",{"trials":4841,"activeCount":103},[],{"intervention":4843,"totalTrials":282,"cells":4844},"adenosine",{"EARLY_PHASE1":4845,"PHASE1":4847,"PHASE2":4849,"PHASE3":4851,"PHASE4":4853,"NA":4878},{"trials":4846,"activeCount":103},[],{"trials":4848,"activeCount":103},[],{"trials":4850,"activeCount":103},[],{"trials":4852,"activeCount":103},[],{"trials":4854,"activeCount":103},[4855,4866],{"nctId":4856,"briefTitle":4857,"status":111,"phases":4858,"primaryCompletion":4859,"completion":4860,"start":4861,"enrollment":4862,"conditions":4863,"interventions":4864},"NCT03557385","Adenosine Contrast CorrELations in Evaluating RevAscularizaTION",[94],"2022-05-04","2023-04-04","2019-01-17",201,[922],[4865,4843],"Iopamidol",{"nctId":4867,"briefTitle":4868,"status":155,"phases":4869,"primaryCompletion":4870,"completion":4870,"start":4871,"enrollment":144,"conditions":4872,"interventions":4875},"NCT03249272","Microvascular Dysfunction in Nonischemic Cardiomyopathy: Insights From CMR Assessment of Coronary Flow Reserve",[94],"2019-03-31","2017-09-05",[4548,4873,4874],"Non-ischemic Dilated Cardiomyopathy","Microvascular Ischaemia of Myocardium",[4876,4877],"Regadenoson","Adenosine",{"trials":4879,"activeCount":103},[],{"intervention":4881,"totalTrials":282,"cells":4882},"Paroxetine CR",{"EARLY_PHASE1":4883,"PHASE1":4885,"PHASE2":4887,"PHASE3":4889,"PHASE4":4891,"NA":4910},{"trials":4884,"activeCount":103},[],{"trials":4886,"activeCount":103},[],{"trials":4888,"activeCount":103},[],{"trials":4890,"activeCount":103},[],{"trials":4892,"activeCount":103},[4893,4903],{"nctId":4894,"briefTitle":4895,"status":111,"phases":4896,"primaryCompletion":4897,"completion":4897,"start":4898,"enrollment":4899,"conditions":4900,"interventions":4902},"NCT00610610","Paroxetine-CR (Paxil-CR) in the Treatment of Patients With Fibromyalgia Syndrome",[94],"2002-12","2002-01",120,[4901],"Fibromyalgia Syndrome",[4881],{"nctId":4904,"briefTitle":4905,"status":111,"phases":4906,"primaryCompletion":4897,"completion":4897,"start":4898,"enrollment":9,"conditions":4907,"interventions":4909},"NCT00610909","Paroxetine - Controlled Release in the Treatment of Irritable Bowel Syndrome (IBS)",[94],[4908],"Irritable Bowel Syndrome",[4881],{"trials":4911,"activeCount":103},[],{"intervention":4913,"totalTrials":132,"cells":4914},"Aprepitant + Dexamethasone",{"EARLY_PHASE1":4915,"PHASE1":4917,"PHASE2":4919,"PHASE3":4921,"PHASE4":4923,"NA":4934},{"trials":4916,"activeCount":103},[],{"trials":4918,"activeCount":103},[],{"trials":4920,"activeCount":103},[],{"trials":4922,"activeCount":103},[],{"trials":4924,"activeCount":103},[4925],{"nctId":4926,"briefTitle":4927,"status":111,"phases":4928,"primaryCompletion":4929,"completion":4929,"start":3189,"enrollment":4930,"conditions":4931,"interventions":4932},"NCT00734929","Aprepitant With Dexamethasone Versus Ondansetron With Dexamethasone for PONV Prophylaxis in Patients Having Craniotomy",[94],"2009-06",115,[1204],[4913,4933],"Ondansetron + Dexamethasone",{"trials":4935,"activeCount":103},[],{"intervention":4933,"totalTrials":132,"cells":4937},{"EARLY_PHASE1":4938,"PHASE1":4940,"PHASE2":4942,"PHASE3":4944,"PHASE4":4946,"NA":4952},{"trials":4939,"activeCount":103},[],{"trials":4941,"activeCount":103},[],{"trials":4943,"activeCount":103},[],{"trials":4945,"activeCount":103},[],{"trials":4947,"activeCount":103},[4948],{"nctId":4926,"briefTitle":4927,"status":111,"phases":4949,"primaryCompletion":4929,"completion":4929,"start":3189,"enrollment":4930,"conditions":4950,"interventions":4951},[94],[1204],[4913,4933],{"trials":4953,"activeCount":103},[],{"intervention":4330,"totalTrials":132,"cells":4955},{"EARLY_PHASE1":4956,"PHASE1":4958,"PHASE2":4960,"PHASE3":4962,"PHASE4":4964,"NA":4970},{"trials":4957,"activeCount":103},[],{"trials":4959,"activeCount":103},[],{"trials":4961,"activeCount":103},[],{"trials":4963,"activeCount":103},[],{"trials":4965,"activeCount":103},[4966],{"nctId":4318,"briefTitle":4319,"status":111,"phases":4967,"primaryCompletion":4321,"completion":4321,"start":4322,"enrollment":4323,"conditions":4968,"interventions":4969},[94],[4325,4326,4327],[4305,4329,4330,4331,4332],{"trials":4971,"activeCount":103},[],{"intervention":4331,"totalTrials":132,"cells":4973},{"EARLY_PHASE1":4974,"PHASE1":4976,"PHASE2":4978,"PHASE3":4980,"PHASE4":4982,"NA":4988},{"trials":4975,"activeCount":103},[],{"trials":4977,"activeCount":103},[],{"trials":4979,"activeCount":103},[],{"trials":4981,"activeCount":103},[],{"trials":4983,"activeCount":103},[4984],{"nctId":4318,"briefTitle":4319,"status":111,"phases":4985,"primaryCompletion":4321,"completion":4321,"start":4322,"enrollment":4323,"conditions":4986,"interventions":4987},[94],[4325,4326,4327],[4305,4329,4330,4331,4332],{"trials":4989,"activeCount":103},[],{"intervention":4332,"totalTrials":132,"cells":4991},{"EARLY_PHASE1":4992,"PHASE1":4994,"PHASE2":4996,"PHASE3":4998,"PHASE4":5000,"NA":5006},{"trials":4993,"activeCount":103},[],{"trials":4995,"activeCount":103},[],{"trials":4997,"activeCount":103},[],{"trials":4999,"activeCount":103},[],{"trials":5001,"activeCount":103},[5002],{"nctId":4318,"briefTitle":4319,"status":111,"phases":5003,"primaryCompletion":4321,"completion":4321,"start":4322,"enrollment":4323,"conditions":5004,"interventions":5005},[94],[4325,4326,4327],[4305,4329,4330,4331,4332],{"trials":5007,"activeCount":103},[],{"intervention":5009,"totalTrials":132,"cells":5010},"Aztreonam Lysine for Inhalation",{"EARLY_PHASE1":5011,"PHASE1":5013,"PHASE2":5015,"PHASE3":5017,"PHASE4":5019,"NA":5028},{"trials":5012,"activeCount":103},[],{"trials":5014,"activeCount":103},[],{"trials":5016,"activeCount":103},[],{"trials":5018,"activeCount":103},[],{"trials":5020,"activeCount":103},[5021],{"nctId":5022,"briefTitle":5023,"status":111,"phases":5024,"primaryCompletion":412,"completion":1612,"start":2797,"enrollment":34,"conditions":5025,"interventions":5027},"NCT01469364","Safety Study of Aztreonam Lysine for Inhalation (AZLI) in the Treatment of Early Bronchiolitis Obliterans Syndrome (BOS)",[94],[5026],"Complication of Transplanted Lung",[5009],{"trials":5029,"activeCount":103},[],{"intervention":2344,"totalTrials":132,"cells":5031},{"EARLY_PHASE1":5032,"PHASE1":5034,"PHASE2":5036,"PHASE3":5038,"PHASE4":5040,"NA":5046},{"trials":5033,"activeCount":103},[],{"trials":5035,"activeCount":103},[],{"trials":5037,"activeCount":103},[],{"trials":5039,"activeCount":103},[],{"trials":5041,"activeCount":103},[5042],{"nctId":2335,"briefTitle":2336,"status":428,"phases":5043,"primaryCompletion":1545,"completion":2338,"start":2339,"enrollment":103,"conditions":5044,"interventions":5045},[94],[2341,2342],[2344,2312,2345],{"trials":5047,"activeCount":103},[],{"intervention":2345,"totalTrials":132,"cells":5049},{"EARLY_PHASE1":5050,"PHASE1":5052,"PHASE2":5054,"PHASE3":5056,"PHASE4":5058,"NA":5064},{"trials":5051,"activeCount":103},[],{"trials":5053,"activeCount":103},[],{"trials":5055,"activeCount":103},[],{"trials":5057,"activeCount":103},[],{"trials":5059,"activeCount":103},[5060],{"nctId":2335,"briefTitle":2336,"status":428,"phases":5061,"primaryCompletion":1545,"completion":2338,"start":2339,"enrollment":103,"conditions":5062,"interventions":5063},[94],[2341,2342],[2344,2312,2345],{"trials":5065,"activeCount":103},[],{"intervention":5067,"totalTrials":132,"cells":5068},"Galcanezumab",{"EARLY_PHASE1":5069,"PHASE1":5071,"PHASE2":5073,"PHASE3":5075,"PHASE4":5077,"NA":5089},{"trials":5070,"activeCount":103},[],{"trials":5072,"activeCount":103},[],{"trials":5074,"activeCount":103},[],{"trials":5076,"activeCount":103},[],{"trials":5078,"activeCount":103},[5079],{"nctId":5080,"briefTitle":5081,"status":111,"phases":5082,"primaryCompletion":5083,"completion":5083,"start":5084,"enrollment":37,"conditions":5085,"interventions":5088},"NCT04158752","Anti-CGRP for Inflammation and Pain Modulation in Small Fiber Neuropathy\u002FFibromyalgia",[94],"2023-01-04","2020-07-24",[5086,5087],"Trigeminal Neuralgia","Glossopharyngeal Neuralgia",[5067],{"trials":5090,"activeCount":103},[],{"intervention":4404,"totalTrials":132,"cells":5092},{"EARLY_PHASE1":5093,"PHASE1":5095,"PHASE2":5097,"PHASE3":5099,"PHASE4":5101,"NA":5107},{"trials":5094,"activeCount":103},[],{"trials":5096,"activeCount":103},[],{"trials":5098,"activeCount":103},[],{"trials":5100,"activeCount":103},[],{"trials":5102,"activeCount":103},[5103],{"nctId":4393,"briefTitle":4394,"status":111,"phases":5104,"primaryCompletion":4396,"completion":4396,"start":4397,"enrollment":4398,"conditions":5105,"interventions":5106},[94],[4400,4401,4402],[4404,4405,4370],{"trials":5108,"activeCount":103},[],{"intervention":5110,"totalTrials":132,"cells":5111},"Isovue",{"EARLY_PHASE1":5112,"PHASE1":5114,"PHASE2":5116,"PHASE3":5118,"PHASE4":5120,"NA":5130},{"trials":5113,"activeCount":103},[],{"trials":5115,"activeCount":103},[],{"trials":5117,"activeCount":103},[],{"trials":5119,"activeCount":103},[],{"trials":5121,"activeCount":103},[5122],{"nctId":5123,"briefTitle":5124,"status":111,"phases":5125,"primaryCompletion":217,"completion":217,"start":5126,"enrollment":1452,"conditions":5127,"interventions":5129},"NCT02291718","Thoracoabdominal Arortic CTA Study",[94],"2014-01",[5128],"Thoracic Aortic Aneurysm",[5110],{"trials":5131,"activeCount":103},[],{"intervention":5133,"totalTrials":132,"cells":5134},"Tetanus, Diphtheria, and Pertussis Vaccine",{"EARLY_PHASE1":5135,"PHASE1":5137,"PHASE2":5139,"PHASE3":5141,"PHASE4":5143,"NA":5157},{"trials":5136,"activeCount":103},[],{"trials":5138,"activeCount":103},[],{"trials":5140,"activeCount":103},[],{"trials":5142,"activeCount":103},[],{"trials":5144,"activeCount":103},[5145],{"nctId":5146,"briefTitle":5147,"status":111,"phases":5148,"primaryCompletion":5149,"completion":5150,"start":5151,"enrollment":5152,"conditions":5153,"interventions":5154},"NCT02783170","Safety and Immunogenicity of Simultaneous Tdap and IIV in Pregnant Women",[94],"2018-04-03","2018-05-10","2016-09",81,[805],[5133,5155,5156],"2016-2017 Quadrivalent Inactivated Influenza Vaccine","2017-2018 Quadrivalent Inactivated Influenza Vaccine",{"trials":5158,"activeCount":103},[],{"intervention":5155,"totalTrials":132,"cells":5160},{"EARLY_PHASE1":5161,"PHASE1":5163,"PHASE2":5165,"PHASE3":5167,"PHASE4":5169,"NA":5175},{"trials":5162,"activeCount":103},[],{"trials":5164,"activeCount":103},[],{"trials":5166,"activeCount":103},[],{"trials":5168,"activeCount":103},[],{"trials":5170,"activeCount":103},[5171],{"nctId":5146,"briefTitle":5147,"status":111,"phases":5172,"primaryCompletion":5149,"completion":5150,"start":5151,"enrollment":5152,"conditions":5173,"interventions":5174},[94],[805],[5133,5155,5156],{"trials":5176,"activeCount":103},[],{"intervention":5156,"totalTrials":132,"cells":5178},{"EARLY_PHASE1":5179,"PHASE1":5181,"PHASE2":5183,"PHASE3":5185,"PHASE4":5187,"NA":5193},{"trials":5180,"activeCount":103},[],{"trials":5182,"activeCount":103},[],{"trials":5184,"activeCount":103},[],{"trials":5186,"activeCount":103},[],{"trials":5188,"activeCount":103},[5189],{"nctId":5146,"briefTitle":5147,"status":111,"phases":5190,"primaryCompletion":5149,"completion":5150,"start":5151,"enrollment":5152,"conditions":5191,"interventions":5192},[94],[805],[5133,5155,5156],{"trials":5194,"activeCount":103},[],{"intervention":5196,"totalTrials":132,"cells":5197},"Intravenous acetaminophen",{"EARLY_PHASE1":5198,"PHASE1":5200,"PHASE2":5202,"PHASE3":5204,"PHASE4":5206,"NA":5221},{"trials":5199,"activeCount":103},[],{"trials":5201,"activeCount":103},[],{"trials":5203,"activeCount":103},[],{"trials":5205,"activeCount":103},[],{"trials":5207,"activeCount":103},[5208],{"nctId":5209,"briefTitle":5210,"status":111,"phases":5211,"primaryCompletion":5212,"completion":5213,"start":5214,"enrollment":5152,"conditions":5215,"interventions":5219},"NCT02839876","Intravenous Versus Oral Acetaminophen in Primary Total Hip Arthroplasty",[94],"2018-10-02","2018-10-31","2017-03-14",[5216,5217,5218],"Osteoarthritis","Acetaminophen","Arthroplasty, Hip Replacement",[5196,5220],"Oral acetaminophen",{"trials":5222,"activeCount":103},[],{"intervention":5220,"totalTrials":132,"cells":5224},{"EARLY_PHASE1":5225,"PHASE1":5227,"PHASE2":5229,"PHASE3":5231,"PHASE4":5233,"NA":5239},{"trials":5226,"activeCount":103},[],{"trials":5228,"activeCount":103},[],{"trials":5230,"activeCount":103},[],{"trials":5232,"activeCount":103},[],{"trials":5234,"activeCount":103},[5235],{"nctId":5209,"briefTitle":5210,"status":111,"phases":5236,"primaryCompletion":5212,"completion":5213,"start":5214,"enrollment":5152,"conditions":5237,"interventions":5238},[94],[5216,5217,5218],[5196,5220],{"trials":5240,"activeCount":103},[],{"intervention":5242,"totalTrials":132,"cells":5243},"FLUAD®",{"EARLY_PHASE1":5244,"PHASE1":5246,"PHASE2":5248,"PHASE3":5250,"PHASE4":5252,"NA":5265},{"trials":5245,"activeCount":103},[],{"trials":5247,"activeCount":103},[],{"trials":5249,"activeCount":103},[],{"trials":5251,"activeCount":103},[],{"trials":5253,"activeCount":103},[5254],{"nctId":5255,"briefTitle":5256,"status":111,"phases":5257,"primaryCompletion":5258,"completion":5258,"start":5259,"enrollment":5260,"conditions":5261,"interventions":5263},"NCT03183908","FLUAD® vs. Fluzone® High-Dose Study",[94],"2019-02-14","2017-08-28",757,[36,4508,4509,5262,4510],"Side Effect of Drug",[5242,5264],"Fluzone® High-Dose",{"trials":5266,"activeCount":103},[],{"intervention":5264,"totalTrials":132,"cells":5268},{"EARLY_PHASE1":5269,"PHASE1":5271,"PHASE2":5273,"PHASE3":5275,"PHASE4":5277,"NA":5283},{"trials":5270,"activeCount":103},[],{"trials":5272,"activeCount":103},[],{"trials":5274,"activeCount":103},[],{"trials":5276,"activeCount":103},[],{"trials":5278,"activeCount":103},[5279],{"nctId":5255,"briefTitle":5256,"status":111,"phases":5280,"primaryCompletion":5258,"completion":5258,"start":5259,"enrollment":5260,"conditions":5281,"interventions":5282},[94],[36,4508,4509,5262,4510],[5242,5264],{"trials":5284,"activeCount":103},[],{"intervention":4473,"totalTrials":132,"cells":5286},{"EARLY_PHASE1":5287,"PHASE1":5289,"PHASE2":5291,"PHASE3":5293,"PHASE4":5295,"NA":5301},{"trials":5288,"activeCount":103},[],{"trials":5290,"activeCount":103},[],{"trials":5292,"activeCount":103},[],{"trials":5294,"activeCount":103},[],{"trials":5296,"activeCount":103},[5297],{"nctId":4466,"briefTitle":4467,"status":111,"phases":5298,"primaryCompletion":2857,"completion":2857,"start":1222,"enrollment":4469,"conditions":5299,"interventions":5300},[94],[4471],[4453,4473],{"trials":5302,"activeCount":103},[],{"intervention":5304,"totalTrials":132,"cells":5305},"Ropivacaine 0.1% Injectable Solution",{"EARLY_PHASE1":5306,"PHASE1":5308,"PHASE2":5310,"PHASE3":5312,"PHASE4":5314,"NA":5325},{"trials":5307,"activeCount":103},[],{"trials":5309,"activeCount":103},[],{"trials":5311,"activeCount":103},[],{"trials":5313,"activeCount":103},[],{"trials":5315,"activeCount":103},[5316],{"nctId":5317,"briefTitle":5318,"status":111,"phases":5319,"primaryCompletion":5320,"completion":5320,"start":5321,"enrollment":2935,"conditions":5322,"interventions":5323},"NCT05068661","Comparing Effectiveness of CSE Versus DPE for Labor Analgesia",[94],"2023-12-07","2021-11-21",[3035],[5304,5324],"Bupivacaine 0.25% Injectable Solution",{"trials":5326,"activeCount":103},[],{"intervention":5324,"totalTrials":132,"cells":5328},{"EARLY_PHASE1":5329,"PHASE1":5331,"PHASE2":5333,"PHASE3":5335,"PHASE4":5337,"NA":5343},{"trials":5330,"activeCount":103},[],{"trials":5332,"activeCount":103},[],{"trials":5334,"activeCount":103},[],{"trials":5336,"activeCount":103},[],{"trials":5338,"activeCount":103},[5339],{"nctId":5317,"briefTitle":5318,"status":111,"phases":5340,"primaryCompletion":5320,"completion":5320,"start":5321,"enrollment":2935,"conditions":5341,"interventions":5342},[94],[3035],[5304,5324],{"trials":5344,"activeCount":103},[],{"intervention":5346,"totalTrials":132,"cells":5347},"ABC block with bupivacaine\u002Fliposomal bupivacaine",{"EARLY_PHASE1":5348,"PHASE1":5350,"PHASE2":5352,"PHASE3":5354,"PHASE4":5356,"NA":5367},{"trials":5349,"activeCount":103},[],{"trials":5351,"activeCount":103},[],{"trials":5353,"activeCount":103},[],{"trials":5355,"activeCount":103},[],{"trials":5357,"activeCount":103},[5358],{"nctId":5359,"briefTitle":5360,"status":428,"phases":5361,"primaryCompletion":5362,"completion":5362,"start":5363,"enrollment":103,"conditions":5364,"interventions":5365},"NCT05589363","ABC Blocks for Cardiac Surgery",[94],"2025-07","2024-11",[36],[5346,5366],"ABC block with saline",{"trials":5368,"activeCount":103},[],{"intervention":5366,"totalTrials":132,"cells":5370},{"EARLY_PHASE1":5371,"PHASE1":5373,"PHASE2":5375,"PHASE3":5377,"PHASE4":5379,"NA":5385},{"trials":5372,"activeCount":103},[],{"trials":5374,"activeCount":103},[],{"trials":5376,"activeCount":103},[],{"trials":5378,"activeCount":103},[],{"trials":5380,"activeCount":103},[5381],{"nctId":5359,"briefTitle":5360,"status":428,"phases":5382,"primaryCompletion":5362,"completion":5362,"start":5363,"enrollment":103,"conditions":5383,"interventions":5384},[94],[36],[5346,5366],{"trials":5386,"activeCount":103},[],{"intervention":5388,"totalTrials":132,"cells":5389},"Saxagliptin",{"EARLY_PHASE1":5390,"PHASE1":5392,"PHASE2":5394,"PHASE3":5396,"PHASE4":5398,"NA":5408},{"trials":5391,"activeCount":103},[],{"trials":5393,"activeCount":103},[],{"trials":5395,"activeCount":103},[],{"trials":5397,"activeCount":103},[],{"trials":5399,"activeCount":103},[5400],{"nctId":5401,"briefTitle":5402,"status":155,"phases":5403,"primaryCompletion":2812,"completion":2812,"start":2797,"enrollment":2944,"conditions":5404,"interventions":5407},"NCT01765270","Mechanistic Assessment of the Properties of Saxagliptin in Subjects Undergoing Coronary Artery Bypass Graft Surgery",[94],[5405,5406],"Type 2 Diabetes Mellitus","Cardiovascular Disease",[5388],{"trials":5409,"activeCount":103},[],{"intervention":5411,"totalTrials":132,"cells":5412},"Flucelvax",{"EARLY_PHASE1":5413,"PHASE1":5415,"PHASE2":5417,"PHASE3":5419,"PHASE4":5421,"NA":5434},{"trials":5414,"activeCount":103},[],{"trials":5416,"activeCount":103},[],{"trials":5418,"activeCount":103},[],{"trials":5420,"activeCount":103},[],{"trials":5422,"activeCount":103},[5423],{"nctId":5424,"briefTitle":5425,"status":111,"phases":5426,"primaryCompletion":5427,"completion":274,"start":5428,"enrollment":5429,"conditions":5430,"interventions":5432},"NCT06518577","Immunogenicity of Influenza Vaccinations",[94],"2024-12-09","2024-09-09",605,[5431],"Influenza",[5411,5433],"Flublok",{"trials":5435,"activeCount":103},[],{"intervention":5433,"totalTrials":132,"cells":5437},{"EARLY_PHASE1":5438,"PHASE1":5440,"PHASE2":5442,"PHASE3":5444,"PHASE4":5446,"NA":5452},{"trials":5439,"activeCount":103},[],{"trials":5441,"activeCount":103},[],{"trials":5443,"activeCount":103},[],{"trials":5445,"activeCount":103},[],{"trials":5447,"activeCount":103},[5448],{"nctId":5424,"briefTitle":5425,"status":111,"phases":5449,"primaryCompletion":5427,"completion":274,"start":5428,"enrollment":5429,"conditions":5450,"interventions":5451},[94],[5431],[5411,5433],{"trials":5453,"activeCount":103},[],{"intervention":5455,"totalTrials":132,"cells":5456},"Acetylcysteine",{"EARLY_PHASE1":5457,"PHASE1":5459,"PHASE2":5461,"PHASE3":5463,"PHASE4":5465,"NA":5475},{"trials":5458,"activeCount":103},[],{"trials":5460,"activeCount":103},[],{"trials":5462,"activeCount":103},[],{"trials":5464,"activeCount":103},[],{"trials":5466,"activeCount":103},[5467],{"nctId":5468,"briefTitle":5469,"status":111,"phases":5470,"primaryCompletion":2821,"completion":2650,"start":4642,"enrollment":25,"conditions":5471,"interventions":5473},"NCT02168387","Efficacy of Percussive Ventilation Therapy (MetaNeb ®) Compared With Mucolytic Agents for Atelectasis in the Mechanically Ventilated Pediatric Patient",[94],[5472],"Atelectasis",[5455,5474],"dornase alfa",{"trials":5476,"activeCount":103},[],{"intervention":5474,"totalTrials":132,"cells":5478},{"EARLY_PHASE1":5479,"PHASE1":5481,"PHASE2":5483,"PHASE3":5485,"PHASE4":5487,"NA":5493},{"trials":5480,"activeCount":103},[],{"trials":5482,"activeCount":103},[],{"trials":5484,"activeCount":103},[],{"trials":5486,"activeCount":103},[],{"trials":5488,"activeCount":103},[5489],{"nctId":5468,"briefTitle":5469,"status":111,"phases":5490,"primaryCompletion":2821,"completion":2650,"start":4642,"enrollment":25,"conditions":5491,"interventions":5492},[94],[5472],[5455,5474],{"trials":5494,"activeCount":103},[],{"intervention":4513,"totalTrials":132,"cells":5496},{"EARLY_PHASE1":5497,"PHASE1":5499,"PHASE2":5501,"PHASE3":5503,"PHASE4":5505,"NA":5511},{"trials":5498,"activeCount":103},[],{"trials":5500,"activeCount":103},[],{"trials":5502,"activeCount":103},[],{"trials":5504,"activeCount":103},[],{"trials":5506,"activeCount":103},[5507],{"nctId":4501,"briefTitle":4502,"status":111,"phases":5508,"primaryCompletion":4504,"completion":1681,"start":4505,"enrollment":4506,"conditions":5509,"interventions":5510},[94],[4508,4509,4510,4511],[4513,4488],{"trials":5512,"activeCount":103},[],{"intervention":5514,"totalTrials":132,"cells":5515},"Talc",{"EARLY_PHASE1":5516,"PHASE1":5518,"PHASE2":5520,"PHASE3":5522,"PHASE4":5524,"NA":5534},{"trials":5517,"activeCount":103},[],{"trials":5519,"activeCount":103},[],{"trials":5521,"activeCount":103},[],{"trials":5523,"activeCount":103},[],{"trials":5525,"activeCount":103},[5526],{"nctId":5527,"briefTitle":5528,"status":155,"phases":5529,"primaryCompletion":5530,"completion":5530,"start":3051,"enrollment":402,"conditions":5531,"interventions":5533},"NCT04792970","Randomized Controlled Trial of Talc Instillation In Addition To Daily Drainage Through a Tunneled Pleural Catheter to Improve Rates of Outpatient Pleurodesis in Patients With Malignant Pleural Effusion",[94],"2022-10-07",[5532],"Malignant Pleural Effusion",[5514],{"trials":5535,"activeCount":103},[],{"intervention":4484,"totalTrials":132,"cells":5537},{"EARLY_PHASE1":5538,"PHASE1":5540,"PHASE2":5542,"PHASE3":5544,"PHASE4":5546,"NA":5552},{"trials":5539,"activeCount":103},[],{"trials":5541,"activeCount":103},[],{"trials":5543,"activeCount":103},[],{"trials":5545,"activeCount":103},[],{"trials":5547,"activeCount":103},[5548],{"nctId":4475,"briefTitle":4476,"status":111,"phases":5549,"primaryCompletion":2813,"completion":2813,"start":4478,"enrollment":4479,"conditions":5550,"interventions":5551},[94],[4481],[4483,4484],{"trials":5553,"activeCount":103},[],{"intervention":5555,"totalTrials":132,"cells":5556},"Naltrexone for extended-release injectable suspension",{"EARLY_PHASE1":5557,"PHASE1":5559,"PHASE2":5561,"PHASE3":5563,"PHASE4":5565,"NA":5576},{"trials":5558,"activeCount":103},[],{"trials":5560,"activeCount":103},[],{"trials":5562,"activeCount":103},[],{"trials":5564,"activeCount":103},[],{"trials":5566,"activeCount":103},[5567],{"nctId":5568,"briefTitle":5569,"status":111,"phases":5570,"primaryCompletion":446,"completion":446,"start":5571,"enrollment":1180,"conditions":5572,"interventions":5574},"NCT02978417","Feasibility Study of Extended-release Naltrexone (Vivitrol) in Drug Court Settings",[94],"2017-09-21",[5573],"Opioid-Related Disorders",[5555,5575],"Oral naltrexone",{"trials":5577,"activeCount":103},[],{"intervention":5575,"totalTrials":132,"cells":5579},{"EARLY_PHASE1":5580,"PHASE1":5582,"PHASE2":5584,"PHASE3":5586,"PHASE4":5588,"NA":5594},{"trials":5581,"activeCount":103},[],{"trials":5583,"activeCount":103},[],{"trials":5585,"activeCount":103},[],{"trials":5587,"activeCount":103},[],{"trials":5589,"activeCount":103},[5590],{"nctId":5568,"briefTitle":5569,"status":111,"phases":5591,"primaryCompletion":446,"completion":446,"start":5571,"enrollment":1180,"conditions":5592,"interventions":5593},[94],[5573],[5555,5575],{"trials":5595,"activeCount":103},[],{"intervention":5597,"totalTrials":132,"cells":5598},"Epclusa",{"EARLY_PHASE1":5599,"PHASE1":5601,"PHASE2":5603,"PHASE3":5605,"PHASE4":5607,"NA":5619},{"trials":5600,"activeCount":103},[],{"trials":5602,"activeCount":103},[],{"trials":5604,"activeCount":103},[],{"trials":5606,"activeCount":103},[],{"trials":5608,"activeCount":103},[5609],{"nctId":5610,"briefTitle":5611,"status":155,"phases":5612,"primaryCompletion":5613,"completion":5613,"start":5614,"enrollment":132,"conditions":5615,"interventions":5618},"NCT03207399","Lung Transplantation in Chronic HCV Infection With Post Transplant EPCLUSA Treatment",[94],"2019-03-25","2017-09-15",[5616,5617],"Hepatitis C, Chronic","Lung Transplant",[5597],{"trials":5620,"activeCount":103},[],{"intervention":5622,"totalTrials":132,"cells":5623},"RiaSTAP",{"EARLY_PHASE1":5624,"PHASE1":5626,"PHASE2":5628,"PHASE3":5630,"PHASE4":5632,"NA":5642},{"trials":5625,"activeCount":103},[],{"trials":5627,"activeCount":103},[],{"trials":5629,"activeCount":103},[],{"trials":5631,"activeCount":103},[],{"trials":5633,"activeCount":103},[5634],{"nctId":5635,"briefTitle":5636,"status":111,"phases":5637,"primaryCompletion":1202,"completion":1202,"start":4642,"enrollment":5638,"conditions":5639,"interventions":5641},"NCT01300286","Open Label Use Of RiaStap During Aortic Reconstruction",[94],23,[5640],"Coagulopathic Bleeding",[5622],{"trials":5643,"activeCount":103},[],{"intervention":5645,"totalTrials":132,"cells":5646},"Asenapine 5-20 mg daily",{"EARLY_PHASE1":5647,"PHASE1":5649,"PHASE2":5651,"PHASE3":5653,"PHASE4":5655,"NA":5666},{"trials":5648,"activeCount":103},[],{"trials":5650,"activeCount":103},[],{"trials":5652,"activeCount":103},[],{"trials":5654,"activeCount":103},[],{"trials":5656,"activeCount":103},[5657],{"nctId":5658,"briefTitle":5659,"status":111,"phases":5660,"primaryCompletion":1233,"completion":2812,"start":5661,"enrollment":5662,"conditions":5663,"interventions":5665},"NCT01670019","Antidepressant Plus Asenapine Versus Antidepressant Plus Placebo for Depression",[94],"2012-10",46,[5664],"Major Depressive Disorder Without Psychotic Features",[5645],{"trials":5667,"activeCount":103},[],{"intervention":5669,"totalTrials":132,"cells":5670},"Etonogestrel implant",{"EARLY_PHASE1":5671,"PHASE1":5673,"PHASE2":5675,"PHASE3":5677,"PHASE4":5679,"NA":5688},{"trials":5672,"activeCount":103},[],{"trials":5674,"activeCount":103},[],{"trials":5676,"activeCount":103},[],{"trials":5678,"activeCount":103},[],{"trials":5680,"activeCount":103},[5681],{"nctId":5682,"briefTitle":5683,"status":111,"phases":5684,"primaryCompletion":1612,"completion":1612,"start":2638,"enrollment":9,"conditions":5685,"interventions":5687},"NCT01767285","Immediate vs. Delayed Postpartum Etonogestrel Implant",[94],[5686],"Continuation Rate of Contraceptive Implant",[5669],{"trials":5689,"activeCount":103},[],{"intervention":5691,"totalTrials":132,"cells":5692},"Chloroprocaine Hcl 3% Inj",{"EARLY_PHASE1":5693,"PHASE1":5695,"PHASE2":5697,"PHASE3":5699,"PHASE4":5701,"NA":5713},{"trials":5694,"activeCount":103},[],{"trials":5696,"activeCount":103},[],{"trials":5698,"activeCount":103},[],{"trials":5700,"activeCount":103},[],{"trials":5702,"activeCount":103},[5703],{"nctId":5704,"briefTitle":5705,"status":111,"phases":5706,"primaryCompletion":5707,"completion":5707,"start":5708,"enrollment":5709,"conditions":5710,"interventions":5712},"NCT03805438","ED90 of 3% Chloroprocaine for Cervical Cerclage",[94],"2020-10-23","2019-02-07",47,[5711],"Cerclage, Cervical",[5691],{"trials":5714,"activeCount":103},[],{"intervention":5716,"totalTrials":132,"cells":5717},"Amicar",{"EARLY_PHASE1":5718,"PHASE1":5720,"PHASE2":5722,"PHASE3":5724,"PHASE4":5726,"NA":5740},{"trials":5719,"activeCount":103},[],{"trials":5721,"activeCount":103},[],{"trials":5723,"activeCount":103},[],{"trials":5725,"activeCount":103},[],{"trials":5727,"activeCount":103},[5728],{"nctId":5729,"briefTitle":5730,"status":111,"phases":5731,"primaryCompletion":5732,"completion":5732,"start":1544,"enrollment":5733,"conditions":5734,"interventions":5738},"NCT02030821","TXA vs. Amicar in Total Knee and Hip Arthroplasty",[94],"2017-11-12",246,[5735,5736,5737],"Blood Loss","Hip Arthritis","Knee Arthritis",[5716,5739],"TXA",{"trials":5741,"activeCount":103},[],{"intervention":5739,"totalTrials":132,"cells":5743},{"EARLY_PHASE1":5744,"PHASE1":5746,"PHASE2":5748,"PHASE3":5750,"PHASE4":5752,"NA":5758},{"trials":5745,"activeCount":103},[],{"trials":5747,"activeCount":103},[],{"trials":5749,"activeCount":103},[],{"trials":5751,"activeCount":103},[],{"trials":5753,"activeCount":103},[5754],{"nctId":5729,"briefTitle":5730,"status":111,"phases":5755,"primaryCompletion":5732,"completion":5732,"start":1544,"enrollment":5733,"conditions":5756,"interventions":5757},[94],[5735,5736,5737],[5716,5739],{"trials":5759,"activeCount":103},[],{"intervention":5761,"totalTrials":132,"cells":5762},"Razadyne ER",{"EARLY_PHASE1":5763,"PHASE1":5765,"PHASE2":5767,"PHASE3":5769,"PHASE4":5771,"NA":5784},{"trials":5764,"activeCount":103},[],{"trials":5766,"activeCount":103},[],{"trials":5768,"activeCount":103},[],{"trials":5770,"activeCount":103},[],{"trials":5772,"activeCount":103},[5773],{"nctId":5774,"briefTitle":5775,"status":155,"phases":5776,"primaryCompletion":5777,"completion":5778,"start":5779,"enrollment":402,"conditions":5780,"interventions":5782},"NCT00369603","Functional Brain Imaging of Medication Treatment Response in Mild Alzheimer's Disease Patients",[94],"2007-10","2007-11","2006-10",[5781],"Alzheimer's Disease",[5761,5783],"Aricept",{"trials":5785,"activeCount":103},[],{"intervention":5783,"totalTrials":132,"cells":5787},{"EARLY_PHASE1":5788,"PHASE1":5790,"PHASE2":5792,"PHASE3":5794,"PHASE4":5796,"NA":5802},{"trials":5789,"activeCount":103},[],{"trials":5791,"activeCount":103},[],{"trials":5793,"activeCount":103},[],{"trials":5795,"activeCount":103},[],{"trials":5797,"activeCount":103},[5798],{"nctId":5774,"briefTitle":5775,"status":155,"phases":5799,"primaryCompletion":5777,"completion":5778,"start":5779,"enrollment":402,"conditions":5800,"interventions":5801},[94],[5781],[5761,5783],{"trials":5803,"activeCount":103},[],{"intervention":5805,"totalTrials":132,"cells":5806},"ivabradine",{"EARLY_PHASE1":5807,"PHASE1":5809,"PHASE2":5811,"PHASE3":5813,"PHASE4":5815,"NA":5825},{"trials":5808,"activeCount":103},[],{"trials":5810,"activeCount":103},[],{"trials":5812,"activeCount":103},[],{"trials":5814,"activeCount":103},[],{"trials":5816,"activeCount":103},[5817],{"nctId":5818,"briefTitle":5819,"status":111,"phases":5820,"primaryCompletion":5821,"completion":5821,"start":1221,"enrollment":5822,"conditions":5823,"interventions":5824},"NCT02827500","Predischarge Initiation of Ivabradine in the Management of Heart Failure (PRIME-HF)",[94],"2018-10-15",104,[21],[5805],{"trials":5826,"activeCount":103},[],{"intervention":5828,"totalTrials":132,"cells":5829},"Proguanil Oral",{"EARLY_PHASE1":5830,"PHASE1":5832,"PHASE2":5834,"PHASE3":5836,"PHASE4":5838,"NA":5850},{"trials":5831,"activeCount":103},[],{"trials":5833,"activeCount":103},[],{"trials":5835,"activeCount":103},[],{"trials":5837,"activeCount":103},[],{"trials":5839,"activeCount":103},[5840],{"nctId":5841,"briefTitle":5842,"status":111,"phases":5843,"primaryCompletion":5844,"completion":5844,"start":5845,"enrollment":5733,"conditions":5846,"interventions":5847},"NCT03178643","Enhancing Preventive Therapy of Malaria In Children With Sickle Cell Anemia in East Africa (EPiTOMISE)",[94],"2020-12-16","2018-01-23",[802],[5828,5848,5849],"Sulfadoxine\u002FPyrimethanine-Amodiaquine","Dihydroartemisinin-Piperaquine",{"trials":5851,"activeCount":103},[],{"intervention":5848,"totalTrials":132,"cells":5853},{"EARLY_PHASE1":5854,"PHASE1":5856,"PHASE2":5858,"PHASE3":5860,"PHASE4":5862,"NA":5868},{"trials":5855,"activeCount":103},[],{"trials":5857,"activeCount":103},[],{"trials":5859,"activeCount":103},[],{"trials":5861,"activeCount":103},[],{"trials":5863,"activeCount":103},[5864],{"nctId":5841,"briefTitle":5842,"status":111,"phases":5865,"primaryCompletion":5844,"completion":5844,"start":5845,"enrollment":5733,"conditions":5866,"interventions":5867},[94],[802],[5828,5848,5849],{"trials":5869,"activeCount":103},[],{"intervention":5849,"totalTrials":132,"cells":5871},{"EARLY_PHASE1":5872,"PHASE1":5874,"PHASE2":5876,"PHASE3":5878,"PHASE4":5880,"NA":5886},{"trials":5873,"activeCount":103},[],{"trials":5875,"activeCount":103},[],{"trials":5877,"activeCount":103},[],{"trials":5879,"activeCount":103},[],{"trials":5881,"activeCount":103},[5882],{"nctId":5841,"briefTitle":5842,"status":111,"phases":5883,"primaryCompletion":5844,"completion":5844,"start":5845,"enrollment":5733,"conditions":5884,"interventions":5885},[94],[802],[5828,5848,5849],{"trials":5887,"activeCount":103},[],{"intervention":5889,"totalTrials":132,"cells":5890},"0.59 mg Fluocinolone Acetonide implant",{"EARLY_PHASE1":5891,"PHASE1":5893,"PHASE2":5895,"PHASE3":5897,"PHASE4":5899,"NA":5909},{"trials":5892,"activeCount":103},[],{"trials":5894,"activeCount":103},[],{"trials":5896,"activeCount":103},[],{"trials":5898,"activeCount":103},[],{"trials":5900,"activeCount":103},[5901],{"nctId":5902,"briefTitle":5903,"status":111,"phases":5904,"primaryCompletion":205,"completion":205,"start":5905,"enrollment":3237,"conditions":5906,"interventions":5908},"NCT00543296","Re-implantation of a Fluocinolone Acetonide Implant for Non-infectious Uveitis Affecting the Posterior Segment",[94],"2004-03",[5907],"Uveitis",[5889],{"trials":5910,"activeCount":103},[],{"intervention":5912,"totalTrials":132,"cells":5913},"Eszopiclone",{"EARLY_PHASE1":5914,"PHASE1":5916,"PHASE2":5918,"PHASE3":5920,"PHASE4":5922,"NA":5933},{"trials":5915,"activeCount":103},[],{"trials":5917,"activeCount":103},[],{"trials":5919,"activeCount":103},[],{"trials":5921,"activeCount":103},[],{"trials":5923,"activeCount":103},[5924],{"nctId":5925,"briefTitle":5926,"status":111,"phases":5927,"primaryCompletion":3104,"completion":3104,"start":5928,"enrollment":5929,"conditions":5930,"interventions":5932},"NCT00365976","Study of the Insomnia in Patients With Low Back Pain",[94],"2006-08",58,[5931],"Primary Insomnia",[5912],{"trials":5934,"activeCount":103},[],{"intervention":5936,"totalTrials":132,"cells":5937},"Propranolol",{"EARLY_PHASE1":5938,"PHASE1":5940,"PHASE2":5942,"PHASE3":5944,"PHASE4":5946,"NA":5956},{"trials":5939,"activeCount":103},[],{"trials":5941,"activeCount":103},[],{"trials":5943,"activeCount":103},[],{"trials":5945,"activeCount":103},[],{"trials":5947,"activeCount":103},[5948],{"nctId":5949,"briefTitle":5950,"status":111,"phases":5951,"primaryCompletion":5952,"completion":5952,"start":5953,"enrollment":219,"conditions":5954,"interventions":5955},"NCT03309943","Neurobehavioral Substrates of Propranolol's Effects on Drug Cue Reactivity",[94],"2019-07-15","2018-01-16",[2824],[5936],{"trials":5957,"activeCount":103},[],{"intervention":5959,"totalTrials":132,"cells":5960},"Methylphenidate transdermal system",{"EARLY_PHASE1":5961,"PHASE1":5963,"PHASE2":5965,"PHASE3":5967,"PHASE4":5969,"NA":5982},{"trials":5962,"activeCount":103},[],{"trials":5964,"activeCount":103},[],{"trials":5966,"activeCount":103},[],{"trials":5968,"activeCount":103},[],{"trials":5970,"activeCount":103},[5971],{"nctId":5972,"briefTitle":5973,"status":111,"phases":5974,"primaryCompletion":1545,"completion":1545,"start":3122,"enrollment":5975,"conditions":5976,"interventions":5978},"NCT00889915","Comparing the Effectiveness of New Versus Older Treatments for Attention Deficit Hyperactivity Disorder (The NOTA Study)",[94],228,[5977],"Attention Deficit Disorder With Hyperactivity",[5959,5979,5980,5981],"Lisdexamfetamine dimesylate","Osmotic-release oral system methylphenidate","Mixed amphetamine salts extended release",{"trials":5983,"activeCount":103},[],{"intervention":5979,"totalTrials":132,"cells":5985},{"EARLY_PHASE1":5986,"PHASE1":5988,"PHASE2":5990,"PHASE3":5992,"PHASE4":5994,"NA":6000},{"trials":5987,"activeCount":103},[],{"trials":5989,"activeCount":103},[],{"trials":5991,"activeCount":103},[],{"trials":5993,"activeCount":103},[],{"trials":5995,"activeCount":103},[5996],{"nctId":5972,"briefTitle":5973,"status":111,"phases":5997,"primaryCompletion":1545,"completion":1545,"start":3122,"enrollment":5975,"conditions":5998,"interventions":5999},[94],[5977],[5959,5979,5980,5981],{"trials":6001,"activeCount":103},[],{"intervention":5980,"totalTrials":132,"cells":6003},{"EARLY_PHASE1":6004,"PHASE1":6006,"PHASE2":6008,"PHASE3":6010,"PHASE4":6012,"NA":6018},{"trials":6005,"activeCount":103},[],{"trials":6007,"activeCount":103},[],{"trials":6009,"activeCount":103},[],{"trials":6011,"activeCount":103},[],{"trials":6013,"activeCount":103},[6014],{"nctId":5972,"briefTitle":5973,"status":111,"phases":6015,"primaryCompletion":1545,"completion":1545,"start":3122,"enrollment":5975,"conditions":6016,"interventions":6017},[94],[5977],[5959,5979,5980,5981],{"trials":6019,"activeCount":103},[],{"intervention":5981,"totalTrials":132,"cells":6021},{"EARLY_PHASE1":6022,"PHASE1":6024,"PHASE2":6026,"PHASE3":6028,"PHASE4":6030,"NA":6036},{"trials":6023,"activeCount":103},[],{"trials":6025,"activeCount":103},[],{"trials":6027,"activeCount":103},[],{"trials":6029,"activeCount":103},[],{"trials":6031,"activeCount":103},[6032],{"nctId":5972,"briefTitle":5973,"status":111,"phases":6033,"primaryCompletion":1545,"completion":1545,"start":3122,"enrollment":5975,"conditions":6034,"interventions":6035},[94],[5977],[5959,5979,5980,5981],{"trials":6037,"activeCount":103},[],{"intervention":6039,"totalTrials":132,"cells":6040},"Liposomal Bupivicaine",{"EARLY_PHASE1":6041,"PHASE1":6043,"PHASE2":6045,"PHASE3":6047,"PHASE4":6049,"NA":6061},{"trials":6042,"activeCount":103},[],{"trials":6044,"activeCount":103},[],{"trials":6046,"activeCount":103},[],{"trials":6048,"activeCount":103},[],{"trials":6050,"activeCount":103},[6051],{"nctId":6052,"briefTitle":6053,"status":111,"phases":6054,"primaryCompletion":6055,"completion":6055,"start":6056,"enrollment":219,"conditions":6057,"interventions":6060},"NCT03496610","Surgeon Infiltration QL Block Comparison",[94],"2023-02-23","2021-01-25",[6058,6059],"Quadratus Lumborum Block","Surgical Wound Infiltration",[6039],{"trials":6062,"activeCount":103},[],{"intervention":6064,"totalTrials":132,"cells":6065},"Iloprost and nitric oxide administration",{"EARLY_PHASE1":6066,"PHASE1":6068,"PHASE2":6070,"PHASE3":6072,"PHASE4":6074,"NA":6085},{"trials":6067,"activeCount":103},[],{"trials":6069,"activeCount":103},[],{"trials":6071,"activeCount":103},[],{"trials":6073,"activeCount":103},[],{"trials":6075,"activeCount":103},[6076],{"nctId":6077,"briefTitle":6078,"status":155,"phases":6079,"primaryCompletion":6080,"completion":6081,"start":6082,"enrollment":2112,"conditions":6083,"interventions":6084},"NCT03044314","Outpatient Vasodilator Assessment Using Iloprost in Pulmonary Hypertension",[94],"2019-06-20","2020-05-19","2017-07-21",[1635],[6064],{"trials":6086,"activeCount":103},[],{"intervention":6088,"totalTrials":132,"cells":6089},"iNO",{"EARLY_PHASE1":6090,"PHASE1":6092,"PHASE2":6094,"PHASE3":6096,"PHASE4":6098,"NA":6113},{"trials":6091,"activeCount":103},[],{"trials":6093,"activeCount":103},[],{"trials":6095,"activeCount":103},[],{"trials":6097,"activeCount":103},[],{"trials":6099,"activeCount":103},[6100],{"nctId":6101,"briefTitle":6102,"status":111,"phases":6103,"primaryCompletion":6104,"completion":6105,"start":6106,"enrollment":6107,"conditions":6108,"interventions":6111},"NCT03081052","Inhaled Selective Pulmonary Vasodilators for Advanced Heart Failure Therapies and Lung Transplantation Outcomes",[94],"2020-10-05","2021-09-05","2017-05-04",519,[6109,6110],"Heart Transplant Surgery","Lung Transplant Surgery",[6088,6112],"iEPO",{"trials":6114,"activeCount":103},[],{"intervention":6112,"totalTrials":132,"cells":6116},{"EARLY_PHASE1":6117,"PHASE1":6119,"PHASE2":6121,"PHASE3":6123,"PHASE4":6125,"NA":6131},{"trials":6118,"activeCount":103},[],{"trials":6120,"activeCount":103},[],{"trials":6122,"activeCount":103},[],{"trials":6124,"activeCount":103},[],{"trials":6126,"activeCount":103},[6127],{"nctId":6101,"briefTitle":6102,"status":111,"phases":6128,"primaryCompletion":6104,"completion":6105,"start":6106,"enrollment":6107,"conditions":6129,"interventions":6130},[94],[6109,6110],[6088,6112],{"trials":6132,"activeCount":103},[],{"intervention":6134,"totalTrials":132,"cells":6135},"FLUAD® Quadrivalent",{"EARLY_PHASE1":6136,"PHASE1":6138,"PHASE2":6140,"PHASE3":6142,"PHASE4":6144,"NA":6158},{"trials":6137,"activeCount":103},[],{"trials":6139,"activeCount":103},[],{"trials":6141,"activeCount":103},[],{"trials":6143,"activeCount":103},[],{"trials":6145,"activeCount":103},[6146],{"nctId":6147,"briefTitle":6148,"status":111,"phases":6149,"primaryCompletion":6150,"completion":6151,"start":6152,"enrollment":6153,"conditions":6154,"interventions":6155},"NCT05007041","Simultaneous RZV and aIIV4 Vaccination",[94],"2023-03-04","2023-06-08","2021-09-21",267,[36,4508,4509,4510],[6134,6156,6157],"Fluzone® High-Dose Quadrivalent","SHINGRIX®",{"trials":6159,"activeCount":103},[],{"intervention":6156,"totalTrials":132,"cells":6161},{"EARLY_PHASE1":6162,"PHASE1":6164,"PHASE2":6166,"PHASE3":6168,"PHASE4":6170,"NA":6176},{"trials":6163,"activeCount":103},[],{"trials":6165,"activeCount":103},[],{"trials":6167,"activeCount":103},[],{"trials":6169,"activeCount":103},[],{"trials":6171,"activeCount":103},[6172],{"nctId":6147,"briefTitle":6148,"status":111,"phases":6173,"primaryCompletion":6150,"completion":6151,"start":6152,"enrollment":6153,"conditions":6174,"interventions":6175},[94],[36,4508,4509,4510],[6134,6156,6157],{"trials":6177,"activeCount":103},[],{"intervention":6157,"totalTrials":132,"cells":6179},{"EARLY_PHASE1":6180,"PHASE1":6182,"PHASE2":6184,"PHASE3":6186,"PHASE4":6188,"NA":6194},{"trials":6181,"activeCount":103},[],{"trials":6183,"activeCount":103},[],{"trials":6185,"activeCount":103},[],{"trials":6187,"activeCount":103},[],{"trials":6189,"activeCount":103},[6190],{"nctId":6147,"briefTitle":6148,"status":111,"phases":6191,"primaryCompletion":6150,"completion":6151,"start":6152,"enrollment":6153,"conditions":6192,"interventions":6193},[94],[36,4508,4509,4510],[6134,6156,6157],{"trials":6195,"activeCount":103},[],{"intervention":2355,"totalTrials":132,"cells":6197},{"EARLY_PHASE1":6198,"PHASE1":6200,"PHASE2":6202,"PHASE3":6204,"PHASE4":6206,"NA":6212},{"trials":6199,"activeCount":103},[],{"trials":6201,"activeCount":103},[],{"trials":6203,"activeCount":103},[],{"trials":6205,"activeCount":103},[],{"trials":6207,"activeCount":103},[6208],{"nctId":2347,"briefTitle":2348,"status":155,"phases":6209,"primaryCompletion":2350,"completion":2350,"start":2351,"enrollment":2023,"conditions":6210,"interventions":6211},[94],[2341,2353],[2312,2355],{"trials":6213,"activeCount":103},[],{"intervention":6215,"totalTrials":132,"cells":6216},"Open-label flexibly dosed milnacipran",{"EARLY_PHASE1":6217,"PHASE1":6219,"PHASE2":6221,"PHASE3":6223,"PHASE4":6225,"NA":6235},{"trials":6218,"activeCount":103},[],{"trials":6220,"activeCount":103},[],{"trials":6222,"activeCount":103},[],{"trials":6224,"activeCount":103},[],{"trials":6226,"activeCount":103},[6227],{"nctId":6228,"briefTitle":6229,"status":111,"phases":6230,"primaryCompletion":2813,"completion":2813,"start":3235,"enrollment":1170,"conditions":6231,"interventions":6234},"NCT01780389","Open-label Milnacipran for Persistent Knee Pain One Year After Total Knee Arthroplasty (TKA)",[94],[6232,6233],"Knee Pain After Total Knee Arthroplasty","Osteoarthritis Pain",[6215],{"trials":6236,"activeCount":103},[],{"intervention":5217,"totalTrials":132,"cells":6238},{"EARLY_PHASE1":6239,"PHASE1":6241,"PHASE2":6243,"PHASE3":6245,"PHASE4":6247,"NA":6257},{"trials":6240,"activeCount":103},[],{"trials":6242,"activeCount":103},[],{"trials":6244,"activeCount":103},[],{"trials":6246,"activeCount":103},[],{"trials":6248,"activeCount":103},[6249],{"nctId":6250,"briefTitle":6251,"status":111,"phases":6252,"primaryCompletion":6253,"completion":6253,"start":5661,"enrollment":6254,"conditions":6255,"interventions":6256},"NCT01699815","Time of Intravenous Acetaminophen Administration",[94],"2013-08",126,[5216],[5217],{"trials":6258,"activeCount":103},[],{"intervention":485,"totalTrials":132,"cells":6260},{"EARLY_PHASE1":6261,"PHASE1":6263,"PHASE2":6265,"PHASE3":6267,"PHASE4":6269,"NA":6275},{"trials":6262,"activeCount":103},[],{"trials":6264,"activeCount":103},[],{"trials":6266,"activeCount":103},[],{"trials":6268,"activeCount":103},[],{"trials":6270,"activeCount":103},[6271],{"nctId":473,"briefTitle":474,"status":111,"phases":6272,"primaryCompletion":476,"completion":477,"start":478,"enrollment":479,"conditions":6273,"interventions":6274},[94],[481,263],[249,437,483,484,485],{"trials":6276,"activeCount":103},[],{"intervention":6278,"totalTrials":132,"cells":6279},"Antipsychotic\u002FRisperidone Consta",{"EARLY_PHASE1":6280,"PHASE1":6282,"PHASE2":6284,"PHASE3":6286,"PHASE4":6288,"NA":6297},{"trials":6281,"activeCount":103},[],{"trials":6283,"activeCount":103},[],{"trials":6285,"activeCount":103},[],{"trials":6287,"activeCount":103},[],{"trials":6289,"activeCount":103},[6290],{"nctId":6291,"briefTitle":6292,"status":155,"phases":6293,"primaryCompletion":6294,"start":2602,"enrollment":34,"conditions":6295,"interventions":6296},"NCT00314613","Functional Brain Imaging and Employment in First-Episode Psychotic Patients Treated With Risperdal",[94],"2006-12",[2341],[6278],{"trials":6298,"activeCount":103},[],{"intervention":6300,"totalTrials":132,"cells":6301},"Ropivacaine 0.2% Injectable Solution",{"EARLY_PHASE1":6302,"PHASE1":6304,"PHASE2":6306,"PHASE3":6308,"PHASE4":6310,"NA":6323},{"trials":6303,"activeCount":103},[],{"trials":6305,"activeCount":103},[],{"trials":6307,"activeCount":103},[],{"trials":6309,"activeCount":103},[],{"trials":6311,"activeCount":103},[6312],{"nctId":6313,"briefTitle":6314,"status":111,"phases":6315,"primaryCompletion":6316,"completion":1264,"start":6317,"enrollment":6318,"conditions":6319,"interventions":6322},"NCT05688670","Regional Anesthesia Following Pediatric Cardiac Surgery",[94],"2024-10-18","2023-03-29",52,[6320,6321,247],"Atrial Septal Defect","Ventricular Septal Defect",[6300],{"trials":6324,"activeCount":103},[],{"intervention":6326,"totalTrials":132,"cells":6327},"Pregabalin",{"EARLY_PHASE1":6328,"PHASE1":6330,"PHASE2":6332,"PHASE3":6334,"PHASE4":6336,"NA":6345},{"trials":6329,"activeCount":103},[],{"trials":6331,"activeCount":103},[],{"trials":6333,"activeCount":103},[],{"trials":6335,"activeCount":103},[],{"trials":6337,"activeCount":103},[6338],{"nctId":6339,"briefTitle":6340,"status":111,"phases":6341,"primaryCompletion":3484,"completion":3484,"start":2980,"enrollment":127,"conditions":6342,"interventions":6344},"NCT00573261","A Randomized Double-Blind Study Testing the Effects of Pregabalin on Diabetic Neuropathy",[94],[6343],"Diabetic Neuropathy",[6326],{"trials":6346,"activeCount":103},[],{"intervention":6348,"totalTrials":132,"cells":6349},"Liposomal bupivacaine",{"EARLY_PHASE1":6350,"PHASE1":6352,"PHASE2":6354,"PHASE3":6356,"PHASE4":6358,"NA":6369},{"trials":6351,"activeCount":103},[],{"trials":6353,"activeCount":103},[],{"trials":6355,"activeCount":103},[],{"trials":6357,"activeCount":103},[],{"trials":6359,"activeCount":103},[6360],{"nctId":6361,"briefTitle":6362,"status":111,"phases":6363,"primaryCompletion":1831,"completion":1831,"start":2298,"enrollment":4184,"conditions":6364,"interventions":6366},"NCT06575699","Rectus Sheath Block for Analgesia After Gynecological Laparotomy",[94],[6365],"Gynecologic Surgical Procedures",[6348,6367,6368],"Bupivacaine Hydrochloride","Bupivacaine-Hydromorphone Cassette",{"trials":6370,"activeCount":103},[],{"intervention":6367,"totalTrials":132,"cells":6372},{"EARLY_PHASE1":6373,"PHASE1":6375,"PHASE2":6377,"PHASE3":6379,"PHASE4":6381,"NA":6387},{"trials":6374,"activeCount":103},[],{"trials":6376,"activeCount":103},[],{"trials":6378,"activeCount":103},[],{"trials":6380,"activeCount":103},[],{"trials":6382,"activeCount":103},[6383],{"nctId":6361,"briefTitle":6362,"status":111,"phases":6384,"primaryCompletion":1831,"completion":1831,"start":2298,"enrollment":4184,"conditions":6385,"interventions":6386},[94],[6365],[6348,6367,6368],{"trials":6388,"activeCount":103},[],{"intervention":6368,"totalTrials":132,"cells":6390},{"EARLY_PHASE1":6391,"PHASE1":6393,"PHASE2":6395,"PHASE3":6397,"PHASE4":6399,"NA":6405},{"trials":6392,"activeCount":103},[],{"trials":6394,"activeCount":103},[],{"trials":6396,"activeCount":103},[],{"trials":6398,"activeCount":103},[],{"trials":6400,"activeCount":103},[6401],{"nctId":6361,"briefTitle":6362,"status":111,"phases":6402,"primaryCompletion":1831,"completion":1831,"start":2298,"enrollment":4184,"conditions":6403,"interventions":6404},[94],[6365],[6348,6367,6368],{"trials":6406,"activeCount":103},[],{"intervention":6408,"totalTrials":132,"cells":6409},"Oxybutynin extended release",{"EARLY_PHASE1":6410,"PHASE1":6412,"PHASE2":6414,"PHASE3":6416,"PHASE4":6418,"NA":6430},{"trials":6411,"activeCount":103},[],{"trials":6413,"activeCount":103},[],{"trials":6415,"activeCount":103},[],{"trials":6417,"activeCount":103},[],{"trials":6419,"activeCount":103},[6420],{"nctId":6421,"briefTitle":6422,"status":155,"phases":6423,"primaryCompletion":6424,"completion":6424,"start":6425,"enrollment":6426,"conditions":6427,"interventions":6429},"NCT02176642","Comparison of Combination Therapy vs Single Agent Therapy for Treatment of Urge Incontinence.",[94],"2016-11-21","2014-08",55,[6428],"Urinary Urge Incontinence",[6408],{"trials":6431,"activeCount":103},[],{"intervention":6433,"totalTrials":132,"cells":6434},"ramelteon",{"EARLY_PHASE1":6435,"PHASE1":6437,"PHASE2":6439,"PHASE3":6441,"PHASE4":6443,"NA":6451},{"trials":6436,"activeCount":103},[],{"trials":6438,"activeCount":103},[],{"trials":6440,"activeCount":103},[],{"trials":6442,"activeCount":103},[],{"trials":6444,"activeCount":103},[6445],{"nctId":6446,"briefTitle":6447,"status":111,"phases":6448,"primaryCompletion":3175,"start":205,"enrollment":734,"conditions":6449,"interventions":6450},"NCT02156271","Mechanisms of Sleep Latency and Health: The Effect of a Melatonin Receptor Agonist in Inflammation and Insulin Resistance",[94],[3746],[6433],{"trials":6452,"activeCount":103},[],{"intervention":6454,"totalTrials":132,"cells":6455},"Patiromer Oral Powder Product",{"EARLY_PHASE1":6456,"PHASE1":6458,"PHASE2":6460,"PHASE3":6462,"PHASE4":6464,"NA":6476},{"trials":6457,"activeCount":103},[],{"trials":6459,"activeCount":103},[],{"trials":6461,"activeCount":103},[],{"trials":6463,"activeCount":103},[],{"trials":6465,"activeCount":103},[6466],{"nctId":6467,"briefTitle":6468,"status":111,"phases":6469,"primaryCompletion":6470,"completion":6470,"start":6080,"enrollment":6471,"conditions":6472,"interventions":6475},"NCT03781089","Patiromer Efficacy to Reduce Episodic Hyperkalemia in End Stage Renal Disease Patients",[94],"2023-03-15",36,[6473,6474],"Hyperkalemia","End Stage Renal Disease",[6454],{"trials":6477,"activeCount":103},[],{"intervention":4770,"totalTrials":132,"cells":6479},{"EARLY_PHASE1":6480,"PHASE1":6482,"PHASE2":6484,"PHASE3":6486,"PHASE4":6488,"NA":6494},{"trials":6481,"activeCount":103},[],{"trials":6483,"activeCount":103},[],{"trials":6485,"activeCount":103},[],{"trials":6487,"activeCount":103},[],{"trials":6489,"activeCount":103},[6490],{"nctId":4760,"briefTitle":4761,"status":111,"phases":6491,"primaryCompletion":4763,"completion":4764,"start":4765,"enrollment":4766,"conditions":6492,"interventions":6493},[94],[4341,574,4768],[4747,4770],{"trials":6495,"activeCount":103},[],{"intervention":6497,"totalTrials":132,"cells":6498},"Hyperbaric bupivacaine",{"EARLY_PHASE1":6499,"PHASE1":6501,"PHASE2":6503,"PHASE3":6505,"PHASE4":6507,"NA":6517},{"trials":6500,"activeCount":103},[],{"trials":6502,"activeCount":103},[],{"trials":6504,"activeCount":103},[],{"trials":6506,"activeCount":103},[],{"trials":6508,"activeCount":103},[6509],{"nctId":6510,"briefTitle":6511,"status":428,"phases":6512,"primaryCompletion":6513,"completion":6513,"start":6514,"enrollment":103,"conditions":6515,"interventions":6516},"NCT05017584","ED90 of 0.75% Bupivacaine for Bilateral Tubal Ligation (BTL)",[94],"2024-01-01","2023-01",[36],[6497],{"trials":6518,"activeCount":103},[],{"intervention":6520,"totalTrials":132,"cells":6521},"Glucophage",{"EARLY_PHASE1":6522,"PHASE1":6524,"PHASE2":6526,"PHASE3":6528,"PHASE4":6530,"NA":6539},{"trials":6523,"activeCount":103},[],{"trials":6525,"activeCount":103},[],{"trials":6527,"activeCount":103},[],{"trials":6529,"activeCount":103},[],{"trials":6531,"activeCount":103},[6532],{"nctId":6533,"briefTitle":6534,"status":155,"phases":6535,"primaryCompletion":1202,"completion":1202,"start":3122,"enrollment":160,"conditions":6536,"interventions":6538},"NCT00736385","Metformin for the Treatment of Nonalcoholic Fatty Liver Disease (NAFLD)",[94],[6537],"Fatty Liver",[6520],{"trials":6540,"activeCount":103},[],{"intervention":6542,"totalTrials":132,"cells":6543},"Morphine Sulfate",{"EARLY_PHASE1":6544,"PHASE1":6546,"PHASE2":6548,"PHASE3":6550,"PHASE4":6552,"NA":6564},{"trials":6545,"activeCount":103},[],{"trials":6547,"activeCount":103},[],{"trials":6549,"activeCount":103},[],{"trials":6551,"activeCount":103},[],{"trials":6553,"activeCount":103},[6554],{"nctId":6555,"briefTitle":6556,"status":111,"phases":6557,"primaryCompletion":6558,"completion":6559,"start":6560,"enrollment":6561,"conditions":6562,"interventions":6563},"NCT02222246","Comparing Acute Pain Management Protocols for Patients With Sickle Cell Disease",[94],"2016-05-31","2016-06-30","2015-03-15",106,[4291],[483,6542,483,6542],{"trials":6565,"activeCount":103},[],{"intervention":186,"totalTrials":132,"cells":6567},{"EARLY_PHASE1":6568,"PHASE1":6570,"PHASE2":6572,"PHASE3":6574,"PHASE4":6576,"NA":6582},{"trials":6569,"activeCount":103},[],{"trials":6571,"activeCount":103},[],{"trials":6573,"activeCount":103},[],{"trials":6575,"activeCount":103},[],{"trials":6577,"activeCount":103},[6578],{"nctId":177,"briefTitle":178,"status":111,"phases":6579,"primaryCompletion":180,"completion":181,"start":182,"enrollment":127,"conditions":6580,"interventions":6581},[94],[184],[186,98],{"trials":6583,"activeCount":103},[],{"intervention":6585,"totalTrials":132,"cells":6586},"Wellbutrin SR 300Mg Extended-Release",{"EARLY_PHASE1":6587,"PHASE1":6589,"PHASE2":6591,"PHASE3":6593,"PHASE4":6595,"NA":6605},{"trials":6588,"activeCount":103},[],{"trials":6590,"activeCount":103},[],{"trials":6592,"activeCount":103},[],{"trials":6594,"activeCount":103},[],{"trials":6596,"activeCount":103},[6597],{"nctId":6598,"briefTitle":6599,"status":111,"phases":6600,"primaryCompletion":6601,"completion":6601,"start":4338,"enrollment":206,"conditions":6602,"interventions":6604},"NCT03126682","Effect of Bupropion on Seizure Threshold in Depressed Patients",[94],"2018-05-31",[6603],"MDD",[6585],{"trials":6606,"activeCount":103},[],{"intervention":6608,"totalTrials":132,"cells":6609},"Nifedipine Extended-Release",{"EARLY_PHASE1":6610,"PHASE1":6612,"PHASE2":6614,"PHASE3":6616,"PHASE4":6618,"NA":6630},{"trials":6611,"activeCount":103},[],{"trials":6613,"activeCount":103},[],{"trials":6615,"activeCount":103},[],{"trials":6617,"activeCount":103},[],{"trials":6619,"activeCount":103},[6620],{"nctId":6621,"briefTitle":6622,"status":155,"phases":6623,"primaryCompletion":6624,"completion":6625,"start":6626,"enrollment":2944,"conditions":6627,"interventions":6629},"NCT04349124","Persistent Postpartum Hypertension Pilot Trial",[94],"2021-02-12","2021-03-04","2020-08-25",[6628],"Hypertension in Pregnancy",[6608],{"trials":6631,"activeCount":103},[],{"intervention":6633,"totalTrials":132,"cells":6634},"Transfusion of rejuvenated and washed autolgous RBCs",{"EARLY_PHASE1":6635,"PHASE1":6637,"PHASE2":6639,"PHASE3":6641,"PHASE4":6643,"NA":6655},{"trials":6636,"activeCount":103},[],{"trials":6638,"activeCount":103},[],{"trials":6640,"activeCount":103},[],{"trials":6642,"activeCount":103},[],{"trials":6644,"activeCount":103},[6645],{"nctId":6646,"briefTitle":6647,"status":155,"phases":6648,"primaryCompletion":6649,"completion":6649,"start":6650,"enrollment":99,"conditions":6651,"interventions":6653},"NCT03089047","Rejuvenated RBC and VO2 Max in Healthy Subjects",[94],"2018-04-18","2017-09-29",[6652],"Erythrocyte Transfusion",[6633,6654],"Transfusion of washed autolgous RBCs",{"trials":6656,"activeCount":103},[],{"intervention":6654,"totalTrials":132,"cells":6658},{"EARLY_PHASE1":6659,"PHASE1":6661,"PHASE2":6663,"PHASE3":6665,"PHASE4":6667,"NA":6673},{"trials":6660,"activeCount":103},[],{"trials":6662,"activeCount":103},[],{"trials":6664,"activeCount":103},[],{"trials":6666,"activeCount":103},[],{"trials":6668,"activeCount":103},[6669],{"nctId":6646,"briefTitle":6647,"status":155,"phases":6670,"primaryCompletion":6649,"completion":6649,"start":6650,"enrollment":99,"conditions":6671,"interventions":6672},[94],[6652],[6633,6654],{"trials":6674,"activeCount":103},[],{"intervention":6676,"totalTrials":132,"cells":6677},"fos-amprenavir calcium, ritonavir",{"EARLY_PHASE1":6678,"PHASE1":6680,"PHASE2":6682,"PHASE3":6684,"PHASE4":6686,"NA":6695},{"trials":6679,"activeCount":103},[],{"trials":6681,"activeCount":103},[],{"trials":6683,"activeCount":103},[],{"trials":6685,"activeCount":103},[],{"trials":6687,"activeCount":103},[6688],{"nctId":6689,"briefTitle":6690,"status":111,"phases":6691,"primaryCompletion":2943,"completion":2943,"start":2980,"enrollment":1133,"conditions":6692,"interventions":6693},"NCT00335270","A Randomized, Prospective Study of the Efficacy, Safety and Tolerability of Two Doses of GW433908Ritonavir Given With Abacavir\u002FLamivudine Fixed Dose Combination",[94],[3125],[6676,6694],"abacavir\u002Flamivudine as Epzicom",{"trials":6696,"activeCount":103},[],{"intervention":6694,"totalTrials":132,"cells":6698},{"EARLY_PHASE1":6699,"PHASE1":6701,"PHASE2":6703,"PHASE3":6705,"PHASE4":6707,"NA":6713},{"trials":6700,"activeCount":103},[],{"trials":6702,"activeCount":103},[],{"trials":6704,"activeCount":103},[],{"trials":6706,"activeCount":103},[],{"trials":6708,"activeCount":103},[6709],{"nctId":6689,"briefTitle":6690,"status":111,"phases":6710,"primaryCompletion":2943,"completion":2943,"start":2980,"enrollment":1133,"conditions":6711,"interventions":6712},[94],[3125],[6676,6694],{"trials":6714,"activeCount":103},[],{"intervention":6716,"totalTrials":132,"cells":6717},"Ropivicaine 0.5%",{"EARLY_PHASE1":6718,"PHASE1":6720,"PHASE2":6722,"PHASE3":6724,"PHASE4":6726,"NA":6735},{"trials":6719,"activeCount":103},[],{"trials":6721,"activeCount":103},[],{"trials":6723,"activeCount":103},[],{"trials":6725,"activeCount":103},[],{"trials":6727,"activeCount":103},[6728],{"nctId":6729,"briefTitle":6730,"status":111,"phases":6731,"primaryCompletion":3175,"completion":3175,"start":2963,"enrollment":6732,"conditions":6733,"interventions":6734},"NCT00620828","The Role of Intra-Operative Intracapsular Blocks in Post-Operative Pain Management Following Total Knee Arthroplasty",[94],67,[5216],[6716],{"trials":6736,"activeCount":103},[],{"intervention":6738,"totalTrials":132,"cells":6739},"Desipramine",{"EARLY_PHASE1":6740,"PHASE1":6742,"PHASE2":6744,"PHASE3":6746,"PHASE4":6748,"NA":6759},{"trials":6741,"activeCount":103},[],{"trials":6743,"activeCount":103},[],{"trials":6745,"activeCount":103},[],{"trials":6747,"activeCount":103},[],{"trials":6749,"activeCount":103},[6750],{"nctId":6751,"briefTitle":6752,"status":155,"phases":6753,"primaryCompletion":6754,"completion":6754,"start":6755,"enrollment":402,"conditions":6756,"interventions":6758},"NCT03726996","Desipramine in Infantile Neuroaxonal Dystrophy (INAD).",[94],"2019-08-30","2019-01-14",[6757],"Infantile Neuroaxonal Dystrophy",[6738],{"trials":6760,"activeCount":103},[],{"intervention":6762,"totalTrials":132,"cells":6763},"daptomycin 6 mg\u002Fkg IV",{"EARLY_PHASE1":6764,"PHASE1":6766,"PHASE2":6768,"PHASE3":6770,"PHASE4":6772,"NA":6781},{"trials":6765,"activeCount":103},[],{"trials":6767,"activeCount":103},[],{"trials":6769,"activeCount":103},[],{"trials":6771,"activeCount":103},[],{"trials":6773,"activeCount":103},[6774],{"nctId":6775,"briefTitle":6776,"status":155,"phases":6777,"primaryCompletion":2922,"completion":2922,"start":3123,"enrollment":160,"conditions":6778,"interventions":6780},"NCT00572260","A Pilot Study of Daptomycin for Antimicrobial Prophylaxis",[94],[6779],"Antimicrobial Prophylaxis",[6762],{"trials":6782,"activeCount":103},[],{"intervention":6784,"totalTrials":132,"cells":6785},"Aspirin 81Mg Ec Tab",{"EARLY_PHASE1":6786,"PHASE1":6788,"PHASE2":6790,"PHASE3":6792,"PHASE4":6794,"NA":6806},{"trials":6787,"activeCount":103},[],{"trials":6789,"activeCount":103},[],{"trials":6791,"activeCount":103},[],{"trials":6793,"activeCount":103},[],{"trials":6795,"activeCount":103},[6796],{"nctId":6797,"briefTitle":6798,"status":111,"phases":6799,"primaryCompletion":6800,"completion":6800,"start":6801,"enrollment":6802,"conditions":6803,"interventions":6805},"NCT05889468","Postpartum ASA and NT-proBNP",[94],"2024-05-21","2023-07-01",114,[6804],"Blood Pressure",[6784],{"trials":6807,"activeCount":103},[],{"intervention":6809,"totalTrials":132,"cells":6810},"Dural puncture epidural",{"EARLY_PHASE1":6811,"PHASE1":6813,"PHASE2":6815,"PHASE3":6817,"PHASE4":6819,"NA":6831},{"trials":6812,"activeCount":103},[],{"trials":6814,"activeCount":103},[],{"trials":6816,"activeCount":103},[],{"trials":6818,"activeCount":103},[],{"trials":6820,"activeCount":103},[6821],{"nctId":6822,"briefTitle":6823,"status":111,"phases":6824,"primaryCompletion":4200,"completion":4200,"start":6825,"enrollment":6826,"conditions":6827,"interventions":6829},"NCT03074695","DPE Technique in Labor Epidural for Morbidly Obese Women",[94],"2017-04-01",141,[6828,3035],"Morbid Obesity",[6809,6830],"Standard Epidural",{"trials":6832,"activeCount":103},[],{"intervention":6830,"totalTrials":132,"cells":6834},{"EARLY_PHASE1":6835,"PHASE1":6837,"PHASE2":6839,"PHASE3":6841,"PHASE4":6843,"NA":6849},{"trials":6836,"activeCount":103},[],{"trials":6838,"activeCount":103},[],{"trials":6840,"activeCount":103},[],{"trials":6842,"activeCount":103},[],{"trials":6844,"activeCount":103},[6845],{"nctId":6822,"briefTitle":6823,"status":111,"phases":6846,"primaryCompletion":4200,"completion":4200,"start":6825,"enrollment":6826,"conditions":6847,"interventions":6848},[94],[6828,3035],[6809,6830],{"trials":6850,"activeCount":103},[],{"intervention":6852,"totalTrials":132,"cells":6853},"Exparel",{"EARLY_PHASE1":6854,"PHASE1":6856,"PHASE2":6858,"PHASE3":6860,"PHASE4":6862,"NA":6875},{"trials":6855,"activeCount":103},[],{"trials":6857,"activeCount":103},[],{"trials":6859,"activeCount":103},[],{"trials":6861,"activeCount":103},[],{"trials":6863,"activeCount":103},[6864],{"nctId":6865,"briefTitle":6866,"status":111,"phases":6867,"primaryCompletion":6868,"completion":6869,"start":6870,"enrollment":2847,"conditions":6871,"interventions":6874},"NCT03827291","QL Block With Exparel in Colectomy",[94],"2022-12-02","2022-12-09","2019-10-31",[6872,6873],"Laparotomy","Colectomy",[6852],{"trials":6876,"activeCount":103},[],{"intervention":6878,"totalTrials":132,"cells":6879},"Inhaled Iloprost",{"EARLY_PHASE1":6880,"PHASE1":6882,"PHASE2":6884,"PHASE3":6886,"PHASE4":6888,"NA":6896},{"trials":6881,"activeCount":103},[],{"trials":6883,"activeCount":103},[],{"trials":6885,"activeCount":103},[],{"trials":6887,"activeCount":103},[],{"trials":6889,"activeCount":103},[6890],{"nctId":6891,"briefTitle":6892,"status":155,"phases":6893,"primaryCompletion":3091,"completion":3091,"start":3132,"enrollment":2112,"conditions":6894,"interventions":6895},"NCT02170519","Inhaled Aerosolized Prostacyclin for Pulmonary Hypertension Requiring Inhaled Nitric Oxide",[94],[1635],[6878],{"trials":6897,"activeCount":103},[],{"intervention":6899,"totalTrials":132,"cells":6900},"Indocyanine Green",{"EARLY_PHASE1":6901,"PHASE1":6903,"PHASE2":6905,"PHASE3":6907,"PHASE4":6909,"NA":6919},{"trials":6902,"activeCount":103},[],{"trials":6904,"activeCount":103},[],{"trials":6906,"activeCount":103},[],{"trials":6908,"activeCount":103},[],{"trials":6910,"activeCount":103},[6911],{"nctId":6912,"briefTitle":6913,"status":428,"phases":6914,"primaryCompletion":5845,"completion":5845,"start":6915,"enrollment":103,"conditions":6916,"interventions":6918},"NCT03155464","Intraoperative ICG for Systemic Sclerosis",[94],"2017-06-01",[6917],"Systemic Sclerosis",[6899],{"trials":6920,"activeCount":103},[],{"intervention":6922,"totalTrials":132,"cells":6923},"Nitrofurantoin",{"EARLY_PHASE1":6924,"PHASE1":6926,"PHASE2":6928,"PHASE3":6930,"PHASE4":6932,"NA":6942},{"trials":6925,"activeCount":103},[],{"trials":6927,"activeCount":103},[],{"trials":6929,"activeCount":103},[],{"trials":6931,"activeCount":103},[],{"trials":6933,"activeCount":103},[6934],{"nctId":6935,"briefTitle":6936,"status":111,"phases":6937,"primaryCompletion":2797,"completion":1168,"start":2660,"enrollment":6938,"conditions":6939,"interventions":6941},"NCT01450800","Suppressive Therapy With Oral Antibiotics for Prevention of Postoperative Urinary Tract Infection (UTI)",[94],163,[6940],"Urinary Tract Infection",[6922],{"trials":6943,"activeCount":103},[],{"intervention":6945,"totalTrials":132,"cells":6946},"Fixed dose combination zidovudine\u002Flamivudine\u002Fabacavir",{"EARLY_PHASE1":6947,"PHASE1":6949,"PHASE2":6951,"PHASE3":6953,"PHASE4":6955,"NA":6966},{"trials":6948,"activeCount":103},[],{"trials":6950,"activeCount":103},[],{"trials":6952,"activeCount":103},[],{"trials":6954,"activeCount":103},[],{"trials":6956,"activeCount":103},[6957],{"nctId":6958,"briefTitle":6959,"status":111,"phases":6960,"primaryCompletion":3189,"completion":3189,"start":6961,"enrollment":6962,"conditions":6963,"interventions":6965},"NCT00851630","Tuberculosis and Human Immunodeficiency Virus (HIV) Immune Reconstitution Syndrome Trial (THIRST)",[94],"2004-06",70,[3125,6964],"Tuberculosis",[6945],{"trials":6967,"activeCount":103},[],{"intervention":6969,"totalTrials":132,"cells":6970},"CBT + NRT",{"EARLY_PHASE1":6971,"PHASE1":6973,"PHASE2":6975,"PHASE3":6977,"PHASE4":6979,"NA":6988},{"trials":6972,"activeCount":103},[],{"trials":6974,"activeCount":103},[],{"trials":6976,"activeCount":103},[],{"trials":6978,"activeCount":103},[],{"trials":6980,"activeCount":103},[6981],{"nctId":6982,"briefTitle":6983,"status":155,"phases":6984,"primaryCompletion":5928,"start":2622,"enrollment":6985,"conditions":6986,"interventions":6987},"NCT00224419","Testing Pharmacological Therapies for Pregnant Smokers",[94],181,[1066,805],[6969],{"trials":6989,"activeCount":103},[],{"intervention":6991,"totalTrials":132,"cells":6992},"Ephedrine",{"EARLY_PHASE1":6993,"PHASE1":6995,"PHASE2":6997,"PHASE3":6999,"PHASE4":7001,"NA":7013},{"trials":6994,"activeCount":103},[],{"trials":6996,"activeCount":103},[],{"trials":6998,"activeCount":103},[],{"trials":7000,"activeCount":103},[],{"trials":7002,"activeCount":103},[7003],{"nctId":7004,"briefTitle":7005,"status":155,"phases":7006,"primaryCompletion":7007,"completion":7007,"start":7008,"enrollment":2570,"conditions":7009,"interventions":7011},"NCT02025426","Phenylephrine Versus Ephedrine in Pre-eclampsia",[94],"2016-07-08","2012-09",[7010],"Pre-eclampsia",[7012,6991],"Phenylephrine",{"trials":7014,"activeCount":103},[],{"intervention":7016,"totalTrials":132,"cells":7017},"EMLA",{"EARLY_PHASE1":7018,"PHASE1":7020,"PHASE2":7022,"PHASE3":7024,"PHASE4":7026,"NA":7038},{"trials":7019,"activeCount":103},[],{"trials":7021,"activeCount":103},[],{"trials":7023,"activeCount":103},[],{"trials":7025,"activeCount":103},[],{"trials":7027,"activeCount":103},[7028],{"nctId":7029,"briefTitle":7030,"status":155,"phases":7031,"primaryCompletion":7032,"completion":7032,"start":7033,"enrollment":31,"conditions":7034,"interventions":7036},"NCT03654417","Pain Perception During Vulvar Biopsy",[94],"2019-03-12","2018-09-17",[7035],"Any Condition Requiring Vulvar Biopsy",[7016,7037],"Lidocaine",{"trials":7039,"activeCount":103},[],{"intervention":1215,"totalTrials":132,"cells":7041},{"EARLY_PHASE1":7042,"PHASE1":7044,"PHASE2":7046,"PHASE3":7048,"PHASE4":7050,"NA":7056},{"trials":7043,"activeCount":103},[],{"trials":7045,"activeCount":103},[],{"trials":7047,"activeCount":103},[],{"trials":7049,"activeCount":103},[],{"trials":7051,"activeCount":103},[7052],{"nctId":1207,"briefTitle":1208,"status":155,"phases":7053,"primaryCompletion":1210,"completion":1210,"start":1211,"enrollment":1212,"conditions":7054,"interventions":7055},[94],[263],[689,1215],{"trials":7057,"activeCount":103},[],{"intervention":7059,"totalTrials":132,"cells":7060},"Perampanel",{"EARLY_PHASE1":7061,"PHASE1":7063,"PHASE2":7065,"PHASE3":7067,"PHASE4":7069,"NA":7080},{"trials":7062,"activeCount":103},[],{"trials":7064,"activeCount":103},[],{"trials":7066,"activeCount":103},[],{"trials":7068,"activeCount":103},[],{"trials":7070,"activeCount":103},[7071],{"nctId":7072,"briefTitle":7073,"status":111,"phases":7074,"primaryCompletion":5214,"completion":7075,"start":7076,"enrollment":99,"conditions":7077,"interventions":7079},"NCT02363933","Perampanel in Seizure Patients With Primary Glial Brain Tumors",[94],"2017-04-10","2015-04-07",[7078],"Brain Tumor, Primary",[7059],{"trials":7081,"activeCount":103},[],{"intervention":7083,"totalTrials":132,"cells":7084},"Montelukast",{"EARLY_PHASE1":7085,"PHASE1":7087,"PHASE2":7089,"PHASE3":7091,"PHASE4":7093,"NA":7103},{"trials":7086,"activeCount":103},[],{"trials":7088,"activeCount":103},[],{"trials":7090,"activeCount":103},[],{"trials":7092,"activeCount":103},[],{"trials":7094,"activeCount":103},[7095],{"nctId":7096,"briefTitle":7097,"status":155,"phases":7098,"primaryCompletion":7099,"completion":7099,"start":7100,"enrollment":28,"conditions":7101,"interventions":7102},"NCT01016847","Moderate to Persistent Asthma in the Obese Subject",[94],"2013-11","2010-01",[208],[7083],{"trials":7104,"activeCount":103},[],{"intervention":4344,"totalTrials":132,"cells":7106},{"EARLY_PHASE1":7107,"PHASE1":7109,"PHASE2":7111,"PHASE3":7113,"PHASE4":7115,"NA":7121},{"trials":7108,"activeCount":103},[],{"trials":7110,"activeCount":103},[],{"trials":7112,"activeCount":103},[],{"trials":7114,"activeCount":103},[],{"trials":7116,"activeCount":103},[7117],{"nctId":4334,"briefTitle":4335,"status":111,"phases":7118,"primaryCompletion":4337,"completion":4337,"start":4338,"enrollment":4339,"conditions":7119,"interventions":7120},[94],[4341,574,4342],[4305,4329,4344],{"trials":7122,"activeCount":103},[],{"intervention":7124,"totalTrials":132,"cells":7125},"Total intravenous anesthesia with propofol",{"EARLY_PHASE1":7126,"PHASE1":7128,"PHASE2":7130,"PHASE3":7132,"PHASE4":7134,"NA":7148},{"trials":7127,"activeCount":103},[],{"trials":7129,"activeCount":103},[],{"trials":7131,"activeCount":103},[],{"trials":7133,"activeCount":103},[],{"trials":7135,"activeCount":103},[7136],{"nctId":7137,"briefTitle":7138,"status":111,"phases":7139,"primaryCompletion":7140,"completion":7140,"start":7099,"enrollment":7141,"conditions":7142,"interventions":7146},"NCT01993836","Markers of Alzheimers Disease and Cognitive Outcomes After Perioperative Care",[94],"2019-01-10",191,[7143,7144,7145],"Alzheimers Disease","Postoperative Delirium","Post Operative Cognitive Dysfunction",[7124,7147],"General anesthesia with isoflurane",{"trials":7149,"activeCount":103},[],{"intervention":7147,"totalTrials":132,"cells":7151},{"EARLY_PHASE1":7152,"PHASE1":7154,"PHASE2":7156,"PHASE3":7158,"PHASE4":7160,"NA":7166},{"trials":7153,"activeCount":103},[],{"trials":7155,"activeCount":103},[],{"trials":7157,"activeCount":103},[],{"trials":7159,"activeCount":103},[],{"trials":7161,"activeCount":103},[7162],{"nctId":7137,"briefTitle":7138,"status":111,"phases":7163,"primaryCompletion":7140,"completion":7140,"start":7099,"enrollment":7141,"conditions":7164,"interventions":7165},[94],[7143,7144,7145],[7124,7147],{"trials":7167,"activeCount":103},[],{"intervention":210,"totalTrials":132,"cells":7169},{"EARLY_PHASE1":7170,"PHASE1":7172,"PHASE2":7174,"PHASE3":7176,"PHASE4":7178,"NA":7184},{"trials":7171,"activeCount":103},[],{"trials":7173,"activeCount":103},[],{"trials":7175,"activeCount":103},[],{"trials":7177,"activeCount":103},[],{"trials":7179,"activeCount":103},[7180],{"nctId":201,"briefTitle":202,"status":111,"phases":7181,"primaryCompletion":204,"completion":204,"start":205,"enrollment":206,"conditions":7182,"interventions":7183},[94],[208],[210,211,212],{"trials":7185,"activeCount":103},[],{"intervention":212,"totalTrials":132,"cells":7187},{"EARLY_PHASE1":7188,"PHASE1":7190,"PHASE2":7192,"PHASE3":7194,"PHASE4":7196,"NA":7202},{"trials":7189,"activeCount":103},[],{"trials":7191,"activeCount":103},[],{"trials":7193,"activeCount":103},[],{"trials":7195,"activeCount":103},[],{"trials":7197,"activeCount":103},[7198],{"nctId":201,"briefTitle":202,"status":111,"phases":7199,"primaryCompletion":204,"completion":204,"start":205,"enrollment":206,"conditions":7200,"interventions":7201},[94],[208],[210,211,212],{"trials":7203,"activeCount":103},[],{"intervention":7205,"totalTrials":132,"cells":7206},"LCZ696",{"EARLY_PHASE1":7207,"PHASE1":7209,"PHASE2":7211,"PHASE3":7213,"PHASE4":7215,"NA":7230},{"trials":7208,"activeCount":103},[],{"trials":7210,"activeCount":103},[],{"trials":7212,"activeCount":103},[],{"trials":7214,"activeCount":103},[],{"trials":7216,"activeCount":103},[7217],{"nctId":7218,"briefTitle":7219,"status":111,"phases":7220,"primaryCompletion":7221,"completion":7222,"start":7223,"enrollment":7224,"conditions":7225,"interventions":7226},"NCT02816736","EntrestoTM (LCZ696) In Advanced Heart Failure (LIFE Study)",[94],"2020-09-15","2020-09-29","2017-03-02",365,[21],[7205,7227,7228,7229],"valsartan","LCZ696 placebo","valsartan placebo",{"trials":7231,"activeCount":103},[],{"intervention":7227,"totalTrials":132,"cells":7233},{"EARLY_PHASE1":7234,"PHASE1":7236,"PHASE2":7238,"PHASE3":7240,"PHASE4":7242,"NA":7248},{"trials":7235,"activeCount":103},[],{"trials":7237,"activeCount":103},[],{"trials":7239,"activeCount":103},[],{"trials":7241,"activeCount":103},[],{"trials":7243,"activeCount":103},[7244],{"nctId":7218,"briefTitle":7219,"status":111,"phases":7245,"primaryCompletion":7221,"completion":7222,"start":7223,"enrollment":7224,"conditions":7246,"interventions":7247},[94],[21],[7205,7227,7228,7229],{"trials":7249,"activeCount":103},[],{"intervention":7228,"totalTrials":132,"cells":7251},{"EARLY_PHASE1":7252,"PHASE1":7254,"PHASE2":7256,"PHASE3":7258,"PHASE4":7260,"NA":7266},{"trials":7253,"activeCount":103},[],{"trials":7255,"activeCount":103},[],{"trials":7257,"activeCount":103},[],{"trials":7259,"activeCount":103},[],{"trials":7261,"activeCount":103},[7262],{"nctId":7218,"briefTitle":7219,"status":111,"phases":7263,"primaryCompletion":7221,"completion":7222,"start":7223,"enrollment":7224,"conditions":7264,"interventions":7265},[94],[21],[7205,7227,7228,7229],{"trials":7267,"activeCount":103},[],{"intervention":7229,"totalTrials":132,"cells":7269},{"EARLY_PHASE1":7270,"PHASE1":7272,"PHASE2":7274,"PHASE3":7276,"PHASE4":7278,"NA":7284},{"trials":7271,"activeCount":103},[],{"trials":7273,"activeCount":103},[],{"trials":7275,"activeCount":103},[],{"trials":7277,"activeCount":103},[],{"trials":7279,"activeCount":103},[7280],{"nctId":7218,"briefTitle":7219,"status":111,"phases":7281,"primaryCompletion":7221,"completion":7222,"start":7223,"enrollment":7224,"conditions":7282,"interventions":7283},[94],[21],[7205,7227,7228,7229],{"trials":7285,"activeCount":103},[],{"intervention":7287,"totalTrials":132,"cells":7288},"1.5% Lidocaine",{"EARLY_PHASE1":7289,"PHASE1":7291,"PHASE2":7293,"PHASE3":7295,"PHASE4":7297,"NA":7309},{"trials":7290,"activeCount":103},[],{"trials":7292,"activeCount":103},[],{"trials":7294,"activeCount":103},[],{"trials":7296,"activeCount":103},[],{"trials":7298,"activeCount":103},[7299],{"nctId":7300,"briefTitle":7301,"status":111,"phases":7302,"primaryCompletion":7303,"completion":7304,"start":7305,"enrollment":2570,"conditions":7306,"interventions":7308},"NCT06843343","Dispersion Following ESP Versus ITP Blocks Using Lidocaine Study",[94],"2025-07-26","2025-08-01","2025-06-10",[7307,778],"Acute Pain, Postoperative",[7287],{"trials":7310,"activeCount":103},[],{"intervention":3328,"totalTrials":132,"cells":7312},{"EARLY_PHASE1":7313,"PHASE1":7315,"PHASE2":7317,"PHASE3":7319,"PHASE4":7321,"NA":7327},{"trials":7314,"activeCount":103},[],{"trials":7316,"activeCount":103},[],{"trials":7318,"activeCount":103},[],{"trials":7320,"activeCount":103},[],{"trials":7322,"activeCount":103},[7323],{"nctId":3320,"briefTitle":3321,"status":111,"phases":7324,"primaryCompletion":3323,"completion":3323,"start":3324,"enrollment":1452,"conditions":7325,"interventions":7326},[94],[3326],[3328,3329],{"trials":7328,"activeCount":103},[],{"intervention":7330,"totalTrials":132,"cells":7331},"Simultaneous Vaccination",{"EARLY_PHASE1":7332,"PHASE1":7334,"PHASE2":7336,"PHASE3":7338,"PHASE4":7340,"NA":7354},{"trials":7333,"activeCount":103},[],{"trials":7335,"activeCount":103},[],{"trials":7337,"activeCount":103},[],{"trials":7339,"activeCount":103},[],{"trials":7341,"activeCount":103},[7342],{"nctId":7343,"briefTitle":7344,"status":111,"phases":7345,"primaryCompletion":7346,"completion":7347,"start":7348,"enrollment":7349,"conditions":7350,"interventions":7352},"NCT06020118","Comparative Immunogenicity of Concomitant vs Sequential mRNA COVID-19 and Influenza Vaccinations",[94],"2024-03-07","2024-05-17","2023-09-25",455,[5431,7351],"COVID-19",[7330,7353,7353],"Sequential Vaccination",{"trials":7355,"activeCount":103},[],{"intervention":7353,"totalTrials":132,"cells":7357},{"EARLY_PHASE1":7358,"PHASE1":7360,"PHASE2":7362,"PHASE3":7364,"PHASE4":7366,"NA":7372},{"trials":7359,"activeCount":103},[],{"trials":7361,"activeCount":103},[],{"trials":7363,"activeCount":103},[],{"trials":7365,"activeCount":103},[],{"trials":7367,"activeCount":103},[7368],{"nctId":7343,"briefTitle":7344,"status":111,"phases":7369,"primaryCompletion":7346,"completion":7347,"start":7348,"enrollment":7349,"conditions":7370,"interventions":7371},[94],[5431,7351],[7330,7353,7353],{"trials":7373,"activeCount":103},[],{"intervention":4715,"totalTrials":132,"cells":7375},{"EARLY_PHASE1":7376,"PHASE1":7378,"PHASE2":7380,"PHASE3":7382,"PHASE4":7384,"NA":7390},{"trials":7377,"activeCount":103},[],{"trials":7379,"activeCount":103},[],{"trials":7381,"activeCount":103},[],{"trials":7383,"activeCount":103},[],{"trials":7385,"activeCount":103},[7386],{"nctId":4709,"briefTitle":4710,"status":111,"phases":7387,"primaryCompletion":3143,"completion":3143,"start":4712,"enrollment":219,"conditions":7388,"interventions":7389},[94],[343,3746],[4715,4690],{"trials":7391,"activeCount":103},[],{"intervention":7393,"totalTrials":132,"cells":7394},"Sofosbuvir\u002Fledipasvir fixed dose combination",{"EARLY_PHASE1":7395,"PHASE1":7397,"PHASE2":7399,"PHASE3":7401,"PHASE4":7403,"NA":7415},{"trials":7396,"activeCount":103},[],{"trials":7398,"activeCount":103},[],{"trials":7400,"activeCount":103},[],{"trials":7402,"activeCount":103},[],{"trials":7404,"activeCount":103},[7405],{"nctId":7406,"briefTitle":7407,"status":111,"phases":7408,"primaryCompletion":7409,"completion":7410,"start":4289,"enrollment":1893,"conditions":7411,"interventions":7414},"NCT02858180","Hepatitis C Virus(HCV) Heart and Lung Study",[94],"2019-04-11","2019-07-04",[5616,21,7412,7413],"Pulmonary Disease, Chronic Obstructive","Lung Diseases, Interstitial",[7393],{"trials":7416,"activeCount":103},[],{"intervention":4838,"totalTrials":132,"cells":7418},{"EARLY_PHASE1":7419,"PHASE1":7421,"PHASE2":7423,"PHASE3":7425,"PHASE4":7427,"NA":7433},{"trials":7420,"activeCount":103},[],{"trials":7422,"activeCount":103},[],{"trials":7424,"activeCount":103},[],{"trials":7426,"activeCount":103},[],{"trials":7428,"activeCount":103},[7429],{"nctId":4831,"briefTitle":4832,"status":155,"phases":7430,"primaryCompletion":3313,"completion":3313,"start":4834,"enrollment":219,"conditions":7431,"interventions":7432},[94],[4836],[4809,4838,4839],{"trials":7434,"activeCount":103},[],{"intervention":4839,"totalTrials":132,"cells":7436},{"EARLY_PHASE1":7437,"PHASE1":7439,"PHASE2":7441,"PHASE3":7443,"PHASE4":7445,"NA":7451},{"trials":7438,"activeCount":103},[],{"trials":7440,"activeCount":103},[],{"trials":7442,"activeCount":103},[],{"trials":7444,"activeCount":103},[],{"trials":7446,"activeCount":103},[7447],{"nctId":4831,"briefTitle":4832,"status":155,"phases":7448,"primaryCompletion":3313,"completion":3313,"start":4834,"enrollment":219,"conditions":7449,"interventions":7450},[94],[4836],[4809,4838,4839],{"trials":7452,"activeCount":103},[],{"intervention":7454,"totalTrials":132,"cells":7455},"Asenapine 10 mg daily in the evening",{"EARLY_PHASE1":7456,"PHASE1":7458,"PHASE2":7460,"PHASE3":7462,"PHASE4":7464,"NA":7474},{"trials":7457,"activeCount":103},[],{"trials":7459,"activeCount":103},[],{"trials":7461,"activeCount":103},[],{"trials":7463,"activeCount":103},[],{"trials":7465,"activeCount":103},[7466],{"nctId":7467,"briefTitle":7468,"status":111,"phases":7469,"primaryCompletion":7470,"completion":7099,"start":1169,"enrollment":34,"conditions":7471,"interventions":7472},"NCT01549041","Once-Daily Asenapine for Schizophrenia",[94],"2013-04",[2341],[7454,7473],"Asenapine 5 mg twice daily",{"trials":7475,"activeCount":103},[],{"intervention":7473,"totalTrials":132,"cells":7477},{"EARLY_PHASE1":7478,"PHASE1":7480,"PHASE2":7482,"PHASE3":7484,"PHASE4":7486,"NA":7492},{"trials":7479,"activeCount":103},[],{"trials":7481,"activeCount":103},[],{"trials":7483,"activeCount":103},[],{"trials":7485,"activeCount":103},[],{"trials":7487,"activeCount":103},[7488],{"nctId":7467,"briefTitle":7468,"status":111,"phases":7489,"primaryCompletion":7470,"completion":7099,"start":1169,"enrollment":34,"conditions":7490,"interventions":7491},[94],[2341],[7454,7473],{"trials":7493,"activeCount":103},[],{"intervention":3046,"totalTrials":132,"cells":7495},{"EARLY_PHASE1":7496,"PHASE1":7498,"PHASE2":7500,"PHASE3":7502,"PHASE4":7504,"NA":7510},{"trials":7497,"activeCount":103},[],{"trials":7499,"activeCount":103},[],{"trials":7501,"activeCount":103},[],{"trials":7503,"activeCount":103},[],{"trials":7505,"activeCount":103},[7506],{"nctId":3038,"briefTitle":3039,"status":111,"phases":7507,"primaryCompletion":3041,"completion":3042,"start":2836,"enrollment":3043,"conditions":7508,"interventions":7509},[94],[36],[165,3046],{"trials":7511,"activeCount":103},[],{"intervention":223,"totalTrials":132,"cells":7513},{"EARLY_PHASE1":7514,"PHASE1":7516,"PHASE2":7518,"PHASE3":7520,"PHASE4":7522,"NA":7528},{"trials":7515,"activeCount":103},[],{"trials":7517,"activeCount":103},[],{"trials":7519,"activeCount":103},[],{"trials":7521,"activeCount":103},[],{"trials":7523,"activeCount":103},[7524],{"nctId":214,"briefTitle":215,"status":111,"phases":7525,"primaryCompletion":217,"completion":217,"start":218,"enrollment":219,"conditions":7526,"interventions":7527},[94],[221],[223,224,98],{"trials":7529,"activeCount":103},[],{"intervention":224,"totalTrials":132,"cells":7531},{"EARLY_PHASE1":7532,"PHASE1":7534,"PHASE2":7536,"PHASE3":7538,"PHASE4":7540,"NA":7546},{"trials":7533,"activeCount":103},[],{"trials":7535,"activeCount":103},[],{"trials":7537,"activeCount":103},[],{"trials":7539,"activeCount":103},[],{"trials":7541,"activeCount":103},[7542],{"nctId":214,"briefTitle":215,"status":111,"phases":7543,"primaryCompletion":217,"completion":217,"start":218,"enrollment":219,"conditions":7544,"interventions":7545},[94],[221],[223,224,98],{"trials":7547,"activeCount":103},[],{"intervention":7549,"totalTrials":132,"cells":7550},"Depot Risperidone Microsphere",{"EARLY_PHASE1":7551,"PHASE1":7553,"PHASE2":7555,"PHASE3":7557,"PHASE4":7559,"NA":7569},{"trials":7552,"activeCount":103},[],{"trials":7554,"activeCount":103},[],{"trials":7556,"activeCount":103},[],{"trials":7558,"activeCount":103},[],{"trials":7560,"activeCount":103},[7561],{"nctId":7562,"briefTitle":7563,"status":111,"phases":7564,"primaryCompletion":2602,"completion":2602,"start":7565,"enrollment":7566,"conditions":7567,"interventions":7568},"NCT00215579","Determining the Effects of Risperdal Consta in Patients With Psychotic Disorders and Incomplete Adherence",[94],"2004-04",64,[2341,2342],[7549],{"trials":7570,"activeCount":103},[],{"intervention":7572,"totalTrials":132,"cells":7573},"doxercalciferol",{"EARLY_PHASE1":7574,"PHASE1":7576,"PHASE2":7578,"PHASE3":7580,"PHASE4":7582,"NA":7593},{"trials":7575,"activeCount":103},[],{"trials":7577,"activeCount":103},[],{"trials":7579,"activeCount":103},[],{"trials":7581,"activeCount":103},[],{"trials":7583,"activeCount":103},[7584],{"nctId":7585,"briefTitle":7586,"status":111,"phases":7587,"primaryCompletion":7588,"completion":7588,"start":3189,"enrollment":1212,"conditions":7589,"interventions":7592},"NCT00528788","How Vitamin D Analogues Affect Endothelial Cells in Patients on Dialysis",[94],"2012-08",[7590,7591],"Hyperparathyroidism, Secondary","Kidney Failure, Chronic",[7572],{"trials":7594,"activeCount":103},[],{"intervention":3057,"totalTrials":132,"cells":7596},{"EARLY_PHASE1":7597,"PHASE1":7599,"PHASE2":7601,"PHASE3":7603,"PHASE4":7605,"NA":7611},{"trials":7598,"activeCount":103},[],{"trials":7600,"activeCount":103},[],{"trials":7602,"activeCount":103},[],{"trials":7604,"activeCount":103},[],{"trials":7606,"activeCount":103},[7607],{"nctId":3048,"briefTitle":3049,"status":155,"phases":7608,"primaryCompletion":3051,"completion":3052,"start":3053,"enrollment":2944,"conditions":7609,"interventions":7610},[94],[263,3055],[165,3057],{"trials":7612,"activeCount":103},[],{"intervention":7614,"totalTrials":132,"cells":7615},"FloSeal Matrix",{"EARLY_PHASE1":7616,"PHASE1":7618,"PHASE2":7620,"PHASE3":7622,"PHASE4":7624,"NA":7633},{"trials":7617,"activeCount":103},[],{"trials":7619,"activeCount":103},[],{"trials":7621,"activeCount":103},[],{"trials":7623,"activeCount":103},[],{"trials":7625,"activeCount":103},[7626],{"nctId":7627,"briefTitle":7628,"status":155,"phases":7629,"primaryCompletion":7008,"completion":7008,"start":4929,"enrollment":193,"conditions":7630,"interventions":7632},"NCT00742313","Effect on Bleeding When Using FloSeal Matrix™ in Subjects Undergoing Endoscopic Vein Harvest (EVH)",[94],[7631],"Bleeding",[7614],{"trials":7634,"activeCount":103},[],{"intervention":4876,"totalTrials":132,"cells":7636},{"EARLY_PHASE1":7637,"PHASE1":7639,"PHASE2":7641,"PHASE3":7643,"PHASE4":7645,"NA":7651},{"trials":7638,"activeCount":103},[],{"trials":7640,"activeCount":103},[],{"trials":7642,"activeCount":103},[],{"trials":7644,"activeCount":103},[],{"trials":7646,"activeCount":103},[7647],{"nctId":4867,"briefTitle":4868,"status":155,"phases":7648,"primaryCompletion":4870,"completion":4870,"start":4871,"enrollment":144,"conditions":7649,"interventions":7650},[94],[4548,4873,4874],[4876,4877],{"trials":7652,"activeCount":103},[],{"intervention":7654,"totalTrials":132,"cells":7655},"Received HPV vaccine first",{"EARLY_PHASE1":7656,"PHASE1":7658,"PHASE2":7660,"PHASE3":7662,"PHASE4":7664,"NA":7675},{"trials":7657,"activeCount":103},[],{"trials":7659,"activeCount":103},[],{"trials":7661,"activeCount":103},[],{"trials":7663,"activeCount":103},[],{"trials":7665,"activeCount":103},[7666],{"nctId":7667,"briefTitle":7668,"status":111,"phases":7669,"primaryCompletion":7008,"completion":7008,"start":3092,"enrollment":2954,"conditions":7670,"interventions":7673},"NCT00862810","Alternate Dosing Schedules Study for HPV Vaccine",[94],[7671,7672],"Cervical Cancer","Genital Warts",[7654,7674],"Received concomitant vaccines first",{"trials":7676,"activeCount":103},[],{"intervention":7674,"totalTrials":132,"cells":7678},{"EARLY_PHASE1":7679,"PHASE1":7681,"PHASE2":7683,"PHASE3":7685,"PHASE4":7687,"NA":7693},{"trials":7680,"activeCount":103},[],{"trials":7682,"activeCount":103},[],{"trials":7684,"activeCount":103},[],{"trials":7686,"activeCount":103},[],{"trials":7688,"activeCount":103},[7689],{"nctId":7667,"briefTitle":7668,"status":111,"phases":7690,"primaryCompletion":7008,"completion":7008,"start":3092,"enrollment":2954,"conditions":7691,"interventions":7692},[94],[7671,7672],[7654,7674],{"trials":7694,"activeCount":103},[],{"intervention":7696,"totalTrials":132,"cells":7697},"pitocin",{"EARLY_PHASE1":7698,"PHASE1":7700,"PHASE2":7702,"PHASE3":7704,"PHASE4":7706,"NA":7715},{"trials":7699,"activeCount":103},[],{"trials":7701,"activeCount":103},[],{"trials":7703,"activeCount":103},[],{"trials":7705,"activeCount":103},[],{"trials":7707,"activeCount":103},[7708],{"nctId":7709,"briefTitle":7710,"status":111,"phases":7711,"primaryCompletion":3092,"completion":3092,"start":2943,"enrollment":1266,"conditions":7712,"interventions":7714},"NCT02150954","Foley Bulb With Low Dose Pitocin Versus Foley Bulb With a Standard Incremental Infusion Protocol for the Induction of Labor",[94],[7713],"Induction of Labor",[7696],{"trials":7716,"activeCount":103},[],{"intervention":7718,"totalTrials":132,"cells":7719},"Quadrivalent Recombinant Influenza Vaccine",{"EARLY_PHASE1":7720,"PHASE1":7722,"PHASE2":7724,"PHASE3":7726,"PHASE4":7728,"NA":7740},{"trials":7721,"activeCount":103},[],{"trials":7723,"activeCount":103},[],{"trials":7725,"activeCount":103},[],{"trials":7727,"activeCount":103},[],{"trials":7729,"activeCount":103},[7730],{"nctId":7731,"briefTitle":7732,"status":111,"phases":7733,"primaryCompletion":7734,"completion":7734,"start":7735,"enrollment":7736,"conditions":7737,"interventions":7738},"NCT03969641","Safety of RIV4 Versus IIV4 in Pregnant Women",[94],"2021-09-29","2019-09-05",384,[4524,575,4523],[7718,7739],"Quadrivalent Inactivated Influenza Vaccine",{"trials":7741,"activeCount":103},[],{"intervention":7739,"totalTrials":132,"cells":7743},{"EARLY_PHASE1":7744,"PHASE1":7746,"PHASE2":7748,"PHASE3":7750,"PHASE4":7752,"NA":7758},{"trials":7745,"activeCount":103},[],{"trials":7747,"activeCount":103},[],{"trials":7749,"activeCount":103},[],{"trials":7751,"activeCount":103},[],{"trials":7753,"activeCount":103},[7754],{"nctId":7731,"briefTitle":7732,"status":111,"phases":7755,"primaryCompletion":7734,"completion":7734,"start":7735,"enrollment":7736,"conditions":7756,"interventions":7757},[94],[4524,575,4523],[7718,7739],{"trials":7759,"activeCount":103},[],{"intervention":2805,"totalTrials":1170,"cells":7761},{"EARLY_PHASE1":7762,"PHASE1":7764,"PHASE2":7766,"PHASE3":7777,"PHASE4":7802,"NA":7804},{"trials":7763,"activeCount":103},[],{"trials":7765,"activeCount":103},[],{"trials":7767,"activeCount":103},[7768],{"nctId":7769,"briefTitle":7770,"status":111,"phases":7771,"primaryCompletion":1222,"completion":412,"start":2797,"enrollment":7772,"conditions":7773,"interventions":7774},"NCT01806779","Combination Bupropion \u002F Varenicline for Smoking Cessation in Male Smokers",[92],376,[2802],[7775,7776,2805],"Chantix","Zyban",{"trials":7778,"activeCount":103},[7779,7783,7794,7798],{"nctId":2794,"briefTitle":2795,"status":111,"phases":7780,"primaryCompletion":2797,"completion":2798,"start":2799,"enrollment":2800,"conditions":7781,"interventions":7782},[93],[2802],[2804,396,2805,2806],{"nctId":7784,"briefTitle":7785,"status":111,"phases":7786,"primaryCompletion":2813,"completion":4802,"start":3105,"enrollment":7787,"conditions":7788,"interventions":7789},"NCT00894166","Evaluation of a Tailored Smoking Cessation Treatment Algorithm Based on Initial Treatment Response and Genotype",[93],606,[2838],[7790,7791,7792,7793,7791,7792,7793],"Nicotine Patches","Nicotine patches, then bupropion & nicotine patches","Nicotine patches, then varenicline","Nicotine patches, then nicotine patches",{"nctId":2808,"briefTitle":2809,"status":111,"phases":7795,"primaryCompletion":2811,"completion":2812,"start":2813,"enrollment":2814,"conditions":7796,"interventions":7797},[93],[2802],[2804,396,2805],{"nctId":2818,"briefTitle":2819,"status":155,"phases":7799,"primaryCompletion":2798,"completion":2798,"start":2821,"enrollment":2822,"conditions":7800,"interventions":7801},[92,93],[2824,2802],[2826,2827,2828],{"trials":7803,"activeCount":103},[],{"trials":7805,"activeCount":103},[],{"intervention":7807,"totalTrials":402,"cells":7808},"Sildenafil Citrate",{"EARLY_PHASE1":7809,"PHASE1":7811,"PHASE2":7822,"PHASE3":7842,"PHASE4":7854,"NA":7856},{"trials":7810,"activeCount":103},[],{"trials":7812,"activeCount":103},[7813],{"nctId":7814,"briefTitle":7815,"status":111,"phases":7816,"primaryCompletion":1169,"completion":1169,"start":1234,"enrollment":206,"conditions":7817,"interventions":7820},"NCT01219023","Treatment of Palmar Plantar Erythrodysesthesia (PPE) With Topical Sildenafil",[91],[7818,7819],"Hand Foot Syndrome","Palmar Plantar Erythrodysesthesia",[7821],"sildenafil citrate",{"trials":7823,"activeCount":103},[7824,7834],{"nctId":7825,"briefTitle":7826,"status":111,"phases":7827,"primaryCompletion":7828,"completion":7828,"start":5952,"enrollment":1668,"conditions":7829,"interventions":7833},"NCT03686813","Sildenafil for Swimming-Induced Pulmonary Edema (SIPE) Prevention",[92],"2021-10-29",[7830,7831,7832],"Edema, Pulmonary","Immersion","Diving",[7807],{"nctId":7835,"briefTitle":7836,"status":155,"phases":7837,"primaryCompletion":1233,"completion":1233,"start":2797,"enrollment":206,"conditions":7838,"interventions":7840},"NCT01830790","Effects of Sildenafil on Choroidal Thickness in AMD",[92],[7839],"Age-related Macular Degeneration",[7841],"Sildenafil citrate",{"trials":7843,"activeCount":103},[7844],{"nctId":7845,"briefTitle":7846,"status":111,"phases":7847,"primaryCompletion":3105,"completion":4823,"start":7848,"enrollment":7849,"conditions":7850,"interventions":7853},"NCT00517933","Sildenafil Trial of Exercise Performance in Idiopathic Pulmonary Fibrosis",[93],"2007-08",180,[7851,7852],"Pulmonary Fibrosis","Hypertension, Pulmonary",[7807],{"trials":7855,"activeCount":103},[],{"trials":7857,"activeCount":103},[],{"intervention":2914,"totalTrials":229,"cells":7859},{"EARLY_PHASE1":7860,"PHASE1":7862,"PHASE2":7873,"PHASE3":7879,"PHASE4":7885,"NA":7887},{"trials":7861,"activeCount":103},[],{"trials":7863,"activeCount":103},[7864],{"nctId":7865,"briefTitle":7866,"status":155,"phases":7867,"primaryCompletion":7868,"completion":7868,"start":7869,"enrollment":448,"conditions":7870,"interventions":7871},"NCT03011645","Gene-by-Stress Interactions in Intervention Studies Significance",[91],"2020-01-28","2018-05-24",[660],[2914,7872],"Lorcaserin",{"trials":7874,"activeCount":103},[7875],{"nctId":2906,"briefTitle":2907,"status":111,"phases":7876,"primaryCompletion":2909,"completion":204,"start":2910,"enrollment":2530,"conditions":7877,"interventions":7878},[92],[2912],[2914,2897],{"trials":7880,"activeCount":103},[7881],{"nctId":2949,"briefTitle":2950,"status":111,"phases":7882,"primaryCompletion":2952,"completion":2952,"start":2953,"enrollment":2954,"conditions":7883,"interventions":7884},[92,93],[2956],[2914,2897,2958],{"trials":7886,"activeCount":103},[],{"trials":7888,"activeCount":103},[],{"intervention":7890,"totalTrials":282,"cells":7891},"Dalteparin",{"EARLY_PHASE1":7892,"PHASE1":7894,"PHASE2":7896,"PHASE3":7905,"PHASE4":7916,"NA":7918},{"trials":7893,"activeCount":103},[],{"trials":7895,"activeCount":103},[],{"trials":7897,"activeCount":103},[7898],{"nctId":7899,"briefTitle":7900,"status":111,"phases":7901,"primaryCompletion":2798,"completion":4653,"start":2351,"enrollment":2023,"conditions":7902,"interventions":7904},"NCT01419977","Treatment of Sickle Cell Patients Hospitalized in Pain Crisis With Prophylactic Dose Low-molecular-weight Heparin (LMWH) Versus Placebo",[92],[4291,7903],"Vaso-occlusive Crisis",[7890],{"trials":7906,"activeCount":103},[7907],{"nctId":7908,"briefTitle":7909,"status":111,"phases":7910,"primaryCompletion":1625,"completion":1625,"start":204,"enrollment":7911,"conditions":7912,"interventions":7915},"NCT00786474","Effectiveness of Bridging Anticoagulation for Surgery (The BRIDGE Study)",[93],1884,[7913,7914],"Arterial Thromboembolic Events","Atrial Fibrillation",[7890],{"trials":7917,"activeCount":103},[],{"trials":7919,"activeCount":103},[],{"intervention":7921,"totalTrials":282,"cells":7922},"Sildenafil",{"EARLY_PHASE1":7923,"PHASE1":7934,"PHASE2":7936,"PHASE3":7938,"PHASE4":7947,"NA":7949},{"trials":7924,"activeCount":103},[7925],{"nctId":7926,"briefTitle":7927,"status":111,"phases":7928,"primaryCompletion":7929,"completion":7929,"start":3123,"enrollment":206,"conditions":7930,"interventions":7933},"NCT00815646","Prevention and Treatment of Immersion Pulmonary Edema",[90],"2015-12",[7931,7932],"Immersion Pulmonary Edema (IPE)","Swimming Induced Pulmonary Edema (SIPE)",[7921],{"trials":7935,"activeCount":103},[],{"trials":7937,"activeCount":103},[],{"trials":7939,"activeCount":103},[7940],{"nctId":7941,"briefTitle":7942,"status":111,"phases":7943,"primaryCompletion":7008,"completion":7008,"start":2922,"enrollment":7944,"conditions":7945,"interventions":7946},"NCT00763867","Evaluating the Effectiveness of Sildenafil at Improving Health Outcomes and Exercise Ability in People With Diastolic Heart Failure (The RELAX Study)",[93],216,[21],[7921],{"trials":7948,"activeCount":103},[],{"trials":7950,"activeCount":103},[],{"intervention":7952,"totalTrials":282,"cells":7953},"quetiapine",{"EARLY_PHASE1":7954,"PHASE1":7956,"PHASE2":7958,"PHASE3":7960,"PHASE4":7979,"NA":7981},{"trials":7955,"activeCount":103},[],{"trials":7957,"activeCount":103},[],{"trials":7959,"activeCount":103},[],{"trials":7961,"activeCount":103},[7962,7969],{"nctId":7963,"briefTitle":7964,"status":111,"phases":7965,"completion":7966,"start":5905,"enrollment":1893,"conditions":7967,"interventions":7968},"NCT00215254","Quetiapine in Social Anxiety Disorder",[92,93],"2006-02",[2912],[7952],{"nctId":7970,"briefTitle":7971,"status":111,"phases":7972,"primaryCompletion":7973,"completion":7973,"start":7974,"enrollment":9,"conditions":7975,"interventions":7976},"NCT02720198","Levomilnacipran ER vs. Adjunctive Quetiapine for Adults With Inadequate Relief With SSRIs in MDD",[93],"2018-06-12","2017-01-23",[3488],[7977,7978],"Levomilnacipran","Quetiapine",{"trials":7980,"activeCount":103},[],{"trials":7982,"activeCount":103},[],{"intervention":7984,"totalTrials":132,"cells":7985},"Esmolol",{"EARLY_PHASE1":7986,"PHASE1":7988,"PHASE2":7990,"PHASE3":7992,"PHASE4":8002,"NA":8004},{"trials":7987,"activeCount":103},[],{"trials":7989,"activeCount":103},[],{"trials":7991,"activeCount":103},[],{"trials":7993,"activeCount":103},[7994],{"nctId":7995,"briefTitle":7996,"status":155,"phases":7997,"primaryCompletion":2798,"completion":2798,"start":3104,"enrollment":7998,"conditions":7999,"interventions":8001},"NCT01208402","Esmolol for Treatment of Perioperative Tachycardia",[93],76,[8000],"High-risk, Non-cardiovascular Surgeries",[7984],{"trials":8003,"activeCount":103},[],{"trials":8005,"activeCount":103},[],{"intervention":3410,"totalTrials":132,"cells":8007},{"EARLY_PHASE1":8008,"PHASE1":8010,"PHASE2":8012,"PHASE3":8014,"PHASE4":8020,"NA":8022},{"trials":8009,"activeCount":103},[],{"trials":8011,"activeCount":103},[],{"trials":8013,"activeCount":103},[],{"trials":8015,"activeCount":103},[8016],{"nctId":3402,"briefTitle":3403,"status":111,"phases":8017,"primaryCompletion":3405,"completion":3405,"start":3406,"enrollment":3407,"conditions":8018,"interventions":8019},[93],[21],[3410,381],{"trials":8021,"activeCount":103},[],{"trials":8023,"activeCount":103},[],{"intervention":2806,"totalTrials":132,"cells":8025},{"EARLY_PHASE1":8026,"PHASE1":8028,"PHASE2":8030,"PHASE3":8032,"PHASE4":8038,"NA":8040},{"trials":8027,"activeCount":103},[],{"trials":8029,"activeCount":103},[],{"trials":8031,"activeCount":103},[],{"trials":8033,"activeCount":103},[8034],{"nctId":2794,"briefTitle":2795,"status":111,"phases":8035,"primaryCompletion":2797,"completion":2798,"start":2799,"enrollment":2800,"conditions":8036,"interventions":8037},[93],[2802],[2804,396,2805,2806],{"trials":8039,"activeCount":103},[],{"trials":8041,"activeCount":103},[],{"intervention":8043,"totalTrials":132,"cells":8044},"Counseling and active drug intervention",{"EARLY_PHASE1":8045,"PHASE1":8047,"PHASE2":8049,"PHASE3":8051,"PHASE4":8062,"NA":8064},{"trials":8046,"activeCount":103},[],{"trials":8048,"activeCount":103},[],{"trials":8050,"activeCount":103},[],{"trials":8052,"activeCount":103},[8053],{"nctId":8054,"briefTitle":8055,"status":111,"phases":8056,"primaryCompletion":8057,"completion":8057,"start":8058,"enrollment":144,"conditions":8059,"interventions":8061},"NCT03416621","Project Q Pilot: Smoking Cessation for Light Smokers",[93],"2020-02-29","2018-05-17",[8060],"Tobacco Use Cessation",[8043],{"trials":8063,"activeCount":103},[],{"trials":8065,"activeCount":103},[],{"intervention":4646,"totalTrials":132,"cells":8067},{"EARLY_PHASE1":8068,"PHASE1":8070,"PHASE2":8072,"PHASE3":8074,"PHASE4":8080,"NA":8082},{"trials":8069,"activeCount":103},[],{"trials":8071,"activeCount":103},[],{"trials":8073,"activeCount":103},[],{"trials":8075,"activeCount":103},[8076],{"nctId":4639,"briefTitle":4640,"status":111,"phases":8077,"primaryCompletion":4642,"completion":4642,"start":2339,"enrollment":2847,"conditions":8078,"interventions":8079},[93],[4644],[4628,4646],{"trials":8081,"activeCount":103},[],{"trials":8083,"activeCount":103},[],{"intervention":8085,"totalTrials":132,"cells":8086},"Stepped pharmacologic care",{"EARLY_PHASE1":8087,"PHASE1":8089,"PHASE2":8091,"PHASE3":8093,"PHASE4":8103,"NA":8105},{"trials":8088,"activeCount":103},[],{"trials":8090,"activeCount":103},[],{"trials":8092,"activeCount":103},[],{"trials":8094,"activeCount":103},[8095],{"nctId":8096,"briefTitle":8097,"status":111,"phases":8098,"primaryCompletion":413,"completion":8099,"start":2921,"enrollment":8100,"conditions":8101,"interventions":8102},"NCT00608491","Effectiveness of Ultrafiltration in Treating People With Acute Decompensated Heart Failure and Cardiorenal Syndrome (The CARRESS Study)",[93],"2012-06",188,[21],[8085],{"trials":8104,"activeCount":103},[],{"trials":8106,"activeCount":103},[],{"intervention":3195,"totalTrials":132,"cells":8108},{"EARLY_PHASE1":8109,"PHASE1":8111,"PHASE2":8113,"PHASE3":8115,"PHASE4":8121,"NA":8123},{"trials":8110,"activeCount":103},[],{"trials":8112,"activeCount":103},[],{"trials":8114,"activeCount":103},[],{"trials":8116,"activeCount":103},[8117],{"nctId":3186,"briefTitle":3187,"status":111,"phases":8118,"primaryCompletion":3189,"completion":2921,"start":2695,"enrollment":3190,"conditions":8119,"interventions":8120},[92,93],[3192],[3194,3195],{"trials":8122,"activeCount":103},[],{"trials":8124,"activeCount":103},[],{"intervention":8126,"totalTrials":132,"cells":8127},"Armodafinil",{"EARLY_PHASE1":8128,"PHASE1":8130,"PHASE2":8132,"PHASE3":8134,"PHASE4":8144,"NA":8146},{"trials":8129,"activeCount":103},[],{"trials":8131,"activeCount":103},[],{"trials":8133,"activeCount":103},[],{"trials":8135,"activeCount":103},[8136],{"nctId":8137,"briefTitle":8138,"status":111,"phases":8139,"primaryCompletion":217,"completion":217,"start":2351,"enrollment":5152,"conditions":8140,"interventions":8143},"NCT02151253","Cross-over Study of Armodafinil Treatment of Daytime Sleepiness Associated With Treated Nocturia",[92,93],[8141,8142],"Nocturia","Daytime Sleepiness",[8126],{"trials":8145,"activeCount":103},[],{"trials":8147,"activeCount":103},[],{"intervention":8149,"totalTrials":132,"cells":8150},"Intranasal xylitol spray",{"EARLY_PHASE1":8151,"PHASE1":8153,"PHASE2":8155,"PHASE3":8157,"PHASE4":8167,"NA":8169},{"trials":8152,"activeCount":103},[],{"trials":8154,"activeCount":103},[],{"trials":8156,"activeCount":103},[],{"trials":8158,"activeCount":103},[8159],{"nctId":8160,"briefTitle":8161,"status":428,"phases":8162,"primaryCompletion":8163,"completion":8163,"start":8163,"enrollment":103,"conditions":8164,"interventions":8166},"NCT02950311","Xylitol for Otitis Media",[92,93],"2017-11-20",[8165],"Otitis Media With Effusion",[8149],{"trials":8168,"activeCount":103},[],{"trials":8170,"activeCount":103},[],{"intervention":8172,"totalTrials":132,"cells":8173},"duloxetine vs. escitalopram",{"EARLY_PHASE1":8174,"PHASE1":8176,"PHASE2":8178,"PHASE3":8180,"PHASE4":8188,"NA":8190},{"trials":8175,"activeCount":103},[],{"trials":8177,"activeCount":103},[],{"trials":8179,"activeCount":103},[],{"trials":8181,"activeCount":103},[8182],{"nctId":8183,"briefTitle":8184,"status":111,"phases":8185,"completion":7848,"start":2629,"enrollment":37,"conditions":8186,"interventions":8187},"NCT00215228","Effects of Duloxetine vs. Escitalopram on Heart Rate Variability in Depression",[92,93],[3488],[8172],{"trials":8189,"activeCount":103},[],{"trials":8191,"activeCount":103},[],{"intervention":8193,"totalTrials":132,"cells":8194},"Tolvaptan",{"EARLY_PHASE1":8195,"PHASE1":8197,"PHASE2":8199,"PHASE3":8201,"PHASE4":8212,"NA":8214},{"trials":8196,"activeCount":103},[],{"trials":8198,"activeCount":103},[],{"trials":8200,"activeCount":103},[],{"trials":8202,"activeCount":103},[8203],{"nctId":8204,"briefTitle":8205,"status":111,"phases":8206,"primaryCompletion":8207,"completion":8207,"start":5661,"enrollment":8208,"conditions":8209,"interventions":8211},"NCT01644331","Targeting Acute Congestion With Tolvaptan in Congestive Heart Failure",[93],"2016-02",257,[21,8210],"Dyspnea",[8193],{"trials":8213,"activeCount":103},[],{"trials":8215,"activeCount":103},[],{"intervention":8217,"totalTrials":132,"cells":8218},"Dextenza 0.4Mg Ophthalmic Insert",{"EARLY_PHASE1":8219,"PHASE1":8221,"PHASE2":8223,"PHASE3":8225,"PHASE4":8238,"NA":8240},{"trials":8220,"activeCount":103},[],{"trials":8222,"activeCount":103},[],{"trials":8224,"activeCount":103},[],{"trials":8226,"activeCount":103},[8227],{"nctId":8228,"briefTitle":8229,"status":428,"phases":8230,"primaryCompletion":8231,"completion":8231,"start":8232,"enrollment":103,"conditions":8233,"interventions":8236},"NCT04563559","PREFERENTIAL Study",[92,93],"2021-11","2020-11",[8234,8235],"Cataract Surgery","Glaucoma Surgery",[8217,8237],"Prednisolone Acetate 1% Ophthalmic Suspension [PRED FORTE]",{"trials":8239,"activeCount":103},[],{"trials":8241,"activeCount":103},[],{"intervention":8237,"totalTrials":132,"cells":8243},{"EARLY_PHASE1":8244,"PHASE1":8246,"PHASE2":8248,"PHASE3":8250,"PHASE4":8256,"NA":8258},{"trials":8245,"activeCount":103},[],{"trials":8247,"activeCount":103},[],{"trials":8249,"activeCount":103},[],{"trials":8251,"activeCount":103},[8252],{"nctId":8228,"briefTitle":8229,"status":428,"phases":8253,"primaryCompletion":8231,"completion":8231,"start":8232,"enrollment":103,"conditions":8254,"interventions":8255},[92,93],[8234,8235],[8217,8237],{"trials":8257,"activeCount":103},[],{"trials":8259,"activeCount":103},[],{"intervention":7791,"totalTrials":132,"cells":8261},{"EARLY_PHASE1":8262,"PHASE1":8264,"PHASE2":8266,"PHASE3":8268,"PHASE4":8274,"NA":8276},{"trials":8263,"activeCount":103},[],{"trials":8265,"activeCount":103},[],{"trials":8267,"activeCount":103},[],{"trials":8269,"activeCount":103},[8270],{"nctId":7784,"briefTitle":7785,"status":111,"phases":8271,"primaryCompletion":2813,"completion":4802,"start":3105,"enrollment":7787,"conditions":8272,"interventions":8273},[93],[2838],[7790,7791,7792,7793,7791,7792,7793],{"trials":8275,"activeCount":103},[],{"trials":8277,"activeCount":103},[],{"intervention":7792,"totalTrials":132,"cells":8279},{"EARLY_PHASE1":8280,"PHASE1":8282,"PHASE2":8284,"PHASE3":8286,"PHASE4":8292,"NA":8294},{"trials":8281,"activeCount":103},[],{"trials":8283,"activeCount":103},[],{"trials":8285,"activeCount":103},[],{"trials":8287,"activeCount":103},[8288],{"nctId":7784,"briefTitle":7785,"status":111,"phases":8289,"primaryCompletion":2813,"completion":4802,"start":3105,"enrollment":7787,"conditions":8290,"interventions":8291},[93],[2838],[7790,7791,7792,7793,7791,7792,7793],{"trials":8293,"activeCount":103},[],{"trials":8295,"activeCount":103},[],{"intervention":7793,"totalTrials":132,"cells":8297},{"EARLY_PHASE1":8298,"PHASE1":8300,"PHASE2":8302,"PHASE3":8304,"PHASE4":8310,"NA":8312},{"trials":8299,"activeCount":103},[],{"trials":8301,"activeCount":103},[],{"trials":8303,"activeCount":103},[],{"trials":8305,"activeCount":103},[8306],{"nctId":7784,"briefTitle":7785,"status":111,"phases":8307,"primaryCompletion":2813,"completion":4802,"start":3105,"enrollment":7787,"conditions":8308,"interventions":8309},[93],[2838],[7790,7791,7792,7793,7791,7792,7793],{"trials":8311,"activeCount":103},[],{"trials":8313,"activeCount":103},[],{"intervention":8315,"totalTrials":132,"cells":8316},"Furosemide-Q12 hour bolus",{"EARLY_PHASE1":8317,"PHASE1":8319,"PHASE2":8321,"PHASE3":8323,"PHASE4":8336,"NA":8338},{"trials":8318,"activeCount":103},[],{"trials":8320,"activeCount":103},[],{"trials":8322,"activeCount":103},[],{"trials":8324,"activeCount":103},[8325],{"nctId":8326,"briefTitle":8327,"status":111,"phases":8328,"primaryCompletion":7100,"completion":2338,"start":8329,"enrollment":8330,"conditions":8331,"interventions":8332},"NCT00577135","Determining Optimal Dose and Duration of Diuretic Treatment in People With Acute Heart Failure (The DOSE-AHF Study)",[93],"2008-02",308,[21],[8315,8333,8334,8335],"Furosemide-Continuous","Furosemide-Low Intensification","Furosemide-High Intensification",{"trials":8337,"activeCount":103},[],{"trials":8339,"activeCount":103},[],{"intervention":8333,"totalTrials":132,"cells":8341},{"EARLY_PHASE1":8342,"PHASE1":8344,"PHASE2":8346,"PHASE3":8348,"PHASE4":8354,"NA":8356},{"trials":8343,"activeCount":103},[],{"trials":8345,"activeCount":103},[],{"trials":8347,"activeCount":103},[],{"trials":8349,"activeCount":103},[8350],{"nctId":8326,"briefTitle":8327,"status":111,"phases":8351,"primaryCompletion":7100,"completion":2338,"start":8329,"enrollment":8330,"conditions":8352,"interventions":8353},[93],[21],[8315,8333,8334,8335],{"trials":8355,"activeCount":103},[],{"trials":8357,"activeCount":103},[],{"intervention":8334,"totalTrials":132,"cells":8359},{"EARLY_PHASE1":8360,"PHASE1":8362,"PHASE2":8364,"PHASE3":8366,"PHASE4":8372,"NA":8374},{"trials":8361,"activeCount":103},[],{"trials":8363,"activeCount":103},[],{"trials":8365,"activeCount":103},[],{"trials":8367,"activeCount":103},[8368],{"nctId":8326,"briefTitle":8327,"status":111,"phases":8369,"primaryCompletion":7100,"completion":2338,"start":8329,"enrollment":8330,"conditions":8370,"interventions":8371},[93],[21],[8315,8333,8334,8335],{"trials":8373,"activeCount":103},[],{"trials":8375,"activeCount":103},[],{"intervention":8335,"totalTrials":132,"cells":8377},{"EARLY_PHASE1":8378,"PHASE1":8380,"PHASE2":8382,"PHASE3":8384,"PHASE4":8390,"NA":8392},{"trials":8379,"activeCount":103},[],{"trials":8381,"activeCount":103},[],{"trials":8383,"activeCount":103},[],{"trials":8385,"activeCount":103},[8386],{"nctId":8326,"briefTitle":8327,"status":111,"phases":8387,"primaryCompletion":7100,"completion":2338,"start":8329,"enrollment":8330,"conditions":8388,"interventions":8389},[93],[21],[8315,8333,8334,8335],{"trials":8391,"activeCount":103},[],{"trials":8393,"activeCount":103},[],{"intervention":8395,"totalTrials":132,"cells":8396},"Dilaudid",{"EARLY_PHASE1":8397,"PHASE1":8399,"PHASE2":8401,"PHASE3":8403,"PHASE4":8415,"NA":8417},{"trials":8398,"activeCount":103},[],{"trials":8400,"activeCount":103},[],{"trials":8402,"activeCount":103},[],{"trials":8404,"activeCount":103},[8405],{"nctId":8406,"briefTitle":8407,"status":155,"phases":8408,"primaryCompletion":217,"completion":217,"start":8409,"enrollment":8410,"conditions":8411,"interventions":8414},"NCT01986946","Epidural Analgesia Versus IV Analgesia in Lumbar Spine Fusions",[93],"2013-10",17,[8412,36,8413],"Lumbar Spine Fusion","Back Pain",[8395],{"trials":8416,"activeCount":103},[],{"trials":8418,"activeCount":103},[],{"intervention":8420,"totalTrials":132,"cells":8421},"(FDC) ELV\u002FCOBI\u002FFTC\u002FTDF",{"EARLY_PHASE1":8422,"PHASE1":8424,"PHASE2":8426,"PHASE3":8428,"PHASE4":8437,"NA":8439},{"trials":8423,"activeCount":103},[],{"trials":8425,"activeCount":103},[],{"trials":8427,"activeCount":103},[],{"trials":8429,"activeCount":103},[8430],{"nctId":8431,"briefTitle":8432,"status":111,"phases":8433,"primaryCompletion":1934,"completion":8434,"start":7008,"enrollment":4398,"conditions":8435,"interventions":8436},"NCT01694420","Treatment of Acute HIV Infection With Quad Fixed-dose Combination (FDC) Tablet",[93],"2017-02",[3125],[8420],{"trials":8438,"activeCount":103},[],{"trials":8440,"activeCount":103},[],{"intervention":8442,"totalTrials":132,"cells":8443},"RhuMab-E25",{"EARLY_PHASE1":8444,"PHASE1":8446,"PHASE2":8448,"PHASE3":8450,"PHASE4":8460,"NA":8462},{"trials":8445,"activeCount":103},[],{"trials":8447,"activeCount":103},[],{"trials":8449,"activeCount":103},[],{"trials":8451,"activeCount":103},[8452],{"nctId":8453,"briefTitle":8454,"status":111,"phases":8455,"primaryCompletion":2594,"completion":2594,"start":8456,"enrollment":544,"conditions":8457,"interventions":8459},"NCT00829179","Role of RhuMab-E25 in Reducing Exhaled Nitric Oxide (NO) in Allergic Asthma",[93],"2002-10",[8458],"Allergic Asthma",[8442],{"trials":8461,"activeCount":103},[],{"trials":8463,"activeCount":103},[],{"intervention":8465,"totalTrials":132,"cells":8466},"Vilazodone",{"EARLY_PHASE1":8467,"PHASE1":8469,"PHASE2":8471,"PHASE3":8473,"PHASE4":8482,"NA":8484},{"trials":8468,"activeCount":103},[],{"trials":8470,"activeCount":103},[],{"trials":8472,"activeCount":103},[],{"trials":8474,"activeCount":103},[8475],{"nctId":8476,"briefTitle":8477,"status":111,"phases":8478,"primaryCompletion":2811,"completion":2811,"start":1202,"enrollment":6962,"conditions":8479,"interventions":8481},"NCT02015546","Switching From Generic Selective Serotonin Reuptake Inhibitors (SSRIs) and Selective Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs) to Three Different Dose Initiation Strategies With Vilazodone",[93],[8480],"Major Depressive Disorder (MDD)",[8465],{"trials":8483,"activeCount":103},[],{"trials":8485,"activeCount":103},[],{"intervention":8487,"totalTrials":132,"cells":8488},"Bimatoprost eyelash gel",{"EARLY_PHASE1":8489,"PHASE1":8491,"PHASE2":8493,"PHASE3":8495,"PHASE4":8505,"NA":8507},{"trials":8490,"activeCount":103},[],{"trials":8492,"activeCount":103},[],{"trials":8494,"activeCount":103},[],{"trials":8496,"activeCount":103},[8497],{"nctId":8498,"briefTitle":8499,"status":111,"phases":8500,"primaryCompletion":3189,"completion":2909,"start":3254,"enrollment":544,"conditions":8501,"interventions":8504},"NCT01200251","Study of Bimatoprost Gel on Eyelash Growth",[93],[8502,8503],"Madarosis","Hypotrichosis",[8487],{"trials":8506,"activeCount":103},[],{"trials":8508,"activeCount":103},[],{"intervention":8510,"totalTrials":132,"cells":8511},"Active Medication Alone",{"EARLY_PHASE1":8512,"PHASE1":8514,"PHASE2":8516,"PHASE3":8518,"PHASE4":8528,"NA":8530},{"trials":8513,"activeCount":103},[],{"trials":8515,"activeCount":103},[],{"trials":8517,"activeCount":103},[],{"trials":8519,"activeCount":103},[8520],{"nctId":8521,"briefTitle":8522,"status":111,"phases":8523,"primaryCompletion":4256,"completion":4256,"start":4898,"enrollment":8524,"conditions":8525,"interventions":8527},"NCT00023595","Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",[93],2136,[660,8526,2926,2937],"Coronary Disease",[8510],{"trials":8529,"activeCount":103},[],{"trials":8531,"activeCount":103},[],{"intervention":8533,"totalTrials":132,"cells":8534},"Serotonin reuptake inhibitors management",{"EARLY_PHASE1":8535,"PHASE1":8537,"PHASE2":8539,"PHASE3":8541,"PHASE4":8552,"NA":8554},{"trials":8536,"activeCount":103},[],{"trials":8538,"activeCount":103},[],{"trials":8540,"activeCount":103},[],{"trials":8542,"activeCount":103},[8543],{"nctId":8544,"briefTitle":8545,"status":111,"phases":8546,"primaryCompletion":8547,"completion":8547,"start":8548,"enrollment":8549,"conditions":8550,"interventions":8551},"NCT00074815","Treatment of Obsessive Compulsive Disorder in Children",[93],"2009-11","2003-09",124,[2946],[8533],{"trials":8553,"activeCount":103},[],{"trials":8555,"activeCount":103},[],{"intervention":8557,"totalTrials":132,"cells":8558},"sertraline and risperidone",{"EARLY_PHASE1":8559,"PHASE1":8561,"PHASE2":8563,"PHASE3":8565,"PHASE4":8573,"NA":8575},{"trials":8560,"activeCount":103},[],{"trials":8562,"activeCount":103},[],{"trials":8564,"activeCount":103},[],{"trials":8566,"activeCount":103},[8567],{"nctId":8568,"briefTitle":8569,"status":111,"phases":8570,"completion":2934,"start":7565,"enrollment":684,"conditions":8571,"interventions":8572},"NCT00215241","Risperidone Augmentation for PTSD",[92,93],[3192],[8557],{"trials":8574,"activeCount":103},[],{"trials":8576,"activeCount":103},[],{"intervention":7977,"totalTrials":132,"cells":8578},{"EARLY_PHASE1":8579,"PHASE1":8581,"PHASE2":8583,"PHASE3":8585,"PHASE4":8591,"NA":8593},{"trials":8580,"activeCount":103},[],{"trials":8582,"activeCount":103},[],{"trials":8584,"activeCount":103},[],{"trials":8586,"activeCount":103},[8587],{"nctId":7970,"briefTitle":7971,"status":111,"phases":8588,"primaryCompletion":7973,"completion":7973,"start":7974,"enrollment":9,"conditions":8589,"interventions":8590},[93],[3488],[7977,7978],{"trials":8592,"activeCount":103},[],{"trials":8594,"activeCount":103},[],{"intervention":8596,"totalTrials":132,"cells":8597},"Cognitive-behavioral therapy and paroxetine-CR",{"EARLY_PHASE1":8598,"PHASE1":8600,"PHASE2":8602,"PHASE3":8604,"PHASE4":8613,"NA":8615},{"trials":8599,"activeCount":103},[],{"trials":8601,"activeCount":103},[],{"trials":8603,"activeCount":103},[],{"trials":8605,"activeCount":103},[8606],{"nctId":8607,"briefTitle":8608,"status":111,"phases":8609,"completion":431,"start":4897,"enrollment":8410,"conditions":8610,"interventions":8612},"NCT00215163","Paroxetine-CR to Treat Post-Traumatic Stress Disorder (PTSD) Symptomatic After Initial Exposure Therapy",[92,93],[8611],"Stress Disorders, Post-Traumatic",[8596],{"trials":8614,"activeCount":103},[],{"trials":8616,"activeCount":103},[],{"intervention":8618,"totalTrials":132,"cells":8619},"Optimal medical therapy",{"EARLY_PHASE1":8620,"PHASE1":8622,"PHASE2":8624,"PHASE3":8626,"PHASE4":8635,"NA":8637},{"trials":8621,"activeCount":103},[],{"trials":8623,"activeCount":103},[],{"trials":8625,"activeCount":103},[],{"trials":8627,"activeCount":103},[8628],{"nctId":8629,"briefTitle":8630,"status":155,"phases":8631,"primaryCompletion":4478,"completion":4478,"start":2921,"enrollment":282,"conditions":8632,"interventions":8634},"NCT00608140","Effectiveness of Surgical Mitral Valve Repair Versus Medical Treatment for People With Significant Mitral Regurgitation and Non-ischemic Congestive Heart Failure",[93],[8633,21],"Mitral Valve Insufficiency",[8618],{"trials":8636,"activeCount":103},[],{"trials":8638,"activeCount":103},[],{"intervention":8640,"totalTrials":132,"cells":8641},"Standard-of-Care plus Dexmedetomidine",{"EARLY_PHASE1":8642,"PHASE1":8644,"PHASE2":8646,"PHASE3":8648,"PHASE4":8660,"NA":8662},{"trials":8643,"activeCount":103},[],{"trials":8645,"activeCount":103},[],{"trials":8647,"activeCount":103},[],{"trials":8649,"activeCount":103},[8650],{"nctId":8651,"briefTitle":8652,"status":111,"phases":8653,"primaryCompletion":7099,"completion":7099,"start":4823,"enrollment":8654,"conditions":8655,"interventions":8659},"NCT01169467","Cerebral Perfusion Pressure Using Precedex and Other Sedatives",[93],89,[8656,8657,8658],"Endotracheal Intubation","Continuous IV Sedation","ICP Monitoring",[8640],{"trials":8661,"activeCount":103},[],{"trials":8663,"activeCount":103},[],{"intervention":2958,"totalTrials":132,"cells":8665},{"EARLY_PHASE1":8666,"PHASE1":8668,"PHASE2":8670,"PHASE3":8672,"PHASE4":8678,"NA":8680},{"trials":8667,"activeCount":103},[],{"trials":8669,"activeCount":103},[],{"trials":8671,"activeCount":103},[],{"trials":8673,"activeCount":103},[8674],{"nctId":2949,"briefTitle":2950,"status":111,"phases":8675,"primaryCompletion":2952,"completion":2952,"start":2953,"enrollment":2954,"conditions":8676,"interventions":8677},[92,93],[2956],[2914,2897,2958],{"trials":8679,"activeCount":103},[],{"trials":8681,"activeCount":103},[],{"intervention":8683,"totalTrials":132,"cells":8684},"paroxetine versus duloxetine",{"EARLY_PHASE1":8685,"PHASE1":8687,"PHASE2":8689,"PHASE3":8691,"PHASE4":8701,"NA":8703},{"trials":8686,"activeCount":103},[],{"trials":8688,"activeCount":103},[],{"trials":8690,"activeCount":103},[],{"trials":8692,"activeCount":103},[8693],{"nctId":8694,"briefTitle":8695,"status":111,"phases":8696,"completion":3603,"start":8697,"enrollment":127,"conditions":8698,"interventions":8700},"NCT00136383","Comparing Paroxetine and Duloxetine on Cardiovascular Measures",[92,93],"2005-03",[8699],"Depressive Symptoms",[8683],{"trials":8702,"activeCount":103},[],{"trials":8704,"activeCount":103},[],{"intervention":8706,"totalTrials":132,"cells":8707},"N-acetylcysteine",{"EARLY_PHASE1":8708,"PHASE1":8710,"PHASE2":8712,"PHASE3":8714,"PHASE4":8723,"NA":8725},{"trials":8709,"activeCount":103},[],{"trials":8711,"activeCount":103},[],{"trials":8713,"activeCount":103},[],{"trials":8715,"activeCount":103},[8716],{"nctId":8717,"briefTitle":8718,"status":111,"phases":8719,"primaryCompletion":8409,"completion":5126,"start":4823,"enrollment":8720,"conditions":8721,"interventions":8722},"NCT00650091","Evaluating the Effectiveness of Prednisone, Azathioprine, and N-acetylcysteine in Patients With IPF",[93],264,[7851],[8706],{"trials":8724,"activeCount":103},[],{"trials":8726,"activeCount":103},[],{"intervention":8728,"totalTrials":132,"cells":8729},"Dextromethophan",{"EARLY_PHASE1":8730,"PHASE1":8732,"PHASE2":8734,"PHASE3":8736,"PHASE4":8745,"NA":8747},{"trials":8731,"activeCount":103},[],{"trials":8733,"activeCount":103},[],{"trials":8735,"activeCount":103},[],{"trials":8737,"activeCount":103},[8738],{"nctId":8739,"briefTitle":8740,"status":428,"phases":8741,"primaryCompletion":1221,"completion":1221,"start":2857,"enrollment":103,"conditions":8742,"interventions":8744},"NCT02212275","Cortical Metrics in Intervention Trials With Autism Spectrum Disorders",[92,93],[8743],"Autism Spectrum Disorders",[8728],{"trials":8746,"activeCount":103},[],{"trials":8748,"activeCount":103},[],{"intervention":8750,"totalTrials":448,"cells":8751},"carmustine",{"EARLY_PHASE1":8752,"PHASE1":8754,"PHASE2":8790,"PHASE3":8813,"PHASE4":8815,"NA":8817},{"trials":8753,"activeCount":103},[],{"trials":8755,"activeCount":103},[8756,8765,8774,8782],{"nctId":8757,"briefTitle":8758,"status":111,"phases":8759,"primaryCompletion":8760,"completion":8760,"start":8761,"conditions":8762,"interventions":8763},"NCT00003463","Carmustine Wafers Plus Irinotecan in Treating Patients With Recurrent Supratentorial High Grade Gliomas",[91],"2002-07","1998-07",[33],[8750,2606,8764],"polifeprosan 20 with carmustine implant",{"nctId":8766,"briefTitle":8767,"status":111,"phases":8768,"primaryCompletion":8769,"completion":8769,"start":8770,"enrollment":6471,"conditions":8771,"interventions":8772},"NCT00002986","Chemotherapy in Treating Patients With Recurrent Malignant Glioma",[91],"2004-05","1997-02",[33],[8750,8773],"topotecan hydrochloride",{"nctId":8775,"briefTitle":8776,"status":111,"phases":8777,"primaryCompletion":2603,"completion":2603,"start":8778,"enrollment":8779,"conditions":8780,"interventions":8781},"NCT00003348","Carmustine Plus O(6)-Benzylguanine in Treating Patients With Recurrent or Progressive Gliomas of the Brain",[91],"1998-05",56,[33],[2615,8750],{"nctId":8783,"briefTitle":8784,"status":111,"phases":8785,"primaryCompletion":8786,"completion":8786,"start":8787,"enrollment":6471,"conditions":8788,"interventions":8789},"NCT00002988","Irinotecan Plus Carmustine in Treating Patients With Recurrent Primary Malignant Glioma",[91],"2000-11","1997-04",[33],[8750,2606],{"trials":8791,"activeCount":103},[8792,8799,8806],{"nctId":8793,"briefTitle":8794,"status":111,"phases":8795,"primaryCompletion":8796,"completion":8796,"start":2603,"conditions":8797,"interventions":8798},"NCT00005081","Carmustine Plus O6-benzylguanine in Treating Patients With Recurrent or Progressive Glioma",[92],"2001-04",[33],[2615,8750],{"nctId":8800,"briefTitle":8801,"status":111,"phases":8802,"completion":4654,"start":8803,"enrollment":2639,"conditions":8804,"interventions":8805},"NCT00003467","Carmustine in Treating Adults With Recurrent Supratentorial Low-Grade Glioma",[92],"1998-01",[33],[8750,8764],{"nctId":8807,"briefTitle":8808,"status":428,"phases":8809,"completion":8810,"enrollment":103,"conditions":8811,"interventions":8812},"NCT00046878","Carmustine and O(6)-Benzylguanine in Treating Patients With Newly Diagnosed Supratentorial Glioblastoma Multiforme",[92],"2002-08",[33],[2615,8750],{"trials":8814,"activeCount":103},[],{"trials":8816,"activeCount":103},[],{"trials":8818,"activeCount":103},[],{"intervention":1673,"totalTrials":448,"cells":8820},{"EARLY_PHASE1":8821,"PHASE1":8823,"PHASE2":8835,"PHASE3":8883,"PHASE4":8885,"NA":8887},{"trials":8822,"activeCount":103},[],{"trials":8824,"activeCount":103},[8825],{"nctId":8826,"briefTitle":8827,"status":111,"phases":8828,"primaryCompletion":205,"completion":205,"start":8548,"enrollment":2570,"conditions":8829,"interventions":8831},"NCT00281788","Combination Chemotherapy and Radiation Therapy in Treating Patients With Esophageal Cancer or Gastroesophageal Junction Cancer",[91],[8830],"Esophageal Cancer",[8832,8833,8834],"capecitabine","carboplatin","paclitaxel",{"trials":8836,"activeCount":103},[8837,8845,8853,8862,8872,8876],{"nctId":8838,"briefTitle":8839,"status":111,"phases":8840,"completion":8841,"start":8842,"enrollment":305,"conditions":8843,"interventions":8844},"NCT00002749","Carboplatin in Patients With Progressive Gliomas",[92],"2000-03","1993-02",[33],[8833],{"nctId":8846,"briefTitle":8847,"status":111,"phases":8848,"primaryCompletion":3092,"completion":4823,"start":8849,"enrollment":1452,"conditions":8850,"interventions":8851},"NCT00090610","Second-Line Treatment for Patients With Platinum-Sensitive Ovarian Cancer",[92],"2003-10",[1670],[8852,1673],"Docetaxel",{"nctId":8854,"briefTitle":8855,"status":111,"phases":8856,"primaryCompletion":8857,"completion":8857,"start":2963,"enrollment":8858,"conditions":8859,"interventions":8860},"NCT00479674","Phase II Study With Abraxane, Bevacizumab and Carboplatin in Triple Negative Metastatic Breast Cancer",[92],"2014-03",41,[18],[8861,1675,1673],"Abraxane",{"nctId":8863,"briefTitle":8864,"status":111,"phases":8865,"primaryCompletion":8866,"completion":8867,"start":8868,"enrollment":206,"conditions":8869,"interventions":8871},"NCT03128008","Locally Advanced NSCLC Hyperfractionated RT",[92],"2019-01-16","2021-01-27","2017-12-07",[8870],"Carcinoma, Non Small Cell Lung (NSCLC)",[1673,1674],{"nctId":1663,"briefTitle":1664,"status":111,"phases":8873,"primaryCompletion":1666,"completion":1666,"start":1667,"enrollment":1668,"conditions":8874,"interventions":8875},[91,92],[1670,1671],[1645,1673,1674,1675],{"nctId":8877,"briefTitle":8878,"status":155,"phases":8879,"primaryCompletion":2812,"completion":2812,"start":2660,"enrollment":206,"conditions":8880,"interventions":8882},"NCT01207102","Study Of Abraxane® And Carboplatin As First-Line Treatment For Triple Negative Metastatic Breast Cancer",[92],[8881],"Metastatic Breast Cancer",[8861,1673],{"trials":8884,"activeCount":103},[],{"trials":8886,"activeCount":103},[],{"trials":8888,"activeCount":103},[],{"intervention":8890,"totalTrials":1170,"cells":8891},"Dasatinib",{"EARLY_PHASE1":8892,"PHASE1":8894,"PHASE2":8906,"PHASE3":8938,"PHASE4":8940,"NA":8942},{"trials":8893,"activeCount":103},[],{"trials":8895,"activeCount":103},[8896],{"nctId":8897,"briefTitle":8898,"status":155,"phases":8899,"primaryCompletion":1234,"completion":2821,"start":3486,"enrollment":34,"conditions":8900,"interventions":8903},"NCT00598091","A Phase I\u002FExpansion Study of Dasatinib",[91],[8901,8902],"Refractory Solid Tumors","Pancreatic Adenocarcinoma",[8904,8905,8904,8905],"gemcitabine","dasatinib",{"trials":8907,"activeCount":103},[8908,8915,8922,8931],{"nctId":8909,"briefTitle":8910,"status":155,"phases":8911,"primaryCompletion":3103,"completion":3103,"start":5778,"enrollment":282,"conditions":8912,"interventions":8914},"NCT00564876","Phase II Study Evaluating The Safety And Response To Neoadjuvant Dasatinib In Early Stage Non-Small Cell Lung Cancer",[92],[8913],"Carcinoma, Non-Small-Cell Lung",[8890],{"nctId":8916,"briefTitle":8917,"status":111,"phases":8918,"primaryCompletion":2351,"completion":2351,"start":5777,"enrollment":144,"conditions":8919,"interventions":8921},"NCT00546104","Phase II Dasatinib Study in Advanced Breast Cancer",[92],[8920],"Advanced Breast Cancer",[8890],{"nctId":8923,"briefTitle":8924,"status":155,"phases":8925,"primaryCompletion":8926,"completion":6253,"start":3105,"enrollment":8927,"conditions":8928,"interventions":8929},"NCT00918385","Genomic Guided Therapy With Dasatinib or Nilutamide in Metastatic Castration-Resistant Prostate Cancer",[92],"2012-02",57,[24],[8930,8890],"Nilutamide",{"nctId":8932,"briefTitle":8933,"status":155,"phases":8934,"primaryCompletion":8935,"completion":8935,"start":2922,"enrollment":31,"conditions":8936,"interventions":8937},"NCT00787267","Phase II Study of Dasatinib in Previously Treated Patients With Advanced NSCLC",[92],"2013-06",[1684],[8890],{"trials":8939,"activeCount":103},[],{"trials":8941,"activeCount":103},[],{"trials":8943,"activeCount":103},[],{"intervention":8852,"totalTrials":1170,"cells":8945},{"EARLY_PHASE1":8946,"PHASE1":8948,"PHASE2":8950,"PHASE3":8991,"PHASE4":8993,"NA":8995},{"trials":8947,"activeCount":103},[],{"trials":8949,"activeCount":103},[],{"trials":8951,"activeCount":103},[8952,8956,8965,8973,8982],{"nctId":8846,"briefTitle":8847,"status":111,"phases":8953,"primaryCompletion":3092,"completion":4823,"start":8849,"enrollment":1452,"conditions":8954,"interventions":8955},[92],[1670],[8852,1673],{"nctId":8957,"briefTitle":8958,"status":155,"phases":8959,"primaryCompletion":2351,"completion":2351,"start":2963,"enrollment":3190,"conditions":8960,"interventions":8961},"NCT00476827","A Phase II Safety and Tolerability Study of Bevacizumab When Added to Single-agent Chemotherapy to Treat Patient With Breast Cancer Metastatic to Brain",[92],[18],[1675,8852,8962,1674,8963,8964],"CPT-11","Vinorelbine Tartrate","Gemcitabine",{"nctId":8966,"briefTitle":8967,"status":155,"phases":8968,"primaryCompletion":2870,"completion":8969,"start":2909,"enrollment":6471,"conditions":8970,"interventions":8971},"NCT00734851","Multimodality Phase II Study in Prostate Cancer",[92],"2014-11",[24],[8852,8972],"Sunitinib",{"nctId":8974,"briefTitle":8975,"status":155,"phases":8976,"primaryCompletion":4823,"completion":7100,"start":3176,"enrollment":2570,"conditions":8977,"interventions":8979},"NCT02157116","Dose-Dense Induction\u002FNeoadjuvant Chemotherapy in Locally Advanced Non-Small Cell Lung Cancer",[92],[8978],"Non-small Cell Lung Cancer",[8980,8852,8981],"cisplatin","Pegfilgrastim",{"nctId":8983,"briefTitle":8984,"status":155,"phases":8985,"primaryCompletion":1234,"completion":4642,"start":2910,"enrollment":8986,"conditions":8987,"interventions":8988},"NCT02127372","Maximum Tolerated Dose, Safety and Efficacy of Docetaxel \u002F Cisplatin + STI571",[91,92],43,[8978],[8989,8852,8990],"Docetaxel, Cisplatin and STI571","Cisplatin",{"trials":8992,"activeCount":103},[],{"trials":8994,"activeCount":103},[],{"trials":8996,"activeCount":103},[],{"intervention":8998,"totalTrials":1170,"cells":8999},"melphalan",{"EARLY_PHASE1":9000,"PHASE1":9002,"PHASE2":9042,"PHASE3":9053,"PHASE4":9055,"NA":9057},{"trials":9001,"activeCount":103},[],{"trials":9003,"activeCount":103},[9004,9016,9024,9035],{"nctId":9005,"briefTitle":9006,"status":111,"phases":9007,"primaryCompletion":9008,"start":5777,"enrollment":544,"conditions":9009,"interventions":9011},"NCT00565968","Sorafenib and Isolated Limb Infusion of Melphalan in Treating Patients With Stage III Melanoma of the Arm or Leg",[91],"2009-08",[9010],"Melanoma (Skin)",[8998,9012,9013,9014,9015],"sorafenib tosylate","gene expression analysis","protein expression analysis","western blotting",{"nctId":9017,"briefTitle":9018,"status":428,"phases":9019,"primaryCompletion":1545,"start":2339,"enrollment":103,"conditions":9020,"interventions":9021},"NCT00661336","A Phase I Trial of Normothermic Isolated Limb Infusion (ILI) With Melphalan Plus Buthionine Sulfoximine (BSO) in Patients With Locally Advanced Malignant Melanoma",[91],[9010],[9022,8998,9023],"buthionine sulfoximine","microarray analysis",{"nctId":9025,"briefTitle":9026,"status":111,"phases":9027,"primaryCompletion":9028,"completion":9028,"start":9029,"enrollment":2230,"conditions":9030,"interventions":9034},"NCT00002750","Melphalan in Patients With Neoplastic Meningitis",[91],"2001-05","1992-12",[33,9031,9032,9033,1670],"Extragonadal Germ Cell Tumor","Leukemia","Lymphoma",[8998],{"nctId":9036,"briefTitle":9037,"status":428,"phases":9038,"start":8778,"enrollment":103,"conditions":9039,"interventions":9040},"NCT00003435","Antiviral Therapy Plus Either Peripheral Stem Cell or Umbilical Cord Blood Transplantation in Treating Patients Who Are HIV Positive and Have Hematologic Cancer",[91],[9032,9033],[9041,8998],"anti-thymocyte globulin",{"trials":9043,"activeCount":103},[9044],{"nctId":9045,"briefTitle":9046,"status":111,"phases":9047,"primaryCompletion":8329,"completion":8329,"start":2594,"enrollment":1223,"conditions":9048,"interventions":9050},"NCT00734149","Bortezomib With Melphalan and Prednisone for Multiple Myeloma",[92],[9049],"Multiple Myeloma",[1184,9051,9052],"Melphalan","Prednisone",{"trials":9054,"activeCount":103},[],{"trials":9056,"activeCount":103},[],{"trials":9058,"activeCount":103},[],{"intervention":2606,"totalTrials":402,"cells":9060},{"EARLY_PHASE1":9061,"PHASE1":9063,"PHASE2":9077,"PHASE3":9086,"PHASE4":9088,"NA":9090},{"trials":9062,"activeCount":103},[],{"trials":9064,"activeCount":103},[9065,9069,9073],{"nctId":8757,"briefTitle":8758,"status":111,"phases":9066,"primaryCompletion":8760,"completion":8760,"start":8761,"conditions":9067,"interventions":9068},[91],[33],[8750,2606,8764],{"nctId":2599,"briefTitle":2600,"status":111,"phases":9070,"primaryCompletion":2602,"completion":2602,"start":2603,"conditions":9071,"interventions":9072},[91],[33],[2606,2569],{"nctId":8783,"briefTitle":8784,"status":111,"phases":9074,"primaryCompletion":8786,"completion":8786,"start":8787,"enrollment":6471,"conditions":9075,"interventions":9076},[91],[33],[8750,2606],{"trials":9078,"activeCount":103},[9079],{"nctId":9080,"briefTitle":9081,"status":111,"phases":9082,"primaryCompletion":5928,"completion":4823,"start":3236,"enrollment":2639,"conditions":9083,"interventions":9084},"NCT00268359","Bevacizumab and Irinotecan in Treating Patients With Recurrent or Refractory Gliomas",[92],[33],[9085,2606],"bevacizumab",{"trials":9087,"activeCount":103},[],{"trials":9089,"activeCount":103},[],{"trials":9091,"activeCount":103},[],{"intervention":2615,"totalTrials":402,"cells":9093},{"EARLY_PHASE1":9094,"PHASE1":9096,"PHASE2":9106,"PHASE3":9116,"PHASE4":9118,"NA":9120},{"trials":9095,"activeCount":103},[],{"trials":9097,"activeCount":103},[9098,9102],{"nctId":8775,"briefTitle":8776,"status":111,"phases":9099,"primaryCompletion":2603,"completion":2603,"start":8778,"enrollment":8779,"conditions":9100,"interventions":9101},[91],[33],[2615,8750],{"nctId":2608,"briefTitle":2609,"status":111,"phases":9103,"primaryCompletion":2611,"completion":2611,"start":2612,"conditions":9104,"interventions":9105},[91],[33],[2615,2569],{"trials":9107,"activeCount":103},[9108,9112],{"nctId":8793,"briefTitle":8794,"status":111,"phases":9109,"primaryCompletion":8796,"completion":8796,"start":2603,"conditions":9110,"interventions":9111},[92],[33],[2615,8750],{"nctId":8807,"briefTitle":8808,"status":428,"phases":9113,"completion":8810,"enrollment":103,"conditions":9114,"interventions":9115},[92],[33],[2615,8750],{"trials":9117,"activeCount":103},[],{"trials":9119,"activeCount":103},[],{"trials":9121,"activeCount":103},[],{"intervention":2666,"totalTrials":402,"cells":9123},{"EARLY_PHASE1":9124,"PHASE1":9126,"PHASE2":9136,"PHASE3":9158,"PHASE4":9160,"NA":9162},{"trials":9125,"activeCount":103},[],{"trials":9127,"activeCount":103},[9128],{"nctId":9129,"briefTitle":9130,"status":111,"phases":9131,"primaryCompletion":2660,"completion":4802,"start":3485,"enrollment":2944,"conditions":9132,"interventions":9134},"NCT00735306","Phase I\u002FII Trial of Radiation, Avastin and Tarceva for Pancreatic Adenocarcinoma",[91],[9133],"Pancreatic Cancer",[2666,9135],"Tarceva",{"trials":9137,"activeCount":103},[9138,9148,9152],{"nctId":9139,"briefTitle":9140,"status":155,"phases":9141,"primaryCompletion":9142,"completion":9142,"start":9143,"enrollment":8858,"conditions":9144,"interventions":9145},"NCT01186406","Gliadel, XRT, Temodar, Avastin Followed by Avastin, Temodar for Newly Diagnosed Glioblastoma Multiforme (GBM)",[92],"2014-06-16","2011-04",[1236,2644],[9146,2666,9147],"Gliadel","Temodar",{"nctId":2657,"briefTitle":2658,"status":111,"phases":9149,"primaryCompletion":2660,"completion":2661,"start":205,"enrollment":2662,"conditions":9150,"interventions":9151},[92],[2643,2644,2664],[2666,2586,2667],{"nctId":9153,"briefTitle":9154,"status":111,"phases":9155,"primaryCompletion":3103,"completion":8409,"start":3484,"enrollment":8779,"conditions":9156,"interventions":9157},"NCT00611325","Phase II Avastin + Bortezomib for Patients With Recurrent Malignant Glioma",[92],[2643,2644],[2666,1184],{"trials":9159,"activeCount":103},[],{"trials":9161,"activeCount":103},[],{"trials":9163,"activeCount":103},[],{"intervention":9165,"totalTrials":229,"cells":9166},"Albuterol",{"EARLY_PHASE1":9167,"PHASE1":9169,"PHASE2":9185,"PHASE3":9194,"PHASE4":9196,"NA":9198},{"trials":9168,"activeCount":103},[],{"trials":9170,"activeCount":103},[9171,9178],{"nctId":9172,"briefTitle":9173,"status":111,"phases":9174,"primaryCompletion":7470,"completion":7470,"start":8099,"enrollment":1144,"conditions":9175,"interventions":9177},"NCT01859624","Albuterol in Individuals With Late Onset Pompe Disease (LOPD)",[91],[9176],"Pompe Disease",[9165],{"nctId":9179,"briefTitle":9180,"status":111,"phases":9181,"primaryCompletion":9182,"completion":9182,"start":6253,"enrollment":1170,"conditions":9183,"interventions":9184},"NCT01895998","Quantifying the Presence of Lung Disease and Pulmonary Hypertension in Children With Sickle Cell Disease",[91],"2014-04",[4291],[9165],{"trials":9186,"activeCount":103},[9187],{"nctId":9188,"briefTitle":9189,"status":111,"phases":9190,"primaryCompletion":9191,"completion":9191,"start":8935,"enrollment":3190,"conditions":9192,"interventions":9193},"NCT01885936","Safety and Efficacy of Albuterol in Individuals With Late-onset Pompe Disease",[91,92],"2016-12-16",[9176],[9165],{"trials":9195,"activeCount":103},[],{"trials":9197,"activeCount":103},[],{"trials":9199,"activeCount":103},[],{"intervention":1185,"totalTrials":229,"cells":9201},{"EARLY_PHASE1":9202,"PHASE1":9204,"PHASE2":9206,"PHASE3":9235,"PHASE4":9237,"NA":9239},{"trials":9203,"activeCount":103},[],{"trials":9205,"activeCount":103},[],{"trials":9207,"activeCount":103},[9208,9215,9231],{"nctId":9209,"briefTitle":9210,"status":111,"phases":9211,"primaryCompletion":4478,"completion":4478,"start":8697,"enrollment":1144,"conditions":9212,"interventions":9214},"NCT00286325","Rituximab in the Treatment of Patients With Bullous Pemphigoid",[91,92],[9213],"Bullous Pemphigoid",[1185],{"nctId":9216,"briefTitle":9217,"status":111,"phases":9218,"primaryCompletion":9219,"completion":9220,"start":9221,"enrollment":25,"conditions":9222,"interventions":9224},"NCT00577629","Chemotherapy With Monoclonal Antibody and Radioimmunotherapy for High-Risk B-Cell Non-Hodgkins Lymphoma",[92],"2012-04-08","2016-11-03","2005-06-18",[9223],"Lymphoma, B-Cell",[9225,9226,9227,9228,9229,9230],"cyclophosphamide","etoposide","rituximab","cytarabine","doxorubicin","tositumomab",{"nctId":1175,"briefTitle":1176,"status":155,"phases":9232,"primaryCompletion":1178,"completion":1168,"start":1179,"enrollment":1180,"conditions":9233,"interventions":9234},[92],[1182],[1184,1185,1186,1187,689],{"trials":9236,"activeCount":103},[],{"trials":9238,"activeCount":103},[],{"trials":9240,"activeCount":103},[],{"intervention":4576,"totalTrials":229,"cells":9242},{"EARLY_PHASE1":9243,"PHASE1":9245,"PHASE2":9247,"PHASE3":9271,"PHASE4":9273,"NA":9275},{"trials":9244,"activeCount":103},[],{"trials":9246,"activeCount":103},[],{"trials":9248,"activeCount":103},[9249,9259,9267],{"nctId":9250,"briefTitle":9251,"status":111,"phases":9252,"primaryCompletion":3105,"completion":3105,"start":9253,"enrollment":9254,"conditions":9255,"interventions":9257},"NCT00041392","Effects of Magnesium on Individuals Undergoing Coronary Artery Bypass Graft Surgery",[92],"2001-12",389,[8526,2937,660,9256],"Neurologic Manifestations",[9258,4576],"Magnesium",{"nctId":9260,"briefTitle":9261,"status":155,"phases":9262,"primaryCompletion":2339,"completion":2339,"start":3123,"enrollment":448,"conditions":9263,"interventions":9265},"NCT00508118","NICardipine Neuroprotection in AortiC Surgery (NICNACS)",[92],[9264],"Aortic Aneurysm, Thoracic",[9266,4576],"Nicardipine",{"nctId":4570,"briefTitle":4571,"status":111,"phases":9268,"primaryCompletion":2943,"completion":2943,"start":205,"enrollment":127,"conditions":9269,"interventions":9270},[92],[4574],[4561,4576],{"trials":9272,"activeCount":103},[],{"trials":9274,"activeCount":103},[],{"trials":9276,"activeCount":103},[],{"intervention":9278,"totalTrials":229,"cells":9279},"Pembrolizumab",{"EARLY_PHASE1":9280,"PHASE1":9282,"PHASE2":9284,"PHASE3":9316,"PHASE4":9318,"NA":9320},{"trials":9281,"activeCount":103},[],{"trials":9283,"activeCount":103},[],{"trials":9285,"activeCount":103},[9286,9298,9306],{"nctId":9287,"briefTitle":9288,"status":111,"phases":9289,"primaryCompletion":9290,"completion":9291,"start":9292,"enrollment":9293,"conditions":9294,"interventions":9296},"NCT03043664","Study of Pembrolizumab With Lanreotide Depot for Gastroenteropancreatic Neuroendocrine Tumors",[91,92],"2021-05-03","2022-06-07","2017-07-01",22,[9295],"Gastroenteropancreatic Neuroendocrine Tumors",[9297,9278],"Lanreotide",{"nctId":9299,"briefTitle":9300,"status":428,"phases":9301,"primaryCompletion":856,"completion":856,"start":9302,"enrollment":103,"conditions":9303,"interventions":9304},"NCT04569461","Trimodality Approach of Low Dose iOnizing Radiation With or Without Neoadjuvant Pembrolizumab and Prostatectomy for Men With Intermediate\u002FHigh Risk Prostate Cancer (TALON)",[92],"2025-06",[24],[9305],"pembrolizumab",{"nctId":9307,"briefTitle":9308,"status":111,"phases":9309,"primaryCompletion":9310,"completion":9311,"start":9312,"enrollment":2847,"conditions":9313,"interventions":9315},"NCT03064490","Pembrolizumab, Radiotherapy, and Chemotherapy in Neoadjuvant Treatment of Malignant Esophago-gastric Diseases (PROCEED)",[92],"2023-02-24","2023-11-22","2017-10-17",[9314],"Locally Advanced Esophageal and Gastric Cancers (EGC)",[9278],{"trials":9317,"activeCount":103},[],{"trials":9319,"activeCount":103},[],{"trials":9321,"activeCount":103},[],{"intervention":8972,"totalTrials":229,"cells":9323},{"EARLY_PHASE1":9324,"PHASE1":9326,"PHASE2":9328,"PHASE3":9351,"PHASE4":9353,"NA":9355},{"trials":9325,"activeCount":103},[],{"trials":9327,"activeCount":103},[],{"trials":9329,"activeCount":103},[9330,9338,9342],{"nctId":9331,"briefTitle":9332,"status":111,"phases":9333,"primaryCompletion":1625,"completion":1612,"start":3104,"enrollment":2982,"conditions":9334,"interventions":9336},"NCT01108445","Phase II Study of Afinitor vs. Sutent in Patients With Metastatic Non-Clear Cell Renal Cell Carcinoma",[92],[9335],"Advanced Non-clear Cell Renal Cell Carcinoma",[9337,8972],"Everolimus",{"nctId":8966,"briefTitle":8967,"status":155,"phases":9339,"primaryCompletion":2870,"completion":8969,"start":2909,"enrollment":6471,"conditions":9340,"interventions":9341},[92],[24],[8852,8972],{"nctId":9343,"briefTitle":9344,"status":111,"phases":9345,"primaryCompletion":9346,"completion":9346,"start":9347,"enrollment":448,"conditions":9348,"interventions":9350},"NCT03109015","Alternative Schedule Sunitinib in Metastatic Renal Cell Carcinoma: Cardiopulmonary Exercise Testing",[92],"2019-10-08","2017-09-27",[9349],"Carcinoma, Renal Cell",[8972,8972],{"trials":9352,"activeCount":103},[],{"trials":9354,"activeCount":103},[],{"trials":9356,"activeCount":103},[],{"intervention":9052,"totalTrials":229,"cells":9358},{"EARLY_PHASE1":9359,"PHASE1":9361,"PHASE2":9363,"PHASE3":9386,"PHASE4":9388,"NA":9390},{"trials":9360,"activeCount":103},[],{"trials":9362,"activeCount":103},[],{"trials":9364,"activeCount":103},[9365,9376,9382],{"nctId":9366,"briefTitle":9367,"status":111,"phases":9368,"primaryCompletion":9369,"completion":9370,"start":9371,"enrollment":31,"conditions":9372,"interventions":9373},"NCT01717053","Abiraterone, Radiotherapy and Short-Term Androgen Deprivation in Unfavorable Localized Prostate Cancer",[92],"2017-08-24","2021-08-31","2014-01-17",[24],[9374,9375,9052],"Abiraterone acetate","Androgen deprivation",{"nctId":9377,"briefTitle":9378,"status":111,"phases":9379,"primaryCompletion":9346,"completion":9346,"start":8409,"enrollment":1133,"conditions":9380,"interventions":9381},"NCT01940276","Abiraterone Race in Metastatic Castrate-resistant Prostate Cancer",[92],[24],[9374,9052],{"nctId":9045,"briefTitle":9046,"status":111,"phases":9383,"primaryCompletion":8329,"completion":8329,"start":2594,"enrollment":1223,"conditions":9384,"interventions":9385},[92],[9049],[1184,9051,9052],{"trials":9387,"activeCount":103},[],{"trials":9389,"activeCount":103},[],{"trials":9391,"activeCount":103},[],{"intervention":2597,"totalTrials":229,"cells":9393},{"EARLY_PHASE1":9394,"PHASE1":9396,"PHASE2":9406,"PHASE3":9412,"PHASE4":9414,"NA":9416},{"trials":9395,"activeCount":103},[],{"trials":9397,"activeCount":103},[9398,9402],{"nctId":2590,"briefTitle":2591,"status":111,"phases":9399,"primaryCompletion":2593,"completion":2593,"start":2594,"enrollment":1591,"conditions":9400,"interventions":9401},[91],[33],[2597,2569],{"nctId":3216,"briefTitle":3217,"status":111,"phases":9403,"primaryCompletion":3091,"start":2629,"enrollment":31,"conditions":9404,"interventions":9405},[91],[33],[3209,2597,3221],{"trials":9407,"activeCount":103},[9408],{"nctId":3232,"briefTitle":3233,"status":111,"phases":9409,"primaryCompletion":3092,"completion":3235,"start":3236,"enrollment":3237,"conditions":9410,"interventions":9411},[92],[2643,2644],[3209,2597],{"trials":9413,"activeCount":103},[],{"trials":9415,"activeCount":103},[],{"trials":9417,"activeCount":103},[],{"intervention":1184,"totalTrials":229,"cells":9419},{"EARLY_PHASE1":9420,"PHASE1":9422,"PHASE2":9424,"PHASE3":9438,"PHASE4":9440,"NA":9442},{"trials":9421,"activeCount":103},[],{"trials":9423,"activeCount":103},[],{"trials":9425,"activeCount":103},[9426,9430,9434],{"nctId":9153,"briefTitle":9154,"status":111,"phases":9427,"primaryCompletion":3103,"completion":8409,"start":3484,"enrollment":8779,"conditions":9428,"interventions":9429},[92],[2643,2644],[2666,1184],{"nctId":9045,"briefTitle":9046,"status":111,"phases":9431,"primaryCompletion":8329,"completion":8329,"start":2594,"enrollment":1223,"conditions":9432,"interventions":9433},[92],[9049],[1184,9051,9052],{"nctId":1175,"briefTitle":1176,"status":155,"phases":9435,"primaryCompletion":1178,"completion":1168,"start":1179,"enrollment":1180,"conditions":9436,"interventions":9437},[92],[1182],[1184,1185,1186,1187,689],{"trials":9439,"activeCount":103},[],{"trials":9441,"activeCount":103},[],{"trials":9443,"activeCount":103},[],{"intervention":8764,"totalTrials":282,"cells":9445},{"EARLY_PHASE1":9446,"PHASE1":9448,"PHASE2":9454,"PHASE3":9460,"PHASE4":9462,"NA":9464},{"trials":9447,"activeCount":103},[],{"trials":9449,"activeCount":103},[9450],{"nctId":8757,"briefTitle":8758,"status":111,"phases":9451,"primaryCompletion":8760,"completion":8760,"start":8761,"conditions":9452,"interventions":9453},[91],[33],[8750,2606,8764],{"trials":9455,"activeCount":103},[9456],{"nctId":8800,"briefTitle":8801,"status":111,"phases":9457,"completion":4654,"start":8803,"enrollment":2639,"conditions":9458,"interventions":9459},[92],[33],[8750,8764],{"trials":9461,"activeCount":103},[],{"trials":9463,"activeCount":103},[],{"trials":9465,"activeCount":103},[],{"intervention":9467,"totalTrials":282,"cells":9468},"Meclizine",{"EARLY_PHASE1":9469,"PHASE1":9471,"PHASE2":9482,"PHASE3":9492,"PHASE4":9494,"NA":9496},{"trials":9470,"activeCount":103},[],{"trials":9472,"activeCount":103},[9473],{"nctId":9474,"briefTitle":9475,"status":111,"phases":9476,"primaryCompletion":7008,"completion":7008,"start":9477,"enrollment":9478,"conditions":9479,"interventions":9481},"NCT01537471","The Effects of Antihistamines on Pre-Pulse Inhibition",[91],"2012-01",117,[9480],"Healthy",[9467,9467],{"trials":9483,"activeCount":103},[9484],{"nctId":9485,"briefTitle":9486,"status":111,"phases":9487,"primaryCompletion":1202,"completion":2798,"start":2660,"enrollment":9488,"conditions":9489,"interventions":9490},"NCT01443858","Meclizine as a Potential Smoking Cessation Treatment",[92],146,[2838],[9467,9491],"Nicotine Patch",{"trials":9493,"activeCount":103},[],{"trials":9495,"activeCount":103},[],{"trials":9497,"activeCount":103},[],{"intervention":9499,"totalTrials":282,"cells":9500},"monoclonal antibody Me1-14 F(ab')2",{"EARLY_PHASE1":9501,"PHASE1":9503,"PHASE2":9512,"PHASE3":9521,"PHASE4":9523,"NA":9525},{"trials":9502,"activeCount":103},[],{"trials":9504,"activeCount":103},[9505],{"nctId":9506,"briefTitle":9507,"status":111,"phases":9508,"primaryCompletion":8796,"completion":8796,"start":8842,"enrollment":2230,"conditions":9509,"interventions":9511},"NCT00002754","Monoclonal Antibody Therapy in Treating Patients With Primary or Metastatic Melanoma or Brain Tumors",[91],[33,9010,9510],"Metastatic Cancer",[9499],{"trials":9513,"activeCount":103},[9514],{"nctId":9515,"briefTitle":9516,"status":111,"phases":9517,"completion":8769,"start":9518,"enrollment":2230,"conditions":9519,"interventions":9520},"NCT00002751","Monoclonal Antibody Therapy in Treating Patients With Brain Metastases",[91,92],"1989-07",[9510],[9499],{"trials":9522,"activeCount":103},[],{"trials":9524,"activeCount":103},[],{"trials":9526,"activeCount":103},[],{"intervention":9228,"totalTrials":282,"cells":9528},{"EARLY_PHASE1":9529,"PHASE1":9531,"PHASE2":9533,"PHASE3":9552,"PHASE4":9554,"NA":9556},{"trials":9530,"activeCount":103},[],{"trials":9532,"activeCount":103},[],{"trials":9534,"activeCount":103},[9535,9539],{"nctId":9216,"briefTitle":9217,"status":111,"phases":9536,"primaryCompletion":9219,"completion":9220,"start":9221,"enrollment":25,"conditions":9537,"interventions":9538},[92],[9223],[9225,9226,9227,9228,9229,9230],{"nctId":9540,"briefTitle":9541,"status":111,"phases":9542,"primaryCompletion":9543,"completion":9544,"start":4653,"enrollment":2822,"conditions":9545,"interventions":9548},"NCT02046122","Adoptive Transfer of Haplo-identical DLI for AML and MDS",[91,92],"2017-06-15","2019-07-31",[9546,9547],"Acute Myeloid Leukemia","Myelodysplastic Syndrome",[9549,9550,9551],"Idarubicin","Cytarabine","DLI",{"trials":9553,"activeCount":103},[],{"trials":9555,"activeCount":103},[],{"trials":9557,"activeCount":103},[],{"intervention":9559,"totalTrials":282,"cells":9560},"irinotecan",{"EARLY_PHASE1":9561,"PHASE1":9563,"PHASE2":9565,"PHASE3":9577,"PHASE4":9579,"NA":9581},{"trials":9562,"activeCount":103},[],{"trials":9564,"activeCount":103},[],{"trials":9566,"activeCount":103},[9567,9573],{"nctId":9568,"briefTitle":9569,"status":111,"phases":9570,"primaryCompletion":6294,"completion":204,"start":2602,"enrollment":544,"conditions":9571,"interventions":9572},"NCT00352521","Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) With Bevacizumab and Irinotecan for Malignant Glioma",[92],[33],[9085,9559],{"nctId":2657,"briefTitle":2658,"status":111,"phases":9574,"primaryCompletion":2660,"completion":2661,"start":205,"enrollment":2662,"conditions":9575,"interventions":9576},[92],[2643,2644,2664],[2666,2586,2667],{"trials":9578,"activeCount":103},[],{"trials":9580,"activeCount":103},[],{"trials":9582,"activeCount":103},[],{"intervention":8832,"totalTrials":282,"cells":9584},{"EARLY_PHASE1":9585,"PHASE1":9587,"PHASE2":9593,"PHASE3":9604,"PHASE4":9606,"NA":9608},{"trials":9586,"activeCount":103},[],{"trials":9588,"activeCount":103},[9589],{"nctId":8826,"briefTitle":8827,"status":111,"phases":9590,"primaryCompletion":205,"completion":205,"start":8548,"enrollment":2570,"conditions":9591,"interventions":9592},[91],[8830],[8832,8833,8834],{"trials":9594,"activeCount":103},[9595],{"nctId":9596,"briefTitle":9597,"status":111,"phases":9598,"primaryCompletion":5126,"completion":4653,"start":3254,"enrollment":9,"conditions":9599,"interventions":9603},"NCT00447330","Oxaliplatin, Capecitabine and Avastin for Metastatic Esophagogastric Adenocarcinoma",[92],[9600,9601,9602],"Esophageal Neoplasms","Stomach Neoplasms","Neoplasm Metastasis",[8832],{"trials":9605,"activeCount":103},[],{"trials":9607,"activeCount":103},[],{"trials":9609,"activeCount":103},[],{"intervention":7775,"totalTrials":282,"cells":9611},{"EARLY_PHASE1":9612,"PHASE1":9614,"PHASE2":9625,"PHASE3":9631,"PHASE4":9633,"NA":9635},{"trials":9613,"activeCount":103},[],{"trials":9615,"activeCount":103},[9616],{"nctId":9617,"briefTitle":9618,"status":428,"phases":9619,"primaryCompletion":9620,"completion":9621,"start":9622,"enrollment":103,"conditions":9623,"interventions":9624},"NCT03069768","Stage Ib Trial of mSMART With Varenicline",[91],"2019-01","2019-06","2018-04",[2802],[7775],{"trials":9626,"activeCount":103},[9627],{"nctId":7769,"briefTitle":7770,"status":111,"phases":9628,"primaryCompletion":1222,"completion":412,"start":2797,"enrollment":7772,"conditions":9629,"interventions":9630},[92],[2802],[7775,7776,2805],{"trials":9632,"activeCount":103},[],{"trials":9634,"activeCount":103},[],{"trials":9636,"activeCount":103},[],{"intervention":9638,"totalTrials":282,"cells":9639},"Sorafenib",{"EARLY_PHASE1":9640,"PHASE1":9642,"PHASE2":9644,"PHASE3":9662,"PHASE4":9664,"NA":9666},{"trials":9641,"activeCount":103},[],{"trials":9643,"activeCount":103},[],{"trials":9645,"activeCount":103},[9646,9654],{"nctId":9647,"briefTitle":9648,"status":111,"phases":9649,"primaryCompletion":2798,"completion":2798,"start":3123,"enrollment":144,"conditions":9650,"interventions":9652},"NCT00815295","Study of Sorafenib\u002FCetuximab in Head and Neck Cancer",[91,92],[9651],"Squamous Cell Cancer",[9638,9653],"Cetuximab",{"nctId":9655,"briefTitle":9656,"status":155,"phases":9657,"primaryCompletion":2813,"completion":2813,"start":2934,"enrollment":2822,"conditions":9658,"interventions":9661},"NCT00510289","Sorafenib in Myelodysplastic Syndrome",[92],[9659,9660],"Myelodysplastic Syndromes","Leukemia, Myelomonocytic, Chronic",[9638],{"trials":9663,"activeCount":103},[],{"trials":9665,"activeCount":103},[],{"trials":9667,"activeCount":103},[],{"intervention":9669,"totalTrials":282,"cells":9670},"Ipilimumab",{"EARLY_PHASE1":9671,"PHASE1":9673,"PHASE2":9683,"PHASE3":9693,"PHASE4":9695,"NA":9697},{"trials":9672,"activeCount":103},[],{"trials":9674,"activeCount":103},[9675],{"nctId":9676,"briefTitle":9677,"status":111,"phases":9678,"primaryCompletion":9679,"completion":9679,"start":1233,"enrollment":402,"conditions":9680,"interventions":9682},"NCT02115243","Trial of Neoadjuvant Ipilimumab Followed by Melphalan Via Isolated Limb Infusion for Patients With Unresectable In-transit Extremity Melanoma",[91],"2015-12-07",[9681],"Unresectable Melanoma",[9669],{"trials":9684,"activeCount":103},[9685],{"nctId":9686,"briefTitle":9687,"status":111,"phases":9688,"primaryCompletion":9689,"completion":9689,"start":2797,"enrollment":1212,"conditions":9690,"interventions":9691},"NCT01820754","Evaluation of Circulating T Cells and Tumor Infiltrating Lymphocytes (TILs) During \u002F After Pre-Surgery Chemotherapy in Non-Small Cell Lung Cancer (NSCLC)",[92],"2018-04-30",[1684],[9669,9692],"Paclitaxel, Cisplatin, Carboplatin",{"trials":9694,"activeCount":103},[],{"trials":9696,"activeCount":103},[],{"trials":9698,"activeCount":103},[],{"intervention":9375,"totalTrials":282,"cells":9700},{"EARLY_PHASE1":9701,"PHASE1":9703,"PHASE2":9705,"PHASE3":9721,"PHASE4":9723,"NA":9725},{"trials":9702,"activeCount":103},[],{"trials":9704,"activeCount":103},[],{"trials":9706,"activeCount":103},[9707,9711],{"nctId":9366,"briefTitle":9367,"status":111,"phases":9708,"primaryCompletion":9369,"completion":9370,"start":9371,"enrollment":31,"conditions":9709,"interventions":9710},[92],[24],[9374,9375,9052],{"nctId":9712,"briefTitle":9713,"status":111,"phases":9714,"primaryCompletion":9715,"completion":9716,"start":9182,"enrollment":28,"conditions":9717,"interventions":9718},"NCT02057939","Salvage Therapeutic Radiation With Enzalutamide and ADT in Men With Recurrent Prostate Cancer (STREAM)",[92],"2018-03-02","2019-06-05",[24],[9719,9720],"enzalutamide","Androgen Deprivation",{"trials":9722,"activeCount":103},[],{"trials":9724,"activeCount":103},[],{"trials":9726,"activeCount":103},[],{"intervention":2702,"totalTrials":282,"cells":9728},{"EARLY_PHASE1":9729,"PHASE1":9731,"PHASE2":9742,"PHASE3":9748,"PHASE4":9750,"NA":9752},{"trials":9730,"activeCount":103},[],{"trials":9732,"activeCount":103},[9733],{"nctId":9734,"briefTitle":9735,"status":155,"phases":9736,"primaryCompletion":9143,"completion":9143,"start":2602,"enrollment":9737,"conditions":9738,"interventions":9739},"NCT00346229","Temperature-Sensitive Liposomal Doxorubicin and Hyperthermia in Treating Women With Locally Recurrent Breast Cancer",[91],29,[18],[2702,9740,9741],"pegfilgrastim","lyso-thermosensitive liposomal doxorubicin",{"trials":9743,"activeCount":103},[9744],{"nctId":2692,"briefTitle":2693,"status":111,"phases":9745,"primaryCompletion":2695,"completion":2695,"start":2603,"enrollment":34,"conditions":9746,"interventions":9747},[91,92],[33,2697,2698,2699,2674,1670,546,2700],[2702,2569],{"trials":9749,"activeCount":103},[],{"trials":9751,"activeCount":103},[],{"trials":9753,"activeCount":103},[],{"intervention":9740,"totalTrials":282,"cells":9755},{"EARLY_PHASE1":9756,"PHASE1":9758,"PHASE2":9764,"PHASE3":9770,"PHASE4":9772,"NA":9774},{"trials":9757,"activeCount":103},[],{"trials":9759,"activeCount":103},[9760],{"nctId":9734,"briefTitle":9735,"status":155,"phases":9761,"primaryCompletion":9143,"completion":9143,"start":2602,"enrollment":9737,"conditions":9762,"interventions":9763},[91],[18],[2702,9740,9741],{"trials":9765,"activeCount":103},[9766],{"nctId":8974,"briefTitle":8975,"status":155,"phases":9767,"primaryCompletion":4823,"completion":7100,"start":3176,"enrollment":2570,"conditions":9768,"interventions":9769},[92],[8978],[8980,8852,8981],{"trials":9771,"activeCount":103},[],{"trials":9773,"activeCount":103},[],{"trials":9775,"activeCount":103},[],{"intervention":9777,"totalTrials":282,"cells":9778},"Temodar and O6-Benzylguanine",{"EARLY_PHASE1":9779,"PHASE1":9781,"PHASE2":9790,"PHASE3":9800,"PHASE4":9802,"NA":9804},{"trials":9780,"activeCount":103},[],{"trials":9782,"activeCount":103},[9783],{"nctId":9784,"briefTitle":9785,"status":111,"phases":9786,"primaryCompletion":7848,"completion":3485,"start":9787,"enrollment":22,"conditions":9788,"interventions":9789},"NCT00612989","Ph I 5-day Temozolomide + O6-BG in Treatment of Pts w Recurrent \u002F Progressive GBM",[91],"2005-02",[2643,2644],[9777],{"trials":9791,"activeCount":103},[9792],{"nctId":9793,"briefTitle":9794,"status":111,"phases":9795,"primaryCompletion":2980,"completion":9796,"start":8456,"enrollment":6732,"conditions":9797,"interventions":9799},"NCT00613093","Ph. II Temozolomide + O6-BG in Treatment of Pts w Temozolomide-Resistant Malignant Glioma",[92],"2008-08",[1236,9798],"Anaplastic Glioma",[9777],{"trials":9801,"activeCount":103},[],{"trials":9803,"activeCount":103},[],{"trials":9805,"activeCount":103},[],{"intervention":8861,"totalTrials":282,"cells":9807},{"EARLY_PHASE1":9808,"PHASE1":9810,"PHASE2":9812,"PHASE3":9822,"PHASE4":9824,"NA":9826},{"trials":9809,"activeCount":103},[],{"trials":9811,"activeCount":103},[],{"trials":9813,"activeCount":103},[9814,9818],{"nctId":8854,"briefTitle":8855,"status":111,"phases":9815,"primaryCompletion":8857,"completion":8857,"start":2963,"enrollment":8858,"conditions":9816,"interventions":9817},[92],[18],[8861,1675,1673],{"nctId":8877,"briefTitle":8878,"status":155,"phases":9819,"primaryCompletion":2812,"completion":2812,"start":2660,"enrollment":206,"conditions":9820,"interventions":9821},[92],[8881],[8861,1673],{"trials":9823,"activeCount":103},[],{"trials":9825,"activeCount":103},[],{"trials":9827,"activeCount":103},[],{"intervention":8964,"totalTrials":282,"cells":9829},{"EARLY_PHASE1":9830,"PHASE1":9832,"PHASE2":9838,"PHASE3":9844,"PHASE4":9846,"NA":9848},{"trials":9831,"activeCount":103},[],{"trials":9833,"activeCount":103},[9834],{"nctId":8897,"briefTitle":8898,"status":155,"phases":9835,"primaryCompletion":1234,"completion":2821,"start":3486,"enrollment":34,"conditions":9836,"interventions":9837},[91],[8901,8902],[8904,8905,8904,8905],{"trials":9839,"activeCount":103},[9840],{"nctId":8957,"briefTitle":8958,"status":155,"phases":9841,"primaryCompletion":2351,"completion":2351,"start":2963,"enrollment":3190,"conditions":9842,"interventions":9843},[92],[18],[1675,8852,8962,1674,8963,8964],{"trials":9845,"activeCount":103},[],{"trials":9847,"activeCount":103},[],{"trials":9849,"activeCount":103},[],{"intervention":7872,"totalTrials":282,"cells":9851},{"EARLY_PHASE1":9852,"PHASE1":9854,"PHASE2":9860,"PHASE3":9873,"PHASE4":9875,"NA":9877},{"trials":9853,"activeCount":103},[],{"trials":9855,"activeCount":103},[9856],{"nctId":7865,"briefTitle":7866,"status":155,"phases":9857,"primaryCompletion":7868,"completion":7868,"start":7869,"enrollment":448,"conditions":9858,"interventions":9859},[91],[660],[2914,7872],{"trials":9861,"activeCount":103},[9862],{"nctId":9863,"briefTitle":9864,"status":111,"phases":9865,"primaryCompletion":9866,"completion":9867,"start":3032,"enrollment":9868,"conditions":9869,"interventions":9870},"NCT02906644","Combination Nicotine Patch \u002F Lorcaserin for Smoking Cessation",[92],"2018-03-27","2018-10-18",97,[2802],[9871,9872],"lorcaserin","nicotine patch",{"trials":9874,"activeCount":103},[],{"trials":9876,"activeCount":103},[],{"trials":9878,"activeCount":103},[],{"intervention":8980,"totalTrials":282,"cells":9880},{"EARLY_PHASE1":9881,"PHASE1":9883,"PHASE2":9885,"PHASE3":9895,"PHASE4":9897,"NA":9899},{"trials":9882,"activeCount":103},[],{"trials":9884,"activeCount":103},[],{"trials":9886,"activeCount":103},[9887,9891],{"nctId":8974,"briefTitle":8975,"status":155,"phases":9888,"primaryCompletion":4823,"completion":7100,"start":3176,"enrollment":2570,"conditions":9889,"interventions":9890},[92],[8978],[8980,8852,8981],{"nctId":8983,"briefTitle":8984,"status":155,"phases":9892,"primaryCompletion":1234,"completion":4642,"start":2910,"enrollment":8986,"conditions":9893,"interventions":9894},[91,92],[8978],[8989,8852,8990],{"trials":9896,"activeCount":103},[],{"trials":9898,"activeCount":103},[],{"trials":9900,"activeCount":103},[],{"intervention":9902,"totalTrials":132,"cells":9903},"Beetroot Juice (Beet-It Stamina Shot) & Supervised Exercise Training",{"EARLY_PHASE1":9904,"PHASE1":9906,"PHASE2":9908,"PHASE3":9918,"PHASE4":9920,"NA":9922},{"trials":9905,"activeCount":103},[],{"trials":9907,"activeCount":103},[],{"trials":9909,"activeCount":103},[9910],{"nctId":9911,"briefTitle":9912,"status":111,"phases":9913,"primaryCompletion":8969,"completion":8969,"start":8099,"enrollment":9914,"conditions":9915,"interventions":9917},"NCT01684930","Nitrites, Exercise, and Peripheral Arterial Disease",[92],32,[9916],"Peripheral Arterial Disease",[9902],{"trials":9919,"activeCount":103},[],{"trials":9921,"activeCount":103},[],{"trials":9923,"activeCount":103},[],{"intervention":9925,"totalTrials":132,"cells":9926},"Splanchnic nerve block",{"EARLY_PHASE1":9927,"PHASE1":9929,"PHASE2":9931,"PHASE3":9941,"PHASE4":9943,"NA":9945},{"trials":9928,"activeCount":103},[],{"trials":9930,"activeCount":103},[],{"trials":9932,"activeCount":103},[9933],{"nctId":9934,"briefTitle":9935,"status":111,"phases":9936,"primaryCompletion":9937,"completion":9937,"start":9938,"enrollment":1170,"conditions":9939,"interventions":9940},"NCT04575428","Splanchnic Nerve Block for Therapy of Chronic Heart Failure (Splanchnic III)",[92],"2021-06-16","2020-02-05",[2927],[9925],{"trials":9942,"activeCount":103},[],{"trials":9944,"activeCount":103},[],{"trials":9946,"activeCount":103},[],{"intervention":3170,"totalTrials":132,"cells":9948},{"EARLY_PHASE1":9949,"PHASE1":9951,"PHASE2":9953,"PHASE3":9959,"PHASE4":9961,"NA":9963},{"trials":9950,"activeCount":103},[],{"trials":9952,"activeCount":103},[],{"trials":9954,"activeCount":103},[9955],{"nctId":3161,"briefTitle":3162,"status":155,"phases":9956,"primaryCompletion":3164,"completion":3164,"start":3165,"enrollment":402,"conditions":9957,"interventions":9958},[92],[3167,3168,2664],[3170,399],{"trials":9960,"activeCount":103},[],{"trials":9962,"activeCount":103},[],{"trials":9964,"activeCount":103},[],{"intervention":3274,"totalTrials":132,"cells":9966},{"EARLY_PHASE1":9967,"PHASE1":9969,"PHASE2":9971,"PHASE3":9977,"PHASE4":9979,"NA":9981},{"trials":9968,"activeCount":103},[],{"trials":9970,"activeCount":103},[],{"trials":9972,"activeCount":103},[9973],{"nctId":3269,"briefTitle":3270,"status":428,"phases":9974,"primaryCompletion":2870,"enrollment":103,"conditions":9975,"interventions":9976},[92],[2641],[3274,3260],{"trials":9978,"activeCount":103},[],{"trials":9980,"activeCount":103},[],{"trials":9982,"activeCount":103},[],{"intervention":9984,"totalTrials":132,"cells":9985},"Immunotherapy",{"EARLY_PHASE1":9986,"PHASE1":9988,"PHASE2":9990,"PHASE3":10001,"PHASE4":10003,"NA":10005},{"trials":9987,"activeCount":103},[],{"trials":9989,"activeCount":103},[],{"trials":9991,"activeCount":103},[9992],{"nctId":9993,"briefTitle":9994,"status":428,"phases":9995,"primaryCompletion":9996,"completion":9996,"start":9997,"enrollment":103,"conditions":9998,"interventions":10000},"NCT04650490","SRS Timing With Immune Checkpoint Inhibition in Patients With Untreated Brain Metastases From Non-small Cell Lung Cancer",[92],"2026-03","2023-03",[9999,1684],"Brain Metastases",[9984],{"trials":10002,"activeCount":103},[],{"trials":10004,"activeCount":103},[],{"trials":10006,"activeCount":103},[],{"intervention":10008,"totalTrials":132,"cells":10009},"Sunitinib Malate",{"EARLY_PHASE1":10010,"PHASE1":10012,"PHASE2":10014,"PHASE3":10023,"PHASE4":10025,"NA":10027},{"trials":10011,"activeCount":103},[],{"trials":10013,"activeCount":103},[],{"trials":10015,"activeCount":103},[10016],{"nctId":10017,"briefTitle":10018,"status":111,"phases":10019,"primaryCompletion":7008,"completion":1168,"start":2934,"enrollment":34,"conditions":10020,"interventions":10022},"NCT00672594","Study of Sunitinib Malate in Patients With Newly Diagnosed Prostate Cancer Prior to Prostatectomy",[92],[24,10021],"Prostatectomy",[10008],{"trials":10024,"activeCount":103},[],{"trials":10026,"activeCount":103},[],{"trials":10028,"activeCount":103},[],{"intervention":10030,"totalTrials":132,"cells":10031},"Propranolol Hcl 40mg Tab",{"EARLY_PHASE1":10032,"PHASE1":10034,"PHASE2":10036,"PHASE3":10050,"PHASE4":10052,"NA":10054},{"trials":10033,"activeCount":103},[],{"trials":10035,"activeCount":103},[],{"trials":10037,"activeCount":103},[10038],{"nctId":10039,"briefTitle":10040,"status":428,"phases":10041,"primaryCompletion":10042,"completion":10043,"start":10044,"enrollment":103,"conditions":10045,"interventions":10049},"NCT04421209","Analgesic Effects of Perioperative Propranolol Administration for Spine Surgery",[92],"2021-06-30","2021-09-30","2020-12",[10046,10047,10048],"Lumbar Disc Disease","Spinal Fusion","Degenerative Disc Disease",[10030],{"trials":10051,"activeCount":103},[],{"trials":10053,"activeCount":103},[],{"trials":10055,"activeCount":103},[],{"intervention":10057,"totalTrials":132,"cells":10058},"Temodar and Irinotecan",{"EARLY_PHASE1":10059,"PHASE1":10061,"PHASE2":10063,"PHASE3":10071,"PHASE4":10073,"NA":10075},{"trials":10060,"activeCount":103},[],{"trials":10062,"activeCount":103},[],{"trials":10064,"activeCount":103},[10065],{"nctId":10066,"briefTitle":10067,"status":111,"phases":10068,"primaryCompletion":205,"completion":4929,"start":2695,"enrollment":8858,"conditions":10069,"interventions":10070},"NCT00616005","Ph. II Treatment of Adults w Primary Malignant Glioma w Irinotecan + Temozolomide",[92],[2643],[10057],{"trials":10072,"activeCount":103},[],{"trials":10074,"activeCount":103},[],{"trials":10076,"activeCount":103},[],{"intervention":10078,"totalTrials":132,"cells":10079},"aldesleukin",{"EARLY_PHASE1":10080,"PHASE1":10082,"PHASE2":10084,"PHASE3":10096,"PHASE4":10098,"NA":10100},{"trials":10081,"activeCount":103},[],{"trials":10083,"activeCount":103},[],{"trials":10085,"activeCount":103},[10086],{"nctId":10087,"briefTitle":10088,"status":111,"phases":10089,"primaryCompletion":10090,"completion":9787,"start":10091,"conditions":10092,"interventions":10093},"NCT00003229","Vaccine Therapy in Treating Patients With Metastatic Melanoma Who Are Undergoing Surgery for Lymph Node and Tumor Removal",[91,92],"2000-04","1997-07",[9010],[10078,10094,10095],"gp100 antigen","tyrosinase peptide",{"trials":10097,"activeCount":103},[],{"trials":10099,"activeCount":103},[],{"trials":10101,"activeCount":103},[],{"intervention":10094,"totalTrials":132,"cells":10103},{"EARLY_PHASE1":10104,"PHASE1":10106,"PHASE2":10108,"PHASE3":10114,"PHASE4":10116,"NA":10118},{"trials":10105,"activeCount":103},[],{"trials":10107,"activeCount":103},[],{"trials":10109,"activeCount":103},[10110],{"nctId":10087,"briefTitle":10088,"status":111,"phases":10111,"primaryCompletion":10090,"completion":9787,"start":10091,"conditions":10112,"interventions":10113},[91,92],[9010],[10078,10094,10095],{"trials":10115,"activeCount":103},[],{"trials":10117,"activeCount":103},[],{"trials":10119,"activeCount":103},[],{"intervention":10095,"totalTrials":132,"cells":10121},{"EARLY_PHASE1":10122,"PHASE1":10124,"PHASE2":10126,"PHASE3":10132,"PHASE4":10134,"NA":10136},{"trials":10123,"activeCount":103},[],{"trials":10125,"activeCount":103},[],{"trials":10127,"activeCount":103},[10128],{"nctId":10087,"briefTitle":10088,"status":111,"phases":10129,"primaryCompletion":10090,"completion":9787,"start":10091,"conditions":10130,"interventions":10131},[91,92],[9010],[10078,10094,10095],{"trials":10133,"activeCount":103},[],{"trials":10135,"activeCount":103},[],{"trials":10137,"activeCount":103},[],{"intervention":10139,"totalTrials":132,"cells":10140},"IV Zometa",{"EARLY_PHASE1":10141,"PHASE1":10143,"PHASE2":10145,"PHASE3":10155,"PHASE4":10157,"NA":10159},{"trials":10142,"activeCount":103},[],{"trials":10144,"activeCount":103},[],{"trials":10146,"activeCount":103},[10147],{"nctId":10148,"briefTitle":10149,"status":111,"phases":10150,"primaryCompletion":4383,"completion":7008,"start":3176,"enrollment":9,"conditions":10151,"interventions":10154},"NCT00301873","Zoledronate in Preventing Osteoporosis in Patients With Primary Malignant Glioma",[92],[10152,1533,10153],"Brain Tumors","Central Nervous System(CNS)Malignancies",[10139],{"trials":10156,"activeCount":103},[],{"trials":10158,"activeCount":103},[],{"trials":10160,"activeCount":103},[],{"intervention":3285,"totalTrials":132,"cells":10162},{"EARLY_PHASE1":10163,"PHASE1":10165,"PHASE2":10167,"PHASE3":10173,"PHASE4":10175,"NA":10177},{"trials":10164,"activeCount":103},[],{"trials":10166,"activeCount":103},[],{"trials":10168,"activeCount":103},[10169],{"nctId":3276,"briefTitle":3277,"status":111,"phases":10170,"primaryCompletion":3279,"completion":3280,"start":3281,"enrollment":19,"conditions":10171,"interventions":10172},[92],[3283],[3285,3260],{"trials":10174,"activeCount":103},[],{"trials":10176,"activeCount":103},[],{"trials":10178,"activeCount":103},[],{"intervention":9226,"totalTrials":132,"cells":10180},{"EARLY_PHASE1":10181,"PHASE1":10183,"PHASE2":10185,"PHASE3":10191,"PHASE4":10193,"NA":10195},{"trials":10182,"activeCount":103},[],{"trials":10184,"activeCount":103},[],{"trials":10186,"activeCount":103},[10187],{"nctId":9216,"briefTitle":9217,"status":111,"phases":10188,"primaryCompletion":9219,"completion":9220,"start":9221,"enrollment":25,"conditions":10189,"interventions":10190},[92],[9223],[9225,9226,9227,9228,9229,9230],{"trials":10192,"activeCount":103},[],{"trials":10194,"activeCount":103},[],{"trials":10196,"activeCount":103},[],{"intervention":9230,"totalTrials":132,"cells":10198},{"EARLY_PHASE1":10199,"PHASE1":10201,"PHASE2":10203,"PHASE3":10209,"PHASE4":10211,"NA":10213},{"trials":10200,"activeCount":103},[],{"trials":10202,"activeCount":103},[],{"trials":10204,"activeCount":103},[10205],{"nctId":9216,"briefTitle":9217,"status":111,"phases":10206,"primaryCompletion":9219,"completion":9220,"start":9221,"enrollment":25,"conditions":10207,"interventions":10208},[92],[9223],[9225,9226,9227,9228,9229,9230],{"trials":10210,"activeCount":103},[],{"trials":10212,"activeCount":103},[],{"trials":10214,"activeCount":103},[],{"intervention":10216,"totalTrials":132,"cells":10217},"Imatinib Mesylate & Hydroxyurea",{"EARLY_PHASE1":10218,"PHASE1":10220,"PHASE2":10222,"PHASE3":10230,"PHASE4":10232,"NA":10234},{"trials":10219,"activeCount":103},[],{"trials":10221,"activeCount":103},[],{"trials":10223,"activeCount":103},[10224],{"nctId":10225,"briefTitle":10226,"status":111,"phases":10227,"primaryCompletion":3122,"completion":8099,"start":7966,"enrollment":7566,"conditions":10228,"interventions":10229},"NCT00615927","Phase II Imatinib + Hydroxyurea in Treatment of Patients With Recurrent\u002FProgressive Grade II Low-Grade Glioma (LGG)",[92],[2643,2644],[10216],{"trials":10231,"activeCount":103},[],{"trials":10233,"activeCount":103},[],{"trials":10235,"activeCount":103},[],{"intervention":9258,"totalTrials":132,"cells":10237},{"EARLY_PHASE1":10238,"PHASE1":10240,"PHASE2":10242,"PHASE3":10248,"PHASE4":10250,"NA":10252},{"trials":10239,"activeCount":103},[],{"trials":10241,"activeCount":103},[],{"trials":10243,"activeCount":103},[10244],{"nctId":9250,"briefTitle":9251,"status":111,"phases":10245,"primaryCompletion":3105,"completion":3105,"start":9253,"enrollment":9254,"conditions":10246,"interventions":10247},[92],[8526,2937,660,9256],[9258,4576],{"trials":10249,"activeCount":103},[],{"trials":10251,"activeCount":103},[],{"trials":10253,"activeCount":103},[],{"intervention":9549,"totalTrials":132,"cells":10255},{"EARLY_PHASE1":10256,"PHASE1":10258,"PHASE2":10260,"PHASE3":10266,"PHASE4":10268,"NA":10270},{"trials":10257,"activeCount":103},[],{"trials":10259,"activeCount":103},[],{"trials":10261,"activeCount":103},[10262],{"nctId":9540,"briefTitle":9541,"status":111,"phases":10263,"primaryCompletion":9543,"completion":9544,"start":4653,"enrollment":2822,"conditions":10264,"interventions":10265},[91,92],[9546,9547],[9549,9550,9551],{"trials":10267,"activeCount":103},[],{"trials":10269,"activeCount":103},[],{"trials":10271,"activeCount":103},[],{"intervention":9551,"totalTrials":132,"cells":10273},{"EARLY_PHASE1":10274,"PHASE1":10276,"PHASE2":10278,"PHASE3":10284,"PHASE4":10286,"NA":10288},{"trials":10275,"activeCount":103},[],{"trials":10277,"activeCount":103},[],{"trials":10279,"activeCount":103},[10280],{"nctId":9540,"briefTitle":9541,"status":111,"phases":10281,"primaryCompletion":9543,"completion":9544,"start":4653,"enrollment":2822,"conditions":10282,"interventions":10283},[91,92],[9546,9547],[9549,9550,9551],{"trials":10285,"activeCount":103},[],{"trials":10287,"activeCount":103},[],{"trials":10289,"activeCount":103},[],{"intervention":9297,"totalTrials":132,"cells":10291},{"EARLY_PHASE1":10292,"PHASE1":10294,"PHASE2":10296,"PHASE3":10302,"PHASE4":10304,"NA":10306},{"trials":10293,"activeCount":103},[],{"trials":10295,"activeCount":103},[],{"trials":10297,"activeCount":103},[10298],{"nctId":9287,"briefTitle":9288,"status":111,"phases":10299,"primaryCompletion":9290,"completion":9291,"start":9292,"enrollment":9293,"conditions":10300,"interventions":10301},[91,92],[9295],[9297,9278],{"trials":10303,"activeCount":103},[],{"trials":10305,"activeCount":103},[],{"trials":10307,"activeCount":103},[],{"intervention":10309,"totalTrials":132,"cells":10310},"azacitidine",{"EARLY_PHASE1":10311,"PHASE1":10313,"PHASE2":10315,"PHASE3":10327,"PHASE4":10329,"NA":10331},{"trials":10312,"activeCount":103},[],{"trials":10314,"activeCount":103},[],{"trials":10316,"activeCount":103},[10317],{"nctId":10318,"briefTitle":10319,"status":155,"phases":10320,"primaryCompletion":2797,"completion":1220,"start":10321,"enrollment":160,"conditions":10322,"interventions":10325},"NCT01121757","Epigenetic Modulation in Relapsed\u002FRefractory Follicular Lymphoma and Marginal Zone Lymphoma",[92],"2010-04",[10323,10324],"Follicular Lymphoma","Marginal Zone Lymphoma",[10309,10326],"lenalidomide",{"trials":10328,"activeCount":103},[],{"trials":10330,"activeCount":103},[],{"trials":10332,"activeCount":103},[],{"intervention":10326,"totalTrials":132,"cells":10334},{"EARLY_PHASE1":10335,"PHASE1":10337,"PHASE2":10339,"PHASE3":10345,"PHASE4":10347,"NA":10349},{"trials":10336,"activeCount":103},[],{"trials":10338,"activeCount":103},[],{"trials":10340,"activeCount":103},[10341],{"nctId":10318,"briefTitle":10319,"status":155,"phases":10342,"primaryCompletion":2797,"completion":1220,"start":10321,"enrollment":160,"conditions":10343,"interventions":10344},[92],[10323,10324],[10309,10326],{"trials":10346,"activeCount":103},[],{"trials":10348,"activeCount":103},[],{"trials":10350,"activeCount":103},[],{"intervention":10352,"totalTrials":132,"cells":10353},"PPI deprescribing",{"EARLY_PHASE1":10354,"PHASE1":10356,"PHASE2":10358,"PHASE3":10369,"PHASE4":10371,"NA":10373},{"trials":10355,"activeCount":103},[],{"trials":10357,"activeCount":103},[],{"trials":10359,"activeCount":103},[10360],{"nctId":10361,"briefTitle":10362,"status":111,"phases":10363,"primaryCompletion":10364,"completion":10364,"start":10365,"enrollment":4398,"conditions":10366,"interventions":10368},"NCT05070351","Deprescribing Proton Pump Inhibitors to Reduce Post-TIPS Hepatic Encephalopathy",[91,92],"2025-06-02","2022-01-03",[10367],"Hepatic Encephalopathy",[10352],{"trials":10370,"activeCount":103},[],{"trials":10372,"activeCount":103},[],{"trials":10374,"activeCount":103},[],{"intervention":10376,"totalTrials":132,"cells":10377},"Alirocumab",{"EARLY_PHASE1":10378,"PHASE1":10380,"PHASE2":10382,"PHASE3":10395,"PHASE4":10397,"NA":10399},{"trials":10379,"activeCount":103},[],{"trials":10381,"activeCount":103},[],{"trials":10383,"activeCount":103},[10384],{"nctId":10385,"briefTitle":10386,"status":10387,"phases":10388,"primaryCompletion":3706,"completion":10389,"start":10390,"enrollment":6254,"conditions":10391,"interventions":10392},"NCT06385262","TOP 2301: Neoadjuvant Chemo for NSCLC","SUSPENDED",[92],"2029-10-30","2025-03-17",[1684],[10376,10393,10394],"Cemiplimab","Chemotherapy",{"trials":10396,"activeCount":103},[],{"trials":10398,"activeCount":103},[],{"trials":10400,"activeCount":103},[],{"intervention":10393,"totalTrials":132,"cells":10402},{"EARLY_PHASE1":10403,"PHASE1":10405,"PHASE2":10407,"PHASE3":10413,"PHASE4":10415,"NA":10417},{"trials":10404,"activeCount":103},[],{"trials":10406,"activeCount":103},[],{"trials":10408,"activeCount":103},[10409],{"nctId":10385,"briefTitle":10386,"status":10387,"phases":10410,"primaryCompletion":3706,"completion":10389,"start":10390,"enrollment":6254,"conditions":10411,"interventions":10412},[92],[1684],[10376,10393,10394],{"trials":10414,"activeCount":103},[],{"trials":10416,"activeCount":103},[],{"trials":10418,"activeCount":103},[],{"intervention":10394,"totalTrials":132,"cells":10420},{"EARLY_PHASE1":10421,"PHASE1":10423,"PHASE2":10425,"PHASE3":10431,"PHASE4":10433,"NA":10435},{"trials":10422,"activeCount":103},[],{"trials":10424,"activeCount":103},[],{"trials":10426,"activeCount":103},[10427],{"nctId":10385,"briefTitle":10386,"status":10387,"phases":10428,"primaryCompletion":3706,"completion":10389,"start":10390,"enrollment":6254,"conditions":10429,"interventions":10430},[92],[1684],[10376,10393,10394],{"trials":10432,"activeCount":103},[],{"trials":10434,"activeCount":103},[],{"trials":10436,"activeCount":103},[],{"intervention":10438,"totalTrials":132,"cells":10439},"Vorinostat",{"EARLY_PHASE1":10440,"PHASE1":10442,"PHASE2":10444,"PHASE3":10454,"PHASE4":10456,"NA":10458},{"trials":10441,"activeCount":103},[],{"trials":10443,"activeCount":103},[],{"trials":10445,"activeCount":103},[10446],{"nctId":10447,"briefTitle":10448,"status":111,"phases":10449,"primaryCompletion":1222,"completion":8207,"start":2638,"enrollment":19,"conditions":10450,"interventions":10453},"NCT01738646","Ph II SAHA and Bevacizumab for Recurrent Malignant Glioma Patients",[92],[10451,2641,10452],"Recurrent Glioblastoma Multiforme","Adult Brain Tumor",[10438,1675],{"trials":10455,"activeCount":103},[],{"trials":10457,"activeCount":103},[],{"trials":10459,"activeCount":103},[],{"intervention":9266,"totalTrials":132,"cells":10461},{"EARLY_PHASE1":10462,"PHASE1":10464,"PHASE2":10466,"PHASE3":10472,"PHASE4":10474,"NA":10476},{"trials":10463,"activeCount":103},[],{"trials":10465,"activeCount":103},[],{"trials":10467,"activeCount":103},[10468],{"nctId":9260,"briefTitle":9261,"status":155,"phases":10469,"primaryCompletion":2339,"completion":2339,"start":3123,"enrollment":448,"conditions":10470,"interventions":10471},[92],[9264],[9266,4576],{"trials":10473,"activeCount":103},[],{"trials":10475,"activeCount":103},[],{"trials":10477,"activeCount":103},[],{"intervention":9653,"totalTrials":132,"cells":10479},{"EARLY_PHASE1":10480,"PHASE1":10482,"PHASE2":10484,"PHASE3":10490,"PHASE4":10492,"NA":10494},{"trials":10481,"activeCount":103},[],{"trials":10483,"activeCount":103},[],{"trials":10485,"activeCount":103},[10486],{"nctId":9647,"briefTitle":9648,"status":111,"phases":10487,"primaryCompletion":2798,"completion":2798,"start":3123,"enrollment":144,"conditions":10488,"interventions":10489},[91,92],[9651],[9638,9653],{"trials":10491,"activeCount":103},[],{"trials":10493,"activeCount":103},[],{"trials":10495,"activeCount":103},[],{"intervention":9692,"totalTrials":132,"cells":10497},{"EARLY_PHASE1":10498,"PHASE1":10500,"PHASE2":10502,"PHASE3":10508,"PHASE4":10510,"NA":10512},{"trials":10499,"activeCount":103},[],{"trials":10501,"activeCount":103},[],{"trials":10503,"activeCount":103},[10504],{"nctId":9686,"briefTitle":9687,"status":111,"phases":10505,"primaryCompletion":9689,"completion":9689,"start":2797,"enrollment":1212,"conditions":10506,"interventions":10507},[92],[1684],[9669,9692],{"trials":10509,"activeCount":103},[],{"trials":10511,"activeCount":103},[],{"trials":10513,"activeCount":103},[],{"intervention":9337,"totalTrials":132,"cells":10515},{"EARLY_PHASE1":10516,"PHASE1":10518,"PHASE2":10520,"PHASE3":10526,"PHASE4":10528,"NA":10530},{"trials":10517,"activeCount":103},[],{"trials":10519,"activeCount":103},[],{"trials":10521,"activeCount":103},[10522],{"nctId":9331,"briefTitle":9332,"status":111,"phases":10523,"primaryCompletion":1625,"completion":1612,"start":3104,"enrollment":2982,"conditions":10524,"interventions":10525},[92],[9335],[9337,8972],{"trials":10527,"activeCount":103},[],{"trials":10529,"activeCount":103},[],{"trials":10531,"activeCount":103},[],{"intervention":10533,"totalTrials":132,"cells":10534},"EF5",{"EARLY_PHASE1":10535,"PHASE1":10537,"PHASE2":10539,"PHASE3":10548,"PHASE4":10550,"NA":10552},{"trials":10536,"activeCount":103},[],{"trials":10538,"activeCount":103},[],{"trials":10540,"activeCount":103},[10541],{"nctId":10542,"briefTitle":10543,"status":111,"phases":10544,"primaryCompletion":3189,"completion":9182,"start":10545,"enrollment":9,"conditions":10546,"interventions":10547},"NCT00041028","EF5 in Assessing Tumor Response to Anticancer Therapy in Patients With Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer",[92],"2002-05",[4574],[10533],{"trials":10549,"activeCount":103},[],{"trials":10551,"activeCount":103},[],{"trials":10553,"activeCount":103},[],{"intervention":10555,"totalTrials":132,"cells":10556},"Oxaliplatin+Capecitabine+Pembrolizumab",{"EARLY_PHASE1":10557,"PHASE1":10559,"PHASE2":10561,"PHASE3":10573,"PHASE4":10575,"NA":10577},{"trials":10558,"activeCount":103},[],{"trials":10560,"activeCount":103},[],{"trials":10562,"activeCount":103},[10563],{"nctId":10564,"briefTitle":10565,"status":111,"phases":10566,"primaryCompletion":10567,"completion":10567,"start":10568,"enrollment":6471,"conditions":10569,"interventions":10572},"NCT03342937","KeyLargo: Pembrolizumab + Oxaliplatin + Capecitabine in Gastric Cancer",[92],"2023-02-06","2018-01-11",[10570,10571],"Gastric Cancer","Esophagus Cancer",[10555],{"trials":10574,"activeCount":103},[],{"trials":10576,"activeCount":103},[],{"trials":10578,"activeCount":103},[],{"intervention":9146,"totalTrials":132,"cells":10580},{"EARLY_PHASE1":10581,"PHASE1":10583,"PHASE2":10585,"PHASE3":10591,"PHASE4":10593,"NA":10595},{"trials":10582,"activeCount":103},[],{"trials":10584,"activeCount":103},[],{"trials":10586,"activeCount":103},[10587],{"nctId":9139,"briefTitle":9140,"status":155,"phases":10588,"primaryCompletion":9142,"completion":9142,"start":9143,"enrollment":8858,"conditions":10589,"interventions":10590},[92],[1236,2644],[9146,2666,9147],{"trials":10592,"activeCount":103},[],{"trials":10594,"activeCount":103},[],{"trials":10596,"activeCount":103},[],{"intervention":9147,"totalTrials":132,"cells":10598},{"EARLY_PHASE1":10599,"PHASE1":10601,"PHASE2":10603,"PHASE3":10609,"PHASE4":10611,"NA":10613},{"trials":10600,"activeCount":103},[],{"trials":10602,"activeCount":103},[],{"trials":10604,"activeCount":103},[10605],{"nctId":9139,"briefTitle":9140,"status":155,"phases":10606,"primaryCompletion":9142,"completion":9142,"start":9143,"enrollment":8858,"conditions":10607,"interventions":10608},[92],[1236,2644],[9146,2666,9147],{"trials":10610,"activeCount":103},[],{"trials":10612,"activeCount":103},[],{"trials":10614,"activeCount":103},[],{"intervention":10616,"totalTrials":132,"cells":10617},"CERC-501",{"EARLY_PHASE1":10618,"PHASE1":10620,"PHASE2":10622,"PHASE3":10632,"PHASE4":10634,"NA":10636},{"trials":10619,"activeCount":103},[],{"trials":10621,"activeCount":103},[],{"trials":10623,"activeCount":103},[10624],{"nctId":10625,"briefTitle":10626,"status":111,"phases":10627,"primaryCompletion":3031,"completion":10628,"start":218,"enrollment":6938,"conditions":10629,"interventions":10631},"NCT02218736","Fast-Fail Trials in Mood and Anxiety Spectrum Disorders; Kappa Opioid Receptor Phase 2a",[92],"2017-12-01",[10630],"ANXIETY DISORDERS (or Anxiety and Phobic Neuroses)",[10616],{"trials":10633,"activeCount":103},[],{"trials":10635,"activeCount":103},[],{"trials":10637,"activeCount":103},[],{"intervention":10639,"totalTrials":132,"cells":10640},"carcinoembryonic antigen RNA-pulsed DC cancer vaccine",{"EARLY_PHASE1":10641,"PHASE1":10643,"PHASE2":10645,"PHASE3":10655,"PHASE4":10657,"NA":10659},{"trials":10642,"activeCount":103},[],{"trials":10644,"activeCount":103},[],{"trials":10646,"activeCount":103},[10647],{"nctId":10648,"briefTitle":10649,"status":155,"phases":10650,"primaryCompletion":10651,"completion":10651,"start":10652,"enrollment":402,"conditions":10653,"interventions":10654},"NCT00003432","Immunotherapy in Treating Patients With Metastatic Breast Cancer",[91,92],"2002-11","1998-06",[18],[10639],{"trials":10656,"activeCount":103},[],{"trials":10658,"activeCount":103},[],{"trials":10660,"activeCount":103},[],{"intervention":10662,"totalTrials":132,"cells":10663},"panobinostat",{"EARLY_PHASE1":10664,"PHASE1":10666,"PHASE2":10668,"PHASE3":10676,"PHASE4":10678,"NA":10680},{"trials":10665,"activeCount":103},[],{"trials":10667,"activeCount":103},[],{"trials":10669,"activeCount":103},[10670],{"nctId":10671,"briefTitle":10672,"status":428,"phases":10673,"primaryCompletion":9143,"completion":1169,"start":10321,"enrollment":103,"conditions":10674,"interventions":10675},"NCT01115036","A Panobinostat Presurgery",[92],[1660],[10662],{"trials":10677,"activeCount":103},[],{"trials":10679,"activeCount":103},[],{"trials":10681,"activeCount":103},[],{"intervention":10683,"totalTrials":132,"cells":10684},"Empagliflozin10Mg Tab",{"EARLY_PHASE1":10685,"PHASE1":10687,"PHASE2":10689,"PHASE3":10701,"PHASE4":10703,"NA":10705},{"trials":10686,"activeCount":103},[],{"trials":10688,"activeCount":103},[],{"trials":10690,"activeCount":103},[10691],{"nctId":10692,"briefTitle":10693,"status":155,"phases":10694,"primaryCompletion":10695,"completion":10695,"start":10696,"enrollment":544,"conditions":10697,"interventions":10700},"NCT04906213","CardioRenal Effects of SGLT2 Inhibition in Kidney Transplant Recipients",[92],"2026-01-22","2022-07-25",[10698,10699],"Kidney Transplant; Complications","Diabetes Mellitus, Type 2",[10683],{"trials":10702,"activeCount":103},[],{"trials":10704,"activeCount":103},[],{"trials":10706,"activeCount":103},[],{"intervention":10708,"totalTrials":132,"cells":10709},"osimertinib",{"EARLY_PHASE1":10710,"PHASE1":10712,"PHASE2":10714,"PHASE3":10724,"PHASE4":10726,"NA":10728},{"trials":10711,"activeCount":103},[],{"trials":10713,"activeCount":103},[],{"trials":10715,"activeCount":103},[10716],{"nctId":10717,"briefTitle":10718,"status":111,"phases":10719,"primaryCompletion":10720,"completion":10720,"start":10721,"enrollment":8410,"conditions":10722,"interventions":10723},"NCT03434418","A Study Osimertinib in Patients With Stage 4 Non-small Cell Lung Cancer With Uncommon EGFR Mutations",[92],"2022-10-12","2018-06-30",[1684],[10708],{"trials":10725,"activeCount":103},[],{"trials":10727,"activeCount":103},[],{"trials":10729,"activeCount":103},[],{"intervention":10731,"totalTrials":132,"cells":10732},"allopurinol",{"EARLY_PHASE1":10733,"PHASE1":10735,"PHASE2":10737,"PHASE3":10749,"PHASE4":10751,"NA":10753},{"trials":10734,"activeCount":103},[],{"trials":10736,"activeCount":103},[],{"trials":10738,"activeCount":103},[10739],{"nctId":10740,"briefTitle":10741,"status":111,"phases":10742,"primaryCompletion":2811,"completion":2812,"start":10743,"enrollment":10744,"conditions":10745,"interventions":10747},"NCT00987415","Using Allopurinol to Relieve Symptoms in Patients With Heart Failure and High Uric Acid Levels",[92],"2010-05",253,[21,10746],"Elevated Serum Uric Acid",[10731,10748],"sugar pill",{"trials":10750,"activeCount":103},[],{"trials":10752,"activeCount":103},[],{"trials":10754,"activeCount":103},[],{"intervention":10748,"totalTrials":132,"cells":10756},{"EARLY_PHASE1":10757,"PHASE1":10759,"PHASE2":10761,"PHASE3":10767,"PHASE4":10769,"NA":10771},{"trials":10758,"activeCount":103},[],{"trials":10760,"activeCount":103},[],{"trials":10762,"activeCount":103},[10763],{"nctId":10740,"briefTitle":10741,"status":111,"phases":10764,"primaryCompletion":2811,"completion":2812,"start":10743,"enrollment":10744,"conditions":10765,"interventions":10766},[92],[21,10746],[10731,10748],{"trials":10768,"activeCount":103},[],{"trials":10770,"activeCount":103},[],{"trials":10772,"activeCount":103},[],{"intervention":10774,"totalTrials":132,"cells":10775},"Amphetamine",{"EARLY_PHASE1":10776,"PHASE1":10778,"PHASE2":10780,"PHASE3":10792,"PHASE4":10794,"NA":10796},{"trials":10777,"activeCount":103},[],{"trials":10779,"activeCount":103},[],{"trials":10781,"activeCount":103},[10782],{"nctId":10783,"briefTitle":10784,"status":155,"phases":10785,"primaryCompletion":10786,"completion":10787,"start":10788,"enrollment":1668,"conditions":10789,"interventions":10791},"NCT03242772","Impact of Combined Medication and Behavioral Treatment for ASD & ADHD",[92],"2020-12-28","2021-04-19","2018-12-14",[10790,3754],"Autism Spectrum Disorder",[10774],{"trials":10793,"activeCount":103},[],{"trials":10795,"activeCount":103},[],{"trials":10797,"activeCount":103},[],{"intervention":10799,"totalTrials":132,"cells":10800},"Varenicline Adaptive Protocol",{"EARLY_PHASE1":10801,"PHASE1":10803,"PHASE2":10805,"PHASE3":10817,"PHASE4":10819,"NA":10821},{"trials":10802,"activeCount":103},[],{"trials":10804,"activeCount":103},[],{"trials":10806,"activeCount":103},[10807],{"nctId":10808,"briefTitle":10809,"status":111,"phases":10810,"primaryCompletion":10811,"completion":10812,"start":10813,"enrollment":8100,"conditions":10814,"interventions":10815},"NCT02501265","Adaptive Pharmacotherapy for Smoking Cessation",[92],"2020-07-30","2021-05-12","2017-06-06",[2802],[10799,10816],"Nicotine Adaptive Protocol",{"trials":10818,"activeCount":103},[],{"trials":10820,"activeCount":103},[],{"trials":10822,"activeCount":103},[],{"intervention":10816,"totalTrials":132,"cells":10824},{"EARLY_PHASE1":10825,"PHASE1":10827,"PHASE2":10829,"PHASE3":10835,"PHASE4":10837,"NA":10839},{"trials":10826,"activeCount":103},[],{"trials":10828,"activeCount":103},[],{"trials":10830,"activeCount":103},[10831],{"nctId":10808,"briefTitle":10809,"status":111,"phases":10832,"primaryCompletion":10811,"completion":10812,"start":10813,"enrollment":8100,"conditions":10833,"interventions":10834},[92],[2802],[10799,10816],{"trials":10836,"activeCount":103},[],{"trials":10838,"activeCount":103},[],{"trials":10840,"activeCount":103},[],{"intervention":10842,"totalTrials":132,"cells":10843},"K+ supplement",{"EARLY_PHASE1":10844,"PHASE1":10846,"PHASE2":10848,"PHASE3":10859,"PHASE4":10861,"NA":10863},{"trials":10845,"activeCount":103},[],{"trials":10847,"activeCount":103},[],{"trials":10849,"activeCount":103},[10850],{"nctId":10851,"briefTitle":10852,"status":111,"phases":10853,"primaryCompletion":10854,"completion":10854,"start":1544,"enrollment":10855,"conditions":10856,"interventions":10858},"NCT02236598","The Effects of Potassium on Glucose Metabolism in African Americans",[92],"2016-02-29",61,[10857],"Borderline Hypokalemia",[10842],{"trials":10860,"activeCount":103},[],{"trials":10862,"activeCount":103},[],{"trials":10864,"activeCount":103},[],{"intervention":120,"totalTrials":132,"cells":10866},{"EARLY_PHASE1":10867,"PHASE1":10869,"PHASE2":10871,"PHASE3":10877,"PHASE4":10879,"NA":10881},{"trials":10868,"activeCount":103},[],{"trials":10870,"activeCount":103},[],{"trials":10872,"activeCount":103},[10873],{"nctId":109,"briefTitle":110,"status":111,"phases":10874,"primaryCompletion":113,"completion":113,"start":114,"enrollment":115,"conditions":10875,"interventions":10876},[92],[117,118],[120,98],{"trials":10878,"activeCount":103},[],{"trials":10880,"activeCount":103},[],{"trials":10882,"activeCount":103},[],{"intervention":10884,"totalTrials":132,"cells":10885},"Baricitinib",{"EARLY_PHASE1":10886,"PHASE1":10888,"PHASE2":10890,"PHASE3":10900,"PHASE4":10902,"NA":10904},{"trials":10887,"activeCount":103},[],{"trials":10889,"activeCount":103},[],{"trials":10891,"activeCount":103},[10892],{"nctId":10893,"briefTitle":10894,"status":111,"phases":10895,"primaryCompletion":1719,"completion":1719,"start":10896,"enrollment":1144,"conditions":10897,"interventions":10899},"NCT05237388","Janus Kinase-STAT Inhibition to Reduce APOL1 Associated Kidney Disease",[92],"2023-04-20",[10898],"Chronic Kidney Diseases",[10884],{"trials":10901,"activeCount":103},[],{"trials":10903,"activeCount":103},[],{"trials":10905,"activeCount":103},[],{"intervention":10907,"totalTrials":132,"cells":10908},"Voxelotor",{"EARLY_PHASE1":10909,"PHASE1":10911,"PHASE2":10913,"PHASE3":10926,"PHASE4":10928,"NA":10930},{"trials":10910,"activeCount":103},[],{"trials":10912,"activeCount":103},[],{"trials":10914,"activeCount":103},[10915],{"nctId":10916,"briefTitle":10917,"status":155,"phases":10918,"primaryCompletion":10919,"completion":10920,"start":10921,"enrollment":229,"conditions":10922,"interventions":10925},"NCT05289570","Voxelotor for Improving Oxygen Saturation in Adults",[92],"2023-06-28","2023-07-04","2022-05-03",[10923,10924],"Acute Lung Injury","End Stage Lung Disease",[10907],{"trials":10927,"activeCount":103},[],{"trials":10929,"activeCount":103},[],{"trials":10931,"activeCount":103},[],{"intervention":10933,"totalTrials":132,"cells":10934},"tiotropium bromide inhalation powder",{"EARLY_PHASE1":10935,"PHASE1":10937,"PHASE2":10939,"PHASE3":10951,"PHASE4":10953,"NA":10955},{"trials":10936,"activeCount":103},[],{"trials":10938,"activeCount":103},[],{"trials":10940,"activeCount":103},[10941],{"nctId":10942,"briefTitle":10943,"status":428,"phases":10944,"primaryCompletion":10945,"completion":10945,"start":10946,"enrollment":103,"conditions":10947,"interventions":10948},"NCT05838703","Tiotropium Handihaler vs. Tiotropium Respimat in COPD",[92],"2024-05-01","2023-05-01",[2326],[10933,10949,10950],"tiotropium bromide","Hyperpolarized 129XeMRI",{"trials":10952,"activeCount":103},[],{"trials":10954,"activeCount":103},[],{"trials":10956,"activeCount":103},[],{"intervention":10949,"totalTrials":132,"cells":10958},{"EARLY_PHASE1":10959,"PHASE1":10961,"PHASE2":10963,"PHASE3":10969,"PHASE4":10971,"NA":10973},{"trials":10960,"activeCount":103},[],{"trials":10962,"activeCount":103},[],{"trials":10964,"activeCount":103},[10965],{"nctId":10942,"briefTitle":10943,"status":428,"phases":10966,"primaryCompletion":10945,"completion":10945,"start":10946,"enrollment":103,"conditions":10967,"interventions":10968},[92],[2326],[10933,10949,10950],{"trials":10970,"activeCount":103},[],{"trials":10972,"activeCount":103},[],{"trials":10974,"activeCount":103},[],{"intervention":10950,"totalTrials":132,"cells":10976},{"EARLY_PHASE1":10977,"PHASE1":10979,"PHASE2":10981,"PHASE3":10987,"PHASE4":10989,"NA":10991},{"trials":10978,"activeCount":103},[],{"trials":10980,"activeCount":103},[],{"trials":10982,"activeCount":103},[10983],{"nctId":10942,"briefTitle":10943,"status":428,"phases":10984,"primaryCompletion":10945,"completion":10945,"start":10946,"enrollment":103,"conditions":10985,"interventions":10986},[92],[2326],[10933,10949,10950],{"trials":10988,"activeCount":103},[],{"trials":10990,"activeCount":103},[],{"trials":10992,"activeCount":103},[],{"intervention":10994,"totalTrials":132,"cells":10995},"splanchnic nerve anesthesia with a local anesthetic",{"EARLY_PHASE1":10996,"PHASE1":10998,"PHASE2":11000,"PHASE3":11011,"PHASE4":11013,"NA":11015},{"trials":10997,"activeCount":103},[],{"trials":10999,"activeCount":103},[],{"trials":11001,"activeCount":103},[11002],{"nctId":11003,"briefTitle":11004,"status":111,"phases":11005,"primaryCompletion":11006,"completion":11007,"start":11008,"enrollment":2822,"conditions":11009,"interventions":11010},"NCT03453151","Abdominal Nerve Blockade in Chronic Heart Failure.",[91,92],"2019-06-27","2019-12-27","2018-05-01",[21],[10994],{"trials":11012,"activeCount":103},[],{"trials":11014,"activeCount":103},[],{"trials":11016,"activeCount":103},[],{"intervention":11018,"totalTrials":132,"cells":11019},"Clenbuterol",{"EARLY_PHASE1":11020,"PHASE1":11022,"PHASE2":11024,"PHASE3":11037,"PHASE4":11039,"NA":11041},{"trials":11021,"activeCount":103},[],{"trials":11023,"activeCount":103},[],{"trials":11025,"activeCount":103},[11026],{"nctId":11027,"briefTitle":11028,"status":428,"phases":11029,"primaryCompletion":11030,"completion":11031,"start":11032,"enrollment":103,"conditions":11033,"interventions":11035},"NCT04094948","Phase II Clinical Trial of Clenbuterol in Adult Patients With Pompe Disease",[92],"2025-06-30","2025-12-30","2023-01-01",[11034],"Pompe Disease (Late-onset)",[11018,11036],"Placebos",{"trials":11038,"activeCount":103},[],{"trials":11040,"activeCount":103},[],{"trials":11042,"activeCount":103},[],{"intervention":11036,"totalTrials":132,"cells":11044},{"EARLY_PHASE1":11045,"PHASE1":11047,"PHASE2":11049,"PHASE3":11055,"PHASE4":11057,"NA":11059},{"trials":11046,"activeCount":103},[],{"trials":11048,"activeCount":103},[],{"trials":11050,"activeCount":103},[11051],{"nctId":11027,"briefTitle":11028,"status":428,"phases":11052,"primaryCompletion":11030,"completion":11031,"start":11032,"enrollment":103,"conditions":11053,"interventions":11054},[92],[11034],[11018,11036],{"trials":11056,"activeCount":103},[],{"trials":11058,"activeCount":103},[],{"trials":11060,"activeCount":103},[],{"intervention":11062,"totalTrials":132,"cells":11063},"Bevacizumab and Erlotinib",{"EARLY_PHASE1":11064,"PHASE1":11066,"PHASE2":11068,"PHASE3":11076,"PHASE4":11078,"NA":11080},{"trials":11065,"activeCount":103},[],{"trials":11067,"activeCount":103},[],{"trials":11069,"activeCount":103},[11070],{"nctId":11071,"briefTitle":11072,"status":111,"phases":11073,"primaryCompletion":2593,"completion":10321,"start":3254,"enrollment":8927,"conditions":11074,"interventions":11075},"NCT00671970","Phase (Ph) II Bevacizumab + Erlotinib for Patients (Pts) With Recurrent Malignant Glioma (MG)",[92],[2643,2644],[11062],{"trials":11077,"activeCount":103},[],{"trials":11079,"activeCount":103},[],{"trials":11081,"activeCount":103},[],{"intervention":11083,"totalTrials":132,"cells":11084},"Cabozantinib",{"EARLY_PHASE1":11085,"PHASE1":11087,"PHASE2":11089,"PHASE3":11100,"PHASE4":11102,"NA":11104},{"trials":11086,"activeCount":103},[],{"trials":11088,"activeCount":103},[],{"trials":11090,"activeCount":103},[11091],{"nctId":11092,"briefTitle":11093,"status":155,"phases":11094,"primaryCompletion":11095,"completion":11095,"start":158,"enrollment":229,"conditions":11096,"interventions":11099},"NCT03964337","Immediate Prostatectomy vs. Cabozantinib Followed by Prostatectomy in Men With High-Risk Prostate Cancer",[92],"2021-06-04",[24,11097,11098],"Prostate Cancer Adenocarcinoma","Non-Metastatic",[11083],{"trials":11101,"activeCount":103},[],{"trials":11103,"activeCount":103},[],{"trials":11105,"activeCount":103},[],{"intervention":1710,"totalTrials":132,"cells":11107},{"EARLY_PHASE1":11108,"PHASE1":11110,"PHASE2":11112,"PHASE3":11118,"PHASE4":11120,"NA":11122},{"trials":11109,"activeCount":103},[],{"trials":11111,"activeCount":103},[],{"trials":11113,"activeCount":103},[11114],{"nctId":1701,"briefTitle":1702,"status":111,"phases":11115,"primaryCompletion":1704,"completion":1705,"start":1706,"enrollment":193,"conditions":11116,"interventions":11117},[92],[1708],[1710,1711,68,1712],{"trials":11119,"activeCount":103},[],{"trials":11121,"activeCount":103},[],{"trials":11123,"activeCount":103},[],{"intervention":1711,"totalTrials":132,"cells":11125},{"EARLY_PHASE1":11126,"PHASE1":11128,"PHASE2":11130,"PHASE3":11136,"PHASE4":11138,"NA":11140},{"trials":11127,"activeCount":103},[],{"trials":11129,"activeCount":103},[],{"trials":11131,"activeCount":103},[11132],{"nctId":1701,"briefTitle":1702,"status":111,"phases":11133,"primaryCompletion":1704,"completion":1705,"start":1706,"enrollment":193,"conditions":11134,"interventions":11135},[92],[1708],[1710,1711,68,1712],{"trials":11137,"activeCount":103},[],{"trials":11139,"activeCount":103},[],{"trials":11141,"activeCount":103},[],{"intervention":1712,"totalTrials":132,"cells":11143},{"EARLY_PHASE1":11144,"PHASE1":11146,"PHASE2":11148,"PHASE3":11154,"PHASE4":11156,"NA":11158},{"trials":11145,"activeCount":103},[],{"trials":11147,"activeCount":103},[],{"trials":11149,"activeCount":103},[11150],{"nctId":1701,"briefTitle":1702,"status":111,"phases":11151,"primaryCompletion":1704,"completion":1705,"start":1706,"enrollment":193,"conditions":11152,"interventions":11153},[92],[1708],[1710,1711,68,1712],{"trials":11155,"activeCount":103},[],{"trials":11157,"activeCount":103},[],{"trials":11159,"activeCount":103},[],{"intervention":2655,"totalTrials":132,"cells":11161},{"EARLY_PHASE1":11162,"PHASE1":11164,"PHASE2":11166,"PHASE3":11172,"PHASE4":11174,"NA":11176},{"trials":11163,"activeCount":103},[],{"trials":11165,"activeCount":103},[],{"trials":11167,"activeCount":103},[11168],{"nctId":2647,"briefTitle":2648,"status":111,"phases":11169,"primaryCompletion":2650,"completion":2651,"start":2652,"enrollment":684,"conditions":11170,"interventions":11171},[92],[2641,2643,2644],[1675,2586,2655],{"trials":11173,"activeCount":103},[],{"trials":11175,"activeCount":103},[],{"trials":11177,"activeCount":103},[],{"intervention":11179,"totalTrials":132,"cells":11180},"Propranolol LA",{"EARLY_PHASE1":11181,"PHASE1":11183,"PHASE2":11185,"PHASE3":11194,"PHASE4":11196,"NA":11198},{"trials":11182,"activeCount":103},[],{"trials":11184,"activeCount":103},[],{"trials":11186,"activeCount":103},[11187],{"nctId":11188,"briefTitle":11189,"status":111,"phases":11190,"primaryCompletion":11191,"completion":11191,"start":1220,"enrollment":8720,"conditions":11192,"interventions":11193},"NCT02620579","Biopsychosocial Influence on Shoulder Pain",[92],"2021-11-05",[3067],[11179],{"trials":11195,"activeCount":103},[],{"trials":11197,"activeCount":103},[],{"trials":11199,"activeCount":103},[],{"intervention":11201,"totalTrials":132,"cells":11202},"Beetroot Juice (Beet-It Stamina Shot) and Exercise Training",{"EARLY_PHASE1":11203,"PHASE1":11205,"PHASE2":11207,"PHASE3":11216,"PHASE4":11218,"NA":11220},{"trials":11204,"activeCount":103},[],{"trials":11206,"activeCount":103},[],{"trials":11208,"activeCount":103},[11209],{"nctId":11210,"briefTitle":11211,"status":111,"phases":11212,"primaryCompletion":8969,"completion":8969,"start":2350,"enrollment":1668,"conditions":11213,"interventions":11215},"NCT01785524","Dietary Nitrate and Exercise to Augment Exercise Training Benefits in Subjects With DM+PAD",[92],[9916,11214],"Type II Diabetes Mellitus",[11201],{"trials":11217,"activeCount":103},[],{"trials":11219,"activeCount":103},[],{"trials":11221,"activeCount":103},[],{"intervention":11223,"totalTrials":132,"cells":11224},"Sacubitril \u002F Valsartan Oral Tablet [Entresto]",{"EARLY_PHASE1":11225,"PHASE1":11227,"PHASE2":11229,"PHASE3":11240,"PHASE4":11242,"NA":11244},{"trials":11226,"activeCount":103},[],{"trials":11228,"activeCount":103},[],{"trials":11230,"activeCount":103},[11231],{"nctId":11232,"briefTitle":11233,"status":111,"phases":11234,"primaryCompletion":11235,"completion":11235,"start":11236,"enrollment":22,"conditions":11237,"interventions":11239},"NCT04883528","Protecting With ARNI Against Cardiac Consequences of Coronavirus Disease 2019",[91,92],"2023-06-13","2021-08-06",[11238],"Covid19",[11223],{"trials":11241,"activeCount":103},[],{"trials":11243,"activeCount":103},[],{"trials":11245,"activeCount":103},[],{"intervention":8962,"totalTrials":132,"cells":11247},{"EARLY_PHASE1":11248,"PHASE1":11250,"PHASE2":11252,"PHASE3":11258,"PHASE4":11260,"NA":11262},{"trials":11249,"activeCount":103},[],{"trials":11251,"activeCount":103},[],{"trials":11253,"activeCount":103},[11254],{"nctId":8957,"briefTitle":8958,"status":155,"phases":11255,"primaryCompletion":2351,"completion":2351,"start":2963,"enrollment":3190,"conditions":11256,"interventions":11257},[92],[18],[1675,8852,8962,1674,8963,8964],{"trials":11259,"activeCount":103},[],{"trials":11261,"activeCount":103},[],{"trials":11263,"activeCount":103},[],{"intervention":8963,"totalTrials":132,"cells":11265},{"EARLY_PHASE1":11266,"PHASE1":11268,"PHASE2":11270,"PHASE3":11276,"PHASE4":11278,"NA":11280},{"trials":11267,"activeCount":103},[],{"trials":11269,"activeCount":103},[],{"trials":11271,"activeCount":103},[11272],{"nctId":8957,"briefTitle":8958,"status":155,"phases":11273,"primaryCompletion":2351,"completion":2351,"start":2963,"enrollment":3190,"conditions":11274,"interventions":11275},[92],[18],[1675,8852,8962,1674,8963,8964],{"trials":11277,"activeCount":103},[],{"trials":11279,"activeCount":103},[],{"trials":11281,"activeCount":103},[],{"intervention":11283,"totalTrials":132,"cells":11284},"As indicated: Sertraline, bupropion, venlafaxine, mirtazepine, nortriptyline, tranylcypromine, lithium augmentation, etc.",{"EARLY_PHASE1":11285,"PHASE1":11287,"PHASE2":11289,"PHASE3":11298,"PHASE4":11300,"NA":11302},{"trials":11286,"activeCount":103},[],{"trials":11288,"activeCount":103},[],{"trials":11290,"activeCount":103},[11291],{"nctId":11292,"briefTitle":11293,"status":111,"phases":11294,"primaryCompletion":1234,"completion":1234,"start":2934,"enrollment":22,"conditions":11295,"interventions":11297},"NCT00612807","Treatment of Mood and Marriage Study (TOMMS)",[91,92],[3488,11296],"Partner Relational Disorder (V61.10)",[11283],{"trials":11299,"activeCount":103},[],{"trials":11301,"activeCount":103},[],{"trials":11303,"activeCount":103},[],{"intervention":11305,"totalTrials":132,"cells":11306},"Erlotinib + sirolimus",{"EARLY_PHASE1":11307,"PHASE1":11309,"PHASE2":11311,"PHASE3":11319,"PHASE4":11321,"NA":11323},{"trials":11308,"activeCount":103},[],{"trials":11310,"activeCount":103},[],{"trials":11312,"activeCount":103},[11313],{"nctId":11314,"briefTitle":11315,"status":111,"phases":11316,"primaryCompletion":2922,"completion":1545,"start":3486,"enrollment":9914,"conditions":11317,"interventions":11318},"NCT00672243","Ph II Erlotinib + Sirolimus for Pts w Recurrent Malignant Glioma Multiforme",[92],[2643,2644],[11305],{"trials":11320,"activeCount":103},[],{"trials":11322,"activeCount":103},[],{"trials":11324,"activeCount":103},[],{"intervention":547,"totalTrials":132,"cells":11326},{"EARLY_PHASE1":11327,"PHASE1":11329,"PHASE2":11331,"PHASE3":11344,"PHASE4":11346,"NA":11348},{"trials":11328,"activeCount":103},[],{"trials":11330,"activeCount":103},[],{"trials":11332,"activeCount":103},[11333],{"nctId":11334,"briefTitle":11335,"status":111,"phases":11336,"primaryCompletion":11337,"completion":11337,"start":1625,"enrollment":544,"conditions":11338,"interventions":11343},"NCT02363959","Hyperbaric Oxygen Therapy for Lung Transplantation",[92],"2018-09-30",[11339,11340,11341,11342],"Disorder Related to Lung Transplantation","Central Airway Stenosis","Airway Exudative Plaques","Airway Complications Post-Lung Transplantation",[547],{"trials":11345,"activeCount":103},[],{"trials":11347,"activeCount":103},[],{"trials":11349,"activeCount":103},[],{"intervention":11351,"totalTrials":132,"cells":11352},"Nesiritide",{"EARLY_PHASE1":11353,"PHASE1":11355,"PHASE2":11357,"PHASE3":11368,"PHASE4":11370,"NA":11372},{"trials":11354,"activeCount":103},[],{"trials":11356,"activeCount":103},[],{"trials":11358,"activeCount":103},[11359],{"nctId":11360,"briefTitle":11361,"status":111,"phases":11362,"primaryCompletion":2661,"completion":8935,"start":3143,"enrollment":11363,"conditions":11364,"interventions":11366},"NCT01132846","Renal Optimization Strategies Evaluation in Acute Heart Failure and Reliable Evaluation of Dyspnea in the Heart Failure Network (ROSE) Study",[92],360,[11365],"Acute Heart Failure",[11351,11367],"Dopamine",{"trials":11369,"activeCount":103},[],{"trials":11371,"activeCount":103},[],{"trials":11373,"activeCount":103},[],{"intervention":11367,"totalTrials":132,"cells":11375},{"EARLY_PHASE1":11376,"PHASE1":11378,"PHASE2":11380,"PHASE3":11386,"PHASE4":11388,"NA":11390},{"trials":11377,"activeCount":103},[],{"trials":11379,"activeCount":103},[],{"trials":11381,"activeCount":103},[11382],{"nctId":11360,"briefTitle":11361,"status":111,"phases":11383,"primaryCompletion":2661,"completion":8935,"start":3143,"enrollment":11363,"conditions":11384,"interventions":11385},[92],[11365],[11351,11367],{"trials":11387,"activeCount":103},[],{"trials":11389,"activeCount":103},[],{"trials":11391,"activeCount":103},[],{"intervention":11393,"totalTrials":132,"cells":11394},"gefitinib",{"EARLY_PHASE1":11395,"PHASE1":11397,"PHASE2":11399,"PHASE3":11408,"PHASE4":11410,"NA":11412},{"trials":11396,"activeCount":103},[],{"trials":11398,"activeCount":103},[],{"trials":11400,"activeCount":103},[11401],{"nctId":11402,"briefTitle":11403,"status":111,"phases":11404,"completion":1589,"start":11405,"conditions":11406,"interventions":11407},"NCT00016991","ZD 1839 in Treating Patients With Glioblastoma Multiforme in First Relapse",[92],"2001-06",[33],[11393],{"trials":11409,"activeCount":103},[],{"trials":11411,"activeCount":103},[],{"trials":11413,"activeCount":103},[],{"intervention":11415,"totalTrials":132,"cells":11416},"iron sucrose",{"EARLY_PHASE1":11417,"PHASE1":11419,"PHASE2":11421,"PHASE3":11431,"PHASE4":11433,"NA":11435},{"trials":11418,"activeCount":103},[],{"trials":11420,"activeCount":103},[],{"trials":11422,"activeCount":103},[11423],{"nctId":11424,"briefTitle":11425,"status":155,"phases":11426,"primaryCompletion":2350,"completion":2870,"start":2351,"enrollment":2822,"conditions":11427,"interventions":11430},"NCT01309659","Trial To Evaluate the Efficacy of Intravenous Iron in Older Adults With Unexplained Anemia",[92],[11428,11429],"Anemia","Unexplained Anemia (UAE)",[11415,11415],{"trials":11432,"activeCount":103},[],{"trials":11434,"activeCount":103},[],{"trials":11436,"activeCount":103},[],{"intervention":11438,"totalTrials":132,"cells":11439},"Palonosetron",{"EARLY_PHASE1":11440,"PHASE1":11442,"PHASE2":11444,"PHASE3":11452,"PHASE4":11454,"NA":11456},{"trials":11441,"activeCount":103},[],{"trials":11443,"activeCount":103},[],{"trials":11445,"activeCount":103},[11446],{"nctId":11447,"briefTitle":11448,"status":111,"phases":11449,"primaryCompletion":1202,"completion":1202,"start":9008,"enrollment":8927,"conditions":11450,"interventions":11451},"NCT00900757","Intravenous Palonosetron With Radiotherapy and Concomitant Temozolomide",[92],[2641],[11438],{"trials":11453,"activeCount":103},[],{"trials":11455,"activeCount":103},[],{"trials":11457,"activeCount":103},[],{"intervention":11459,"totalTrials":132,"cells":11460},"E-cigarettes",{"EARLY_PHASE1":11461,"PHASE1":11463,"PHASE2":11465,"PHASE3":11475,"PHASE4":11477,"NA":11479},{"trials":11462,"activeCount":103},[],{"trials":11464,"activeCount":103},[],{"trials":11466,"activeCount":103},[11467],{"nctId":11468,"briefTitle":11469,"status":111,"phases":11470,"primaryCompletion":11471,"completion":11471,"start":11472,"enrollment":544,"conditions":11473,"interventions":11474},"NCT02590393","The Role of Nicotine and Non-Nicotine Alkaloids in E-Cigarette Use and Dependence",[91,92],"2022-01-13","2021-05-21",[2802],[11459],{"trials":11476,"activeCount":103},[],{"trials":11478,"activeCount":103},[],{"trials":11480,"activeCount":103},[],{"intervention":11482,"totalTrials":132,"cells":11483},"zolpidem tartrate",{"EARLY_PHASE1":11484,"PHASE1":11486,"PHASE2":11488,"PHASE3":11499,"PHASE4":11501,"NA":11503},{"trials":11485,"activeCount":103},[],{"trials":11487,"activeCount":103},[],{"trials":11489,"activeCount":103},[11490],{"nctId":11491,"briefTitle":11492,"status":111,"phases":11493,"completion":5928,"start":11494,"enrollment":11495,"conditions":11496,"interventions":11498},"NCT00044629","Combined Behavioral\u002FPharmacological Therapy for Insomnia",[92],"2001-09",162,[11497],"Sleep Initiation and Maintenance Disorders",[11482],{"trials":11500,"activeCount":103},[],{"trials":11502,"activeCount":103},[],{"trials":11504,"activeCount":103},[],{"intervention":11506,"totalTrials":132,"cells":11507},"Concurrent decrescendo biochemotherapy regimen",{"EARLY_PHASE1":11508,"PHASE1":11510,"PHASE2":11512,"PHASE3":11521,"PHASE4":11523,"NA":11525},{"trials":11509,"activeCount":103},[],{"trials":11511,"activeCount":103},[],{"trials":11513,"activeCount":103},[11514],{"nctId":11515,"briefTitle":11516,"status":155,"phases":11517,"primaryCompletion":3091,"completion":3091,"start":4712,"enrollment":99,"conditions":11518,"interventions":11519},"NCT00673361","Pilot Trial of \"Chemo-Switch\" Regimen to Treat Advanced Melanoma",[92],[2375],[11506,11520],"Low-dose Temozolomide plus Sorafenib",{"trials":11522,"activeCount":103},[],{"trials":11524,"activeCount":103},[],{"trials":11526,"activeCount":103},[],{"intervention":11520,"totalTrials":132,"cells":11528},{"EARLY_PHASE1":11529,"PHASE1":11531,"PHASE2":11533,"PHASE3":11539,"PHASE4":11541,"NA":11543},{"trials":11530,"activeCount":103},[],{"trials":11532,"activeCount":103},[],{"trials":11534,"activeCount":103},[11535],{"nctId":11515,"briefTitle":11516,"status":155,"phases":11536,"primaryCompletion":3091,"completion":3091,"start":4712,"enrollment":99,"conditions":11537,"interventions":11538},[92],[2375],[11506,11520],{"trials":11540,"activeCount":103},[],{"trials":11542,"activeCount":103},[],{"trials":11544,"activeCount":103},[],{"intervention":11546,"totalTrials":132,"cells":11547},"Spironolactone",{"EARLY_PHASE1":11548,"PHASE1":11550,"PHASE2":11552,"PHASE3":11563,"PHASE4":11565,"NA":11567},{"trials":11549,"activeCount":103},[],{"trials":11551,"activeCount":103},[],{"trials":11553,"activeCount":103},[11554],{"nctId":11555,"briefTitle":11556,"status":111,"phases":11557,"primaryCompletion":11558,"completion":11559,"start":11560,"enrollment":11363,"conditions":11561,"interventions":11562},"NCT02235077","Study of High-dose Spironolactone vs. Placebo Therapy in Acute Heart Failure",[92],"2016-04-12","2016-06-06","2014-12-30",[21],[11546],{"trials":11564,"activeCount":103},[],{"trials":11566,"activeCount":103},[],{"trials":11568,"activeCount":103},[],{"intervention":11570,"totalTrials":132,"cells":11571},"Avastin and Temozolomide",{"EARLY_PHASE1":11572,"PHASE1":11574,"PHASE2":11576,"PHASE3":11584,"PHASE4":11586,"NA":11588},{"trials":11573,"activeCount":103},[],{"trials":11575,"activeCount":103},[],{"trials":11577,"activeCount":103},[11578],{"nctId":11579,"briefTitle":11580,"status":111,"phases":11581,"primaryCompletion":2821,"completion":2821,"start":7848,"enrollment":8858,"conditions":11582,"interventions":11583},"NCT00612339","Avastin in Combination With Temozolomide for Unresectable or Multifocal GBMs and Gliosarcomas",[92],[2643,2644],[11570],{"trials":11585,"activeCount":103},[],{"trials":11587,"activeCount":103},[],{"trials":11589,"activeCount":103},[],{"intervention":11591,"totalTrials":132,"cells":11592},"Bimatoprost",{"EARLY_PHASE1":11593,"PHASE1":11595,"PHASE2":11597,"PHASE3":11607,"PHASE4":11609,"NA":11611},{"trials":11594,"activeCount":103},[],{"trials":11596,"activeCount":103},[],{"trials":11598,"activeCount":103},[11599],{"nctId":11600,"briefTitle":11601,"status":111,"phases":11602,"primaryCompletion":2351,"completion":2351,"start":8547,"enrollment":4398,"conditions":11603,"interventions":11606},"NCT02170662","Topical Bimatoprost Effect on Androgen Dependent Hair Follicles",[92],[11604,11605],"Male Pattern Hair Loss","Androgenetic Alopecia",[11591],{"trials":11608,"activeCount":103},[],{"trials":11610,"activeCount":103},[],{"trials":11612,"activeCount":103},[],{"intervention":11614,"totalTrials":132,"cells":11615},"Rifaximin 550 milligrams",{"EARLY_PHASE1":11616,"PHASE1":11618,"PHASE2":11620,"PHASE3":11630,"PHASE4":11632,"NA":11634},{"trials":11617,"activeCount":103},[],{"trials":11619,"activeCount":103},[],{"trials":11621,"activeCount":103},[11622],{"nctId":11623,"briefTitle":11624,"status":111,"phases":11625,"primaryCompletion":11626,"completion":11626,"start":11627,"enrollment":206,"conditions":11628,"interventions":11629},"NCT03856359","Trial of Rifaximin in Probable Alzheimer's Disease",[92],"2020-11-19","2019-04-09",[5781],[11614],{"trials":11631,"activeCount":103},[],{"trials":11633,"activeCount":103},[],{"trials":11635,"activeCount":103},[],{"intervention":11637,"totalTrials":132,"cells":11638},"Temo + Avastin",{"EARLY_PHASE1":11639,"PHASE1":11641,"PHASE2":11643,"PHASE3":11653,"PHASE4":11655,"NA":11657},{"trials":11640,"activeCount":103},[],{"trials":11642,"activeCount":103},[],{"trials":11644,"activeCount":103},[11645],{"nctId":11646,"briefTitle":11647,"status":111,"phases":11648,"primaryCompletion":4823,"completion":11649,"start":2339,"enrollment":5638,"conditions":11650,"interventions":11651},"NCT00613028","Ph II Bev + Either Temozolomide\u002FEtoposide for GBM Pts Who Have Failed Bev + Irinotecan",[92],"2011-01",[2643,2644],[11637,11652],"VP-16 + Avastin",{"trials":11654,"activeCount":103},[],{"trials":11656,"activeCount":103},[],{"trials":11658,"activeCount":103},[],{"intervention":11652,"totalTrials":132,"cells":11660},{"EARLY_PHASE1":11661,"PHASE1":11663,"PHASE2":11665,"PHASE3":11671,"PHASE4":11673,"NA":11675},{"trials":11662,"activeCount":103},[],{"trials":11664,"activeCount":103},[],{"trials":11666,"activeCount":103},[11667],{"nctId":11646,"briefTitle":11647,"status":111,"phases":11668,"primaryCompletion":4823,"completion":11649,"start":2339,"enrollment":5638,"conditions":11669,"interventions":11670},[92],[2643,2644],[11637,11652],{"trials":11672,"activeCount":103},[],{"trials":11674,"activeCount":103},[],{"trials":11676,"activeCount":103},[],{"intervention":11678,"totalTrials":132,"cells":11679},"Liraglutide",{"EARLY_PHASE1":11680,"PHASE1":11682,"PHASE2":11684,"PHASE3":11692,"PHASE4":11694,"NA":11696},{"trials":11681,"activeCount":103},[],{"trials":11683,"activeCount":103},[],{"trials":11685,"activeCount":103},[11686],{"nctId":11687,"briefTitle":11688,"status":111,"phases":11689,"primaryCompletion":3376,"completion":3376,"start":7470,"enrollment":595,"conditions":11690,"interventions":11691},"NCT01800968","Functional Impact of GLP-1 for Heart Failure Treatment (FIGHT)",[92],[11365],[11678],{"trials":11693,"activeCount":103},[],{"trials":11695,"activeCount":103},[],{"trials":11697,"activeCount":103},[],{"intervention":11699,"totalTrials":132,"cells":11700},"Brexpiprazole",{"EARLY_PHASE1":11701,"PHASE1":11703,"PHASE2":11705,"PHASE3":11715,"PHASE4":11717,"NA":11719},{"trials":11702,"activeCount":103},[],{"trials":11704,"activeCount":103},[],{"trials":11706,"activeCount":103},[11707],{"nctId":11708,"briefTitle":11709,"status":155,"phases":11710,"primaryCompletion":9689,"completion":9689,"start":11711,"enrollment":1893,"conditions":11712,"interventions":11714},"NCT02934932","A Pilot Dose-Response Biomarker Study of Brexpiprazole Treatment in PTSD",[92],"2017-04-25",[11713],"Post Traumatic Stress Disorder",[11699],{"trials":11716,"activeCount":103},[],{"trials":11718,"activeCount":103},[],{"trials":11720,"activeCount":103},[],{"intervention":11722,"totalTrials":132,"cells":11723},"Velcade",{"EARLY_PHASE1":11724,"PHASE1":11726,"PHASE2":11728,"PHASE3":11741,"PHASE4":11743,"NA":11745},{"trials":11725,"activeCount":103},[],{"trials":11727,"activeCount":103},[],{"trials":11729,"activeCount":103},[11730],{"nctId":11731,"briefTitle":11732,"status":155,"phases":11733,"primaryCompletion":11734,"completion":11735,"start":11736,"enrollment":8410,"conditions":11737,"interventions":11738},"NCT01729338","Velcade + Cyclophosphamide in Newly Diagnosed Multiple Myeloma",[92],"2015-12-31","2016-12-31","2012-12-19",[9049],[11722,11739,11740],"Cyclophosphamide","Revlimid",{"trials":11742,"activeCount":103},[],{"trials":11744,"activeCount":103},[],{"trials":11746,"activeCount":103},[],{"intervention":11740,"totalTrials":132,"cells":11748},{"EARLY_PHASE1":11749,"PHASE1":11751,"PHASE2":11753,"PHASE3":11759,"PHASE4":11761,"NA":11763},{"trials":11750,"activeCount":103},[],{"trials":11752,"activeCount":103},[],{"trials":11754,"activeCount":103},[11755],{"nctId":11731,"briefTitle":11732,"status":155,"phases":11756,"primaryCompletion":11734,"completion":11735,"start":11736,"enrollment":8410,"conditions":11757,"interventions":11758},[92],[9049],[11722,11739,11740],{"trials":11760,"activeCount":103},[],{"trials":11762,"activeCount":103},[],{"trials":11764,"activeCount":103},[],{"intervention":11766,"totalTrials":132,"cells":11767},"PSA RNA-pulsed dendritic cell vaccine",{"EARLY_PHASE1":11768,"PHASE1":11770,"PHASE2":11772,"PHASE3":11781,"PHASE4":11783,"NA":11785},{"trials":11769,"activeCount":103},[],{"trials":11771,"activeCount":103},[],{"trials":11773,"activeCount":103},[11774],{"nctId":11775,"briefTitle":11776,"status":111,"phases":11777,"completion":4898,"start":11778,"enrollment":8410,"conditions":11779,"interventions":11780},"NCT00004211","Vaccine Therapy in Treating Patients With Metastatic Prostate Cancer",[91,92],"1999-07",[24],[11766],{"trials":11782,"activeCount":103},[],{"trials":11784,"activeCount":103},[],{"trials":11786,"activeCount":103},[],{"intervention":11788,"totalTrials":132,"cells":11789},"Androgen deprivation therapy",{"EARLY_PHASE1":11790,"PHASE1":11792,"PHASE2":11794,"PHASE3":11806,"PHASE4":11808,"NA":11810},{"trials":11791,"activeCount":103},[],{"trials":11793,"activeCount":103},[],{"trials":11795,"activeCount":103},[11796],{"nctId":11797,"briefTitle":11798,"status":111,"phases":11799,"primaryCompletion":11800,"completion":4322,"start":11801,"enrollment":37,"conditions":11802,"interventions":11804},"NCT02256111","EXTEND Exercise Trial",[92],"2018-02-21","2015-05-13",[11803],"Non-metastatic, Hormone naïve Prostate Cancer",[11805,11788],"Enzalutamide",{"trials":11807,"activeCount":103},[],{"trials":11809,"activeCount":103},[],{"trials":11811,"activeCount":103},[],{"intervention":11813,"totalTrials":132,"cells":11814},"Anti-thrombin III",{"EARLY_PHASE1":11815,"PHASE1":11817,"PHASE2":11819,"PHASE3":11830,"PHASE4":11832,"NA":11834},{"trials":11816,"activeCount":103},[],{"trials":11818,"activeCount":103},[],{"trials":11820,"activeCount":103},[11821],{"nctId":11822,"briefTitle":11823,"status":111,"phases":11824,"primaryCompletion":11825,"completion":11826,"start":2812,"enrollment":1223,"conditions":11827,"interventions":11829},"NCT02103114","Anti-thrombin III (ATIII) vs Placebo in Children (\u003C7mo) Undergoing Open Congenital Cardiac Surgery",[92],"2016-06-27","2016-07-01",[11828],"ATIII Deficiency",[11813],{"trials":11831,"activeCount":103},[],{"trials":11833,"activeCount":103},[],{"trials":11835,"activeCount":103},[],{"intervention":11837,"totalTrials":132,"cells":11838},"Crisaborole",{"EARLY_PHASE1":11839,"PHASE1":11841,"PHASE2":11843,"PHASE3":11854,"PHASE4":11856,"NA":11858},{"trials":11840,"activeCount":103},[],{"trials":11842,"activeCount":103},[],{"trials":11844,"activeCount":103},[11845],{"nctId":11846,"briefTitle":11847,"status":111,"phases":11848,"primaryCompletion":11849,"completion":11849,"start":11850,"enrollment":1144,"conditions":11851,"interventions":11853},"NCT03351114","Pilot Study Evaluating the Efficacy of a Topical PDE4 Inhibitor for Morphea",[92],"2020-03-10","2018-09-01",[11852],"Morphea",[11837],{"trials":11855,"activeCount":103},[],{"trials":11857,"activeCount":103},[],{"trials":11859,"activeCount":103},[],{"intervention":11861,"totalTrials":132,"cells":11862},"Letrozole",{"EARLY_PHASE1":11863,"PHASE1":11865,"PHASE2":11867,"PHASE3":11878,"PHASE4":11880,"NA":11882},{"trials":11864,"activeCount":103},[],{"trials":11866,"activeCount":103},[],{"trials":11868,"activeCount":103},[11869],{"nctId":11870,"briefTitle":11871,"status":111,"phases":11872,"primaryCompletion":11873,"completion":2629,"start":11874,"enrollment":4398,"conditions":11875,"interventions":11876},"NCT00134680","Letrozole, Herceptin in Her2neu +, Estrogen Receptor [ER] and\u002For Progesterone Receptor [PR] Positive, MBC",[92],"2005-01","2000-01",[8881],[11861,11877],"Trastuzumab",{"trials":11879,"activeCount":103},[],{"trials":11881,"activeCount":103},[],{"trials":11883,"activeCount":103},[],{"intervention":11877,"totalTrials":132,"cells":11885},{"EARLY_PHASE1":11886,"PHASE1":11888,"PHASE2":11890,"PHASE3":11896,"PHASE4":11898,"NA":11900},{"trials":11887,"activeCount":103},[],{"trials":11889,"activeCount":103},[],{"trials":11891,"activeCount":103},[11892],{"nctId":11870,"briefTitle":11871,"status":111,"phases":11893,"primaryCompletion":11873,"completion":2629,"start":11874,"enrollment":4398,"conditions":11894,"interventions":11895},[92],[8881],[11861,11877],{"trials":11897,"activeCount":103},[],{"trials":11899,"activeCount":103},[],{"trials":11901,"activeCount":103},[],{"intervention":11903,"totalTrials":132,"cells":11904},"Gliadel\u002FAvastin\u002FCPT-11",{"EARLY_PHASE1":11905,"PHASE1":11907,"PHASE2":11909,"PHASE3":11917,"PHASE4":11919,"NA":11921},{"trials":11906,"activeCount":103},[],{"trials":11908,"activeCount":103},[],{"trials":11910,"activeCount":103},[11911],{"nctId":11912,"briefTitle":11913,"status":155,"phases":11914,"primaryCompletion":2813,"completion":5661,"start":2909,"enrollment":1668,"conditions":11915,"interventions":11916},"NCT00735436","A Study of Gliadel Followed by Avastin + Irinotecan for Glioblastoma Multiforme (GBM)",[92],[2641,1236,2644],[11903],{"trials":11918,"activeCount":103},[],{"trials":11920,"activeCount":103},[],{"trials":11922,"activeCount":103},[],{"intervention":11924,"totalTrials":132,"cells":11925},"cytarabine liposome",{"EARLY_PHASE1":11926,"PHASE1":11928,"PHASE2":11930,"PHASE3":11940,"PHASE4":11942,"NA":11944},{"trials":11927,"activeCount":103},[],{"trials":11929,"activeCount":103},[],{"trials":11931,"activeCount":103},[11932],{"nctId":11933,"briefTitle":11934,"status":155,"phases":11935,"primaryCompletion":4929,"completion":4929,"start":431,"enrollment":402,"conditions":11936,"interventions":11939},"NCT00523939","DepoCyt for Active Lymphomatous or Leukemic Meningitis",[92],[11937,11938],"Neoplastic Meningitis","Lymphoma, B Cell",[11924],{"trials":11941,"activeCount":103},[],{"trials":11943,"activeCount":103},[],{"trials":11945,"activeCount":103},[],{"intervention":11947,"totalTrials":132,"cells":11948},"Belatacept",{"EARLY_PHASE1":11949,"PHASE1":11951,"PHASE2":11953,"PHASE3":11966,"PHASE4":11968,"NA":11970},{"trials":11950,"activeCount":103},[],{"trials":11952,"activeCount":103},[],{"trials":11954,"activeCount":103},[11955],{"nctId":11956,"briefTitle":11957,"status":428,"phases":11958,"primaryCompletion":11959,"completion":11960,"start":3313,"enrollment":103,"conditions":11961,"interventions":11964},"NCT03805178","Lung Transplant Plasmapheresis\u002FBelatacept\u002FCarfilzomib for Antibody Mediated Rejection and Desensitization",[92],"2020-08-01","2020-10-30",[11962,11963],"Lung Transplant Rejection","Antibody-mediated Rejection",[11947,11965],"Carfilzomib",{"trials":11967,"activeCount":103},[],{"trials":11969,"activeCount":103},[],{"trials":11971,"activeCount":103},[],{"intervention":11965,"totalTrials":132,"cells":11973},{"EARLY_PHASE1":11974,"PHASE1":11976,"PHASE2":11978,"PHASE3":11984,"PHASE4":11986,"NA":11988},{"trials":11975,"activeCount":103},[],{"trials":11977,"activeCount":103},[],{"trials":11979,"activeCount":103},[11980],{"nctId":11956,"briefTitle":11957,"status":428,"phases":11981,"primaryCompletion":11959,"completion":11960,"start":3313,"enrollment":103,"conditions":11982,"interventions":11983},[92],[11962,11963],[11947,11965],{"trials":11985,"activeCount":103},[],{"trials":11987,"activeCount":103},[],{"trials":11989,"activeCount":103},[],{"intervention":11991,"totalTrials":132,"cells":11992},"Dextroamphetamine",{"EARLY_PHASE1":11993,"PHASE1":11995,"PHASE2":11997,"PHASE3":12005,"PHASE4":12007,"NA":12009},{"trials":11994,"activeCount":103},[],{"trials":11996,"activeCount":103},[],{"trials":11998,"activeCount":103},[11999],{"nctId":12000,"briefTitle":12001,"status":111,"phases":12002,"primaryCompletion":3603,"completion":3603,"start":8796,"enrollment":4479,"conditions":12003,"interventions":12004},"NCT01905371","Amphetamine-Enhanced Stroke Recovery",[92],[3229],[11991],{"trials":12006,"activeCount":103},[],{"trials":12008,"activeCount":103},[],{"trials":12010,"activeCount":103},[],{"intervention":12012,"totalTrials":132,"cells":12013},"Rivastigmine",{"EARLY_PHASE1":12014,"PHASE1":12016,"PHASE2":12018,"PHASE3":12027,"PHASE4":12029,"NA":12031},{"trials":12015,"activeCount":103},[],{"trials":12017,"activeCount":103},[],{"trials":12019,"activeCount":103},[12020],{"nctId":12021,"briefTitle":12022,"status":111,"phases":12023,"primaryCompletion":12024,"completion":12024,"start":8547,"enrollment":22,"conditions":12025,"interventions":12026},"NCT01084135","Rivastigmine Study in Adolescents With Down Syndrome",[91,92],"2014-02",[3758],[12012],{"trials":12028,"activeCount":103},[],{"trials":12030,"activeCount":103},[],{"trials":12032,"activeCount":103},[],{"intervention":12034,"totalTrials":132,"cells":12035},"Intracoronary delivery of unfractionated bone marrow mononuclear cells",{"EARLY_PHASE1":12036,"PHASE1":12038,"PHASE2":12040,"PHASE3":12049,"PHASE4":12051,"NA":12053},{"trials":12037,"activeCount":103},[],{"trials":12039,"activeCount":103},[],{"trials":12041,"activeCount":103},[12042],{"nctId":12043,"briefTitle":12044,"status":428,"phases":12045,"primaryCompletion":9008,"completion":9008,"start":9008,"enrollment":103,"conditions":12046,"interventions":12048},"NCT00691834","Safety and Efficacy on Cell-based Therapy in Patients With Recent Large Acute Myocardial Infarction",[92],[12047,21],"Acute Myocardial Infarction",[12034],{"trials":12050,"activeCount":103},[],{"trials":12052,"activeCount":103},[],{"trials":12054,"activeCount":103},[],{"intervention":7776,"totalTrials":132,"cells":12056},{"EARLY_PHASE1":12057,"PHASE1":12059,"PHASE2":12061,"PHASE3":12067,"PHASE4":12069,"NA":12071},{"trials":12058,"activeCount":103},[],{"trials":12060,"activeCount":103},[],{"trials":12062,"activeCount":103},[12063],{"nctId":7769,"briefTitle":7770,"status":111,"phases":12064,"primaryCompletion":1222,"completion":412,"start":2797,"enrollment":7772,"conditions":12065,"interventions":12066},[92],[2802],[7775,7776,2805],{"trials":12068,"activeCount":103},[],{"trials":12070,"activeCount":103},[],{"trials":12072,"activeCount":103},[],{"intervention":12074,"totalTrials":132,"cells":12075},"Interferon Alfa-2a",{"EARLY_PHASE1":12076,"PHASE1":12078,"PHASE2":12080,"PHASE3":12089,"PHASE4":12091,"NA":12093},{"trials":12077,"activeCount":103},[],{"trials":12079,"activeCount":103},[],{"trials":12081,"activeCount":103},[12082],{"nctId":12083,"briefTitle":12084,"status":155,"phases":12085,"primaryCompletion":3484,"completion":3484,"start":2695,"enrollment":160,"conditions":12086,"interventions":12088},"NCT02159482","Pilot Study of Interferon Alfa for Patients Who Have Received Cancer Vaccines",[92],[12087],"Cancer",[12074],{"trials":12090,"activeCount":103},[],{"trials":12092,"activeCount":103},[],{"trials":12094,"activeCount":103},[],{"intervention":12096,"totalTrials":132,"cells":12097},"TISSEEL",{"EARLY_PHASE1":12098,"PHASE1":12100,"PHASE2":12102,"PHASE3":12113,"PHASE4":12115,"NA":12117},{"trials":12099,"activeCount":103},[],{"trials":12101,"activeCount":103},[],{"trials":12103,"activeCount":103},[12104],{"nctId":12105,"briefTitle":12106,"status":111,"phases":12107,"primaryCompletion":12108,"completion":12108,"start":12109,"enrollment":1893,"conditions":12110,"interventions":12112},"NCT03276975","A Randomized Trial of CT Fluoroscopy-guided Targeted Autologous Blood and Fibrin Glue Patching for Treatment",[92],"2020-03-19","2017-12-18",[12111],"Cerebrospinal Fluid Leaks",[12096],{"trials":12114,"activeCount":103},[],{"trials":12116,"activeCount":103},[],{"trials":12118,"activeCount":103},[],{"intervention":12120,"totalTrials":132,"cells":12121},"Decitabine, Arsenic Trioxide and Ascorbic Acid",{"EARLY_PHASE1":12122,"PHASE1":12124,"PHASE2":12126,"PHASE3":12134,"PHASE4":12136,"NA":12138},{"trials":12123,"activeCount":103},[],{"trials":12125,"activeCount":103},[],{"trials":12127,"activeCount":103},[12128],{"nctId":12129,"briefTitle":12130,"status":111,"phases":12131,"primaryCompletion":10321,"completion":10321,"start":5778,"enrollment":448,"conditions":12132,"interventions":12133},"NCT00621023","Cephalon Decitabine, Arsenic Trioxide and Ascorbic Acid for Myelodysplastic Syndrome",[92],[9547],[12120],{"trials":12135,"activeCount":103},[],{"trials":12137,"activeCount":103},[],{"trials":12139,"activeCount":103},[],{"intervention":12141,"totalTrials":132,"cells":12142},"apremilast",{"EARLY_PHASE1":12143,"PHASE1":12145,"PHASE2":12147,"PHASE3":12156,"PHASE4":12158,"NA":12160},{"trials":12144,"activeCount":103},[],{"trials":12146,"activeCount":103},[],{"trials":12148,"activeCount":103},[12149],{"nctId":12150,"briefTitle":12151,"status":428,"phases":12152,"primaryCompletion":2933,"completion":7008,"start":3104,"enrollment":103,"conditions":12153,"interventions":12155},"NCT01200264","Apremilast for Chronic Plaque Psoriasis (CPP) Patients Who Have Failed One Course of Biologic Therapy",[92],[12154],"Chronic Plaque Psoriasis",[12141],{"trials":12157,"activeCount":103},[],{"trials":12159,"activeCount":103},[],{"trials":12161,"activeCount":103},[],{"intervention":12163,"totalTrials":132,"cells":12164},"Aspirin and Clopidogrel",{"EARLY_PHASE1":12165,"PHASE1":12167,"PHASE2":12169,"PHASE3":12181,"PHASE4":12183,"NA":12185},{"trials":12166,"activeCount":103},[],{"trials":12168,"activeCount":103},[],{"trials":12170,"activeCount":103},[12171],{"nctId":12172,"briefTitle":12173,"status":111,"phases":12174,"primaryCompletion":12175,"completion":12175,"start":12176,"enrollment":305,"conditions":12177,"interventions":12180},"NCT04219774","NeuroCognition After Carotid Recanalization",[92],"2024-03-14","2020-05-01",[12178,3229,12179],"Cognition Disorder","Occlusion Carotid",[12163],{"trials":12182,"activeCount":103},[],{"trials":12184,"activeCount":103},[],{"trials":12186,"activeCount":103},[],{"intervention":12188,"totalTrials":132,"cells":12189},"Mitomycin-C",{"EARLY_PHASE1":12190,"PHASE1":12192,"PHASE2":12194,"PHASE3":12204,"PHASE4":12206,"NA":12208},{"trials":12191,"activeCount":103},[],{"trials":12193,"activeCount":103},[],{"trials":12195,"activeCount":103},[12196],{"nctId":12197,"briefTitle":12198,"status":111,"phases":12199,"primaryCompletion":12200,"completion":12200,"start":8857,"enrollment":1133,"conditions":12201,"interventions":12203},"NCT02016898","The Effect of Sponge Versus No-Sponge Placement of Mitomycin-C on the Outcomes of Trabeculectomy With Ex-PRESS Glaucoma Filtration Device",[92],"2017-01-17",[12202],"Primary Open Angle Glaucoma",[12188],{"trials":12205,"activeCount":103},[],{"trials":12207,"activeCount":103},[],{"trials":12209,"activeCount":103},[],{"intervention":12211,"totalTrials":132,"cells":12212},"Rituximab, Bortezomib,Y90 ibritumomab tiuxetan",{"EARLY_PHASE1":12213,"PHASE1":12215,"PHASE2":12217,"PHASE3":12226,"PHASE4":12228,"NA":12230},{"trials":12214,"activeCount":103},[],{"trials":12216,"activeCount":103},[],{"trials":12218,"activeCount":103},[12219],{"nctId":12220,"briefTitle":12221,"status":155,"phases":12222,"primaryCompletion":1233,"completion":1233,"start":8926,"enrollment":1170,"conditions":12223,"interventions":12225},"NCT01497275","Zevalin and Velcade in Relapsed\u002FRefractory Mantle Cell Lymphoma",[92],[12224],"Mantle-Cell Lymphoma",[12211],{"trials":12227,"activeCount":103},[],{"trials":12229,"activeCount":103},[],{"trials":12231,"activeCount":103},[],{"intervention":12233,"totalTrials":132,"cells":12234},"Beclomethasone",{"EARLY_PHASE1":12235,"PHASE1":12237,"PHASE2":12239,"PHASE3":12250,"PHASE4":12252,"NA":12254},{"trials":12236,"activeCount":103},[],{"trials":12238,"activeCount":103},[],{"trials":12240,"activeCount":103},[12241],{"nctId":12242,"briefTitle":12243,"status":111,"phases":12244,"primaryCompletion":12245,"completion":12245,"start":12246,"enrollment":3190,"conditions":12247,"interventions":12249},"NCT05970731","Directed Topical Drug Delivery for Treatment for PASC Hyposmia",[92],"2024-10-07","2023-09-05",[12248],"Post Acute Sequelae Covid-19 Hyposmia",[12233],{"trials":12251,"activeCount":103},[],{"trials":12253,"activeCount":103},[],{"trials":12255,"activeCount":103},[],{"intervention":12257,"totalTrials":132,"cells":12258},"Temsirolimus",{"EARLY_PHASE1":12259,"PHASE1":12261,"PHASE2":12263,"PHASE3":12272,"PHASE4":12274,"NA":12276},{"trials":12260,"activeCount":103},[],{"trials":12262,"activeCount":103},[],{"trials":12264,"activeCount":103},[12265],{"nctId":12266,"briefTitle":12267,"status":155,"phases":12268,"primaryCompletion":7588,"completion":7588,"start":204,"enrollment":160,"conditions":12269,"interventions":12270},"NCT00887640","Impact of Temsirolimus Therapy on Circulating Tumor Cell Biology In Men With Castration Resistant Metastatic Prostate Cancer",[92],[24],[12257,12271],"Diphenhydramine",{"trials":12273,"activeCount":103},[],{"trials":12275,"activeCount":103},[],{"trials":12277,"activeCount":103},[],{"intervention":12271,"totalTrials":132,"cells":12279},{"EARLY_PHASE1":12280,"PHASE1":12282,"PHASE2":12284,"PHASE3":12290,"PHASE4":12292,"NA":12294},{"trials":12281,"activeCount":103},[],{"trials":12283,"activeCount":103},[],{"trials":12285,"activeCount":103},[12286],{"nctId":12266,"briefTitle":12267,"status":155,"phases":12287,"primaryCompletion":7588,"completion":7588,"start":204,"enrollment":160,"conditions":12288,"interventions":12289},[92],[24],[12257,12271],{"trials":12291,"activeCount":103},[],{"trials":12293,"activeCount":103},[],{"trials":12295,"activeCount":103},[],{"intervention":1186,"totalTrials":132,"cells":12297},{"EARLY_PHASE1":12298,"PHASE1":12300,"PHASE2":12302,"PHASE3":12308,"PHASE4":12310,"NA":12312},{"trials":12299,"activeCount":103},[],{"trials":12301,"activeCount":103},[],{"trials":12303,"activeCount":103},[12304],{"nctId":1175,"briefTitle":1176,"status":155,"phases":12305,"primaryCompletion":1178,"completion":1168,"start":1179,"enrollment":1180,"conditions":12306,"interventions":12307},[92],[1182],[1184,1185,1186,1187,689],{"trials":12309,"activeCount":103},[],{"trials":12311,"activeCount":103},[],{"trials":12313,"activeCount":103},[],{"intervention":1187,"totalTrials":132,"cells":12315},{"EARLY_PHASE1":12316,"PHASE1":12318,"PHASE2":12320,"PHASE3":12326,"PHASE4":12328,"NA":12330},{"trials":12317,"activeCount":103},[],{"trials":12319,"activeCount":103},[],{"trials":12321,"activeCount":103},[12322],{"nctId":1175,"briefTitle":1176,"status":155,"phases":12323,"primaryCompletion":1178,"completion":1168,"start":1179,"enrollment":1180,"conditions":12324,"interventions":12325},[92],[1182],[1184,1185,1186,1187,689],{"trials":12327,"activeCount":103},[],{"trials":12329,"activeCount":103},[],{"trials":12331,"activeCount":103},[],{"intervention":12333,"totalTrials":132,"cells":12334},"Doxorubicin\u002FCyclophosphamide",{"EARLY_PHASE1":12335,"PHASE1":12337,"PHASE2":12339,"PHASE3":12348,"PHASE4":12350,"NA":12352},{"trials":12336,"activeCount":103},[],{"trials":12338,"activeCount":103},[],{"trials":12340,"activeCount":103},[12341],{"nctId":12342,"briefTitle":12343,"status":155,"phases":12344,"primaryCompletion":7470,"completion":7470,"start":2339,"enrollment":8779,"conditions":12345,"interventions":12347},"NCT00636441","Trial to Evaluate Genomic Expression Profiles to Direct Preoperative Chemotherapy in Early Stage Breast Cancer",[92],[12346],"Early-Stage Breast Cancer",[12333],{"trials":12349,"activeCount":103},[],{"trials":12351,"activeCount":103},[],{"trials":12353,"activeCount":103},[],{"intervention":12355,"totalTrials":132,"cells":12356},"Vinorelbine followed by Cisplatin",{"EARLY_PHASE1":12357,"PHASE1":12359,"PHASE2":12361,"PHASE3":12370,"PHASE4":12372,"NA":12374},{"trials":12358,"activeCount":103},[],{"trials":12360,"activeCount":103},[],{"trials":12362,"activeCount":103},[12363],{"nctId":12364,"briefTitle":12365,"status":155,"phases":12366,"primaryCompletion":9477,"completion":9477,"start":2943,"enrollment":144,"conditions":12367,"interventions":12368},"NCT00545948","Adjuvant Cisplatin With Either Genomic-Guided Vinorelbine or Pemetrexed for Early Stage Non-Small-Cell Lung Cancer",[92],[8913],[12355,12369],"Pemetrexed followed by Cisplatin",{"trials":12371,"activeCount":103},[],{"trials":12373,"activeCount":103},[],{"trials":12375,"activeCount":103},[],{"intervention":12369,"totalTrials":132,"cells":12377},{"EARLY_PHASE1":12378,"PHASE1":12380,"PHASE2":12382,"PHASE3":12388,"PHASE4":12390,"NA":12392},{"trials":12379,"activeCount":103},[],{"trials":12381,"activeCount":103},[],{"trials":12383,"activeCount":103},[12384],{"nctId":12364,"briefTitle":12365,"status":155,"phases":12385,"primaryCompletion":9477,"completion":9477,"start":2943,"enrollment":144,"conditions":12386,"interventions":12387},[92],[8913],[12355,12369],{"trials":12389,"activeCount":103},[],{"trials":12391,"activeCount":103},[],{"trials":12393,"activeCount":103},[],{"intervention":12395,"totalTrials":132,"cells":12396},"Metronomic Temozolomide",{"EARLY_PHASE1":12397,"PHASE1":12399,"PHASE2":12401,"PHASE3":12409,"PHASE4":12411,"NA":12413},{"trials":12398,"activeCount":103},[],{"trials":12400,"activeCount":103},[],{"trials":12402,"activeCount":103},[12403],{"nctId":12404,"briefTitle":12405,"status":111,"phases":12406,"primaryCompletion":2943,"completion":8547,"start":205,"enrollment":9914,"conditions":12407,"interventions":12408},"NCT00501891","Bevacizumab in Combination With Metronomic Temozolomide for Recurrent Malignant Glioma",[92],[1236],[1675,12395],{"trials":12410,"activeCount":103},[],{"trials":12412,"activeCount":103},[],{"trials":12414,"activeCount":103},[],{"intervention":12416,"totalTrials":132,"cells":12417},"Bevacizumab and Etoposide",{"EARLY_PHASE1":12418,"PHASE1":12420,"PHASE2":12422,"PHASE3":12432,"PHASE4":12434,"NA":12436},{"trials":12419,"activeCount":103},[],{"trials":12421,"activeCount":103},[],{"trials":12423,"activeCount":103},[12424],{"nctId":12425,"briefTitle":12426,"status":111,"phases":12427,"primaryCompletion":2922,"completion":12428,"start":4712,"enrollment":12429,"conditions":12430,"interventions":12431},"NCT00612430","Ph II Bevacizumab + Etoposide for Pts w Recurrent MG",[92],"2011-09",59,[2643,2644],[12416],{"trials":12433,"activeCount":103},[],{"trials":12435,"activeCount":103},[],{"trials":12437,"activeCount":103},[],{"intervention":8989,"totalTrials":132,"cells":12439},{"EARLY_PHASE1":12440,"PHASE1":12442,"PHASE2":12444,"PHASE3":12450,"PHASE4":12452,"NA":12454},{"trials":12441,"activeCount":103},[],{"trials":12443,"activeCount":103},[],{"trials":12445,"activeCount":103},[12446],{"nctId":8983,"briefTitle":8984,"status":155,"phases":12447,"primaryCompletion":1234,"completion":4642,"start":2910,"enrollment":8986,"conditions":12448,"interventions":12449},[91,92],[8978],[8989,8852,8990],{"trials":12451,"activeCount":103},[],{"trials":12453,"activeCount":103},[],{"trials":12455,"activeCount":103},[],{"intervention":12457,"totalTrials":132,"cells":12458},"Gliadel wafers in combination with O6-benzylguanine",{"EARLY_PHASE1":12459,"PHASE1":12461,"PHASE2":12463,"PHASE3":12472,"PHASE4":12474,"NA":12476},{"trials":12460,"activeCount":103},[],{"trials":12462,"activeCount":103},[],{"trials":12464,"activeCount":103},[12465],{"nctId":12466,"briefTitle":12467,"status":111,"phases":12468,"primaryCompletion":7848,"completion":3485,"start":7565,"enrollment":6318,"conditions":12469,"interventions":12471},"NCT00362921","Gliadel Wafer and O6-Benzylguanine in Treating Patients With Recurrent Glioblastoma Multiforme",[92],[12470],"Recurrent Adult Brain Tumor",[12457],{"trials":12473,"activeCount":103},[],{"trials":12475,"activeCount":103},[],{"trials":12477,"activeCount":103},[],{"intervention":12479,"totalTrials":132,"cells":12480},"Sorafenib and Temozolomide",{"EARLY_PHASE1":12481,"PHASE1":12483,"PHASE2":12485,"PHASE3":12493,"PHASE4":12495,"NA":12497},{"trials":12482,"activeCount":103},[],{"trials":12484,"activeCount":103},[],{"trials":12486,"activeCount":103},[12487],{"nctId":12488,"briefTitle":12489,"status":111,"phases":12490,"primaryCompletion":3519,"completion":4642,"start":3189,"enrollment":9914,"conditions":12491,"interventions":12492},"NCT00597493","Ph. 2 Sorafenib + Protracted Temozolomide in Recurrent GBM",[92],[10451],[12479],{"trials":12494,"activeCount":103},[],{"trials":12496,"activeCount":103},[],{"trials":12498,"activeCount":103},[],{"intervention":8930,"totalTrials":132,"cells":12500},{"EARLY_PHASE1":12501,"PHASE1":12503,"PHASE2":12505,"PHASE3":12511,"PHASE4":12513,"NA":12515},{"trials":12502,"activeCount":103},[],{"trials":12504,"activeCount":103},[],{"trials":12506,"activeCount":103},[12507],{"nctId":8923,"briefTitle":8924,"status":155,"phases":12508,"primaryCompletion":8926,"completion":6253,"start":3105,"enrollment":8927,"conditions":12509,"interventions":12510},[92],[24],[8930,8890],{"trials":12512,"activeCount":103},[],{"trials":12514,"activeCount":103},[],{"trials":12516,"activeCount":103},[],{"intervention":12518,"totalTrials":132,"cells":12519},"5% lidocaine\u002F5 mg\u002Fml 0.02% estradiol compound cream",{"EARLY_PHASE1":12520,"PHASE1":12522,"PHASE2":12524,"PHASE3":12544,"PHASE4":12546,"NA":12548},{"trials":12521,"activeCount":103},[],{"trials":12523,"activeCount":103},[],{"trials":12525,"activeCount":103},[12526],{"nctId":12527,"briefTitle":12528,"status":111,"phases":12529,"primaryCompletion":12530,"completion":12531,"start":12532,"enrollment":12533,"conditions":12534,"interventions":12542},"NCT03844412","Vestibulodynia: Understanding Pathophysiology and Determining Appropriate Treatments",[92],"2024-03-13","2024-05-30","2019-11-04",209,[12535,12536,4901,4908,12537,12538,12539,12540,8413,12541],"Vestibulodynia","Temporomandibular Disorder","Migraines","Tension Headache","Endometriosis","Interstitial Cystitis","Chronic Fatigue Syndrome",[12518,12543],"Nortriptyline",{"trials":12545,"activeCount":103},[],{"trials":12547,"activeCount":103},[],{"trials":12549,"activeCount":103},[],{"intervention":12543,"totalTrials":132,"cells":12551},{"EARLY_PHASE1":12552,"PHASE1":12554,"PHASE2":12556,"PHASE3":12562,"PHASE4":12564,"NA":12566},{"trials":12553,"activeCount":103},[],{"trials":12555,"activeCount":103},[],{"trials":12557,"activeCount":103},[12558],{"nctId":12527,"briefTitle":12528,"status":111,"phases":12559,"primaryCompletion":12530,"completion":12531,"start":12532,"enrollment":12533,"conditions":12560,"interventions":12561},[92],[12535,12536,4901,4908,12537,12538,12539,12540,8413,12541],[12518,12543],{"trials":12563,"activeCount":103},[],{"trials":12565,"activeCount":103},[],{"trials":12567,"activeCount":103},[],{"intervention":12569,"totalTrials":132,"cells":12570},"Olaparib Oral Product",{"EARLY_PHASE1":12571,"PHASE1":12573,"PHASE2":12575,"PHASE3":12585,"PHASE4":12587,"NA":12589},{"trials":12572,"activeCount":103},[],{"trials":12574,"activeCount":103},[],{"trials":12576,"activeCount":103},[12577],{"nctId":12578,"briefTitle":12579,"status":111,"phases":12580,"primaryCompletion":10042,"completion":12581,"start":358,"enrollment":1223,"conditions":12582,"interventions":12583},"NCT03167619","Phase II Multicenter Study of Durvalumab and Olaparib in Platinum tReated Advanced Triple Negative Breast Cancer (DORA)",[92],"2022-06-30",[4186],[12569,12584],"Olaparib Oral Product in combination with Durvalumab",{"trials":12586,"activeCount":103},[],{"trials":12588,"activeCount":103},[],{"trials":12590,"activeCount":103},[],{"intervention":12584,"totalTrials":132,"cells":12592},{"EARLY_PHASE1":12593,"PHASE1":12595,"PHASE2":12597,"PHASE3":12603,"PHASE4":12605,"NA":12607},{"trials":12594,"activeCount":103},[],{"trials":12596,"activeCount":103},[],{"trials":12598,"activeCount":103},[12599],{"nctId":12578,"briefTitle":12579,"status":111,"phases":12600,"primaryCompletion":10042,"completion":12581,"start":358,"enrollment":1223,"conditions":12601,"interventions":12602},[92],[4186],[12569,12584],{"trials":12604,"activeCount":103},[],{"trials":12606,"activeCount":103},[],{"trials":12608,"activeCount":103},[],{"intervention":12610,"totalTrials":132,"cells":12611},"Cisplatin & Gemcitabine",{"EARLY_PHASE1":12612,"PHASE1":12614,"PHASE2":12616,"PHASE3":12627,"PHASE4":12629,"NA":12631},{"trials":12613,"activeCount":103},[],{"trials":12615,"activeCount":103},[],{"trials":12617,"activeCount":103},[12618],{"nctId":12619,"briefTitle":12620,"status":155,"phases":12621,"primaryCompletion":2933,"completion":2933,"start":2963,"enrollment":2935,"conditions":12622,"interventions":12623},"NCT00509366","Study Using a Genomic Predictor of Platinum Resistance to Guide Therapy in Stage IIIB\u002FIV Non-Small Cell Lung Cancer",[92],[1684],[12610,12624,12625,12626],"Cisplatin & Pemetrexed","Docetaxel & Gemcitabine","Pemetrexed & Gemcitabine",{"trials":12628,"activeCount":103},[],{"trials":12630,"activeCount":103},[],{"trials":12632,"activeCount":103},[],{"intervention":12624,"totalTrials":132,"cells":12634},{"EARLY_PHASE1":12635,"PHASE1":12637,"PHASE2":12639,"PHASE3":12645,"PHASE4":12647,"NA":12649},{"trials":12636,"activeCount":103},[],{"trials":12638,"activeCount":103},[],{"trials":12640,"activeCount":103},[12641],{"nctId":12619,"briefTitle":12620,"status":155,"phases":12642,"primaryCompletion":2933,"completion":2933,"start":2963,"enrollment":2935,"conditions":12643,"interventions":12644},[92],[1684],[12610,12624,12625,12626],{"trials":12646,"activeCount":103},[],{"trials":12648,"activeCount":103},[],{"trials":12650,"activeCount":103},[],{"intervention":12625,"totalTrials":132,"cells":12652},{"EARLY_PHASE1":12653,"PHASE1":12655,"PHASE2":12657,"PHASE3":12663,"PHASE4":12665,"NA":12667},{"trials":12654,"activeCount":103},[],{"trials":12656,"activeCount":103},[],{"trials":12658,"activeCount":103},[12659],{"nctId":12619,"briefTitle":12620,"status":155,"phases":12660,"primaryCompletion":2933,"completion":2933,"start":2963,"enrollment":2935,"conditions":12661,"interventions":12662},[92],[1684],[12610,12624,12625,12626],{"trials":12664,"activeCount":103},[],{"trials":12666,"activeCount":103},[],{"trials":12668,"activeCount":103},[],{"intervention":12626,"totalTrials":132,"cells":12670},{"EARLY_PHASE1":12671,"PHASE1":12673,"PHASE2":12675,"PHASE3":12681,"PHASE4":12683,"NA":12685},{"trials":12672,"activeCount":103},[],{"trials":12674,"activeCount":103},[],{"trials":12676,"activeCount":103},[12677],{"nctId":12619,"briefTitle":12620,"status":155,"phases":12678,"primaryCompletion":2933,"completion":2933,"start":2963,"enrollment":2935,"conditions":12679,"interventions":12680},[92],[1684],[12610,12624,12625,12626],{"trials":12682,"activeCount":103},[],{"trials":12684,"activeCount":103},[],{"trials":12686,"activeCount":103},[],{"intervention":12688,"totalTrials":132,"cells":12689},"Palonosetron (Aloxi) and Dexamethasone",{"EARLY_PHASE1":12690,"PHASE1":12692,"PHASE2":12694,"PHASE3":12704,"PHASE4":12706,"NA":12708},{"trials":12691,"activeCount":103},[],{"trials":12693,"activeCount":103},[],{"trials":12695,"activeCount":103},[12696],{"nctId":12697,"briefTitle":12698,"status":155,"phases":12699,"primaryCompletion":2638,"completion":2638,"start":3484,"enrollment":12700,"conditions":12701,"interventions":12703},"NCT00636805","Aloxi for Prevention of Chemotherapy Induced Nausea and Vomiting in Malignant Glioma Patients Receiving Irinotecan With Bevacizumab",[92],63,[12702],"Brain Cancer",[12688],{"trials":12705,"activeCount":103},[],{"trials":12707,"activeCount":103},[],{"trials":12709,"activeCount":103},[],{"intervention":12711,"totalTrials":132,"cells":12712},"G-CSF plus Plerixafor",{"EARLY_PHASE1":12713,"PHASE1":12715,"PHASE2":12717,"PHASE3":12727,"PHASE4":12729,"NA":12731},{"trials":12714,"activeCount":103},[],{"trials":12716,"activeCount":103},[],{"trials":12718,"activeCount":103},[12719],{"nctId":12720,"briefTitle":12721,"status":111,"phases":12722,"primaryCompletion":3143,"completion":2661,"start":3105,"enrollment":3237,"conditions":12723,"interventions":12726},"NCT00901225","Study of Plerixafor for Rescue of Poor Mobilizers in Autologous Stem Cell Transplant",[92],[9049,12724,12725],"Non-Hodgkins Lymphoma","Hodgkins Disease",[12711],{"trials":12728,"activeCount":103},[],{"trials":12730,"activeCount":103},[],{"trials":12732,"activeCount":103},[],{"intervention":12734,"totalTrials":132,"cells":12735},"Abemaciclib",{"EARLY_PHASE1":12736,"PHASE1":12738,"PHASE2":12740,"PHASE3":12754,"PHASE4":12756,"NA":12758},{"trials":12737,"activeCount":103},[],{"trials":12739,"activeCount":103},[],{"trials":12741,"activeCount":103},[12742],{"nctId":12743,"briefTitle":12744,"status":111,"phases":12745,"primaryCompletion":12746,"completion":12746,"start":12747,"enrollment":1668,"conditions":12748,"interventions":12751},"NCT04352777","Impact of Endocrine Therapy and Abemaciclib on Host and Tumor Immune Cell Repertoire\u002FFunction in Advanced ER+\u002FHER2- Breast Cancer",[92],"2025-06-25","2020-09-14",[8881,12749,12750],"Locally Advanced Breast Cancer","Hormone Receptor Positive Tumor",[12734,12752,12753],"Fulvestrant","Aromatase Inhibitors",{"trials":12755,"activeCount":103},[],{"trials":12757,"activeCount":103},[],{"trials":12759,"activeCount":103},[],{"intervention":12752,"totalTrials":132,"cells":12761},{"EARLY_PHASE1":12762,"PHASE1":12764,"PHASE2":12766,"PHASE3":12772,"PHASE4":12774,"NA":12776},{"trials":12763,"activeCount":103},[],{"trials":12765,"activeCount":103},[],{"trials":12767,"activeCount":103},[12768],{"nctId":12743,"briefTitle":12744,"status":111,"phases":12769,"primaryCompletion":12746,"completion":12746,"start":12747,"enrollment":1668,"conditions":12770,"interventions":12771},[92],[8881,12749,12750],[12734,12752,12753],{"trials":12773,"activeCount":103},[],{"trials":12775,"activeCount":103},[],{"trials":12777,"activeCount":103},[],{"intervention":12753,"totalTrials":132,"cells":12779},{"EARLY_PHASE1":12780,"PHASE1":12782,"PHASE2":12784,"PHASE3":12790,"PHASE4":12792,"NA":12794},{"trials":12781,"activeCount":103},[],{"trials":12783,"activeCount":103},[],{"trials":12785,"activeCount":103},[12786],{"nctId":12743,"briefTitle":12744,"status":111,"phases":12787,"primaryCompletion":12746,"completion":12746,"start":12747,"enrollment":1668,"conditions":12788,"interventions":12789},[92],[8881,12749,12750],[12734,12752,12753],{"trials":12791,"activeCount":103},[],{"trials":12793,"activeCount":103},[],{"trials":12795,"activeCount":103},[],{"intervention":12797,"totalTrials":132,"cells":12798},"Suvorexant 20 mg",{"EARLY_PHASE1":12799,"PHASE1":12801,"PHASE2":12803,"PHASE3":12814,"PHASE4":12816,"NA":12818},{"trials":12800,"activeCount":103},[],{"trials":12802,"activeCount":103},[],{"trials":12804,"activeCount":103},[12805],{"nctId":12806,"briefTitle":12807,"status":111,"phases":12808,"primaryCompletion":12746,"completion":12809,"start":10919,"enrollment":12810,"conditions":12811,"interventions":12813},"NCT05733286","REPOSE Study: Reducing Delirium by Enhancing Postoperative Sleep With Suvorexant",[92],"2025-07-07",142,[12812],"Delirium in Old Age",[12797],{"trials":12815,"activeCount":103},[],{"trials":12817,"activeCount":103},[],{"trials":12819,"activeCount":103},[],{"intervention":12821,"totalTrials":282,"cells":12822},"REMD-477",{"EARLY_PHASE1":12823,"PHASE1":12825,"PHASE2":12843,"PHASE3":12845,"PHASE4":12847,"NA":12849},{"trials":12824,"activeCount":103},[],{"trials":12826,"activeCount":103},[12827,12836],{"nctId":12828,"briefTitle":12829,"status":155,"phases":12830,"primaryCompletion":12831,"completion":12831,"start":12832,"enrollment":132,"conditions":12833,"interventions":12835},"NCT04253223","A Study to Determine Safety and Efficacy of (REMD-477) in Controlling Hyperglycemia Due to Copanlisib",[91],"2021-05-05","2020-04-07",[12834],"Hyperglycemia Drug Induced",[12821],{"nctId":12837,"briefTitle":12838,"status":155,"phases":12839,"primaryCompletion":12831,"completion":12831,"start":12840,"enrollment":132,"conditions":12841,"interventions":12842},"NCT04330625","Glucagon Receptor Inhibition to Enable Breast Cancer Patients to Benefit From PI3K Inhibitor Therapy (REMD-477)",[91],"2020-11-13",[12834],[12821],{"trials":12844,"activeCount":103},[],{"trials":12846,"activeCount":103},[],{"trials":12848,"activeCount":103},[],{"trials":12850,"activeCount":103},[],{"intervention":12852,"totalTrials":132,"cells":12853},"Sodium Nitrite",{"EARLY_PHASE1":12854,"PHASE1":12856,"PHASE2":12867,"PHASE3":12869,"PHASE4":12871,"NA":12873},{"trials":12855,"activeCount":103},[],{"trials":12857,"activeCount":103},[12858],{"nctId":12859,"briefTitle":12860,"status":428,"phases":12861,"primaryCompletion":12862,"completion":12862,"start":12863,"enrollment":103,"conditions":12864,"interventions":12866},"NCT04289558","Nitrite Infusion in Children With Malaria",[91],"2021-10-01","2021-06-01",[12865],"Falciparum Malaria",[12852],{"trials":12868,"activeCount":103},[],{"trials":12870,"activeCount":103},[],{"trials":12872,"activeCount":103},[],{"trials":12874,"activeCount":103},[],{"intervention":12876,"totalTrials":132,"cells":12877},"Eltrombopag",{"EARLY_PHASE1":12878,"PHASE1":12880,"PHASE2":12890,"PHASE3":12892,"PHASE4":12894,"NA":12896},{"trials":12879,"activeCount":103},[],{"trials":12881,"activeCount":103},[12882],{"nctId":12883,"briefTitle":12884,"status":155,"phases":12885,"primaryCompletion":2797,"completion":2797,"start":1169,"enrollment":132,"conditions":12886,"interventions":12889},"NCT01491594","Eltrombopag for the Prevention of Chemotherapy Induced Thrombocytopenia",[91],[12887,3441,12888],"Sarcoma, Soft Tissue","Neoplasms, Connective and Soft Tissue",[12876],{"trials":12891,"activeCount":103},[],{"trials":12893,"activeCount":103},[],{"trials":12895,"activeCount":103},[],{"trials":12897,"activeCount":103},[],{"intervention":12899,"totalTrials":132,"cells":12900},"Temodar and SCH 66336",{"EARLY_PHASE1":12901,"PHASE1":12903,"PHASE2":12912,"PHASE3":12914,"PHASE4":12916,"NA":12918},{"trials":12902,"activeCount":103},[],{"trials":12904,"activeCount":103},[12905],{"nctId":12906,"briefTitle":12907,"status":111,"phases":12908,"primaryCompletion":3091,"completion":430,"start":3113,"enrollment":31,"conditions":12909,"interventions":12911},"NCT00612651","PH I Addition of Farnesyl Transferase Inhibitor to Temozolomide for Pts w Gr 3 & 4 Malignant Gliomas",[91],[2644,2643,12910],"Anaplastic Astrocytoma",[12899],{"trials":12913,"activeCount":103},[],{"trials":12915,"activeCount":103},[],{"trials":12917,"activeCount":103},[],{"trials":12919,"activeCount":103},[],{"intervention":12921,"totalTrials":132,"cells":12922},"Vemurafenib and Trientine",{"EARLY_PHASE1":12923,"PHASE1":12925,"PHASE2":12933,"PHASE3":12935,"PHASE4":12937,"NA":12939},{"trials":12924,"activeCount":103},[],{"trials":12926,"activeCount":103},[12927],{"nctId":12928,"briefTitle":12929,"status":428,"phases":12930,"primaryCompletion":4256,"completion":4256,"start":9182,"enrollment":103,"conditions":12931,"interventions":12932},"NCT02068079","A Pilot Study of Trientine With Vemurafenib for the Treatment BRAF Mutated Metastatic Melanoma",[91],[2375],[12921],{"trials":12934,"activeCount":103},[],{"trials":12936,"activeCount":103},[],{"trials":12938,"activeCount":103},[],{"trials":12940,"activeCount":103},[],{"intervention":12942,"totalTrials":132,"cells":12943},"Sodium bicarbonate",{"EARLY_PHASE1":12944,"PHASE1":12946,"PHASE2":12955,"PHASE3":12957,"PHASE4":12959,"NA":12961},{"trials":12945,"activeCount":103},[],{"trials":12947,"activeCount":103},[12948],{"nctId":12949,"briefTitle":12950,"status":111,"phases":12951,"primaryCompletion":4338,"completion":4338,"start":1612,"enrollment":1180,"conditions":12952,"interventions":12954},"NCT02427594","Acid-Base Compensation in Chronic Kidney Disease",[91],[12953],"Chronic Kidney Disease",[12942],{"trials":12956,"activeCount":103},[],{"trials":12958,"activeCount":103},[],{"trials":12960,"activeCount":103},[],{"trials":12962,"activeCount":103},[],{"intervention":12964,"totalTrials":132,"cells":12965},"carcinoembryonic antigen peptide 1",{"EARLY_PHASE1":12966,"PHASE1":12968,"PHASE2":12977,"PHASE3":12979,"PHASE4":12981,"NA":12983},{"trials":12967,"activeCount":103},[],{"trials":12969,"activeCount":103},[12970],{"nctId":12971,"briefTitle":12972,"status":155,"phases":12973,"primaryCompletion":8810,"completion":8810,"start":10652,"enrollment":1144,"conditions":12974,"interventions":12975},"NCT00003434","Biological Therapy in Stage I, Stage II, or Stage III Surgically Resected Pancreatic Cancer",[91],[9133],[12964,12976],"hepatitis B antigen peptide",{"trials":12978,"activeCount":103},[],{"trials":12980,"activeCount":103},[],{"trials":12982,"activeCount":103},[],{"trials":12984,"activeCount":103},[],{"intervention":12976,"totalTrials":132,"cells":12986},{"EARLY_PHASE1":12987,"PHASE1":12989,"PHASE2":12995,"PHASE3":12997,"PHASE4":12999,"NA":13001},{"trials":12988,"activeCount":103},[],{"trials":12990,"activeCount":103},[12991],{"nctId":12971,"briefTitle":12972,"status":155,"phases":12992,"primaryCompletion":8810,"completion":8810,"start":10652,"enrollment":1144,"conditions":12993,"interventions":12994},[91],[9133],[12964,12976],{"trials":12996,"activeCount":103},[],{"trials":12998,"activeCount":103},[],{"trials":13000,"activeCount":103},[],{"trials":13002,"activeCount":103},[],{"intervention":13004,"totalTrials":132,"cells":13005},"KDS-1001",{"EARLY_PHASE1":13006,"PHASE1":13008,"PHASE2":13018,"PHASE3":13020,"PHASE4":13022,"NA":13024},{"trials":13007,"activeCount":103},[],{"trials":13009,"activeCount":103},[13010],{"nctId":13011,"briefTitle":13012,"status":428,"phases":13013,"primaryCompletion":1248,"completion":126,"start":13014,"enrollment":103,"conditions":13015,"interventions":13017},"NCT04808115","IIT PH1 KDS-1001 in Patients With CML",[91],"2024-12",[13016],"CML (Chronic Myelogenous Leukemia",[13004],{"trials":13019,"activeCount":103},[],{"trials":13021,"activeCount":103},[],{"trials":13023,"activeCount":103},[],{"trials":13025,"activeCount":103},[],{"intervention":13027,"totalTrials":132,"cells":13028},"hCT-MSC",{"EARLY_PHASE1":13029,"PHASE1":13031,"PHASE2":13041,"PHASE3":13043,"PHASE4":13045,"NA":13047},{"trials":13030,"activeCount":103},[],{"trials":13032,"activeCount":103},[13033],{"nctId":13034,"briefTitle":13035,"status":111,"phases":13036,"primaryCompletion":13037,"completion":13037,"start":13038,"enrollment":2944,"conditions":13039,"interventions":13040},"NCT04294290","Open Label Phase I hCT-MSC in Toddlers With Autism Spectrum Disorder",[91],"2022-08-17","2021-02-24",[10790],[13027],{"trials":13042,"activeCount":103},[],{"trials":13044,"activeCount":103},[],{"trials":13046,"activeCount":103},[],{"trials":13048,"activeCount":103},[],{"intervention":13050,"totalTrials":132,"cells":13051},"Autologous Umbilical Cord Blood",{"EARLY_PHASE1":13052,"PHASE1":13054,"PHASE2":13062,"PHASE3":13064,"PHASE4":13066,"NA":13068},{"trials":13053,"activeCount":103},[],{"trials":13055,"activeCount":103},[13056],{"nctId":13057,"briefTitle":13058,"status":111,"phases":13059,"primaryCompletion":7929,"completion":7929,"start":2812,"enrollment":305,"conditions":13060,"interventions":13061},"NCT02176317","Autologous Umbilical Cord Blood Infusion for Children With Autism Spectrum Disorder (ASD)",[91],[10790],[13050],{"trials":13063,"activeCount":103},[],{"trials":13065,"activeCount":103},[],{"trials":13067,"activeCount":103},[],{"trials":13069,"activeCount":103},[],{"intervention":1616,"totalTrials":132,"cells":13071},{"EARLY_PHASE1":13072,"PHASE1":13074,"PHASE2":13080,"PHASE3":13082,"PHASE4":13084,"NA":13086},{"trials":13073,"activeCount":103},[],{"trials":13075,"activeCount":103},[13076],{"nctId":1608,"briefTitle":1609,"status":111,"phases":13077,"primaryCompletion":1611,"completion":1611,"start":1612,"enrollment":34,"conditions":13078,"interventions":13079},[91],[1614],[1616,1601,1617],{"trials":13081,"activeCount":103},[],{"trials":13083,"activeCount":103},[],{"trials":13085,"activeCount":103},[],{"trials":13087,"activeCount":103},[],{"intervention":13089,"totalTrials":132,"cells":13090},"Sildenafil by",{"EARLY_PHASE1":13091,"PHASE1":13093,"PHASE2":13102,"PHASE3":13104,"PHASE4":13106,"NA":13108},{"trials":13092,"activeCount":103},[],{"trials":13094,"activeCount":103},[13095],{"nctId":13096,"briefTitle":13097,"status":111,"phases":13098,"primaryCompletion":1202,"completion":1202,"start":9143,"enrollment":3237,"conditions":13099,"interventions":13101},"NCT01169519","Sildenafil in Single Ventricle Patients",[91],[13100],"Heart Disease",[13089,13089,13089,13089],{"trials":13103,"activeCount":103},[],{"trials":13105,"activeCount":103},[],{"trials":13107,"activeCount":103},[],{"trials":13109,"activeCount":103},[],{"intervention":13111,"totalTrials":132,"cells":13112},"Unrelated Umbilical Cord Blood Transplant",{"EARLY_PHASE1":13113,"PHASE1":13115,"PHASE2":13132,"PHASE3":13134,"PHASE4":13136,"NA":13138},{"trials":13114,"activeCount":103},[],{"trials":13116,"activeCount":103},[13117],{"nctId":13118,"briefTitle":13119,"status":111,"phases":13120,"primaryCompletion":1202,"completion":9182,"start":3144,"enrollment":9293,"conditions":13121,"interventions":13130},"NCT00744692","Reduced Intensity Conditioning for Umbilical Cord Blood Transplant in Pediatric Patients With Non-Malignant Disorders",[91],[13122,13123,13124,13125,13126,13127,13128,13129],"Non Malignant Disorders","Immunodeficiencies","Congenital Marrow Failures","Hemoglobinopathies","Inborn Errors of Metabolism","Sickle Cell","Thalassemia","Lysosomal Storage Disease",[13111,13131],"Reduced Intensity Conditioning",{"trials":13133,"activeCount":103},[],{"trials":13135,"activeCount":103},[],{"trials":13137,"activeCount":103},[],{"trials":13139,"activeCount":103},[],{"intervention":13131,"totalTrials":132,"cells":13141},{"EARLY_PHASE1":13142,"PHASE1":13144,"PHASE2":13150,"PHASE3":13152,"PHASE4":13154,"NA":13156},{"trials":13143,"activeCount":103},[],{"trials":13145,"activeCount":103},[13146],{"nctId":13118,"briefTitle":13119,"status":111,"phases":13147,"primaryCompletion":1202,"completion":9182,"start":3144,"enrollment":9293,"conditions":13148,"interventions":13149},[91],[13122,13123,13124,13125,13126,13127,13128,13129],[13111,13131],{"trials":13151,"activeCount":103},[],{"trials":13153,"activeCount":103},[],{"trials":13155,"activeCount":103},[],{"trials":13157,"activeCount":103},[],{"intervention":13159,"totalTrials":132,"cells":13160},"Mirvetuximab Soravtansine",{"EARLY_PHASE1":13161,"PHASE1":13163,"PHASE2":13174,"PHASE3":13176,"PHASE4":13178,"NA":13180},{"trials":13162,"activeCount":103},[],{"trials":13164,"activeCount":103},[13165],{"nctId":13166,"briefTitle":13167,"status":428,"phases":13168,"primaryCompletion":13169,"completion":13169,"start":13170,"enrollment":103,"conditions":13171,"interventions":13173},"NCT03045393","Mirvetuximab Soravtansine (IMG853) in Folate Receptor Alpha-expressing TNBC",[91],"2018-02-28","2017-04-17",[13172],"Breast Cancer Triple Negative",[13159],{"trials":13175,"activeCount":103},[],{"trials":13177,"activeCount":103},[],{"trials":13179,"activeCount":103},[],{"trials":13181,"activeCount":103},[],{"intervention":9741,"totalTrials":132,"cells":13183},{"EARLY_PHASE1":13184,"PHASE1":13186,"PHASE2":13192,"PHASE3":13194,"PHASE4":13196,"NA":13198},{"trials":13185,"activeCount":103},[],{"trials":13187,"activeCount":103},[13188],{"nctId":9734,"briefTitle":9735,"status":155,"phases":13189,"primaryCompletion":9143,"completion":9143,"start":2602,"enrollment":9737,"conditions":13190,"interventions":13191},[91],[18],[2702,9740,9741],{"trials":13193,"activeCount":103},[],{"trials":13195,"activeCount":103},[],{"trials":13197,"activeCount":103},[],{"trials":13199,"activeCount":103},[],{"intervention":13201,"totalTrials":132,"cells":13202},"Arsenic Trioxide, Ascorbic Acid and Bortezomib",{"EARLY_PHASE1":13203,"PHASE1":13205,"PHASE2":13213,"PHASE3":13215,"PHASE4":13217,"NA":13219},{"trials":13204,"activeCount":103},[],{"trials":13206,"activeCount":103},[13207],{"nctId":13208,"briefTitle":13209,"status":155,"phases":13210,"primaryCompletion":1202,"completion":1202,"start":3485,"enrollment":305,"conditions":13211,"interventions":13212},"NCT00590603","Trisenox, Ascorbic Acid and Bortezomib in Patients With Relapsed\u002FRefractory Multiple Myeloma",[91],[9049],[13201],{"trials":13214,"activeCount":103},[],{"trials":13216,"activeCount":103},[],{"trials":13218,"activeCount":103},[],{"trials":13220,"activeCount":103},[],{"intervention":13222,"totalTrials":132,"cells":13223},"LMB-7 immunotoxin",{"EARLY_PHASE1":13224,"PHASE1":13226,"PHASE2":13235,"PHASE3":13237,"PHASE4":13239,"NA":13241},{"trials":13225,"activeCount":103},[],{"trials":13227,"activeCount":103},[13228],{"nctId":13229,"briefTitle":13230,"status":111,"phases":13231,"primaryCompletion":13232,"completion":13232,"start":2688,"enrollment":1212,"conditions":13233,"interventions":13234},"NCT00003020","LMB-7 Immunotoxin in Treating Patients With Leptomeningeal Metastases",[91],"2000-09",[33],[13222],{"trials":13236,"activeCount":103},[],{"trials":13238,"activeCount":103},[],{"trials":13240,"activeCount":103},[],{"trials":13242,"activeCount":103},[],{"intervention":13244,"totalTrials":132,"cells":13245},"Daptomycin",{"EARLY_PHASE1":13246,"PHASE1":13248,"PHASE2":13256,"PHASE3":13258,"PHASE4":13260,"NA":13262},{"trials":13247,"activeCount":103},[],{"trials":13249,"activeCount":103},[13250],{"nctId":13251,"briefTitle":13252,"status":111,"phases":13253,"primaryCompletion":2933,"completion":2933,"start":7100,"enrollment":544,"conditions":13254,"interventions":13255},"NCT00942149","An Open Label Study to Describe the Pharmacokinetics of Daptomycin in Infants",[91],[604],[13244],{"trials":13257,"activeCount":103},[],{"trials":13259,"activeCount":103},[],{"trials":13261,"activeCount":103},[],{"trials":13263,"activeCount":103},[],{"intervention":13265,"totalTrials":132,"cells":13266},"Temodar, O6-BG, and Irinotecan",{"EARLY_PHASE1":13267,"PHASE1":13269,"PHASE2":13277,"PHASE3":13279,"PHASE4":13281,"NA":13283},{"trials":13268,"activeCount":103},[],{"trials":13270,"activeCount":103},[13271],{"nctId":13272,"briefTitle":13273,"status":111,"phases":13274,"primaryCompletion":1179,"completion":3485,"start":11873,"enrollment":3350,"conditions":13275,"interventions":13276},"NCT00612638","Ph. I Temozolomide + O6-BG + Irinotecan in Treatment of Pts w Recurrent \u002F Progressive Cerebral Anaplastic Gliomas",[91],[2643,2644],[13265],{"trials":13278,"activeCount":103},[],{"trials":13280,"activeCount":103},[],{"trials":13282,"activeCount":103},[],{"trials":13284,"activeCount":103},[],{"intervention":13286,"totalTrials":132,"cells":13287},"CEA peptide 1-6D",{"EARLY_PHASE1":13288,"PHASE1":13290,"PHASE2":13299,"PHASE3":13301,"PHASE4":13303,"NA":13305},{"trials":13289,"activeCount":103},[],{"trials":13291,"activeCount":103},[13292],{"nctId":13293,"briefTitle":13294,"status":111,"phases":13295,"primaryCompletion":5928,"completion":3132,"start":8548,"enrollment":402,"conditions":13296,"interventions":13298},"NCT00057915","Vaccine Therapy in Treating Patients With Refractory Stage IV Cancer",[91],[13297],"Unspecified Adult Solid Tumor, Protocol Specific",[13286],{"trials":13300,"activeCount":103},[],{"trials":13302,"activeCount":103},[],{"trials":13304,"activeCount":103},[],{"trials":13306,"activeCount":103},[],{"intervention":13308,"totalTrials":132,"cells":13309},"Etanercept Optimal dosing",{"EARLY_PHASE1":13310,"PHASE1":13312,"PHASE2":13322,"PHASE3":13324,"PHASE4":13326,"NA":13328},{"trials":13311,"activeCount":103},[],{"trials":13313,"activeCount":103},[13314],{"nctId":13315,"briefTitle":13316,"status":428,"phases":13317,"primaryCompletion":13318,"completion":13318,"start":304,"enrollment":103,"conditions":13319,"interventions":13321},"NCT04585711","Pharmacokinetics and Pharmacodynamics of Biologic Drugs in Obese Patients With Arthritis",[91],"2027-02-28",[1268,13320,15],"Rheumatoid Arthritis",[13308],{"trials":13323,"activeCount":103},[],{"trials":13325,"activeCount":103},[],{"trials":13327,"activeCount":103},[],{"trials":13329,"activeCount":103},[],{"intervention":8773,"totalTrials":132,"cells":13331},{"EARLY_PHASE1":13332,"PHASE1":13334,"PHASE2":13340,"PHASE3":13342,"PHASE4":13344,"NA":13346},{"trials":13333,"activeCount":103},[],{"trials":13335,"activeCount":103},[13336],{"nctId":8766,"briefTitle":8767,"status":111,"phases":13337,"primaryCompletion":8769,"completion":8769,"start":8770,"enrollment":6471,"conditions":13338,"interventions":13339},[91],[33],[8750,8773],{"trials":13341,"activeCount":103},[],{"trials":13343,"activeCount":103},[],{"trials":13345,"activeCount":103},[],{"trials":13347,"activeCount":103},[],{"intervention":13349,"totalTrials":132,"cells":13350},"OCPM Immunotherapeutic Vaccine",{"EARLY_PHASE1":13351,"PHASE1":13353,"PHASE2":13361,"PHASE3":13363,"PHASE4":13365,"NA":13367},{"trials":13352,"activeCount":103},[],{"trials":13354,"activeCount":103},[13355],{"nctId":13356,"briefTitle":13357,"status":111,"phases":13358,"primaryCompletion":7100,"completion":7100,"start":3603,"enrollment":2570,"conditions":13359,"interventions":13360},"NCT00674791","Study of Cancer Peptides Vaccine Plus GM-CSF as Adjuvant Treatment for High Risk (TXN2-3M0) or Metastatic Breast Cancer With No Evidence of Disease",[91],[18],[13349],{"trials":13362,"activeCount":103},[],{"trials":13364,"activeCount":103},[],{"trials":13366,"activeCount":103},[],{"trials":13368,"activeCount":103},[],{"intervention":13370,"totalTrials":132,"cells":13371},"busulfan",{"EARLY_PHASE1":13372,"PHASE1":13374,"PHASE2":13383,"PHASE3":13385,"PHASE4":13387,"NA":13389},{"trials":13373,"activeCount":103},[],{"trials":13375,"activeCount":103},[13376],{"nctId":13377,"briefTitle":13378,"status":111,"phases":13379,"primaryCompletion":2680,"completion":2680,"start":13380,"enrollment":544,"conditions":13381,"interventions":13382},"NCT00003462","Intrathecal Busulfan in Treating Patients With Recurrent, Refractory, or Metastatic Leptomeningeal Tumors",[91],"1998-04",[33],[13370],{"trials":13384,"activeCount":103},[],{"trials":13386,"activeCount":103},[],{"trials":13388,"activeCount":103},[],{"trials":13390,"activeCount":103},[],{"intervention":13392,"totalTrials":132,"cells":13393},"Nicotine Patches, Denicotinized Cigarettes",{"EARLY_PHASE1":13394,"PHASE1":13396,"PHASE2":13404,"PHASE3":13406,"PHASE4":13408,"NA":13410},{"trials":13395,"activeCount":103},[],{"trials":13397,"activeCount":103},[13398],{"nctId":13399,"briefTitle":13400,"status":111,"phases":13401,"primaryCompletion":1222,"completion":1222,"start":3091,"enrollment":8208,"conditions":13402,"interventions":13403},"NCT00831155","Extinction Based Treatment for Nicotine Dependence",[91],[2802],[13392],{"trials":13405,"activeCount":103},[],{"trials":13407,"activeCount":103},[],{"trials":13409,"activeCount":103},[],{"trials":13411,"activeCount":103},[],{"intervention":9012,"totalTrials":132,"cells":13413},{"EARLY_PHASE1":13414,"PHASE1":13416,"PHASE2":13422,"PHASE3":13424,"PHASE4":13426,"NA":13428},{"trials":13415,"activeCount":103},[],{"trials":13417,"activeCount":103},[13418],{"nctId":9005,"briefTitle":9006,"status":111,"phases":13419,"primaryCompletion":9008,"start":5777,"enrollment":544,"conditions":13420,"interventions":13421},[91],[9010],[8998,9012,9013,9014,9015],{"trials":13423,"activeCount":103},[],{"trials":13425,"activeCount":103},[],{"trials":13427,"activeCount":103},[],{"trials":13429,"activeCount":103},[],{"intervention":9013,"totalTrials":132,"cells":13431},{"EARLY_PHASE1":13432,"PHASE1":13434,"PHASE2":13440,"PHASE3":13442,"PHASE4":13444,"NA":13446},{"trials":13433,"activeCount":103},[],{"trials":13435,"activeCount":103},[13436],{"nctId":9005,"briefTitle":9006,"status":111,"phases":13437,"primaryCompletion":9008,"start":5777,"enrollment":544,"conditions":13438,"interventions":13439},[91],[9010],[8998,9012,9013,9014,9015],{"trials":13441,"activeCount":103},[],{"trials":13443,"activeCount":103},[],{"trials":13445,"activeCount":103},[],{"trials":13447,"activeCount":103},[],{"intervention":9014,"totalTrials":132,"cells":13449},{"EARLY_PHASE1":13450,"PHASE1":13452,"PHASE2":13458,"PHASE3":13460,"PHASE4":13462,"NA":13464},{"trials":13451,"activeCount":103},[],{"trials":13453,"activeCount":103},[13454],{"nctId":9005,"briefTitle":9006,"status":111,"phases":13455,"primaryCompletion":9008,"start":5777,"enrollment":544,"conditions":13456,"interventions":13457},[91],[9010],[8998,9012,9013,9014,9015],{"trials":13459,"activeCount":103},[],{"trials":13461,"activeCount":103},[],{"trials":13463,"activeCount":103},[],{"trials":13465,"activeCount":103},[],{"intervention":9015,"totalTrials":132,"cells":13467},{"EARLY_PHASE1":13468,"PHASE1":13470,"PHASE2":13476,"PHASE3":13478,"PHASE4":13480,"NA":13482},{"trials":13469,"activeCount":103},[],{"trials":13471,"activeCount":103},[13472],{"nctId":9005,"briefTitle":9006,"status":111,"phases":13473,"primaryCompletion":9008,"start":5777,"enrollment":544,"conditions":13474,"interventions":13475},[91],[9010],[8998,9012,9013,9014,9015],{"trials":13477,"activeCount":103},[],{"trials":13479,"activeCount":103},[],{"trials":13481,"activeCount":103},[],{"trials":13483,"activeCount":103},[],{"intervention":13485,"totalTrials":132,"cells":13486},"JCXH-211",{"EARLY_PHASE1":13487,"PHASE1":13489,"PHASE2":13501,"PHASE3":13503,"PHASE4":13505,"NA":13507},{"trials":13488,"activeCount":103},[],{"trials":13490,"activeCount":103},[13491],{"nctId":13492,"briefTitle":13493,"status":428,"phases":13494,"primaryCompletion":13495,"completion":13496,"start":13497,"enrollment":103,"conditions":13498,"interventions":13500},"NCT06468605","Safety, Tolerability and Efficacy of JCXH-211 in Patients With Recurrent or Progressive High-Grade Glioma",[91],"2027-10-01","2030-10-01","2025-11-01",[13499],"Recurrent or Progressive High-grade Glioma",[13485],{"trials":13502,"activeCount":103},[],{"trials":13504,"activeCount":103},[],{"trials":13506,"activeCount":103},[],{"trials":13508,"activeCount":103},[],{"intervention":13510,"totalTrials":132,"cells":13511},"Influenza A\u002FCalifornia\u002F04\u002F09",{"EARLY_PHASE1":13512,"PHASE1":13514,"PHASE2":13527,"PHASE3":13529,"PHASE4":13531,"NA":13533},{"trials":13513,"activeCount":103},[],{"trials":13515,"activeCount":103},[13516],{"nctId":13517,"briefTitle":13518,"status":13519,"phases":13520,"primaryCompletion":13521,"completion":13522,"start":13523,"enrollment":193,"conditions":13524,"interventions":13526},"NCT03207152","Biomarkers Predicting Infectivity in an Experimental Human Influenza Model","UNKNOWN",[91],"2018-05-08","2019-02-28","2017-09-11",[13525],"Influenza A",[13510],{"trials":13528,"activeCount":103},[],{"trials":13530,"activeCount":103},[],{"trials":13532,"activeCount":103},[],{"trials":13534,"activeCount":103},[],{"intervention":13536,"totalTrials":132,"cells":13537},"Dronabinol",{"EARLY_PHASE1":13538,"PHASE1":13540,"PHASE2":13551,"PHASE3":13553,"PHASE4":13555,"NA":13557},{"trials":13539,"activeCount":103},[],{"trials":13541,"activeCount":103},[13542],{"nctId":13543,"briefTitle":13544,"status":111,"phases":13545,"primaryCompletion":4802,"completion":1169,"start":2602,"enrollment":4398,"conditions":13546,"interventions":13550},"NCT00314808","A Pilot Study of Dronabinol for Adult Patients With Primary Gliomas",[91],[13547,13548,13549],"Brain Neoplasms","Nausea","Vomiting",[13536],{"trials":13552,"activeCount":103},[],{"trials":13554,"activeCount":103},[],{"trials":13556,"activeCount":103},[],{"trials":13558,"activeCount":103},[],{"intervention":13560,"totalTrials":132,"cells":13561},"Genetic testing and reporting for SLCO1B1*5 allele",{"EARLY_PHASE1":13562,"PHASE1":13564,"PHASE2":13574,"PHASE3":13576,"PHASE4":13578,"NA":13580},{"trials":13563,"activeCount":103},[],{"trials":13565,"activeCount":103},[13566],{"nctId":13567,"briefTitle":13568,"status":111,"phases":13569,"primaryCompletion":1202,"completion":9182,"start":2351,"enrollment":12700,"conditions":13570,"interventions":13573},"NCT01894217","Statin Therapy to Improve Medication Adherence",[91],[13571,13572],"Hypercholesterolemia","HMG COA Reductase Inhibitor Adverse Reaction",[13560],{"trials":13575,"activeCount":103},[],{"trials":13577,"activeCount":103},[],{"trials":13579,"activeCount":103},[],{"trials":13581,"activeCount":103},[],{"intervention":9135,"totalTrials":132,"cells":13583},{"EARLY_PHASE1":13584,"PHASE1":13586,"PHASE2":13592,"PHASE3":13594,"PHASE4":13596,"NA":13598},{"trials":13585,"activeCount":103},[],{"trials":13587,"activeCount":103},[13588],{"nctId":9129,"briefTitle":9130,"status":111,"phases":13589,"primaryCompletion":2660,"completion":4802,"start":3485,"enrollment":2944,"conditions":13590,"interventions":13591},[91],[9133],[2666,9135],{"trials":13593,"activeCount":103},[],{"trials":13595,"activeCount":103},[],{"trials":13597,"activeCount":103},[],{"trials":13599,"activeCount":103},[],{"intervention":13601,"totalTrials":132,"cells":13602},"Ipilumimab",{"EARLY_PHASE1":13603,"PHASE1":13605,"PHASE2":13615,"PHASE3":13617,"PHASE4":13619,"NA":13621},{"trials":13604,"activeCount":103},[],{"trials":13606,"activeCount":103},[13607],{"nctId":13608,"briefTitle":13609,"status":111,"phases":13610,"primaryCompletion":13611,"completion":13611,"start":7099,"enrollment":1212,"conditions":13612,"interventions":13614},"NCT01996202","A Pilot Study of Ipilumimab and Radiation in Poor Prognosis Melanoma",[91],"2018-09",[13613],"High Risk Melanoma",[13601],{"trials":13616,"activeCount":103},[],{"trials":13618,"activeCount":103},[],{"trials":13620,"activeCount":103},[],{"trials":13622,"activeCount":103},[],{"intervention":13624,"totalTrials":132,"cells":13625},"PF-03446962",{"EARLY_PHASE1":13626,"PHASE1":13628,"PHASE2":13638,"PHASE3":13640,"PHASE4":13642,"NA":13644},{"trials":13627,"activeCount":103},[],{"trials":13629,"activeCount":103},[13630],{"nctId":13631,"briefTitle":13632,"status":111,"phases":13633,"primaryCompletion":8207,"completion":1624,"start":6425,"enrollment":160,"conditions":13634,"interventions":13636},"NCT02116894","Safety Study of Regorafenib With PF-03446962 to Treat Colorectal Cancer",[91],[13635],"Colorectal Cancer",[13624,13637],"Regorafenib",{"trials":13639,"activeCount":103},[],{"trials":13641,"activeCount":103},[],{"trials":13643,"activeCount":103},[],{"trials":13645,"activeCount":103},[],{"intervention":13637,"totalTrials":132,"cells":13647},{"EARLY_PHASE1":13648,"PHASE1":13650,"PHASE2":13656,"PHASE3":13658,"PHASE4":13660,"NA":13662},{"trials":13649,"activeCount":103},[],{"trials":13651,"activeCount":103},[13652],{"nctId":13631,"briefTitle":13632,"status":111,"phases":13653,"primaryCompletion":8207,"completion":1624,"start":6425,"enrollment":160,"conditions":13654,"interventions":13655},[91],[13635],[13624,13637],{"trials":13657,"activeCount":103},[],{"trials":13659,"activeCount":103},[],{"trials":13661,"activeCount":103},[],{"trials":13663,"activeCount":103},[],{"intervention":13665,"totalTrials":132,"cells":13666},"Influenza A\u002FTexas\u002F71\u002F2017",{"EARLY_PHASE1":13667,"PHASE1":13669,"PHASE2":13682,"PHASE3":13684,"PHASE4":13686,"NA":13688},{"trials":13668,"activeCount":103},[],{"trials":13670,"activeCount":103},[13671],{"nctId":13672,"briefTitle":13673,"status":111,"phases":13674,"primaryCompletion":13675,"completion":13676,"start":13677,"enrollment":4398,"conditions":13678,"interventions":13680},"NCT06476275","Single Dose Texas 2017 (H3N2) Challenge Study",[91],"2025-01-15","2025-02-10","2024-09-11",[13679],"Influenza Viral Infections",[13665,13681],"Sham placebo",{"trials":13683,"activeCount":103},[],{"trials":13685,"activeCount":103},[],{"trials":13687,"activeCount":103},[],{"trials":13689,"activeCount":103},[],{"intervention":13681,"totalTrials":132,"cells":13691},{"EARLY_PHASE1":13692,"PHASE1":13694,"PHASE2":13700,"PHASE3":13702,"PHASE4":13704,"NA":13706},{"trials":13693,"activeCount":103},[],{"trials":13695,"activeCount":103},[13696],{"nctId":13672,"briefTitle":13673,"status":111,"phases":13697,"primaryCompletion":13675,"completion":13676,"start":13677,"enrollment":4398,"conditions":13698,"interventions":13699},[91],[13679],[13665,13681],{"trials":13701,"activeCount":103},[],{"trials":13703,"activeCount":103},[],{"trials":13705,"activeCount":103},[],{"trials":13707,"activeCount":103},[],{"intervention":13709,"totalTrials":132,"cells":13710},"SU011248 & Irinotecan",{"EARLY_PHASE1":13711,"PHASE1":13713,"PHASE2":13721,"PHASE3":13723,"PHASE4":13725,"NA":13727},{"trials":13712,"activeCount":103},[],{"trials":13714,"activeCount":103},[13715],{"nctId":13716,"briefTitle":13717,"status":111,"phases":13718,"primaryCompletion":1234,"completion":3104,"start":2921,"enrollment":305,"conditions":13719,"interventions":13720},"NCT00611728","Ph I SU011248 + Irinotecan in Treatment of Pts w MG",[91],[2643],[13709],{"trials":13722,"activeCount":103},[],{"trials":13724,"activeCount":103},[],{"trials":13726,"activeCount":103},[],{"trials":13728,"activeCount":103},[],{"intervention":13730,"totalTrials":132,"cells":13731},"recombinant flt3 ligand",{"EARLY_PHASE1":13732,"PHASE1":13734,"PHASE2":13742,"PHASE3":13744,"PHASE4":13746,"NA":13748},{"trials":13733,"activeCount":103},[],{"trials":13735,"activeCount":103},[13736],{"nctId":13737,"briefTitle":13738,"status":111,"phases":13739,"completion":9028,"start":10652,"conditions":13740,"interventions":13741},"NCT00003431","Flt3L in Treating Patients With Metastatic Colorectal Cancer",[91],[13635,9510],[13730],{"trials":13743,"activeCount":103},[],{"trials":13745,"activeCount":103},[],{"trials":13747,"activeCount":103},[],{"trials":13749,"activeCount":103},[],{"intervention":13751,"totalTrials":132,"cells":13752},"Ascorbic Acid",{"EARLY_PHASE1":13753,"PHASE1":13755,"PHASE2":13765,"PHASE3":13767,"PHASE4":13769,"NA":13771},{"trials":13754,"activeCount":103},[],{"trials":13756,"activeCount":103},[13757],{"nctId":13758,"briefTitle":13759,"status":111,"phases":13760,"primaryCompletion":13761,"completion":13761,"start":13762,"enrollment":2230,"conditions":13763,"interventions":13764},"NCT03226431","Use of ARINA-1 in an Intermediate Size Patient Population of Bilateral Lung Transplant Patients With CLAD Grade 0",[91],"2019-06-25","2017-12-11",[5617],[13751],{"trials":13766,"activeCount":103},[],{"trials":13768,"activeCount":103},[],{"trials":13770,"activeCount":103},[],{"trials":13772,"activeCount":103},[],{"intervention":13774,"totalTrials":132,"cells":13775},"Neoral",{"EARLY_PHASE1":13776,"PHASE1":13778,"PHASE2":13790,"PHASE3":13792,"PHASE4":13794,"NA":13796},{"trials":13777,"activeCount":103},[],{"trials":13779,"activeCount":103},[13780],{"nctId":13781,"briefTitle":13782,"status":111,"phases":13783,"completion":3519,"start":7966,"enrollment":127,"conditions":13784,"interventions":13788},"NCT00286871","Randomized Controlled Trial in Liver Transplant Recipients Treated in Steroid Sparing Regimen",[91],[13785,13786,13787],"Chronic Hepatitis C","Organ Transplantation","Immunosuppression",[13774,13789],"Tacrolimus",{"trials":13791,"activeCount":103},[],{"trials":13793,"activeCount":103},[],{"trials":13795,"activeCount":103},[],{"trials":13797,"activeCount":103},[],{"intervention":13789,"totalTrials":132,"cells":13799},{"EARLY_PHASE1":13800,"PHASE1":13802,"PHASE2":13808,"PHASE3":13810,"PHASE4":13812,"NA":13814},{"trials":13801,"activeCount":103},[],{"trials":13803,"activeCount":103},[13804],{"nctId":13781,"briefTitle":13782,"status":111,"phases":13805,"completion":3519,"start":7966,"enrollment":127,"conditions":13806,"interventions":13807},[91],[13785,13786,13787],[13774,13789],{"trials":13809,"activeCount":103},[],{"trials":13811,"activeCount":103},[],{"trials":13813,"activeCount":103},[],{"trials":13815,"activeCount":103},[],{"intervention":13817,"totalTrials":132,"cells":13818},"Vaccination with RNA-transfected mature autologous DC",{"EARLY_PHASE1":13819,"PHASE1":13821,"PHASE2":13829,"PHASE3":13831,"PHASE4":13833,"NA":13835},{"trials":13820,"activeCount":103},[],{"trials":13822,"activeCount":103},[13823],{"nctId":13824,"briefTitle":13825,"status":155,"phases":13826,"primaryCompletion":8409,"completion":8409,"start":7100,"enrollment":282,"conditions":13827,"interventions":13828},"NCT01216436","Local Modulation of Immune Receptors to Enhance the Response to Dendritic Cell Vaccination in Metastatic Melanoma",[91],[2507],[13817],{"trials":13830,"activeCount":103},[],{"trials":13832,"activeCount":103},[],{"trials":13834,"activeCount":103},[],{"trials":13836,"activeCount":103},[],{"intervention":9022,"totalTrials":132,"cells":13838},{"EARLY_PHASE1":13839,"PHASE1":13841,"PHASE2":13847,"PHASE3":13849,"PHASE4":13851,"NA":13853},{"trials":13840,"activeCount":103},[],{"trials":13842,"activeCount":103},[13843],{"nctId":9017,"briefTitle":9018,"status":428,"phases":13844,"primaryCompletion":1545,"start":2339,"enrollment":103,"conditions":13845,"interventions":13846},[91],[9010],[9022,8998,9023],{"trials":13848,"activeCount":103},[],{"trials":13850,"activeCount":103},[],{"trials":13852,"activeCount":103},[],{"trials":13854,"activeCount":103},[],{"intervention":9023,"totalTrials":132,"cells":13856},{"EARLY_PHASE1":13857,"PHASE1":13859,"PHASE2":13865,"PHASE3":13867,"PHASE4":13869,"NA":13871},{"trials":13858,"activeCount":103},[],{"trials":13860,"activeCount":103},[13861],{"nctId":9017,"briefTitle":9018,"status":428,"phases":13862,"primaryCompletion":1545,"start":2339,"enrollment":103,"conditions":13863,"interventions":13864},[91],[9010],[9022,8998,9023],{"trials":13866,"activeCount":103},[],{"trials":13868,"activeCount":103},[],{"trials":13870,"activeCount":103},[],{"trials":13872,"activeCount":103},[],{"intervention":13874,"totalTrials":132,"cells":13875},"Erlotinib and Dasatinib",{"EARLY_PHASE1":13876,"PHASE1":13878,"PHASE2":13887,"PHASE3":13889,"PHASE4":13891,"NA":13893},{"trials":13877,"activeCount":103},[],{"trials":13879,"activeCount":103},[13880],{"nctId":13881,"briefTitle":13882,"status":111,"phases":13883,"primaryCompletion":13884,"completion":13884,"start":3123,"enrollment":5709,"conditions":13885,"interventions":13886},"NCT00609999","Ph I Dasatinib + Erlotinib in Recurrent MG",[91],"2010-07",[2643,2644],[13874],{"trials":13888,"activeCount":103},[],{"trials":13890,"activeCount":103},[],{"trials":13892,"activeCount":103},[],{"trials":13894,"activeCount":103},[],{"intervention":13896,"totalTrials":132,"cells":13897},"Octreotide 1 MG\u002FML",{"EARLY_PHASE1":13898,"PHASE1":13900,"PHASE2":13910,"PHASE3":13912,"PHASE4":13914,"NA":13916},{"trials":13899,"activeCount":103},[],{"trials":13901,"activeCount":103},[13902],{"nctId":13903,"briefTitle":13904,"status":111,"phases":13905,"primaryCompletion":13906,"completion":13906,"start":13907,"enrollment":402,"conditions":13908,"interventions":13909},"NCT05340192","Effect of Octreotide on Saliva",[91],"2020-02-26","2019-09-24",[9480],[13896],{"trials":13911,"activeCount":103},[],{"trials":13913,"activeCount":103},[],{"trials":13915,"activeCount":103},[],{"trials":13917,"activeCount":103},[],{"intervention":13919,"totalTrials":132,"cells":13920},"Lenalidomide, Decitabine",{"EARLY_PHASE1":13921,"PHASE1":13923,"PHASE2":13931,"PHASE3":13933,"PHASE4":13935,"NA":13937},{"trials":13922,"activeCount":103},[],{"trials":13924,"activeCount":103},[13925],{"nctId":13926,"briefTitle":13927,"status":111,"phases":13928,"primaryCompletion":7588,"completion":1178,"start":3092,"enrollment":1893,"conditions":13929,"interventions":13930},"NCT00828802","Lenalidomide and Decitabine in High Grade Myelodysplastic Syndromes",[91],[9659],[13919],{"trials":13932,"activeCount":103},[],{"trials":13934,"activeCount":103},[],{"trials":13936,"activeCount":103},[],{"trials":13938,"activeCount":103},[],{"intervention":13940,"totalTrials":132,"cells":13941},"AVX701",{"EARLY_PHASE1":13942,"PHASE1":13944,"PHASE2":13955,"PHASE3":13957,"PHASE4":13959,"NA":13961},{"trials":13943,"activeCount":103},[],{"trials":13945,"activeCount":103},[13946],{"nctId":13947,"briefTitle":13948,"status":111,"phases":13949,"primaryCompletion":13950,"completion":13951,"start":7099,"enrollment":2944,"conditions":13952,"interventions":13954},"NCT01890213","Immunotherapy With CEA(6D) VRP Vaccine (AVX701) in Patients With Stage III Colorectal Cancer",[91],"2017-06","2019-07",[13953],"Stage III Colon Cancer",[13940],{"trials":13956,"activeCount":103},[],{"trials":13958,"activeCount":103},[],{"trials":13960,"activeCount":103},[],{"trials":13962,"activeCount":103},[],{"intervention":13964,"totalTrials":132,"cells":13965},"Transdermal nicotine skin patches",{"EARLY_PHASE1":13966,"PHASE1":13968,"PHASE2":13977,"PHASE3":13979,"PHASE4":13981,"NA":13983},{"trials":13967,"activeCount":103},[],{"trials":13969,"activeCount":103},[13970],{"nctId":13971,"briefTitle":13972,"status":111,"phases":13973,"primaryCompletion":13974,"completion":13974,"start":3439,"enrollment":4398,"conditions":13975,"interventions":13976},"NCT02266784","Contingency Management, Quitting Smoking, and ADHD",[91],"2017-12-08",[2824,2838],[13964],{"trials":13978,"activeCount":103},[],{"trials":13980,"activeCount":103},[],{"trials":13982,"activeCount":103},[],{"trials":13984,"activeCount":103},[],{"intervention":13986,"totalTrials":132,"cells":13987},"100% Oxygen",{"EARLY_PHASE1":13988,"PHASE1":13990,"PHASE2":14001,"PHASE3":14003,"PHASE4":14005,"NA":14007},{"trials":13989,"activeCount":103},[],{"trials":13991,"activeCount":103},[13992],{"nctId":13993,"briefTitle":13994,"status":111,"phases":13995,"primaryCompletion":13996,"completion":13996,"start":13997,"enrollment":2822,"conditions":13998,"interventions":14000},"NCT06740305","NASA Prebreathe Study",[91],"2025-08-21","2025-05-05",[13999],"Decompression Sickness",[13986],{"trials":14002,"activeCount":103},[],{"trials":14004,"activeCount":103},[],{"trials":14006,"activeCount":103},[],{"trials":14008,"activeCount":103},[],{"intervention":3221,"totalTrials":132,"cells":14010},{"EARLY_PHASE1":14011,"PHASE1":14013,"PHASE2":14019,"PHASE3":14021,"PHASE4":14023,"NA":14025},{"trials":14012,"activeCount":103},[],{"trials":14014,"activeCount":103},[14015],{"nctId":3216,"briefTitle":3217,"status":111,"phases":14016,"primaryCompletion":3091,"start":2629,"enrollment":31,"conditions":14017,"interventions":14018},[91],[33],[3209,2597,3221],{"trials":14020,"activeCount":103},[],{"trials":14022,"activeCount":103},[],{"trials":14024,"activeCount":103},[],{"trials":14026,"activeCount":103},[],{"intervention":9041,"totalTrials":132,"cells":14028},{"EARLY_PHASE1":14029,"PHASE1":14031,"PHASE2":14037,"PHASE3":14039,"PHASE4":14041,"NA":14043},{"trials":14030,"activeCount":103},[],{"trials":14032,"activeCount":103},[14033],{"nctId":9036,"briefTitle":9037,"status":428,"phases":14034,"start":8778,"enrollment":103,"conditions":14035,"interventions":14036},[91],[9032,9033],[9041,8998],{"trials":14038,"activeCount":103},[],{"trials":14040,"activeCount":103},[],{"trials":14042,"activeCount":103},[],{"trials":14044,"activeCount":103},[],{"intervention":14046,"totalTrials":132,"cells":14047},"CEA RNA-pulsed DC cancer vaccine",{"EARLY_PHASE1":14048,"PHASE1":14050,"PHASE2":14061,"PHASE3":14063,"PHASE4":14065,"NA":14067},{"trials":14049,"activeCount":103},[],{"trials":14051,"activeCount":103},[14052],{"nctId":14053,"briefTitle":14054,"status":111,"phases":14055,"primaryCompletion":11405,"completion":8760,"start":8770,"enrollment":1212,"conditions":14056,"interventions":14060},"NCT00004604","Biological Therapy in Treating Patients With Metastatic Cancer",[91],[18,13635,14057,14058,10570,2698,14059,4574,9510,1670,9133,2700],"Extrahepatic Bile Duct Cancer","Gallbladder Cancer","Liver Cancer",[14046],{"trials":14062,"activeCount":103},[],{"trials":14064,"activeCount":103},[],{"trials":14066,"activeCount":103},[],{"trials":14068,"activeCount":103},[],{"intervention":14070,"totalTrials":132,"cells":14071},"fondaparinux sodium",{"EARLY_PHASE1":14072,"PHASE1":14074,"PHASE2":14083,"PHASE3":14085,"PHASE4":14087,"NA":14089},{"trials":14073,"activeCount":103},[],{"trials":14075,"activeCount":103},[14076],{"nctId":14077,"briefTitle":14078,"status":111,"phases":14079,"primaryCompletion":5661,"completion":2350,"start":10743,"enrollment":99,"conditions":14080,"interventions":14082},"NCT01121770","\"Pharmacokinetic Study of Fondaparinux in Inpatients With Renal Dysfunction\"",[91],[14081],"Renal Insufficiency",[14070],{"trials":14084,"activeCount":103},[],{"trials":14086,"activeCount":103},[],{"trials":14088,"activeCount":103},[],{"trials":14090,"activeCount":103},[],{"intervention":14092,"totalTrials":132,"cells":14093},"Quetiapine XR",{"EARLY_PHASE1":14094,"PHASE1":14102,"PHASE2":14104,"PHASE3":14106,"PHASE4":14108,"NA":14110},{"trials":14095,"activeCount":103},[14096],{"nctId":14097,"briefTitle":14098,"status":155,"phases":14099,"primaryCompletion":2933,"completion":1178,"start":3123,"enrollment":6426,"conditions":14100,"interventions":14101},"NCT00606541","An Open Label, Double-blind Discontinuation Study of Quetiapine Extended Release(XR)",[90],[2912],[14092],{"trials":14103,"activeCount":103},[],{"trials":14105,"activeCount":103},[],{"trials":14107,"activeCount":103},[],{"trials":14109,"activeCount":103},[],{"trials":14111,"activeCount":103},[],{"intervention":14113,"totalTrials":132,"cells":14114},"Oral N-acetylcysteine",{"EARLY_PHASE1":14115,"PHASE1":14124,"PHASE2":14126,"PHASE3":14128,"PHASE4":14130,"NA":14132},{"trials":14116,"activeCount":103},[14117],{"nctId":14118,"briefTitle":14119,"status":155,"phases":14120,"primaryCompletion":6253,"completion":6253,"start":2797,"enrollment":206,"conditions":14121,"interventions":14123},"NCT01905696","The Role of S-nitrosohemoglobin in Regulating Systemic Blood Flow During Hypoxia and Normoxia",[90],[14122],"Focus is Determination of the Role of SNO-Hb in Forearm Blood Flow Regulation",[14113],{"trials":14125,"activeCount":103},[],{"trials":14127,"activeCount":103},[],{"trials":14129,"activeCount":103},[],{"trials":14131,"activeCount":103},[],{"trials":14133,"activeCount":103},[],{"intervention":14135,"totalTrials":132,"cells":14136},"buprenorphine\u002Fnaloxone",{"EARLY_PHASE1":14137,"PHASE1":14147,"PHASE2":14149,"PHASE3":14151,"PHASE4":14153,"NA":14155},{"trials":14138,"activeCount":103},[14139],{"nctId":14140,"briefTitle":14141,"status":111,"phases":14142,"primaryCompletion":11006,"completion":11006,"start":14143,"enrollment":14144,"conditions":14145,"interventions":14146},"NCT03248947","Buprenorphine Physician-Pharmacist Collaboration in the Management of Patients With Opioid Use Disorder: CTN 0075",[90],"2018-03-28",71,[344],[14135],{"trials":14148,"activeCount":103},[],{"trials":14150,"activeCount":103},[],{"trials":14152,"activeCount":103},[],{"trials":14154,"activeCount":103},[],{"trials":14156,"activeCount":103},[],{"intervention":14158,"totalTrials":132,"cells":14159},"Insulin",{"EARLY_PHASE1":14160,"PHASE1":14169,"PHASE2":14171,"PHASE3":14173,"PHASE4":14175,"NA":14177},{"trials":14161,"activeCount":103},[14162],{"nctId":14163,"briefTitle":14164,"status":111,"phases":14165,"primaryCompletion":14166,"completion":14166,"start":1222,"enrollment":206,"conditions":14167,"interventions":14168},"NCT02304211","Intra-Arterial Microdosing: Proof-of-Concept in Humans",[90],"2015-07",[9480],[14158],{"trials":14170,"activeCount":103},[],{"trials":14172,"activeCount":103},[],{"trials":14174,"activeCount":103},[],{"trials":14176,"activeCount":103},[],{"trials":14178,"activeCount":103},[],{"intervention":14180,"totalTrials":132,"cells":14181},"Ticagrelor",{"EARLY_PHASE1":14182,"PHASE1":14196,"PHASE2":14198,"PHASE3":14200,"PHASE4":14202,"NA":14204},{"trials":14183,"activeCount":103},[14184],{"nctId":14185,"briefTitle":14186,"status":111,"phases":14187,"primaryCompletion":14188,"completion":14188,"start":14189,"enrollment":14190,"conditions":14191,"interventions":14195},"NCT05278637","GM03 - Platelet RNA Signatures of Aspirin",[90],"2016-12-05","2013-11-01",135,[14192,14193,14180,14194],"Platelet Aggregation Inhibitors","Aspirin","RNA",[14193,14180],{"trials":14197,"activeCount":103},[],{"trials":14199,"activeCount":103},[],{"trials":14201,"activeCount":103},[],{"trials":14203,"activeCount":103},[],{"trials":14205,"activeCount":103},[],{"intervention":14207,"totalTrials":132,"cells":14208},"Administration of radium-223",{"EARLY_PHASE1":14209,"PHASE1":14220,"PHASE2":14222,"PHASE3":14224,"PHASE4":14226,"NA":14228},{"trials":14210,"activeCount":103},[14211],{"nctId":14212,"briefTitle":14213,"status":111,"phases":14214,"primaryCompletion":14215,"completion":14215,"start":14216,"enrollment":544,"conditions":14217,"interventions":14219},"NCT02204943","Pharmacodynamic Study of Radium-223 in Men With Bone Metastatic Castration-Resistant Prostate Cancer",[90],"2017-07-31","2015-05-06",[14218],"Bone Metastatic Castration-Resistant Prostate Cancer",[14207],{"trials":14221,"activeCount":103},[],{"trials":14223,"activeCount":103},[],{"trials":14225,"activeCount":103},[],{"trials":14227,"activeCount":103},[],{"trials":14229,"activeCount":103},[],{"intervention":14231,"totalTrials":132,"cells":14232},"Tributyrin",{"EARLY_PHASE1":14233,"PHASE1":14244,"PHASE2":14246,"PHASE3":14248,"PHASE4":14250,"NA":14252},{"trials":14234,"activeCount":103},[14235],{"nctId":14236,"briefTitle":14237,"status":428,"phases":14238,"primaryCompletion":14239,"completion":775,"start":14240,"enrollment":103,"conditions":14241,"interventions":14243},"NCT05951153","Tributyrin to Promote Gut Health Among Children Undergoing Hematopoietic Cell Transplantation",[90],"2025-11","2024-08-01",[14242],"Hematopoietic Cell Transplantation (HCT)",[14231],{"trials":14245,"activeCount":103},[],{"trials":14247,"activeCount":103},[],{"trials":14249,"activeCount":103},[],{"trials":14251,"activeCount":103},[],{"trials":14253,"activeCount":103},[],{"intervention":14255,"totalTrials":132,"cells":14256},"Evolocumab",{"EARLY_PHASE1":14257,"PHASE1":14268,"PHASE2":14270,"PHASE3":14272,"PHASE4":14274,"NA":14276},{"trials":14258,"activeCount":103},[14259],{"nctId":14260,"briefTitle":14261,"status":111,"phases":14262,"primaryCompletion":14263,"completion":14264,"start":14265,"enrollment":9914,"conditions":14266,"interventions":14267},"NCT04937413","The PCSK9i Inhibitor Evolocumab - a Surgical Trial of Pharamcodynamics and Kinetics Evaluation",[90],"2023-09-13","2023-10-12","2021-10-08",[2641,2643],[14255],{"trials":14269,"activeCount":103},[],{"trials":14271,"activeCount":103},[],{"trials":14273,"activeCount":103},[],{"trials":14275,"activeCount":103},[],{"trials":14277,"activeCount":103},[],{"intervention":14279,"totalTrials":132,"cells":14280},"Isovue-M 200",{"EARLY_PHASE1":14281,"PHASE1":14295,"PHASE2":14297,"PHASE3":14299,"PHASE4":14301,"NA":14303},{"trials":14282,"activeCount":103},[14283],{"nctId":14284,"briefTitle":14285,"status":111,"phases":14286,"primaryCompletion":14287,"completion":14288,"start":14289,"enrollment":206,"conditions":14290,"interventions":14294},"NCT03071328","INJECT: A Pilot Study of Intra-tumoral Injections in Metastatic Urological Cancers",[90],"2021-03-31","2021-04-30","2018-01-08",[14291,14292,14293],"Metastatic Castration-resistant Prostate Cancer (mCRPC)","Metastatic Urothelial Carcinoma","Metastatic Renal Cell Carcinoma",[14279],{"trials":14296,"activeCount":103},[],{"trials":14298,"activeCount":103},[],{"trials":14300,"activeCount":103},[],{"trials":14302,"activeCount":103},[],{"trials":14304,"activeCount":103},[],{"intervention":14306,"totalTrials":132,"cells":14307},"Stress Management Toolkit",{"EARLY_PHASE1":14308,"PHASE1":14319,"PHASE2":14321,"PHASE3":14323,"PHASE4":14325,"NA":14327},{"trials":14309,"activeCount":103},[14310],{"nctId":14311,"briefTitle":14312,"status":111,"phases":14313,"primaryCompletion":14314,"completion":14314,"start":14315,"enrollment":219,"conditions":14316,"interventions":14318},"NCT05465551","Stress Management Toolkit for People Living With Dementia and Their Care Partners",[90],"2025-01-06","2022-12-20",[659,2993,14317],"Caregiver Burden",[14306],{"trials":14320,"activeCount":103},[],{"trials":14322,"activeCount":103},[],{"trials":14324,"activeCount":103},[],{"trials":14326,"activeCount":103},[],{"trials":14328,"activeCount":103},[],{"intervention":14330,"totalTrials":160,"cells":14331},"Nicotine patch",{"EARLY_PHASE1":14332,"PHASE1":14334,"PHASE2":14352,"PHASE3":14379,"PHASE4":14388,"NA":14398},{"trials":14333,"activeCount":103},[],{"trials":14335,"activeCount":103},[14336,14345],{"nctId":14337,"briefTitle":14338,"status":111,"phases":14339,"primaryCompletion":4861,"completion":4861,"start":14340,"enrollment":12700,"conditions":14341,"interventions":14344},"NCT03069482","Feasibility Trial of a Tailored Smoking Cessation App for People With Serious Mental Illness",[91],"2017-05-15",[14342,14343],"Nicotine Addiction","Serious Mental Illness",[14330,2895],{"nctId":14346,"briefTitle":14347,"status":111,"phases":14348,"primaryCompletion":3131,"completion":3131,"start":3092,"enrollment":14349,"conditions":14350,"interventions":14351},"NCT01056926","Neurobiology of Nicotine and Non-nicotine Components of Tobacco Addiction",[91],147,[1066],[14330],{"trials":14353,"activeCount":103},[14354,14358,14367,14371],{"nctId":9485,"briefTitle":9486,"status":111,"phases":14355,"primaryCompletion":1202,"completion":2798,"start":2660,"enrollment":9488,"conditions":14356,"interventions":14357},[92],[2838],[9467,9491],{"nctId":14359,"briefTitle":14360,"status":111,"phases":14361,"primaryCompletion":14362,"completion":14362,"start":14363,"enrollment":14364,"conditions":14365,"interventions":14366},"NCT03492463","The Role of Nicotine Dose and Route of Delivery in Affecting Adoption of E-cigarettes and Reducing Exposure to Toxic Combustion Products",[92],"2021-05-31","2018-08-06",94,[2740],[14330],{"nctId":9863,"briefTitle":9864,"status":111,"phases":14368,"primaryCompletion":9866,"completion":9867,"start":3032,"enrollment":9868,"conditions":14369,"interventions":14370},[92],[2802],[9871,9872],{"nctId":14372,"briefTitle":14373,"status":428,"phases":14374,"primaryCompletion":14375,"completion":4586,"start":14376,"enrollment":103,"conditions":14377,"interventions":14378},"NCT02487953","Electronic Nicotine Delivery Systems as a Smoking Cessation Treatment",[92],"2020-01","2018-07",[2802],[14330],{"trials":14380,"activeCount":103},[14381],{"nctId":14382,"briefTitle":14383,"status":111,"phases":14384,"primaryCompletion":3105,"completion":3105,"start":7848,"enrollment":14385,"conditions":14386,"interventions":14387},"NCT00734617","Concurrent Nicotine Patch \u002F Denicotinized Cigarette Therapy for Smoking Cessation II",[93],479,[2824],[9491],{"trials":14389,"activeCount":103},[14390],{"nctId":14391,"briefTitle":14392,"status":111,"phases":14393,"primaryCompletion":180,"completion":14394,"start":14395,"enrollment":4469,"conditions":14396,"interventions":14397},"NCT03421210","Effects of Smoking Environments on Brain Reactivity",[94],"2019-12-23","2018-03-05",[2824],[14330],{"trials":14399,"activeCount":103},[14400,14409,14416],{"nctId":14401,"briefTitle":14402,"status":111,"phases":14403,"primaryCompletion":14404,"completion":14404,"start":6056,"enrollment":2530,"conditions":14405,"interventions":14408},"NCT04609514","Learn to Quit-HIV Pilot Study",[95],"2022-06-02",[14406,2838,14407],"HIV\u002FAIDS","Tobacco Use Disorder",[14330],{"nctId":14410,"briefTitle":14411,"status":111,"phases":14412,"primaryCompletion":8969,"completion":8969,"start":8547,"enrollment":14413,"conditions":14414,"interventions":14415},"NCT01055886","Supplemental Nicotine Administration for Smoking Cessation in Posttraumatic Stress Disorder (PTSD)",[95],69,[2838],[9872],{"nctId":14417,"briefTitle":14418,"status":111,"phases":14419,"primaryCompletion":14420,"completion":14420,"start":1220,"enrollment":2662,"conditions":14421,"interventions":14422},"NCT02551692","Effects of Smoking Environments on Craving and Smoking (CameraCue2.0)",[95],"2019-01-07",[2824],[9491,2804],{"intervention":1675,"totalTrials":160,"cells":14424},{"EARLY_PHASE1":14425,"PHASE1":14427,"PHASE2":14429,"PHASE3":14471,"PHASE4":14473,"NA":14475},{"trials":14426,"activeCount":103},[],{"trials":14428,"activeCount":103},[],{"trials":14430,"activeCount":103},[14431,14435,14439,14443,14447,14451,14455,14459,14463,14467],{"nctId":9568,"briefTitle":9569,"status":111,"phases":14432,"primaryCompletion":6294,"completion":204,"start":2602,"enrollment":544,"conditions":14433,"interventions":14434},[92],[33],[9085,9559],{"nctId":10447,"briefTitle":10448,"status":111,"phases":14436,"primaryCompletion":1222,"completion":8207,"start":2638,"enrollment":19,"conditions":14437,"interventions":14438},[92],[10451,2641,10452],[10438,1675],{"nctId":9080,"briefTitle":9081,"status":111,"phases":14440,"primaryCompletion":5928,"completion":4823,"start":3236,"enrollment":2639,"conditions":14441,"interventions":14442},[92],[33],[9085,2606],{"nctId":8854,"briefTitle":8855,"status":111,"phases":14444,"primaryCompletion":8857,"completion":8857,"start":2963,"enrollment":8858,"conditions":14445,"interventions":14446},[92],[18],[8861,1675,1673],{"nctId":2634,"briefTitle":2635,"status":111,"phases":14448,"primaryCompletion":2637,"completion":2637,"start":2638,"enrollment":2639,"conditions":14449,"interventions":14450},[92],[2641,2642,2643,2644],[2586,1675],{"nctId":2647,"briefTitle":2648,"status":111,"phases":14452,"primaryCompletion":2650,"completion":2651,"start":2652,"enrollment":684,"conditions":14453,"interventions":14454},[92],[2641,2643,2644],[1675,2586,2655],{"nctId":8957,"briefTitle":8958,"status":155,"phases":14456,"primaryCompletion":2351,"completion":2351,"start":2963,"enrollment":3190,"conditions":14457,"interventions":14458},[92],[18],[1675,8852,8962,1674,8963,8964],{"nctId":1663,"briefTitle":1664,"status":111,"phases":14460,"primaryCompletion":1666,"completion":1666,"start":1667,"enrollment":1668,"conditions":14461,"interventions":14462},[91,92],[1670,1671],[1645,1673,1674,1675],{"nctId":1677,"briefTitle":1678,"status":155,"phases":14464,"primaryCompletion":1680,"completion":1681,"start":1682,"enrollment":448,"conditions":14465,"interventions":14466},[92],[1684],[1645,1675],{"nctId":12404,"briefTitle":12405,"status":111,"phases":14468,"primaryCompletion":2943,"completion":8547,"start":205,"enrollment":9914,"conditions":14469,"interventions":14470},[92],[1236],[1675,12395],{"trials":14472,"activeCount":103},[],{"trials":14474,"activeCount":103},[],{"trials":14476,"activeCount":103},[14477],{"nctId":14478,"briefTitle":14479,"status":111,"phases":14480,"primaryCompletion":2799,"completion":8926,"start":1545,"enrollment":1893,"conditions":14481,"interventions":14482},"NCT01017250","Radiosurgery and Avastin for Recurrent Malignant Gliomas",[95],[2641],[1675],{"intervention":2804,"totalTrials":448,"cells":14484},{"EARLY_PHASE1":14485,"PHASE1":14487,"PHASE2":14489,"PHASE3":14491,"PHASE4":14505,"NA":14530},{"trials":14486,"activeCount":103},[],{"trials":14488,"activeCount":103},[],{"trials":14490,"activeCount":103},[],{"trials":14492,"activeCount":103},[14493,14497,14501],{"nctId":2794,"briefTitle":2795,"status":111,"phases":14494,"primaryCompletion":2797,"completion":2798,"start":2799,"enrollment":2800,"conditions":14495,"interventions":14496},[93],[2802],[2804,396,2805,2806],{"nctId":2808,"briefTitle":2809,"status":111,"phases":14498,"primaryCompletion":2811,"completion":2812,"start":2813,"enrollment":2814,"conditions":14499,"interventions":14500},[93],[2802],[2804,396,2805],{"nctId":2818,"briefTitle":2819,"status":155,"phases":14502,"primaryCompletion":2798,"completion":2798,"start":2821,"enrollment":2822,"conditions":14503,"interventions":14504},[92,93],[2824,2802],[2826,2827,2828],{"trials":14506,"activeCount":103},[14507,14515,14523],{"nctId":14508,"briefTitle":14509,"status":111,"phases":14510,"primaryCompletion":14511,"completion":14511,"start":12532,"enrollment":160,"conditions":14512,"interventions":14514},"NCT04089982","Varenicline Light Smoking Pilot",[94],"2020-03-01",[2838,14513,1066],"Smoking Behaviors",[2804],{"nctId":14516,"briefTitle":14517,"status":111,"phases":14518,"primaryCompletion":14519,"completion":14519,"start":14520,"enrollment":2822,"conditions":14521,"interventions":14522},"NCT06029907","Project HOPES: Healthy Options for Pain and Ending Smoking. A Program for Cancer Survivors.",[94],"2025-08-29","2024-07-15",[2838,36],[2804],{"nctId":14524,"briefTitle":14525,"status":428,"phases":14526,"primaryCompletion":14527,"completion":14527,"start":8231,"enrollment":103,"conditions":14528,"interventions":14529},"NCT04191278","Mobile Health Interventions for Medication Adherence Among PLWH",[94],"2022-07",[14406,1066,2838,3125],[2804],{"trials":14531,"activeCount":103},[14532],{"nctId":14417,"briefTitle":14418,"status":111,"phases":14533,"primaryCompletion":14420,"completion":14420,"start":1220,"enrollment":2662,"conditions":14534,"interventions":14535},[95],[2824],[9491,2804],{"intervention":1674,"totalTrials":1170,"cells":14537},{"EARLY_PHASE1":14538,"PHASE1":14540,"PHASE2":14546,"PHASE3":14560,"PHASE4":14562,"NA":14564},{"trials":14539,"activeCount":103},[],{"trials":14541,"activeCount":103},[14542],{"nctId":8826,"briefTitle":8827,"status":111,"phases":14543,"primaryCompletion":205,"completion":205,"start":8548,"enrollment":2570,"conditions":14544,"interventions":14545},[91],[8830],[8832,8833,8834],{"trials":14547,"activeCount":103},[14548,14552,14556],{"nctId":8863,"briefTitle":8864,"status":111,"phases":14549,"primaryCompletion":8866,"completion":8867,"start":8868,"enrollment":206,"conditions":14550,"interventions":14551},[92],[8870],[1673,1674],{"nctId":8957,"briefTitle":8958,"status":155,"phases":14553,"primaryCompletion":2351,"completion":2351,"start":2963,"enrollment":3190,"conditions":14554,"interventions":14555},[92],[18],[1675,8852,8962,1674,8963,8964],{"nctId":1663,"briefTitle":1664,"status":111,"phases":14557,"primaryCompletion":1666,"completion":1666,"start":1667,"enrollment":1668,"conditions":14558,"interventions":14559},[91,92],[1670,1671],[1645,1673,1674,1675],{"trials":14561,"activeCount":103},[],{"trials":14563,"activeCount":103},[],{"trials":14565,"activeCount":103},[14566],{"nctId":14567,"briefTitle":14568,"status":111,"phases":14569,"primaryCompletion":3439,"completion":3439,"start":8849,"enrollment":14364,"conditions":14570,"interventions":14571},"NCT00131963","A Pharmacogenomics Study for Breast Cancer Patients Undergoing Adjuvant Chemotherapy With Doxorubicin (A)\u002FCyclophosphamide ©) and\u002For Weekly Paclitaxel",[],[18],[9225,9229,8834],{"intervention":483,"totalTrials":402,"cells":14573},{"EARLY_PHASE1":14574,"PHASE1":14576,"PHASE2":14578,"PHASE3":14580,"PHASE4":14586,"NA":14596},{"trials":14575,"activeCount":103},[],{"trials":14577,"activeCount":103},[],{"trials":14579,"activeCount":103},[],{"trials":14581,"activeCount":103},[14582],{"nctId":4729,"briefTitle":4730,"status":155,"phases":14583,"primaryCompletion":4732,"completion":4733,"start":4734,"enrollment":4735,"conditions":14584,"interventions":14585},[93],[4291],[484,483],{"trials":14587,"activeCount":103},[14588,14592],{"nctId":473,"briefTitle":474,"status":111,"phases":14589,"primaryCompletion":476,"completion":477,"start":478,"enrollment":479,"conditions":14590,"interventions":14591},[94],[481,263],[249,437,483,484,485],{"nctId":6555,"briefTitle":6556,"status":111,"phases":14593,"primaryCompletion":6558,"completion":6559,"start":6560,"enrollment":6561,"conditions":14594,"interventions":14595},[94],[4291],[483,6542,483,6542],{"trials":14597,"activeCount":103},[14598],{"nctId":14599,"briefTitle":14600,"status":155,"phases":14601,"primaryCompletion":412,"completion":412,"start":2811,"enrollment":8410,"conditions":14602,"interventions":14604},"NCT02164929","Comparison Study of Transversus Abdominal Plane, Paravertebral and Epidural Blocks in Laparoscopic Colectomy",[95],[14603],"Laparoscopic Colorectal Resection",[14605,14606,14607,14608,14609,14610,7037,14611,483],"Acetaminophen 1g IV","Dexamethasone 4mg","Midazolam up to 2mg","Propofol 1-2.5 mg\u002Fkg","Sevoflurane to keep a bispectral index of between 40-60","Local infiltration with 10 mL of plain ropivacaine 0.25%","Epinephrine",{"intervention":14613,"totalTrials":229,"cells":14614},"Transdermal Nicotine Patch",{"EARLY_PHASE1":14615,"PHASE1":14617,"PHASE2":14619,"PHASE3":14621,"PHASE4":14623,"NA":14625},{"trials":14616,"activeCount":103},[],{"trials":14618,"activeCount":103},[],{"trials":14620,"activeCount":103},[],{"trials":14622,"activeCount":103},[],{"trials":14624,"activeCount":103},[],{"trials":14626,"activeCount":103},[14627,14634,14638],{"nctId":14628,"briefTitle":14629,"status":111,"phases":14630,"primaryCompletion":2813,"completion":2813,"start":2943,"enrollment":9914,"conditions":14631,"interventions":14632},"NCT00736255","Attention Deficit Hyperactivity Disorder (ADHD) Smoking Cessation Study",[95],[3754,2802],[14613,14633],"Lis-dexamphetamine",{"nctId":2875,"briefTitle":2876,"status":111,"phases":14635,"primaryCompletion":2878,"completion":2878,"start":2879,"enrollment":448,"conditions":14636,"interventions":14637},[95],[2824,2881],[2827,2883,2884,2885],{"nctId":2887,"briefTitle":2888,"status":111,"phases":14639,"primaryCompletion":2890,"completion":2890,"start":2891,"enrollment":160,"conditions":14640,"interventions":14641},[95],[1066],[396,2894,2884,2895],{"intervention":2895,"totalTrials":229,"cells":14643},{"EARLY_PHASE1":14644,"PHASE1":14646,"PHASE2":14652,"PHASE3":14654,"PHASE4":14656,"NA":14658},{"trials":14645,"activeCount":103},[],{"trials":14647,"activeCount":103},[14648],{"nctId":14337,"briefTitle":14338,"status":111,"phases":14649,"primaryCompletion":4861,"completion":4861,"start":14340,"enrollment":12700,"conditions":14650,"interventions":14651},[91],[14342,14343],[14330,2895],{"trials":14653,"activeCount":103},[],{"trials":14655,"activeCount":103},[],{"trials":14657,"activeCount":103},[],{"trials":14659,"activeCount":103},[14660,14664],{"nctId":2875,"briefTitle":2876,"status":111,"phases":14661,"primaryCompletion":2878,"completion":2878,"start":2879,"enrollment":448,"conditions":14662,"interventions":14663},[95],[2824,2881],[2827,2883,2884,2885],{"nctId":2887,"briefTitle":2888,"status":111,"phases":14665,"primaryCompletion":2890,"completion":2890,"start":2891,"enrollment":160,"conditions":14666,"interventions":14667},[95],[1066],[396,2894,2884,2895],{"intervention":9225,"totalTrials":229,"cells":14669},{"EARLY_PHASE1":14670,"PHASE1":14672,"PHASE2":14674,"PHASE3":14684,"PHASE4":14686,"NA":14688},{"trials":14671,"activeCount":103},[],{"trials":14673,"activeCount":103},[],{"trials":14675,"activeCount":103},[14676,14680],{"nctId":9216,"briefTitle":9217,"status":111,"phases":14677,"primaryCompletion":9219,"completion":9220,"start":9221,"enrollment":25,"conditions":14678,"interventions":14679},[92],[9223],[9225,9226,9227,9228,9229,9230],{"nctId":11731,"briefTitle":11732,"status":155,"phases":14681,"primaryCompletion":11734,"completion":11735,"start":11736,"enrollment":8410,"conditions":14682,"interventions":14683},[92],[9049],[11722,11739,11740],{"trials":14685,"activeCount":103},[],{"trials":14687,"activeCount":103},[],{"trials":14689,"activeCount":103},[14690],{"nctId":14567,"briefTitle":14568,"status":111,"phases":14691,"primaryCompletion":3439,"completion":3439,"start":8849,"enrollment":14364,"conditions":14692,"interventions":14693},[],[18],[9225,9229,8834],{"intervention":14695,"totalTrials":229,"cells":14696},"therapeutic autologous dendritic cells",{"EARLY_PHASE1":14697,"PHASE1":14699,"PHASE2":14714,"PHASE3":14716,"PHASE4":14718,"NA":14720},{"trials":14698,"activeCount":103},[],{"trials":14700,"activeCount":103},[14701,14708],{"nctId":14702,"briefTitle":14703,"status":111,"phases":14704,"completion":8810,"start":14705,"enrollment":1893,"conditions":14706,"interventions":14707},"NCT00005816","Vaccine Therapy in Treating Patients With Stage III or Stage IV Kidney Cancer",[91],"2000-02",[2699],[14695],{"nctId":14709,"briefTitle":11776,"status":155,"phases":14710,"completion":14711,"start":8786,"enrollment":229,"conditions":14712,"interventions":14713},"NCT00010127",[91],"2003-03",[24],[14695],{"trials":14715,"activeCount":103},[],{"trials":14717,"activeCount":103},[],{"trials":14719,"activeCount":103},[],{"trials":14721,"activeCount":103},[14722],{"nctId":14723,"briefTitle":14724,"status":111,"phases":14725,"primaryCompletion":2981,"completion":8760,"start":14705,"enrollment":229,"conditions":14726,"interventions":14727},"NCT00005956","Biological Therapy in Treating Patients With Advanced Cancer",[95],[18,10570,1670],[14728,14695],"HER-2\u002Fneu intracellular domain protein",{"intervention":9374,"totalTrials":229,"cells":14730},{"EARLY_PHASE1":14731,"PHASE1":14733,"PHASE2":14735,"PHASE3":14745,"PHASE4":14747,"NA":14749},{"trials":14732,"activeCount":103},[],{"trials":14734,"activeCount":103},[],{"trials":14736,"activeCount":103},[14737,14741],{"nctId":9366,"briefTitle":9367,"status":111,"phases":14738,"primaryCompletion":9369,"completion":9370,"start":9371,"enrollment":31,"conditions":14739,"interventions":14740},[92],[24],[9374,9375,9052],{"nctId":9377,"briefTitle":9378,"status":111,"phases":14742,"primaryCompletion":9346,"completion":9346,"start":8409,"enrollment":1133,"conditions":14743,"interventions":14744},[92],[24],[9374,9052],{"trials":14746,"activeCount":103},[],{"trials":14748,"activeCount":103},[],{"trials":14750,"activeCount":103},[14751],{"nctId":14752,"briefTitle":14753,"status":111,"phases":14754,"primaryCompletion":14755,"completion":14755,"start":14756,"enrollment":28,"conditions":14757,"interventions":14758},"NCT02353715","Men With Metastatic Castrate-Resistant Prostate Cancer Treated With Either Sipuleucel-T (Provenge®), Abiraterone Acetate (Zytiga®) or Enzalutamide (Xtandi®) Undergoing Cardiopulmonary EXercise Testing",[],"2018-11-14","2015-07-07",[24],[11805,9374,14759],"Sipuleucel-T",{"intervention":14193,"totalTrials":229,"cells":14761},{"EARLY_PHASE1":14762,"PHASE1":14768,"PHASE2":14770,"PHASE3":14772,"PHASE4":14774,"NA":14784},{"trials":14763,"activeCount":103},[14764],{"nctId":14185,"briefTitle":14186,"status":111,"phases":14765,"primaryCompletion":14188,"completion":14188,"start":14189,"enrollment":14190,"conditions":14766,"interventions":14767},[90],[14192,14193,14180,14194],[14193,14180],{"trials":14769,"activeCount":103},[],{"trials":14771,"activeCount":103},[],{"trials":14773,"activeCount":103},[],{"trials":14775,"activeCount":103},[14776],{"nctId":14777,"briefTitle":14778,"status":111,"phases":14779,"primaryCompletion":14780,"completion":14780,"start":14781,"enrollment":2822,"conditions":14782,"interventions":14783},"NCT04352439","Aspirin for Prevention of Venous Thromboembolism Among Ovarian Cancer Patients Receiving Neoadjuvant Chemotherapy",[94],"2022-03-02","2020-08-08",[4836,1670],[14193],{"trials":14785,"activeCount":103},[14786],{"nctId":14787,"briefTitle":14788,"status":111,"phases":14789,"primaryCompletion":14790,"completion":14790,"start":1934,"enrollment":14791,"conditions":14792,"interventions":14793},"NCT02697916","Aspirin Dosing: A Patient-Centric Trial Assessing Benefits and Long-term",[95],"2020-06-30",15076,[712],[14794],"aspirin",{"intervention":7037,"totalTrials":229,"cells":14796},{"EARLY_PHASE1":14797,"PHASE1":14799,"PHASE2":14801,"PHASE3":14803,"PHASE4":14805,"NA":14811},{"trials":14798,"activeCount":103},[],{"trials":14800,"activeCount":103},[],{"trials":14802,"activeCount":103},[],{"trials":14804,"activeCount":103},[],{"trials":14806,"activeCount":103},[14807],{"nctId":7029,"briefTitle":7030,"status":155,"phases":14808,"primaryCompletion":7032,"completion":7032,"start":7033,"enrollment":31,"conditions":14809,"interventions":14810},[94],[7035],[7016,7037],{"trials":14812,"activeCount":103},[14813,14823],{"nctId":14814,"briefTitle":14815,"status":111,"phases":14816,"primaryCompletion":14817,"completion":14818,"start":204,"enrollment":14819,"conditions":14820,"interventions":14822},"NCT00938964","Lidocaine For Neuroprotection During Cardiac Surgery",[95],"2016-07-18","2017-05-23",550,[14821],"Cognitive Decline",[7037],{"nctId":14599,"briefTitle":14600,"status":155,"phases":14824,"primaryCompletion":412,"completion":412,"start":2811,"enrollment":8410,"conditions":14825,"interventions":14826},[95],[14603],[14605,14606,14607,14608,14609,14610,7037,14611,483],{"intervention":2850,"totalTrials":229,"cells":14828},{"EARLY_PHASE1":14829,"PHASE1":14831,"PHASE2":14833,"PHASE3":14835,"PHASE4":14837,"NA":14843},{"trials":14830,"activeCount":103},[],{"trials":14832,"activeCount":103},[],{"trials":14834,"activeCount":103},[],{"trials":14836,"activeCount":103},[],{"trials":14838,"activeCount":103},[14839],{"nctId":2842,"briefTitle":2843,"status":111,"phases":14840,"primaryCompletion":2845,"completion":2845,"start":2846,"enrollment":2847,"conditions":14841,"interventions":14842},[94],[2341,2824],[2850,396],{"trials":14844,"activeCount":103},[14845,14849],{"nctId":2854,"briefTitle":2855,"status":111,"phases":14846,"primaryCompletion":2857,"completion":2857,"start":2811,"enrollment":1893,"conditions":14847,"interventions":14848},[95],[2859,1066],[396,2861],{"nctId":2867,"briefTitle":2868,"status":111,"phases":14850,"primaryCompletion":2870,"completion":2870,"start":2638,"enrollment":305,"conditions":14851,"interventions":14852},[95],[1066,2872],[396,2850],{"intervention":11805,"totalTrials":229,"cells":14854},{"EARLY_PHASE1":14855,"PHASE1":14857,"PHASE2":14859,"PHASE3":14869,"PHASE4":14871,"NA":14873},{"trials":14856,"activeCount":103},[],{"trials":14858,"activeCount":103},[],{"trials":14860,"activeCount":103},[14861,14865],{"nctId":9712,"briefTitle":9713,"status":111,"phases":14862,"primaryCompletion":9715,"completion":9716,"start":9182,"enrollment":28,"conditions":14863,"interventions":14864},[92],[24],[9719,9720],{"nctId":11797,"briefTitle":11798,"status":111,"phases":14866,"primaryCompletion":11800,"completion":4322,"start":11801,"enrollment":37,"conditions":14867,"interventions":14868},[92],[11803],[11805,11788],{"trials":14870,"activeCount":103},[],{"trials":14872,"activeCount":103},[],{"trials":14874,"activeCount":103},[14875],{"nctId":14752,"briefTitle":14753,"status":111,"phases":14876,"primaryCompletion":14755,"completion":14755,"start":14756,"enrollment":28,"conditions":14877,"interventions":14878},[],[24],[11805,9374,14759],{"intervention":2884,"totalTrials":229,"cells":14880},{"EARLY_PHASE1":14881,"PHASE1":14883,"PHASE2":14885,"PHASE3":14887,"PHASE4":14889,"NA":14891},{"trials":14882,"activeCount":103},[],{"trials":14884,"activeCount":103},[],{"trials":14886,"activeCount":103},[],{"trials":14888,"activeCount":103},[],{"trials":14890,"activeCount":103},[],{"trials":14892,"activeCount":103},[14893,14901,14905],{"nctId":14894,"briefTitle":14895,"status":111,"phases":14896,"primaryCompletion":14897,"completion":14897,"start":12024,"enrollment":14898,"conditions":14899,"interventions":14900},"NCT01830842","Acute and Chronic Nicotine Modulation of Reinforcement Learning",[95],"2016-08-31",54,[14342],[2884],{"nctId":2875,"briefTitle":2876,"status":111,"phases":14902,"primaryCompletion":2878,"completion":2878,"start":2879,"enrollment":448,"conditions":14903,"interventions":14904},[95],[2824,2881],[2827,2883,2884,2885],{"nctId":2887,"briefTitle":2888,"status":111,"phases":14906,"primaryCompletion":2890,"completion":2890,"start":2891,"enrollment":160,"conditions":14907,"interventions":14908},[95],[1066],[396,2894,2884,2895],{"intervention":4405,"totalTrials":282,"cells":14910},{"EARLY_PHASE1":14911,"PHASE1":14913,"PHASE2":14915,"PHASE3":14917,"PHASE4":14919,"NA":14925},{"trials":14912,"activeCount":103},[],{"trials":14914,"activeCount":103},[],{"trials":14916,"activeCount":103},[],{"trials":14918,"activeCount":103},[],{"trials":14920,"activeCount":103},[14921],{"nctId":4393,"briefTitle":4394,"status":111,"phases":14922,"primaryCompletion":4396,"completion":4396,"start":4397,"enrollment":4398,"conditions":14923,"interventions":14924},[94],[4400,4401,4402],[4404,4405,4370],{"trials":14926,"activeCount":103},[14927],{"nctId":14928,"briefTitle":14929,"status":111,"phases":14930,"primaryCompletion":3235,"completion":14931,"start":14932,"enrollment":341,"conditions":14933,"interventions":14935},"NCT00491426","Antimicrobial PK in Infants With Suspected or Confirmed Infection",[],"2010-11","2006-01",[14934],"Infection",[2002,4405,14936,14937,14938,14939,14940,14941],"Piperacillin\u002FTazobactam","Acyclovir","Amphotericin B","Ambisome","Anidulafungin","Caspofungin",{"intervention":14633,"totalTrials":282,"cells":14943},{"EARLY_PHASE1":14944,"PHASE1":14946,"PHASE2":14948,"PHASE3":14950,"PHASE4":14952,"NA":14961},{"trials":14945,"activeCount":103},[],{"trials":14947,"activeCount":103},[],{"trials":14949,"activeCount":103},[],{"trials":14951,"activeCount":103},[],{"trials":14953,"activeCount":103},[14954],{"nctId":14955,"briefTitle":14956,"status":155,"phases":14957,"primaryCompletion":7588,"completion":7588,"start":1545,"enrollment":1180,"conditions":14958,"interventions":14960},"NCT01017263","Vyvanse and Glucose Intolerance in Children With Attention Deficit Hyperactivity Disorder (ADHD) and Obesity",[94],[3754,14959,15],"Glucose Intolerance",[14633],{"trials":14962,"activeCount":103},[14963],{"nctId":14628,"briefTitle":14629,"status":111,"phases":14964,"primaryCompletion":2813,"completion":2813,"start":2943,"enrollment":9914,"conditions":14965,"interventions":14966},[95],[3754,2802],[14613,14633],{"intervention":9229,"totalTrials":282,"cells":14968},{"EARLY_PHASE1":14969,"PHASE1":14971,"PHASE2":14973,"PHASE3":14979,"PHASE4":14981,"NA":14983},{"trials":14970,"activeCount":103},[],{"trials":14972,"activeCount":103},[],{"trials":14974,"activeCount":103},[14975],{"nctId":9216,"briefTitle":9217,"status":111,"phases":14976,"primaryCompletion":9219,"completion":9220,"start":9221,"enrollment":25,"conditions":14977,"interventions":14978},[92],[9223],[9225,9226,9227,9228,9229,9230],{"trials":14980,"activeCount":103},[],{"trials":14982,"activeCount":103},[],{"trials":14984,"activeCount":103},[14985],{"nctId":14567,"briefTitle":14568,"status":111,"phases":14986,"primaryCompletion":3439,"completion":3439,"start":8849,"enrollment":14364,"conditions":14987,"interventions":14988},[],[18],[9225,9229,8834],{"intervention":14990,"totalTrials":282,"cells":14991},"Aripiprazole",{"EARLY_PHASE1":14992,"PHASE1":14994,"PHASE2":15003,"PHASE3":15005,"PHASE4":15007,"NA":15009},{"trials":14993,"activeCount":103},[],{"trials":14995,"activeCount":103},[14996],{"nctId":14997,"briefTitle":14998,"status":111,"phases":14999,"primaryCompletion":3091,"completion":11649,"start":3254,"enrollment":14144,"conditions":15000,"interventions":15001},"NCT00466310","Metabolic Signatures and Biomarkers in Schizophrenia",[91],[2341],[14990,15002],"Risperidone",{"trials":15004,"activeCount":103},[],{"trials":15006,"activeCount":103},[],{"trials":15008,"activeCount":103},[],{"trials":15010,"activeCount":103},[15011],{"nctId":15012,"briefTitle":15013,"status":111,"phases":15014,"primaryCompletion":15015,"completion":15015,"start":7140,"enrollment":4384,"conditions":15016,"interventions":15018},"NCT03522168","Long-term Antipsychotic Pediatric Safety Trial",[],"2023-11-21",[15017],"Weight, Body",[15002,14990],{"intervention":15002,"totalTrials":282,"cells":15020},{"EARLY_PHASE1":15021,"PHASE1":15023,"PHASE2":15029,"PHASE3":15031,"PHASE4":15033,"NA":15035},{"trials":15022,"activeCount":103},[],{"trials":15024,"activeCount":103},[15025],{"nctId":14997,"briefTitle":14998,"status":111,"phases":15026,"primaryCompletion":3091,"completion":11649,"start":3254,"enrollment":14144,"conditions":15027,"interventions":15028},[91],[2341],[14990,15002],{"trials":15030,"activeCount":103},[],{"trials":15032,"activeCount":103},[],{"trials":15034,"activeCount":103},[],{"trials":15036,"activeCount":103},[15037],{"nctId":15012,"briefTitle":15013,"status":111,"phases":15038,"primaryCompletion":15015,"completion":15015,"start":7140,"enrollment":4384,"conditions":15039,"interventions":15040},[],[15017],[15002,14990],{"intervention":15042,"totalTrials":282,"cells":15043},"Atorvastatin",{"EARLY_PHASE1":15044,"PHASE1":15046,"PHASE2":15048,"PHASE3":15050,"PHASE4":15052,"NA":15061},{"trials":15045,"activeCount":103},[],{"trials":15047,"activeCount":103},[],{"trials":15049,"activeCount":103},[],{"trials":15051,"activeCount":103},[],{"trials":15053,"activeCount":103},[15054],{"nctId":15055,"briefTitle":15056,"status":155,"phases":15057,"primaryCompletion":3105,"completion":3105,"start":8329,"enrollment":132,"conditions":15058,"interventions":15060},"NCT02133534","The Effect of Atorvastatin on Endothelial Cell Dysfunction in Chronic Kidney Disease",[94],[12953,15059],"High Cholesterol",[15042],{"trials":15062,"activeCount":103},[15063],{"nctId":15064,"briefTitle":15065,"status":428,"phases":15066,"primaryCompletion":4802,"completion":5661,"start":3235,"enrollment":103,"conditions":15067,"interventions":15069},"NCT01186289","Statin Therapy To Limit Cognitive Dysfunction After Cardiac Surgery",[95],[15068],"Neurocognitive Dysfunction",[15070],"atorvastatin",{"intervention":15072,"totalTrials":282,"cells":15073},"lidocaine gel",{"EARLY_PHASE1":15074,"PHASE1":15076,"PHASE2":15078,"PHASE3":15080,"PHASE4":15082,"NA":15084},{"trials":15075,"activeCount":103},[],{"trials":15077,"activeCount":103},[],{"trials":15079,"activeCount":103},[],{"trials":15081,"activeCount":103},[],{"trials":15083,"activeCount":103},[],{"trials":15085,"activeCount":103},[15086,15093],{"nctId":15087,"briefTitle":15088,"status":111,"phases":15089,"primaryCompletion":4289,"completion":4289,"start":1221,"enrollment":5638,"conditions":15090,"interventions":15092},"NCT02823431","Effect of Urethral Analgesia on Voiding",[95],[15091],"Urethral Analgesia",[15072],{"nctId":15094,"briefTitle":15095,"status":111,"phases":15096,"primaryCompletion":15097,"completion":15097,"start":15098,"enrollment":1668,"conditions":15099,"interventions":15101},"NCT03637582","Contribution of Urethral Sensory Feedback in Voiding Efficiency",[95],"2018-12-21","2018-11-26",[15100],"Urethral Anesthesia",[15072],{"intervention":14759,"totalTrials":282,"cells":15103},{"EARLY_PHASE1":15104,"PHASE1":15106,"PHASE2":15115,"PHASE3":15117,"PHASE4":15119,"NA":15121},{"trials":15105,"activeCount":103},[],{"trials":15107,"activeCount":103},[15108],{"nctId":15109,"briefTitle":15110,"status":111,"phases":15111,"primaryCompletion":15112,"completion":15112,"start":8857,"enrollment":544,"conditions":15113,"interventions":15114},"NCT02036918","Dendreon Lymph Node Biopsy in Metastatic Castrate-Resistant Prostate Cancer",[91],"2019-02-06",[24],[14759],{"trials":15116,"activeCount":103},[],{"trials":15118,"activeCount":103},[],{"trials":15120,"activeCount":103},[],{"trials":15122,"activeCount":103},[15123],{"nctId":14752,"briefTitle":14753,"status":111,"phases":15124,"primaryCompletion":14755,"completion":14755,"start":14756,"enrollment":28,"conditions":15125,"interventions":15126},[],[24],[11805,9374,14759],{"intervention":15128,"totalTrials":282,"cells":15129},"Suboxone",{"EARLY_PHASE1":15130,"PHASE1":15132,"PHASE2":15134,"PHASE3":15136,"PHASE4":15138,"NA":15140},{"trials":15131,"activeCount":103},[],{"trials":15133,"activeCount":103},[],{"trials":15135,"activeCount":103},[],{"trials":15137,"activeCount":103},[],{"trials":15139,"activeCount":103},[],{"trials":15141,"activeCount":103},[15142,15154],{"nctId":15143,"briefTitle":15144,"status":111,"phases":15145,"primaryCompletion":15146,"completion":15146,"start":15147,"enrollment":8410,"conditions":15148,"interventions":15152},"NCT04521920","Providing Suboxone and PrEP Using Telemedicine",[95],"2021-08-30","2020-11-09",[481,15149,15150,15151],"Opioid-use Disorder","Risk Reduction","Hiv",[15128,15153],"PrEP",{"nctId":15155,"briefTitle":15156,"status":111,"phases":15157,"primaryCompletion":15158,"completion":15158,"start":15159,"enrollment":8410,"conditions":15160,"interventions":15162},"NCT05108935","Providing PrEP, Hepatitis C Treatment, and MOUD Through Telemedicine at Greensboro SSP",[95],"2023-03-30","2022-02-17",[481,344,15150,15151,15161],"Hepatitis C",[15128,15163,15164],"Truvada","Mavyret",{"intervention":4865,"totalTrials":282,"cells":15166},{"EARLY_PHASE1":15167,"PHASE1":15169,"PHASE2":15171,"PHASE3":15173,"PHASE4":15175,"NA":15181},{"trials":15168,"activeCount":103},[],{"trials":15170,"activeCount":103},[],{"trials":15172,"activeCount":103},[],{"trials":15174,"activeCount":103},[],{"trials":15176,"activeCount":103},[15177],{"nctId":4856,"briefTitle":4857,"status":111,"phases":15178,"primaryCompletion":4859,"completion":4860,"start":4861,"enrollment":4862,"conditions":15179,"interventions":15180},[94],[922],[4865,4843],{"trials":15182,"activeCount":103},[15183],{"nctId":15184,"briefTitle":15185,"status":155,"phases":15186,"primaryCompletion":15187,"completion":15187,"start":2857,"enrollment":15188,"conditions":15189,"interventions":15191},"NCT02433665","Customized Contrast Media Dose Clinical Trial",[95],"2016-10-06",166,[15190],"CT of the Abdomen and Pelvis With Contrast Material",[4865],{"intervention":15193,"totalTrials":282,"cells":15194},"Valproic Acid",{"EARLY_PHASE1":15195,"PHASE1":15197,"PHASE2":15199,"PHASE3":15210,"PHASE4":15212,"NA":15214},{"trials":15196,"activeCount":103},[],{"trials":15198,"activeCount":103},[],{"trials":15200,"activeCount":103},[15201],{"nctId":15202,"briefTitle":15203,"status":111,"phases":15204,"primaryCompletion":15205,"completion":15205,"start":2811,"enrollment":315,"conditions":15206,"interventions":15209},"NCT01928849","Valproic Acid for the Prevention of Post-Amputation Pain",[92],"2017-09-26",[15207,15208],"Pain, Phantom","Pain, Neuropathic",[15193],{"trials":15211,"activeCount":103},[],{"trials":15213,"activeCount":103},[],{"trials":15215,"activeCount":103},[15216],{"nctId":15217,"briefTitle":15218,"status":111,"phases":15219,"primaryCompletion":3104,"completion":2933,"start":3113,"enrollment":2822,"conditions":15220,"interventions":15222},"NCT00787930","Bipolar Disorder in Late Life",[],[15221],"Bipolar Disorder",[15193],{"intervention":7012,"totalTrials":282,"cells":15224},{"EARLY_PHASE1":15225,"PHASE1":15227,"PHASE2":15229,"PHASE3":15231,"PHASE4":15233,"NA":15239},{"trials":15226,"activeCount":103},[],{"trials":15228,"activeCount":103},[],{"trials":15230,"activeCount":103},[],{"trials":15232,"activeCount":103},[],{"trials":15234,"activeCount":103},[15235],{"nctId":7004,"briefTitle":7005,"status":155,"phases":15236,"primaryCompletion":7007,"completion":7007,"start":7008,"enrollment":2570,"conditions":15237,"interventions":15238},[94],[7010],[7012,6991],{"trials":15240,"activeCount":103},[15241],{"nctId":15242,"briefTitle":15243,"status":111,"phases":15244,"primaryCompletion":9143,"completion":9143,"start":2909,"enrollment":15245,"conditions":15246,"interventions":15247},"NCT01216410","Prevention of Intraoperative Nausea and Vomiting During Cesarean Section",[95],306,[3317],[15248,7012,15249],"Metoclopramide","Combination Group",{"intervention":15251,"totalTrials":282,"cells":15252},"MeTree",{"EARLY_PHASE1":15253,"PHASE1":15255,"PHASE2":15257,"PHASE3":15259,"PHASE4":15261,"NA":15263},{"trials":15254,"activeCount":103},[],{"trials":15256,"activeCount":103},[],{"trials":15258,"activeCount":103},[],{"trials":15260,"activeCount":103},[],{"trials":15262,"activeCount":103},[],{"trials":15264,"activeCount":103},[15265,15273],{"nctId":15266,"briefTitle":15267,"status":111,"phases":15268,"primaryCompletion":15269,"completion":15269,"start":14420,"enrollment":15270,"conditions":15271,"interventions":15272},"NCT04639934","Family History in a Singapore Oncology Population",[],"2019-08-31",102,[18],[15251],{"nctId":15274,"briefTitle":15275,"status":111,"phases":15276,"primaryCompletion":15277,"completion":15277,"start":15278,"enrollment":3529,"conditions":15279,"interventions":15281},"NCT03114553","Family History in a Singaporean Healthy Population",[],"2024-12-10","2017-07-23",[15280],"All",[15251],{"intervention":15283,"totalTrials":132,"cells":15284},"9p21",{"EARLY_PHASE1":15285,"PHASE1":15287,"PHASE2":15289,"PHASE3":15291,"PHASE4":15293,"NA":15295},{"trials":15286,"activeCount":103},[],{"trials":15288,"activeCount":103},[],{"trials":15290,"activeCount":103},[],{"trials":15292,"activeCount":103},[],{"trials":15294,"activeCount":103},[],{"trials":15296,"activeCount":103},[15297],{"nctId":15298,"briefTitle":15299,"status":111,"phases":15300,"primaryCompletion":1233,"completion":3439,"start":5661,"enrollment":144,"conditions":15301,"interventions":15303},"NCT01766271","GENErating Behavior Change, An Integrative Health Coaching and Genetic Risk Testing Pilot",[95],[15302],"Coronary Heart Disease Risk",[15283],{"intervention":15305,"totalTrials":132,"cells":15306},"SLCO1B1*5 allele testing, results reported at randomization",{"EARLY_PHASE1":15307,"PHASE1":15309,"PHASE2":15311,"PHASE3":15313,"PHASE4":15315,"NA":15317},{"trials":15308,"activeCount":103},[],{"trials":15310,"activeCount":103},[],{"trials":15312,"activeCount":103},[],{"trials":15314,"activeCount":103},[],{"trials":15316,"activeCount":103},[],{"trials":15318,"activeCount":103},[15319],{"nctId":15320,"briefTitle":15321,"status":111,"phases":15322,"primaryCompletion":15323,"completion":15323,"start":2798,"enrollment":15324,"conditions":15325,"interventions":15327},"NCT01894230","Genetically Guided Statin Therapy",[95],"2016-04-30",167,[13571,15326],"Hydroxy-methylglutaryl-coenzyme A (HMG Co-A) Reductase Inhibitors Adverse Reaction",[15305,15328,15329],"SLCO1B1*5 allele testing, results reported at end of study","Genetic testing for SLCO1B1*5 allele",{"intervention":15328,"totalTrials":132,"cells":15331},{"EARLY_PHASE1":15332,"PHASE1":15334,"PHASE2":15336,"PHASE3":15338,"PHASE4":15340,"NA":15342},{"trials":15333,"activeCount":103},[],{"trials":15335,"activeCount":103},[],{"trials":15337,"activeCount":103},[],{"trials":15339,"activeCount":103},[],{"trials":15341,"activeCount":103},[],{"trials":15343,"activeCount":103},[15344],{"nctId":15320,"briefTitle":15321,"status":111,"phases":15345,"primaryCompletion":15323,"completion":15323,"start":2798,"enrollment":15324,"conditions":15346,"interventions":15347},[95],[13571,15326],[15305,15328,15329],{"intervention":15329,"totalTrials":132,"cells":15349},{"EARLY_PHASE1":15350,"PHASE1":15352,"PHASE2":15354,"PHASE3":15356,"PHASE4":15358,"NA":15360},{"trials":15351,"activeCount":103},[],{"trials":15353,"activeCount":103},[],{"trials":15355,"activeCount":103},[],{"trials":15357,"activeCount":103},[],{"trials":15359,"activeCount":103},[],{"trials":15361,"activeCount":103},[15362],{"nctId":15320,"briefTitle":15321,"status":111,"phases":15363,"primaryCompletion":15323,"completion":15323,"start":2798,"enrollment":15324,"conditions":15364,"interventions":15365},[95],[13571,15326],[15305,15328,15329],{"intervention":15367,"totalTrials":132,"cells":15368},"Estradiol",{"EARLY_PHASE1":15369,"PHASE1":15371,"PHASE2":15373,"PHASE3":15375,"PHASE4":15377,"NA":15379},{"trials":15370,"activeCount":103},[],{"trials":15372,"activeCount":103},[],{"trials":15374,"activeCount":103},[],{"trials":15376,"activeCount":103},[],{"trials":15378,"activeCount":103},[],{"trials":15380,"activeCount":103},[15381],{"nctId":15382,"briefTitle":15383,"status":428,"phases":15384,"primaryCompletion":4802,"completion":5661,"start":3235,"enrollment":103,"conditions":15385,"interventions":15387},"NCT01200537","Optimizing Ovulation Induction in the Poor Responder",[95],[15386],"IVF Poor Responders",[15367,15388],"Oral Contraceptive Pills",{"intervention":15388,"totalTrials":132,"cells":15390},{"EARLY_PHASE1":15391,"PHASE1":15393,"PHASE2":15395,"PHASE3":15397,"PHASE4":15399,"NA":15401},{"trials":15392,"activeCount":103},[],{"trials":15394,"activeCount":103},[],{"trials":15396,"activeCount":103},[],{"trials":15398,"activeCount":103},[],{"trials":15400,"activeCount":103},[],{"trials":15402,"activeCount":103},[15403],{"nctId":15382,"briefTitle":15383,"status":428,"phases":15404,"primaryCompletion":4802,"completion":5661,"start":3235,"enrollment":103,"conditions":15405,"interventions":15406},[95],[15386],[15367,15388],{"intervention":15408,"totalTrials":132,"cells":15409},"Gemcitabine\u002Fnab-Paclitaxel",{"EARLY_PHASE1":15410,"PHASE1":15412,"PHASE2":15414,"PHASE3":15416,"PHASE4":15418,"NA":15420},{"trials":15411,"activeCount":103},[],{"trials":15413,"activeCount":103},[],{"trials":15415,"activeCount":103},[],{"trials":15417,"activeCount":103},[],{"trials":15419,"activeCount":103},[],{"trials":15421,"activeCount":103},[15422],{"nctId":15423,"briefTitle":15424,"status":111,"phases":15425,"primaryCompletion":15426,"completion":15427,"start":15428,"enrollment":127,"conditions":15429,"interventions":15431},"NCT02318095","Gemcitabine\u002FNab-Paclitaxel With HIGRT in Resectable Pancreatic Cancer",[95],"2018-11-07","2022-11-14","2015-02-17",[15430],"Resectable Pancreatic Cancers",[15408,15432],"Adjuvant chemotheapy",{"intervention":15432,"totalTrials":132,"cells":15434},{"EARLY_PHASE1":15435,"PHASE1":15437,"PHASE2":15439,"PHASE3":15441,"PHASE4":15443,"NA":15445},{"trials":15436,"activeCount":103},[],{"trials":15438,"activeCount":103},[],{"trials":15440,"activeCount":103},[],{"trials":15442,"activeCount":103},[],{"trials":15444,"activeCount":103},[],{"trials":15446,"activeCount":103},[15447],{"nctId":15423,"briefTitle":15424,"status":111,"phases":15448,"primaryCompletion":15426,"completion":15427,"start":15428,"enrollment":127,"conditions":15449,"interventions":15450},[95],[15430],[15408,15432],{"intervention":15452,"totalTrials":132,"cells":15453},"Observational antifungal therapy",{"EARLY_PHASE1":15454,"PHASE1":15456,"PHASE2":15458,"PHASE3":15460,"PHASE4":15462,"NA":15464},{"trials":15455,"activeCount":103},[],{"trials":15457,"activeCount":103},[],{"trials":15459,"activeCount":103},[],{"trials":15461,"activeCount":103},[],{"trials":15463,"activeCount":103},[],{"trials":15465,"activeCount":103},[15466],{"nctId":15467,"briefTitle":15468,"status":111,"phases":15469,"primaryCompletion":9622,"completion":9622,"start":1544,"enrollment":15470,"conditions":15471,"interventions":15473},"NCT01869829","PEACE: Pediatric Antifungal Comparative Effectiveness",[],750,[15472],"Pediatric Invasive Candidiasis",[15452],{"intervention":15475,"totalTrials":132,"cells":15476},"fondaparinux",{"EARLY_PHASE1":15477,"PHASE1":15479,"PHASE2":15481,"PHASE3":15483,"PHASE4":15485,"NA":15487},{"trials":15478,"activeCount":103},[],{"trials":15480,"activeCount":103},[],{"trials":15482,"activeCount":103},[],{"trials":15484,"activeCount":103},[],{"trials":15486,"activeCount":103},[],{"trials":15488,"activeCount":103},[15489],{"nctId":15490,"briefTitle":15491,"status":428,"phases":15492,"completion":9796,"start":7848,"enrollment":103,"conditions":15493,"interventions":15495},"NCT00483600","Pharmacokinetic Study of Fondaparinux in Outpatients With Renal Dysfunction",[95],[15494],"Kidney Diseases",[15475],{"intervention":15497,"totalTrials":132,"cells":15498},"Injection of botulinum toxin A",{"EARLY_PHASE1":15499,"PHASE1":15501,"PHASE2":15503,"PHASE3":15505,"PHASE4":15507,"NA":15509},{"trials":15500,"activeCount":103},[],{"trials":15502,"activeCount":103},[],{"trials":15504,"activeCount":103},[],{"trials":15506,"activeCount":103},[],{"trials":15508,"activeCount":103},[],{"trials":15510,"activeCount":103},[15511],{"nctId":15512,"briefTitle":15513,"status":155,"phases":15514,"primaryCompletion":9182,"completion":9182,"start":413,"enrollment":282,"conditions":15515,"interventions":15518},"NCT01483209","Treatment of Vasopressor-induced Ischemia With Botulinum Toxin A",[95],[15516,15517],"Ischemia","Vasopressor",[15497],{"intervention":15520,"totalTrials":132,"cells":15521},"Zonisamide",{"EARLY_PHASE1":15522,"PHASE1":15524,"PHASE2":15526,"PHASE3":15528,"PHASE4":15530,"NA":15532},{"trials":15523,"activeCount":103},[],{"trials":15525,"activeCount":103},[],{"trials":15527,"activeCount":103},[],{"trials":15529,"activeCount":103},[],{"trials":15531,"activeCount":103},[],{"trials":15533,"activeCount":103},[15534],{"nctId":15535,"briefTitle":15536,"status":111,"phases":15537,"primaryCompletion":12428,"completion":12428,"start":14932,"enrollment":15538,"conditions":15539,"interventions":15540},"NCT00275834","Zonisamide for Weight Reduction in Obese Adults",[95],225,[15],[15520],{"intervention":15542,"totalTrials":132,"cells":15543},"aprepitant",{"EARLY_PHASE1":15544,"PHASE1":15546,"PHASE2":15548,"PHASE3":15550,"PHASE4":15552,"NA":15554},{"trials":15545,"activeCount":103},[],{"trials":15547,"activeCount":103},[],{"trials":15549,"activeCount":103},[],{"trials":15551,"activeCount":103},[],{"trials":15553,"activeCount":103},[],{"trials":15555,"activeCount":103},[15556],{"nctId":15557,"briefTitle":15558,"status":111,"phases":15559,"primaryCompletion":3143,"completion":1178,"start":7848,"enrollment":15560,"conditions":15561,"interventions":15563},"NCT00736073","A Trial of Aprepitant For Prevention of Post-Endoscopic Retrograde Cholangiopancreatography (ERCP) Pancreatitis",[95],73,[15562],"Pancreatitis",[15542],{"intervention":15565,"totalTrials":132,"cells":15566},"Mycophenolate Mofetil",{"EARLY_PHASE1":15567,"PHASE1":15569,"PHASE2":15571,"PHASE3":15573,"PHASE4":15575,"NA":15577},{"trials":15568,"activeCount":103},[],{"trials":15570,"activeCount":103},[],{"trials":15572,"activeCount":103},[],{"trials":15574,"activeCount":103},[],{"trials":15576,"activeCount":103},[],{"trials":15578,"activeCount":103},[15579],{"nctId":15580,"briefTitle":15581,"status":111,"phases":15582,"primaryCompletion":15583,"completion":15583,"start":15584,"enrollment":15324,"conditions":15585,"interventions":15588},"NCT03490539","Disease-Modifying Treatments for Myasthenia Gravis",[],"2021-01-31","2018-05-07",[15586,15587],"Neurological Disorder","Autoimmune Diseases",[15565,15589],"Azathioprine",{"intervention":15589,"totalTrials":132,"cells":15591},{"EARLY_PHASE1":15592,"PHASE1":15594,"PHASE2":15596,"PHASE3":15598,"PHASE4":15600,"NA":15602},{"trials":15593,"activeCount":103},[],{"trials":15595,"activeCount":103},[],{"trials":15597,"activeCount":103},[],{"trials":15599,"activeCount":103},[],{"trials":15601,"activeCount":103},[],{"trials":15603,"activeCount":103},[15604],{"nctId":15580,"briefTitle":15581,"status":111,"phases":15605,"primaryCompletion":15583,"completion":15583,"start":15584,"enrollment":15324,"conditions":15606,"interventions":15607},[],[15586,15587],[15565,15589],{"intervention":15609,"totalTrials":132,"cells":15610},"Perflutren Protein-Type A Microspheres for",{"EARLY_PHASE1":15611,"PHASE1":15613,"PHASE2":15615,"PHASE3":15617,"PHASE4":15619,"NA":15621},{"trials":15612,"activeCount":103},[],{"trials":15614,"activeCount":103},[],{"trials":15616,"activeCount":103},[],{"trials":15618,"activeCount":103},[],{"trials":15620,"activeCount":103},[],{"trials":15622,"activeCount":103},[15623],{"nctId":15624,"briefTitle":15625,"status":111,"phases":15626,"primaryCompletion":3486,"completion":2811,"start":3176,"enrollment":2139,"conditions":15627,"interventions":15630},"NCT00239525","3-D Transcranial Ultrasound Analysis Study",[95],[15628,15629],"Cerebrovascular Accident","Intracranial Hypertension",[15609],{"intervention":15632,"totalTrials":132,"cells":15633},"Lexapro",{"EARLY_PHASE1":15634,"PHASE1":15636,"PHASE2":15638,"PHASE3":15640,"PHASE4":15642,"NA":15644},{"trials":15635,"activeCount":103},[],{"trials":15637,"activeCount":103},[],{"trials":15639,"activeCount":103},[],{"trials":15641,"activeCount":103},[],{"trials":15643,"activeCount":103},[],{"trials":15645,"activeCount":103},[15646],{"nctId":15647,"briefTitle":15648,"status":111,"phases":15649,"primaryCompletion":12176,"completion":15650,"start":7929,"enrollment":315,"conditions":15651,"interventions":15652},"NCT02516332","Exercise and Pharmacotherapy for Anxiety in Cardiac Patients",[95],"2021-05",[2992,5406],[15632],{"intervention":15654,"totalTrials":132,"cells":15655},"Heparin",{"EARLY_PHASE1":15656,"PHASE1":15658,"PHASE2":15660,"PHASE3":15662,"PHASE4":15664,"NA":15666},{"trials":15657,"activeCount":103},[],{"trials":15659,"activeCount":103},[],{"trials":15661,"activeCount":103},[],{"trials":15663,"activeCount":103},[],{"trials":15665,"activeCount":103},[],{"trials":15667,"activeCount":103},[15668],{"nctId":15669,"briefTitle":15670,"status":111,"phases":15671,"primaryCompletion":3092,"completion":2650,"start":431,"enrollment":15672,"conditions":15673,"interventions":15675},"NCT00237328","Risk of Developing Antibodies to Heparin-PF4 After Heart Surgery",[],1015,[15674],"Thrombosis",[15654],{"intervention":15677,"totalTrials":132,"cells":15678},"antiretroviral therapy",{"EARLY_PHASE1":15679,"PHASE1":15681,"PHASE2":15683,"PHASE3":15685,"PHASE4":15687,"NA":15689},{"trials":15680,"activeCount":103},[],{"trials":15682,"activeCount":103},[],{"trials":15684,"activeCount":103},[],{"trials":15686,"activeCount":103},[],{"trials":15688,"activeCount":103},[],{"trials":15690,"activeCount":103},[15691],{"nctId":15692,"briefTitle":15693,"status":111,"phases":15694,"primaryCompletion":1233,"completion":1233,"start":8547,"enrollment":3781,"conditions":15695,"interventions":15697},"NCT01461876","Obesity in HIV After Antiretroviral Therapy",[],[3125,15696,15],"AIDS",[15677],{"intervention":2002,"totalTrials":132,"cells":15699},{"EARLY_PHASE1":15700,"PHASE1":15702,"PHASE2":15704,"PHASE3":15706,"PHASE4":15708,"NA":15710},{"trials":15701,"activeCount":103},[],{"trials":15703,"activeCount":103},[],{"trials":15705,"activeCount":103},[],{"trials":15707,"activeCount":103},[],{"trials":15709,"activeCount":103},[],{"trials":15711,"activeCount":103},[15712],{"nctId":14928,"briefTitle":14929,"status":111,"phases":15713,"primaryCompletion":3235,"completion":14931,"start":14932,"enrollment":341,"conditions":15714,"interventions":15715},[],[14934],[2002,4405,14936,14937,14938,14939,14940,14941],{"intervention":14936,"totalTrials":132,"cells":15717},{"EARLY_PHASE1":15718,"PHASE1":15720,"PHASE2":15722,"PHASE3":15724,"PHASE4":15726,"NA":15728},{"trials":15719,"activeCount":103},[],{"trials":15721,"activeCount":103},[],{"trials":15723,"activeCount":103},[],{"trials":15725,"activeCount":103},[],{"trials":15727,"activeCount":103},[],{"trials":15729,"activeCount":103},[15730],{"nctId":14928,"briefTitle":14929,"status":111,"phases":15731,"primaryCompletion":3235,"completion":14931,"start":14932,"enrollment":341,"conditions":15732,"interventions":15733},[],[14934],[2002,4405,14936,14937,14938,14939,14940,14941],{"intervention":14937,"totalTrials":132,"cells":15735},{"EARLY_PHASE1":15736,"PHASE1":15738,"PHASE2":15740,"PHASE3":15742,"PHASE4":15744,"NA":15746},{"trials":15737,"activeCount":103},[],{"trials":15739,"activeCount":103},[],{"trials":15741,"activeCount":103},[],{"trials":15743,"activeCount":103},[],{"trials":15745,"activeCount":103},[],{"trials":15747,"activeCount":103},[15748],{"nctId":14928,"briefTitle":14929,"status":111,"phases":15749,"primaryCompletion":3235,"completion":14931,"start":14932,"enrollment":341,"conditions":15750,"interventions":15751},[],[14934],[2002,4405,14936,14937,14938,14939,14940,14941],{"intervention":14938,"totalTrials":132,"cells":15753},{"EARLY_PHASE1":15754,"PHASE1":15756,"PHASE2":15758,"PHASE3":15760,"PHASE4":15762,"NA":15764},{"trials":15755,"activeCount":103},[],{"trials":15757,"activeCount":103},[],{"trials":15759,"activeCount":103},[],{"trials":15761,"activeCount":103},[],{"trials":15763,"activeCount":103},[],{"trials":15765,"activeCount":103},[15766],{"nctId":14928,"briefTitle":14929,"status":111,"phases":15767,"primaryCompletion":3235,"completion":14931,"start":14932,"enrollment":341,"conditions":15768,"interventions":15769},[],[14934],[2002,4405,14936,14937,14938,14939,14940,14941],{"intervention":14939,"totalTrials":132,"cells":15771},{"EARLY_PHASE1":15772,"PHASE1":15774,"PHASE2":15776,"PHASE3":15778,"PHASE4":15780,"NA":15782},{"trials":15773,"activeCount":103},[],{"trials":15775,"activeCount":103},[],{"trials":15777,"activeCount":103},[],{"trials":15779,"activeCount":103},[],{"trials":15781,"activeCount":103},[],{"trials":15783,"activeCount":103},[15784],{"nctId":14928,"briefTitle":14929,"status":111,"phases":15785,"primaryCompletion":3235,"completion":14931,"start":14932,"enrollment":341,"conditions":15786,"interventions":15787},[],[14934],[2002,4405,14936,14937,14938,14939,14940,14941],{"intervention":14940,"totalTrials":132,"cells":15789},{"EARLY_PHASE1":15790,"PHASE1":15792,"PHASE2":15794,"PHASE3":15796,"PHASE4":15798,"NA":15800},{"trials":15791,"activeCount":103},[],{"trials":15793,"activeCount":103},[],{"trials":15795,"activeCount":103},[],{"trials":15797,"activeCount":103},[],{"trials":15799,"activeCount":103},[],{"trials":15801,"activeCount":103},[15802],{"nctId":14928,"briefTitle":14929,"status":111,"phases":15803,"primaryCompletion":3235,"completion":14931,"start":14932,"enrollment":341,"conditions":15804,"interventions":15805},[],[14934],[2002,4405,14936,14937,14938,14939,14940,14941],{"intervention":14941,"totalTrials":132,"cells":15807},{"EARLY_PHASE1":15808,"PHASE1":15810,"PHASE2":15812,"PHASE3":15814,"PHASE4":15816,"NA":15818},{"trials":15809,"activeCount":103},[],{"trials":15811,"activeCount":103},[],{"trials":15813,"activeCount":103},[],{"trials":15815,"activeCount":103},[],{"trials":15817,"activeCount":103},[],{"trials":15819,"activeCount":103},[15820],{"nctId":14928,"briefTitle":14929,"status":111,"phases":15821,"primaryCompletion":3235,"completion":14931,"start":14932,"enrollment":341,"conditions":15822,"interventions":15823},[],[14934],[2002,4405,14936,14937,14938,14939,14940,14941],{"intervention":15825,"totalTrials":132,"cells":15826},"Innohep",{"EARLY_PHASE1":15827,"PHASE1":15829,"PHASE2":15831,"PHASE3":15833,"PHASE4":15835,"NA":15837},{"trials":15828,"activeCount":103},[],{"trials":15830,"activeCount":103},[],{"trials":15832,"activeCount":103},[],{"trials":15834,"activeCount":103},[],{"trials":15836,"activeCount":103},[],{"trials":15838,"activeCount":103},[15839],{"nctId":15840,"briefTitle":15841,"status":111,"phases":15842,"primaryCompletion":4712,"completion":4823,"start":4654,"enrollment":127,"conditions":15843,"interventions":15844},"NCT00629447","Innohep for Prophylaxis of Venous Thromboembolism in Brain Tumor Patients",[95],[2582],[15825],{"intervention":15846,"totalTrials":132,"cells":15847},"Trivalent inactivated influenza vaccine",{"EARLY_PHASE1":15848,"PHASE1":15850,"PHASE2":15852,"PHASE3":15854,"PHASE4":15856,"NA":15858},{"trials":15849,"activeCount":103},[],{"trials":15851,"activeCount":103},[],{"trials":15853,"activeCount":103},[],{"trials":15855,"activeCount":103},[],{"trials":15857,"activeCount":103},[],{"trials":15859,"activeCount":103},[15860],{"nctId":15861,"briefTitle":15862,"status":111,"phases":15863,"primaryCompletion":2339,"completion":2339,"start":5777,"enrollment":15864,"conditions":15865,"interventions":15866},"NCT00570037","Feasibility of Cocooning Immunization Strategy With Influenza Vaccine",[95],544,[5431],[15846],{"intervention":15868,"totalTrials":132,"cells":15869},"Immune checkpoint inhibitor (ICI) or chemotherapy alone",{"EARLY_PHASE1":15870,"PHASE1":15872,"PHASE2":15874,"PHASE3":15876,"PHASE4":15878,"NA":15880},{"trials":15871,"activeCount":103},[],{"trials":15873,"activeCount":103},[],{"trials":15875,"activeCount":103},[],{"trials":15877,"activeCount":103},[],{"trials":15879,"activeCount":103},[],{"trials":15881,"activeCount":103},[15882],{"nctId":15883,"briefTitle":15884,"status":428,"phases":15885,"primaryCompletion":15886,"completion":15887,"start":15888,"enrollment":103,"conditions":15889,"interventions":15891},"NCT06283238","Biobanking Upper Gastrointestinal Tumors to Evaluate Response (BURGER With BACON)",[],"2026-03-25","2027-03-25","2025-04-16",[15890],"GastroEsophageal Cancer",[15868],{"intervention":15893,"totalTrials":132,"cells":15894},"Blenrep",{"EARLY_PHASE1":15895,"PHASE1":15897,"PHASE2":15899,"PHASE3":15901,"PHASE4":15903,"NA":15905},{"trials":15896,"activeCount":103},[],{"trials":15898,"activeCount":103},[],{"trials":15900,"activeCount":103},[],{"trials":15902,"activeCount":103},[],{"trials":15904,"activeCount":103},[],{"trials":15906,"activeCount":103},[15907],{"nctId":15908,"briefTitle":15909,"status":111,"phases":15910,"primaryCompletion":15911,"completion":15911,"start":15912,"enrollment":34,"conditions":15913,"interventions":15914},"NCT05986682","Real-World Analysis of Belantamab Mafodotin Care Patterns in Patients With Relapsed and\u002For Refractory Multiple Myeloma",[],"2023-11-07","2023-09-18",[9049],[15893],{"intervention":15916,"totalTrials":132,"cells":15917},"Hyaluronidase",{"EARLY_PHASE1":15918,"PHASE1":15920,"PHASE2":15922,"PHASE3":15924,"PHASE4":15926,"NA":15928},{"trials":15919,"activeCount":103},[],{"trials":15921,"activeCount":103},[],{"trials":15923,"activeCount":103},[],{"trials":15925,"activeCount":103},[],{"trials":15927,"activeCount":103},[],{"trials":15929,"activeCount":103},[15930],{"nctId":15931,"briefTitle":15932,"status":428,"phases":15933,"primaryCompletion":14166,"enrollment":103,"conditions":15934,"interventions":15936},"NCT02059694","Use of Recombinant Hyaluronidase Human is Effective for the Use of Local Blocks for Eyelid's Surgery",[95],[15935],"Upper Eyelid Surgery",[15916],{"intervention":1238,"totalTrials":132,"cells":15938},{"EARLY_PHASE1":15939,"PHASE1":15941,"PHASE2":15943,"PHASE3":15945,"PHASE4":15947,"NA":15949},{"trials":15940,"activeCount":103},[],{"trials":15942,"activeCount":103},[],{"trials":15944,"activeCount":103},[],{"trials":15946,"activeCount":103},[],{"trials":15948,"activeCount":103},[],{"trials":15950,"activeCount":103},[15951],{"nctId":1230,"briefTitle":1231,"status":428,"phases":15952,"primaryCompletion":1233,"completion":1233,"start":1234,"enrollment":103,"conditions":15953,"interventions":15954},[95],[1236],[1238,689],{"intervention":15956,"totalTrials":132,"cells":15957},"Methylprednisolone",{"EARLY_PHASE1":15958,"PHASE1":15960,"PHASE2":15962,"PHASE3":15964,"PHASE4":15966,"NA":15968},{"trials":15959,"activeCount":103},[],{"trials":15961,"activeCount":103},[],{"trials":15963,"activeCount":103},[],{"trials":15965,"activeCount":103},[],{"trials":15967,"activeCount":103},[],{"trials":15969,"activeCount":103},[15970],{"nctId":15971,"briefTitle":15972,"status":111,"phases":15973,"primaryCompletion":15974,"completion":15974,"start":15975,"enrollment":1893,"conditions":15976,"interventions":15978},"NCT04874610","Steroid Metabolism in Obese and Non-Obese Pediatric Patients Hospitalized for Status Asthmaticus",[],"2022-03-31","2021-08-16",[15977,3750],"Pediatric Obesity",[15956],{"intervention":15980,"totalTrials":132,"cells":15981},"T2D medication management",{"EARLY_PHASE1":15982,"PHASE1":15984,"PHASE2":15986,"PHASE3":15988,"PHASE4":15990,"NA":15992},{"trials":15983,"activeCount":103},[],{"trials":15985,"activeCount":103},[],{"trials":15987,"activeCount":103},[],{"trials":15989,"activeCount":103},[],{"trials":15991,"activeCount":103},[],{"trials":15993,"activeCount":103},[15994],{"nctId":15995,"briefTitle":15996,"status":111,"phases":15997,"primaryCompletion":15998,"completion":15998,"start":15912,"enrollment":206,"conditions":15999,"interventions":16002},"NCT05844137","Improving Detection and Evidence-based Care of NAFLD in Latinx and Black Patients With Type 2 Diabetes",[95],"2024-01-29",[16000,16001],"NAFLD","Diabetes Mellitus",[15980],{"intervention":15153,"totalTrials":132,"cells":16004},{"EARLY_PHASE1":16005,"PHASE1":16007,"PHASE2":16009,"PHASE3":16011,"PHASE4":16013,"NA":16015},{"trials":16006,"activeCount":103},[],{"trials":16008,"activeCount":103},[],{"trials":16010,"activeCount":103},[],{"trials":16012,"activeCount":103},[],{"trials":16014,"activeCount":103},[],{"trials":16016,"activeCount":103},[16017],{"nctId":15143,"briefTitle":15144,"status":111,"phases":16018,"primaryCompletion":15146,"completion":15146,"start":15147,"enrollment":8410,"conditions":16019,"interventions":16020},[95],[481,15149,15150,15151],[15128,15153],{"intervention":16022,"totalTrials":132,"cells":16023},"Lidocaine - intra-articular",{"EARLY_PHASE1":16024,"PHASE1":16026,"PHASE2":16028,"PHASE3":16030,"PHASE4":16032,"NA":16034},{"trials":16025,"activeCount":103},[],{"trials":16027,"activeCount":103},[],{"trials":16029,"activeCount":103},[],{"trials":16031,"activeCount":103},[],{"trials":16033,"activeCount":103},[],{"trials":16035,"activeCount":103},[16036],{"nctId":16037,"briefTitle":16038,"status":155,"phases":16039,"primaryCompletion":16040,"completion":16040,"start":16041,"enrollment":8858,"conditions":16042,"interventions":16044},"NCT05465382","Effect of Early Saline Lavage on Synovial Fluid Composition Following Intra Articular Ankle Fractures",[95],"2024-05-07","2022-07-22",[16043],"Intra-Articular Fractures",[16022],{"intervention":15163,"totalTrials":132,"cells":16046},{"EARLY_PHASE1":16047,"PHASE1":16049,"PHASE2":16051,"PHASE3":16053,"PHASE4":16055,"NA":16057},{"trials":16048,"activeCount":103},[],{"trials":16050,"activeCount":103},[],{"trials":16052,"activeCount":103},[],{"trials":16054,"activeCount":103},[],{"trials":16056,"activeCount":103},[],{"trials":16058,"activeCount":103},[16059],{"nctId":15155,"briefTitle":15156,"status":111,"phases":16060,"primaryCompletion":15158,"completion":15158,"start":15159,"enrollment":8410,"conditions":16061,"interventions":16062},[95],[481,344,15150,15151,15161],[15128,15163,15164],{"intervention":15164,"totalTrials":132,"cells":16064},{"EARLY_PHASE1":16065,"PHASE1":16067,"PHASE2":16069,"PHASE3":16071,"PHASE4":16073,"NA":16075},{"trials":16066,"activeCount":103},[],{"trials":16068,"activeCount":103},[],{"trials":16070,"activeCount":103},[],{"trials":16072,"activeCount":103},[],{"trials":16074,"activeCount":103},[],{"trials":16076,"activeCount":103},[16077],{"nctId":15155,"briefTitle":15156,"status":111,"phases":16078,"primaryCompletion":15158,"completion":15158,"start":15159,"enrollment":8410,"conditions":16079,"interventions":16080},[95],[481,344,15150,15151,15161],[15128,15163,15164],{"intervention":16082,"totalTrials":132,"cells":16083},"Nitroglycerin ointment",{"EARLY_PHASE1":16084,"PHASE1":16086,"PHASE2":16088,"PHASE3":16090,"PHASE4":16092,"NA":16094},{"trials":16085,"activeCount":103},[],{"trials":16087,"activeCount":103},[],{"trials":16089,"activeCount":103},[],{"trials":16091,"activeCount":103},[],{"trials":16093,"activeCount":103},[],{"trials":16095,"activeCount":103},[16096],{"nctId":16097,"briefTitle":16098,"status":155,"phases":16099,"primaryCompletion":16100,"completion":16101,"start":16102,"enrollment":160,"conditions":16103,"interventions":16104},"NCT02164318","Effects of Exercise and Improved Nitric Oxide Bioavailability on Arteriovenous Fistula Maturation",[95],"2016-02-18","2017-03-10","2014-09-01",[6474],[16082],{"intervention":16106,"totalTrials":132,"cells":16107},"regional nerve block with a local anesthetic",{"EARLY_PHASE1":16108,"PHASE1":16110,"PHASE2":16112,"PHASE3":16114,"PHASE4":16116,"NA":16118},{"trials":16109,"activeCount":103},[],{"trials":16111,"activeCount":103},[],{"trials":16113,"activeCount":103},[],{"trials":16115,"activeCount":103},[],{"trials":16117,"activeCount":103},[],{"trials":16119,"activeCount":103},[16120],{"nctId":16121,"briefTitle":16122,"status":111,"phases":16123,"primaryCompletion":16124,"completion":16124,"start":16125,"enrollment":1180,"conditions":16126,"interventions":16127},"NCT02669407","Splanchnic Nerve Anesthesia in Heart Failure",[95],"2018-10","2017-01-01",[21],[16106],{"intervention":16129,"totalTrials":132,"cells":16130},"Oxytocin",{"EARLY_PHASE1":16131,"PHASE1":16133,"PHASE2":16135,"PHASE3":16137,"PHASE4":16139,"NA":16141},{"trials":16132,"activeCount":103},[],{"trials":16134,"activeCount":103},[],{"trials":16136,"activeCount":103},[],{"trials":16138,"activeCount":103},[],{"trials":16140,"activeCount":103},[],{"trials":16142,"activeCount":103},[16143],{"nctId":16144,"briefTitle":16145,"status":428,"phases":16146,"primaryCompletion":7929,"completion":7929,"start":1544,"enrollment":103,"conditions":16147,"interventions":16149},"NCT02063568","The Use of Thromboelastometry (ROTEM) to Evaluate the Changes in Coagulation With Two Different Doses of Oxytocin Following Cesarean Delivery",[95],[16148],"Coagulation Changes With Oxytocin",[16129],{"intervention":16151,"totalTrials":132,"cells":16152},"Aflibercept",{"EARLY_PHASE1":16153,"PHASE1":16155,"PHASE2":16157,"PHASE3":16159,"PHASE4":16161,"NA":16163},{"trials":16154,"activeCount":103},[],{"trials":16156,"activeCount":103},[],{"trials":16158,"activeCount":103},[],{"trials":16160,"activeCount":103},[],{"trials":16162,"activeCount":103},[],{"trials":16164,"activeCount":103},[16165],{"nctId":16166,"briefTitle":16167,"status":428,"phases":16168,"primaryCompletion":16169,"completion":16169,"start":1220,"enrollment":103,"conditions":16170,"interventions":16172},"NCT02457026","Adjunctive Photodynamic Therapy + Aflibercept vs. Afilbercept Alone for PDA in NV AMD",[95],"2018-01",[16171],"Neovascular Age-related Macular Degeneration",[16151,16173,16174],"Triamcinolone Acetonide","Verteporfin",{"intervention":16173,"totalTrials":132,"cells":16176},{"EARLY_PHASE1":16177,"PHASE1":16179,"PHASE2":16181,"PHASE3":16183,"PHASE4":16185,"NA":16187},{"trials":16178,"activeCount":103},[],{"trials":16180,"activeCount":103},[],{"trials":16182,"activeCount":103},[],{"trials":16184,"activeCount":103},[],{"trials":16186,"activeCount":103},[],{"trials":16188,"activeCount":103},[16189],{"nctId":16166,"briefTitle":16167,"status":428,"phases":16190,"primaryCompletion":16169,"completion":16169,"start":1220,"enrollment":103,"conditions":16191,"interventions":16192},[95],[16171],[16151,16173,16174],{"intervention":16174,"totalTrials":132,"cells":16194},{"EARLY_PHASE1":16195,"PHASE1":16197,"PHASE2":16199,"PHASE3":16201,"PHASE4":16203,"NA":16205},{"trials":16196,"activeCount":103},[],{"trials":16198,"activeCount":103},[],{"trials":16200,"activeCount":103},[],{"trials":16202,"activeCount":103},[],{"trials":16204,"activeCount":103},[],{"trials":16206,"activeCount":103},[16207],{"nctId":16166,"briefTitle":16167,"status":428,"phases":16208,"primaryCompletion":16169,"completion":16169,"start":1220,"enrollment":103,"conditions":16209,"interventions":16210},[95],[16171],[16151,16173,16174],{"intervention":16212,"totalTrials":132,"cells":16213},"Clevidipine",{"EARLY_PHASE1":16214,"PHASE1":16216,"PHASE2":16218,"PHASE3":16220,"PHASE4":16222,"NA":16224},{"trials":16215,"activeCount":103},[],{"trials":16217,"activeCount":103},[],{"trials":16219,"activeCount":103},[],{"trials":16221,"activeCount":103},[],{"trials":16223,"activeCount":103},[],{"trials":16225,"activeCount":103},[16226],{"nctId":16227,"briefTitle":16228,"status":428,"phases":16229,"primaryCompletion":1202,"completion":1202,"start":2933,"enrollment":103,"conditions":16230,"interventions":16233},"NCT01480531","Pre and or Post Operative Blood Pressure Control With Clevidipine (Cleviprexm Medicines Company) in Aortic Aneurysm \u002F Dissection",[95],[16231,16232],"Aorta Aneurysm","Dissection of Aorta",[16212],{"intervention":16235,"totalTrials":132,"cells":16236},"Medical Therapy",{"EARLY_PHASE1":16237,"PHASE1":16239,"PHASE2":16241,"PHASE3":16243,"PHASE4":16245,"NA":16247},{"trials":16238,"activeCount":103},[],{"trials":16240,"activeCount":103},[],{"trials":16242,"activeCount":103},[],{"trials":16244,"activeCount":103},[],{"trials":16246,"activeCount":103},[],{"trials":16248,"activeCount":103},[16249],{"nctId":16250,"briefTitle":16251,"status":111,"phases":16252,"primaryCompletion":16253,"completion":16253,"start":4256,"enrollment":16254,"conditions":16255,"interventions":16257},"NCT02260752","Patient Centered Results for Uterine Fibroids",[],"2020-04-30",3094,[16256],"Fibroids, Uterine",[16235],{"intervention":16259,"totalTrials":132,"cells":16260},"Both 2nd and 3rd doses on time",{"EARLY_PHASE1":16261,"PHASE1":16263,"PHASE2":16265,"PHASE3":16267,"PHASE4":16269,"NA":16271},{"trials":16262,"activeCount":103},[],{"trials":16264,"activeCount":103},[],{"trials":16266,"activeCount":103},[],{"trials":16268,"activeCount":103},[],{"trials":16270,"activeCount":103},[],{"trials":16272,"activeCount":103},[16273],{"nctId":16274,"briefTitle":16275,"status":111,"phases":16276,"primaryCompletion":7008,"completion":7008,"start":3092,"enrollment":16277,"conditions":16278,"interventions":16279},"NCT02280642","Alternate Dosing Schedules Study for HPV Vaccine (ADS)",[],331,[7671,7672],[16259,16280,16281,16282],"2nd dose late and 3rd dose on time","2nd dose on time and 3rd dose late","Both doses late",{"intervention":16280,"totalTrials":132,"cells":16284},{"EARLY_PHASE1":16285,"PHASE1":16287,"PHASE2":16289,"PHASE3":16291,"PHASE4":16293,"NA":16295},{"trials":16286,"activeCount":103},[],{"trials":16288,"activeCount":103},[],{"trials":16290,"activeCount":103},[],{"trials":16292,"activeCount":103},[],{"trials":16294,"activeCount":103},[],{"trials":16296,"activeCount":103},[16297],{"nctId":16274,"briefTitle":16275,"status":111,"phases":16298,"primaryCompletion":7008,"completion":7008,"start":3092,"enrollment":16277,"conditions":16299,"interventions":16300},[],[7671,7672],[16259,16280,16281,16282],{"intervention":16281,"totalTrials":132,"cells":16302},{"EARLY_PHASE1":16303,"PHASE1":16305,"PHASE2":16307,"PHASE3":16309,"PHASE4":16311,"NA":16313},{"trials":16304,"activeCount":103},[],{"trials":16306,"activeCount":103},[],{"trials":16308,"activeCount":103},[],{"trials":16310,"activeCount":103},[],{"trials":16312,"activeCount":103},[],{"trials":16314,"activeCount":103},[16315],{"nctId":16274,"briefTitle":16275,"status":111,"phases":16316,"primaryCompletion":7008,"completion":7008,"start":3092,"enrollment":16277,"conditions":16317,"interventions":16318},[],[7671,7672],[16259,16280,16281,16282],{"intervention":16282,"totalTrials":132,"cells":16320},{"EARLY_PHASE1":16321,"PHASE1":16323,"PHASE2":16325,"PHASE3":16327,"PHASE4":16329,"NA":16331},{"trials":16322,"activeCount":103},[],{"trials":16324,"activeCount":103},[],{"trials":16326,"activeCount":103},[],{"trials":16328,"activeCount":103},[],{"trials":16330,"activeCount":103},[],{"trials":16332,"activeCount":103},[16333],{"nctId":16274,"briefTitle":16275,"status":111,"phases":16334,"primaryCompletion":7008,"completion":7008,"start":3092,"enrollment":16277,"conditions":16335,"interventions":16336},[],[7671,7672],[16259,16280,16281,16282],{"intervention":16338,"totalTrials":132,"cells":16339},"amiodarone",{"EARLY_PHASE1":16340,"PHASE1":16342,"PHASE2":16344,"PHASE3":16346,"PHASE4":16348,"NA":16350},{"trials":16341,"activeCount":103},[],{"trials":16343,"activeCount":103},[],{"trials":16345,"activeCount":103},[],{"trials":16347,"activeCount":103},[],{"trials":16349,"activeCount":103},[],{"trials":16351,"activeCount":103},[16352],{"nctId":16353,"briefTitle":16354,"status":155,"phases":16355,"primaryCompletion":1233,"completion":1233,"start":2821,"enrollment":2112,"conditions":16356,"interventions":16358},"NCT01576042","Pilot Study of Catheter Ablation for Ventricular Tachycardia in Patients With an Implantable Cardioverter Defibrillator",[95],[16357],"Ventricular Tachycardia",[16338,16359],"sotalol",{"intervention":16359,"totalTrials":132,"cells":16361},{"EARLY_PHASE1":16362,"PHASE1":16364,"PHASE2":16366,"PHASE3":16368,"PHASE4":16370,"NA":16372},{"trials":16363,"activeCount":103},[],{"trials":16365,"activeCount":103},[],{"trials":16367,"activeCount":103},[],{"trials":16369,"activeCount":103},[],{"trials":16371,"activeCount":103},[],{"trials":16373,"activeCount":103},[16374],{"nctId":16353,"briefTitle":16354,"status":155,"phases":16375,"primaryCompletion":1233,"completion":1233,"start":2821,"enrollment":2112,"conditions":16376,"interventions":16377},[95],[16357],[16338,16359],{"intervention":16379,"totalTrials":132,"cells":16380},"Volulyte®",{"EARLY_PHASE1":16381,"PHASE1":16383,"PHASE2":16385,"PHASE3":16387,"PHASE4":16389,"NA":16391},{"trials":16382,"activeCount":103},[],{"trials":16384,"activeCount":103},[],{"trials":16386,"activeCount":103},[],{"trials":16388,"activeCount":103},[],{"trials":16390,"activeCount":103},[],{"trials":16392,"activeCount":103},[16393],{"nctId":16394,"briefTitle":16395,"status":155,"phases":16396,"primaryCompletion":218,"completion":218,"start":2798,"enrollment":2935,"conditions":16397,"interventions":16400},"NCT01874730","KOREAN Enhanced RecOvery Strategy for Colorectal Surgery",[95],[16398,16399],"Goal-oriented Fluid Therapy","Colorectal Surgery",[16379],{"intervention":16402,"totalTrials":132,"cells":16403},"Selective serotonin reuptake inhibitor (SSRI) and serotonin-norepinephrine reuptake inhibitor (SNRI) medications",{"EARLY_PHASE1":16404,"PHASE1":16406,"PHASE2":16408,"PHASE3":16410,"PHASE4":16412,"NA":16414},{"trials":16405,"activeCount":103},[],{"trials":16407,"activeCount":103},[],{"trials":16409,"activeCount":103},[],{"trials":16411,"activeCount":103},[],{"trials":16413,"activeCount":103},[],{"trials":16415,"activeCount":103},[16416],{"nctId":16417,"briefTitle":16418,"status":111,"phases":16419,"primaryCompletion":204,"completion":204,"start":2963,"enrollment":16420,"conditions":16421,"interventions":16425},"NCT00395213","Antidepressant Safety in Kids Study",[],569,[3107,16422,16423,16424],"Depressive Disorders","Eating Disorders","Obsessive Compulsive Disorder",[16402],{"intervention":16427,"totalTrials":132,"cells":16428},"Preemptive Therapy with Anidulafungin",{"EARLY_PHASE1":16429,"PHASE1":16431,"PHASE2":16433,"PHASE3":16435,"PHASE4":16437,"NA":16439},{"trials":16430,"activeCount":103},[],{"trials":16432,"activeCount":103},[],{"trials":16434,"activeCount":103},[],{"trials":16436,"activeCount":103},[],{"trials":16438,"activeCount":103},[],{"trials":16440,"activeCount":103},[16441],{"nctId":16442,"briefTitle":16443,"status":111,"phases":16444,"primaryCompletion":4642,"completion":11649,"start":3175,"enrollment":7566,"conditions":16445,"interventions":16447},"NCT00672841","β-D-Glucan (BDG) Surveillance With Preemptive Anidulafungin vs. Standard Care for Invasive Candidiasis in Surgical Intensive Care Unit (SICU) Patients",[95],[16446],"Invasive Candidiasis",[16427,16448],"Empiric antifungal therapy based on physician discretion.",{"intervention":16448,"totalTrials":132,"cells":16450},{"EARLY_PHASE1":16451,"PHASE1":16453,"PHASE2":16455,"PHASE3":16457,"PHASE4":16459,"NA":16461},{"trials":16452,"activeCount":103},[],{"trials":16454,"activeCount":103},[],{"trials":16456,"activeCount":103},[],{"trials":16458,"activeCount":103},[],{"trials":16460,"activeCount":103},[],{"trials":16462,"activeCount":103},[16463],{"nctId":16442,"briefTitle":16443,"status":111,"phases":16464,"primaryCompletion":4642,"completion":11649,"start":3175,"enrollment":7566,"conditions":16465,"interventions":16466},[95],[16446],[16427,16448],{"intervention":16468,"totalTrials":132,"cells":16469},"ACE-I Cessation group",{"EARLY_PHASE1":16470,"PHASE1":16472,"PHASE2":16474,"PHASE3":16476,"PHASE4":16478,"NA":16480},{"trials":16471,"activeCount":103},[],{"trials":16473,"activeCount":103},[],{"trials":16475,"activeCount":103},[],{"trials":16477,"activeCount":103},[],{"trials":16479,"activeCount":103},[],{"trials":16481,"activeCount":103},[16482],{"nctId":16483,"briefTitle":16484,"status":155,"phases":16485,"primaryCompletion":16486,"completion":16486,"start":8935,"enrollment":12429,"conditions":16487,"interventions":16490},"NCT01867047","ACE-Inhibitor Effects on Total Hip and Knee Arthroplasty Patients",[95],"2016-06-24",[16488,16489],"Adverse Effects of Angiotensin-converting-enzyme Inhibitors","Hypotension",[16468,16491],"ACE-I Continuation group",{"intervention":16491,"totalTrials":132,"cells":16493},{"EARLY_PHASE1":16494,"PHASE1":16496,"PHASE2":16498,"PHASE3":16500,"PHASE4":16502,"NA":16504},{"trials":16495,"activeCount":103},[],{"trials":16497,"activeCount":103},[],{"trials":16499,"activeCount":103},[],{"trials":16501,"activeCount":103},[],{"trials":16503,"activeCount":103},[],{"trials":16505,"activeCount":103},[16506],{"nctId":16483,"briefTitle":16484,"status":155,"phases":16507,"primaryCompletion":16486,"completion":16486,"start":8935,"enrollment":12429,"conditions":16508,"interventions":16509},[95],[16488,16489],[16468,16491],{"intervention":16511,"totalTrials":132,"cells":16512},"CGRP antibody",{"EARLY_PHASE1":16513,"PHASE1":16515,"PHASE2":16517,"PHASE3":16519,"PHASE4":16521,"NA":16523},{"trials":16514,"activeCount":103},[],{"trials":16516,"activeCount":103},[],{"trials":16518,"activeCount":103},[],{"trials":16520,"activeCount":103},[],{"trials":16522,"activeCount":103},[],{"trials":16524,"activeCount":103},[16525],{"nctId":16526,"briefTitle":16527,"status":111,"phases":16528,"primaryCompletion":16529,"completion":16529,"start":16530,"enrollment":28,"conditions":16531,"interventions":16533},"NCT06018025","NDPH Biomarker Study in Children and Adolescents",[],"2025-05-29","2024-04-15",[16532],"New Persistent Daily Headache",[16511],{"intervention":16535,"totalTrials":132,"cells":16536},"Dolutegravir",{"EARLY_PHASE1":16537,"PHASE1":16539,"PHASE2":16541,"PHASE3":16543,"PHASE4":16545,"NA":16547},{"trials":16538,"activeCount":103},[],{"trials":16540,"activeCount":103},[],{"trials":16542,"activeCount":103},[],{"trials":16544,"activeCount":103},[],{"trials":16546,"activeCount":103},[],{"trials":16548,"activeCount":103},[16549],{"nctId":16550,"briefTitle":16551,"status":111,"phases":16552,"primaryCompletion":16553,"completion":16553,"start":16554,"enrollment":16555,"conditions":16556,"interventions":16558},"NCT04862975","Pharmacokinetics of Antiretroviral Drugs in Lactating Women and Breastmilk Fed Infants Under 6 Months of Age in Botswana",[],"2025-01-30","2024-01-09",164,[361,16557,343],"Breastmilk Fed Infants of Mothers on Select DOI",[16535,16559,16560,16561],"Lamivudine","Emtricitabine","Tenofovir Disoproxil Fumarate",{"intervention":16559,"totalTrials":132,"cells":16563},{"EARLY_PHASE1":16564,"PHASE1":16566,"PHASE2":16568,"PHASE3":16570,"PHASE4":16572,"NA":16574},{"trials":16565,"activeCount":103},[],{"trials":16567,"activeCount":103},[],{"trials":16569,"activeCount":103},[],{"trials":16571,"activeCount":103},[],{"trials":16573,"activeCount":103},[],{"trials":16575,"activeCount":103},[16576],{"nctId":16550,"briefTitle":16551,"status":111,"phases":16577,"primaryCompletion":16553,"completion":16553,"start":16554,"enrollment":16555,"conditions":16578,"interventions":16579},[],[361,16557,343],[16535,16559,16560,16561],{"intervention":16560,"totalTrials":132,"cells":16581},{"EARLY_PHASE1":16582,"PHASE1":16584,"PHASE2":16586,"PHASE3":16588,"PHASE4":16590,"NA":16592},{"trials":16583,"activeCount":103},[],{"trials":16585,"activeCount":103},[],{"trials":16587,"activeCount":103},[],{"trials":16589,"activeCount":103},[],{"trials":16591,"activeCount":103},[],{"trials":16593,"activeCount":103},[16594],{"nctId":16550,"briefTitle":16551,"status":111,"phases":16595,"primaryCompletion":16553,"completion":16553,"start":16554,"enrollment":16555,"conditions":16596,"interventions":16597},[],[361,16557,343],[16535,16559,16560,16561],{"intervention":16561,"totalTrials":132,"cells":16599},{"EARLY_PHASE1":16600,"PHASE1":16602,"PHASE2":16604,"PHASE3":16606,"PHASE4":16608,"NA":16610},{"trials":16601,"activeCount":103},[],{"trials":16603,"activeCount":103},[],{"trials":16605,"activeCount":103},[],{"trials":16607,"activeCount":103},[],{"trials":16609,"activeCount":103},[],{"trials":16611,"activeCount":103},[16612],{"nctId":16550,"briefTitle":16551,"status":111,"phases":16613,"primaryCompletion":16553,"completion":16553,"start":16554,"enrollment":16555,"conditions":16614,"interventions":16615},[],[361,16557,343],[16535,16559,16560,16561],{"intervention":16617,"totalTrials":132,"cells":16618},"Metronidazole cream",{"EARLY_PHASE1":16619,"PHASE1":16621,"PHASE2":16623,"PHASE3":16625,"PHASE4":16627,"NA":16629},{"trials":16620,"activeCount":103},[],{"trials":16622,"activeCount":103},[],{"trials":16624,"activeCount":103},[],{"trials":16626,"activeCount":103},[],{"trials":16628,"activeCount":103},[],{"trials":16630,"activeCount":103},[16631],{"nctId":16632,"briefTitle":16633,"status":111,"phases":16634,"primaryCompletion":16635,"completion":16635,"start":16636,"enrollment":3237,"conditions":16637,"interventions":16639},"NCT06434519","Metronidazole SC Penetrance With Moisturizers",[95],"2025-11-04","2024-09-03",[16638],"Rosacea, Erythematotelangiectatic",[16617],{"intervention":14728,"totalTrials":132,"cells":16641},{"EARLY_PHASE1":16642,"PHASE1":16644,"PHASE2":16646,"PHASE3":16648,"PHASE4":16650,"NA":16652},{"trials":16643,"activeCount":103},[],{"trials":16645,"activeCount":103},[],{"trials":16647,"activeCount":103},[],{"trials":16649,"activeCount":103},[],{"trials":16651,"activeCount":103},[],{"trials":16653,"activeCount":103},[16654],{"nctId":14723,"briefTitle":14724,"status":111,"phases":16655,"primaryCompletion":2981,"completion":8760,"start":14705,"enrollment":229,"conditions":16656,"interventions":16657},[95],[18,10570,1670],[14728,14695],{"intervention":16659,"totalTrials":132,"cells":16660},"Patient-Controlled Analgesia",{"EARLY_PHASE1":16661,"PHASE1":16663,"PHASE2":16665,"PHASE3":16667,"PHASE4":16669,"NA":16671},{"trials":16662,"activeCount":103},[],{"trials":16664,"activeCount":103},[],{"trials":16666,"activeCount":103},[],{"trials":16668,"activeCount":103},[],{"trials":16670,"activeCount":103},[],{"trials":16672,"activeCount":103},[16673],{"nctId":16674,"briefTitle":16675,"status":155,"phases":16676,"primaryCompletion":1624,"completion":1624,"start":6425,"enrollment":206,"conditions":16677,"interventions":16679},"NCT02192879","TEA vs. PVB vs. PCA in Liver Resection Surgery",[95],[16678],"Pain Management Strategies in Liver Resection Surgery",[16659],{"intervention":14605,"totalTrials":132,"cells":16681},{"EARLY_PHASE1":16682,"PHASE1":16684,"PHASE2":16686,"PHASE3":16688,"PHASE4":16690,"NA":16692},{"trials":16683,"activeCount":103},[],{"trials":16685,"activeCount":103},[],{"trials":16687,"activeCount":103},[],{"trials":16689,"activeCount":103},[],{"trials":16691,"activeCount":103},[],{"trials":16693,"activeCount":103},[16694],{"nctId":14599,"briefTitle":14600,"status":155,"phases":16695,"primaryCompletion":412,"completion":412,"start":2811,"enrollment":8410,"conditions":16696,"interventions":16697},[95],[14603],[14605,14606,14607,14608,14609,14610,7037,14611,483],{"intervention":14606,"totalTrials":132,"cells":16699},{"EARLY_PHASE1":16700,"PHASE1":16702,"PHASE2":16704,"PHASE3":16706,"PHASE4":16708,"NA":16710},{"trials":16701,"activeCount":103},[],{"trials":16703,"activeCount":103},[],{"trials":16705,"activeCount":103},[],{"trials":16707,"activeCount":103},[],{"trials":16709,"activeCount":103},[],{"trials":16711,"activeCount":103},[16712],{"nctId":14599,"briefTitle":14600,"status":155,"phases":16713,"primaryCompletion":412,"completion":412,"start":2811,"enrollment":8410,"conditions":16714,"interventions":16715},[95],[14603],[14605,14606,14607,14608,14609,14610,7037,14611,483],{"intervention":14607,"totalTrials":132,"cells":16717},{"EARLY_PHASE1":16718,"PHASE1":16720,"PHASE2":16722,"PHASE3":16724,"PHASE4":16726,"NA":16728},{"trials":16719,"activeCount":103},[],{"trials":16721,"activeCount":103},[],{"trials":16723,"activeCount":103},[],{"trials":16725,"activeCount":103},[],{"trials":16727,"activeCount":103},[],{"trials":16729,"activeCount":103},[16730],{"nctId":14599,"briefTitle":14600,"status":155,"phases":16731,"primaryCompletion":412,"completion":412,"start":2811,"enrollment":8410,"conditions":16732,"interventions":16733},[95],[14603],[14605,14606,14607,14608,14609,14610,7037,14611,483],{"intervention":14608,"totalTrials":132,"cells":16735},{"EARLY_PHASE1":16736,"PHASE1":16738,"PHASE2":16740,"PHASE3":16742,"PHASE4":16744,"NA":16746},{"trials":16737,"activeCount":103},[],{"trials":16739,"activeCount":103},[],{"trials":16741,"activeCount":103},[],{"trials":16743,"activeCount":103},[],{"trials":16745,"activeCount":103},[],{"trials":16747,"activeCount":103},[16748],{"nctId":14599,"briefTitle":14600,"status":155,"phases":16749,"primaryCompletion":412,"completion":412,"start":2811,"enrollment":8410,"conditions":16750,"interventions":16751},[95],[14603],[14605,14606,14607,14608,14609,14610,7037,14611,483],{"intervention":14609,"totalTrials":132,"cells":16753},{"EARLY_PHASE1":16754,"PHASE1":16756,"PHASE2":16758,"PHASE3":16760,"PHASE4":16762,"NA":16764},{"trials":16755,"activeCount":103},[],{"trials":16757,"activeCount":103},[],{"trials":16759,"activeCount":103},[],{"trials":16761,"activeCount":103},[],{"trials":16763,"activeCount":103},[],{"trials":16765,"activeCount":103},[16766],{"nctId":14599,"briefTitle":14600,"status":155,"phases":16767,"primaryCompletion":412,"completion":412,"start":2811,"enrollment":8410,"conditions":16768,"interventions":16769},[95],[14603],[14605,14606,14607,14608,14609,14610,7037,14611,483],{"intervention":14610,"totalTrials":132,"cells":16771},{"EARLY_PHASE1":16772,"PHASE1":16774,"PHASE2":16776,"PHASE3":16778,"PHASE4":16780,"NA":16782},{"trials":16773,"activeCount":103},[],{"trials":16775,"activeCount":103},[],{"trials":16777,"activeCount":103},[],{"trials":16779,"activeCount":103},[],{"trials":16781,"activeCount":103},[],{"trials":16783,"activeCount":103},[16784],{"nctId":14599,"briefTitle":14600,"status":155,"phases":16785,"primaryCompletion":412,"completion":412,"start":2811,"enrollment":8410,"conditions":16786,"interventions":16787},[95],[14603],[14605,14606,14607,14608,14609,14610,7037,14611,483],{"intervention":14611,"totalTrials":132,"cells":16789},{"EARLY_PHASE1":16790,"PHASE1":16792,"PHASE2":16794,"PHASE3":16796,"PHASE4":16798,"NA":16800},{"trials":16791,"activeCount":103},[],{"trials":16793,"activeCount":103},[],{"trials":16795,"activeCount":103},[],{"trials":16797,"activeCount":103},[],{"trials":16799,"activeCount":103},[],{"trials":16801,"activeCount":103},[16802],{"nctId":14599,"briefTitle":14600,"status":155,"phases":16803,"primaryCompletion":412,"completion":412,"start":2811,"enrollment":8410,"conditions":16804,"interventions":16805},[95],[14603],[14605,14606,14607,14608,14609,14610,7037,14611,483],{"intervention":15248,"totalTrials":132,"cells":16807},{"EARLY_PHASE1":16808,"PHASE1":16810,"PHASE2":16812,"PHASE3":16814,"PHASE4":16816,"NA":16818},{"trials":16809,"activeCount":103},[],{"trials":16811,"activeCount":103},[],{"trials":16813,"activeCount":103},[],{"trials":16815,"activeCount":103},[],{"trials":16817,"activeCount":103},[],{"trials":16819,"activeCount":103},[16820],{"nctId":15242,"briefTitle":15243,"status":111,"phases":16821,"primaryCompletion":9143,"completion":9143,"start":2909,"enrollment":15245,"conditions":16822,"interventions":16823},[95],[3317],[15248,7012,15249],{"intervention":15249,"totalTrials":132,"cells":16825},{"EARLY_PHASE1":16826,"PHASE1":16828,"PHASE2":16830,"PHASE3":16832,"PHASE4":16834,"NA":16836},{"trials":16827,"activeCount":103},[],{"trials":16829,"activeCount":103},[],{"trials":16831,"activeCount":103},[],{"trials":16833,"activeCount":103},[],{"trials":16835,"activeCount":103},[],{"trials":16837,"activeCount":103},[16838],{"nctId":15242,"briefTitle":15243,"status":111,"phases":16839,"primaryCompletion":9143,"completion":9143,"start":2909,"enrollment":15245,"conditions":16840,"interventions":16841},[95],[3317],[15248,7012,15249],{"intervention":16843,"totalTrials":132,"cells":16844},"subtenons anesthetic - preservative-free bupivacaine 0.75%",{"EARLY_PHASE1":16845,"PHASE1":16847,"PHASE2":16849,"PHASE3":16851,"PHASE4":16853,"NA":16855},{"trials":16846,"activeCount":103},[],{"trials":16848,"activeCount":103},[],{"trials":16850,"activeCount":103},[],{"trials":16852,"activeCount":103},[],{"trials":16854,"activeCount":103},[],{"trials":16856,"activeCount":103},[16857],{"nctId":16858,"briefTitle":16859,"status":111,"phases":16860,"primaryCompletion":1222,"start":2797,"enrollment":8927,"conditions":16861,"interventions":16863},"NCT01812044","Postoperative Subtenons Anesthesia for Postoperative Pain in Pediatric Strabismus Surgery",[95],[16862],"Strabismus",[16843,16864,16865,16866],"topical anesthetic - 0.5 cc of lidocaine 3.5% ophthalmic gel","topical control - 0.5 cc of Hypromellose 0.3% gel","subtenons control - 0.5 cc of Normal Saline",{"intervention":16864,"totalTrials":132,"cells":16868},{"EARLY_PHASE1":16869,"PHASE1":16871,"PHASE2":16873,"PHASE3":16875,"PHASE4":16877,"NA":16879},{"trials":16870,"activeCount":103},[],{"trials":16872,"activeCount":103},[],{"trials":16874,"activeCount":103},[],{"trials":16876,"activeCount":103},[],{"trials":16878,"activeCount":103},[],{"trials":16880,"activeCount":103},[16881],{"nctId":16858,"briefTitle":16859,"status":111,"phases":16882,"primaryCompletion":1222,"start":2797,"enrollment":8927,"conditions":16883,"interventions":16884},[95],[16862],[16843,16864,16865,16866],{"intervention":16865,"totalTrials":132,"cells":16886},{"EARLY_PHASE1":16887,"PHASE1":16889,"PHASE2":16891,"PHASE3":16893,"PHASE4":16895,"NA":16897},{"trials":16888,"activeCount":103},[],{"trials":16890,"activeCount":103},[],{"trials":16892,"activeCount":103},[],{"trials":16894,"activeCount":103},[],{"trials":16896,"activeCount":103},[],{"trials":16898,"activeCount":103},[16899],{"nctId":16858,"briefTitle":16859,"status":111,"phases":16900,"primaryCompletion":1222,"start":2797,"enrollment":8927,"conditions":16901,"interventions":16902},[95],[16862],[16843,16864,16865,16866],{"intervention":16866,"totalTrials":132,"cells":16904},{"EARLY_PHASE1":16905,"PHASE1":16907,"PHASE2":16909,"PHASE3":16911,"PHASE4":16913,"NA":16915},{"trials":16906,"activeCount":103},[],{"trials":16908,"activeCount":103},[],{"trials":16910,"activeCount":103},[],{"trials":16912,"activeCount":103},[],{"trials":16914,"activeCount":103},[],{"trials":16916,"activeCount":103},[16917],{"nctId":16858,"briefTitle":16859,"status":111,"phases":16918,"primaryCompletion":1222,"start":2797,"enrollment":8927,"conditions":16919,"interventions":16920},[95],[16862],[16843,16864,16865,16866],{"intervention":16922,"totalTrials":132,"cells":16923},"inhalation anesthesia with isoflurane vs. TIVA with propofol",{"EARLY_PHASE1":16924,"PHASE1":16926,"PHASE2":16928,"PHASE3":16930,"PHASE4":16932,"NA":16934},{"trials":16925,"activeCount":103},[],{"trials":16927,"activeCount":103},[],{"trials":16929,"activeCount":103},[],{"trials":16931,"activeCount":103},[],{"trials":16933,"activeCount":103},[],{"trials":16935,"activeCount":103},[16936],{"nctId":16937,"briefTitle":16938,"status":111,"phases":16939,"primaryCompletion":2811,"completion":2811,"start":2593,"enrollment":3781,"conditions":16940,"interventions":16943},"NCT00788008","Cognitive Effects of Inhalational Versus Intravenous General Anesthesia in the Elderly",[95],[16941,16942,162,195],"Lumbar Spondylosis","Cervical Spondylosis",[16922],{"intervention":16945,"totalTrials":132,"cells":16946},"MiraLax",{"EARLY_PHASE1":16947,"PHASE1":16949,"PHASE2":16951,"PHASE3":16953,"PHASE4":16955,"NA":16957},{"trials":16948,"activeCount":103},[],{"trials":16950,"activeCount":103},[],{"trials":16952,"activeCount":103},[],{"trials":16954,"activeCount":103},[],{"trials":16956,"activeCount":103},[],{"trials":16958,"activeCount":103},[16959],{"nctId":16960,"briefTitle":16961,"status":111,"phases":16962,"primaryCompletion":412,"completion":1612,"start":7008,"enrollment":2982,"conditions":16963,"interventions":16965},"NCT01691742","MiraLAX Versus Placebo to Prevent Constipation Following Urogynecologic Surgery",[95],[16964],"Post Procedural Constipation",[16945,16966],"Rescue Laxative",{"intervention":16966,"totalTrials":132,"cells":16968},{"EARLY_PHASE1":16969,"PHASE1":16971,"PHASE2":16973,"PHASE3":16975,"PHASE4":16977,"NA":16979},{"trials":16970,"activeCount":103},[],{"trials":16972,"activeCount":103},[],{"trials":16974,"activeCount":103},[],{"trials":16976,"activeCount":103},[],{"trials":16978,"activeCount":103},[],{"trials":16980,"activeCount":103},[16981],{"nctId":16960,"briefTitle":16961,"status":111,"phases":16982,"primaryCompletion":412,"completion":1612,"start":7008,"enrollment":2982,"conditions":16983,"interventions":16984},[95],[16964],[16945,16966],{"intervention":16986,"totalTrials":132,"cells":16987},"Octreotide",{"EARLY_PHASE1":16988,"PHASE1":16990,"PHASE2":16992,"PHASE3":16994,"PHASE4":16996,"NA":16998},{"trials":16989,"activeCount":103},[],{"trials":16991,"activeCount":103},[],{"trials":16993,"activeCount":103},[],{"trials":16995,"activeCount":103},[],{"trials":16997,"activeCount":103},[],{"trials":16999,"activeCount":103},[17000],{"nctId":17001,"briefTitle":17002,"status":155,"phases":17003,"primaryCompletion":3122,"completion":3104,"start":6294,"enrollment":1170,"conditions":17004,"interventions":17006},"NCT00399893","Octreotide Therapy in Children and Young Adults With Prader-Willi Syndrome (PWS)",[95],[17005],"Prader-Willi Syndrome",[16986],{"intervention":17008,"totalTrials":132,"cells":17009},"chromosomal translocation analysis",{"EARLY_PHASE1":17010,"PHASE1":17012,"PHASE2":17014,"PHASE3":17016,"PHASE4":17018,"NA":17020},{"trials":17011,"activeCount":103},[],{"trials":17013,"activeCount":103},[],{"trials":17015,"activeCount":103},[],{"trials":17017,"activeCount":103},[],{"trials":17019,"activeCount":103},[],{"trials":17021,"activeCount":103},[17022],{"nctId":17023,"briefTitle":17024,"status":111,"phases":17025,"primaryCompletion":13232,"completion":17026,"start":17027,"enrollment":2822,"conditions":17028,"interventions":17029},"NCT00006342","Genetic Study in Patients Receiving Treatment for Hodgkin's Disease or Childhood Brain Tumor",[],"2001-01","1997-01",[33,9033],[17008,17030,17031],"gene rearrangement analysis","mutation analysis",{"intervention":17030,"totalTrials":132,"cells":17033},{"EARLY_PHASE1":17034,"PHASE1":17036,"PHASE2":17038,"PHASE3":17040,"PHASE4":17042,"NA":17044},{"trials":17035,"activeCount":103},[],{"trials":17037,"activeCount":103},[],{"trials":17039,"activeCount":103},[],{"trials":17041,"activeCount":103},[],{"trials":17043,"activeCount":103},[],{"trials":17045,"activeCount":103},[17046],{"nctId":17023,"briefTitle":17024,"status":111,"phases":17047,"primaryCompletion":13232,"completion":17026,"start":17027,"enrollment":2822,"conditions":17048,"interventions":17049},[],[33,9033],[17008,17030,17031],{"intervention":17031,"totalTrials":132,"cells":17051},{"EARLY_PHASE1":17052,"PHASE1":17054,"PHASE2":17056,"PHASE3":17058,"PHASE4":17060,"NA":17062},{"trials":17053,"activeCount":103},[],{"trials":17055,"activeCount":103},[],{"trials":17057,"activeCount":103},[],{"trials":17059,"activeCount":103},[],{"trials":17061,"activeCount":103},[],{"trials":17063,"activeCount":103},[17064],{"nctId":17023,"briefTitle":17024,"status":111,"phases":17065,"primaryCompletion":13232,"completion":17026,"start":17027,"enrollment":2822,"conditions":17066,"interventions":17067},[],[33,9033],[17008,17030,17031],{"intervention":17069,"totalTrials":132,"cells":17070},"Fresh frozen plasma",{"EARLY_PHASE1":17071,"PHASE1":17073,"PHASE2":17075,"PHASE3":17077,"PHASE4":17079,"NA":17081},{"trials":17072,"activeCount":103},[],{"trials":17074,"activeCount":103},[],{"trials":17076,"activeCount":103},[],{"trials":17078,"activeCount":103},[],{"trials":17080,"activeCount":103},[],{"trials":17082,"activeCount":103},[17083],{"nctId":17084,"briefTitle":17085,"status":111,"phases":17086,"primaryCompletion":16100,"completion":1934,"start":2798,"enrollment":144,"conditions":17087,"interventions":17089},"NCT01903863","The Effect of Prophylactic FFP Administration on ECMO Circuit Longevity",[95],[17088],"Extracorporeal Membrane Oxygenation",[17069],{"intervention":17091,"totalTrials":132,"cells":17092},"gadofosveset",{"EARLY_PHASE1":17093,"PHASE1":17095,"PHASE2":17097,"PHASE3":17099,"PHASE4":17101,"NA":17103},{"trials":17094,"activeCount":103},[],{"trials":17096,"activeCount":103},[],{"trials":17098,"activeCount":103},[],{"trials":17100,"activeCount":103},[],{"trials":17102,"activeCount":103},[],{"trials":17104,"activeCount":103},[17105],{"nctId":17106,"briefTitle":17107,"status":111,"phases":17108,"primaryCompletion":2650,"completion":2798,"start":2660,"enrollment":34,"conditions":17109,"interventions":17110},"NCT01431300","Dose-varied Evaluation of Ablavar-enhanced MR Angiography of the Central Veins of the Chest in Healthy Participants",[95],[9480],[17091],{"intervention":17112,"totalTrials":132,"cells":17113},"Genetic risk counseling",{"EARLY_PHASE1":17114,"PHASE1":17116,"PHASE2":17118,"PHASE3":17120,"PHASE4":17122,"NA":17124},{"trials":17115,"activeCount":103},[],{"trials":17117,"activeCount":103},[],{"trials":17119,"activeCount":103},[],{"trials":17121,"activeCount":103},[],{"trials":17123,"activeCount":103},[],{"trials":17125,"activeCount":103},[17126],{"nctId":17127,"briefTitle":17128,"status":111,"phases":17129,"primaryCompletion":17130,"completion":17130,"start":2798,"enrollment":17131,"conditions":17132,"interventions":17135},"NCT01884545","Genetic Risk and Health Coaching for Type 2 Diabetes and Coronary Heart Disease",[95],"2017-02-01",220,[17133,17134],"Coronary Heart Disease, Susceptibility to, 5","Prediabetic State",[17112]]